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Background: Contraception remains the cornerstone of the global strategy to prevent 
unintended pregnancy, as well as horizontal and perinatal/postnatal HIV transmission in women 
living with HIV (WLHIV), including female adolescents living with HIV (ALHIV). Although increased 
data and research on WLHIV contraception has provided opportunities to strengthen 
contraception services in HIV programmes, little is known about ALHIV contraceptive behaviours 
and needs, as well influences on their access to and utilisation of contraceptive services to inform 
the design of strategies that would enhance optimal contraceptive services in ALHIV 
programmes. 
 
Methods: A mixed-methods design included a cross-sectional study of female ALHIV (n=303) 
through a questionnaire survey, and semi-structured in-depth interviews with both system- and 
service delivery–level providers (N=19). Quantitative data were analysed using Stata 15. 
Quantitative analyses include descriptive statistics and regression modelling, including 
multinomial and multivariate logistic regressions.  Thematic analysis of qualitative data was 
conducted using Nvivo 11. Quantitative and qualitative data were triangulated in the 
interpretation of results.  
 
Results: Contraceptive prevalence (83.5%) is extremely high among all the female ALHIV and even 
higher among sexually active female ALHIV (86.8%), and contraceptive prevalence rates are at 
least 20% higher than the South Africa Demographic and Health Survey  (SADHS) rate for the 
general population of female adolescents or  sexually active female adolescents. The rate of 
unmet need for contraception (23.6%) remains considerable. Contraceptive prevalence is also 
high among both female with peri/postnatally acquired HIV (pALHIV) and horizontally acquired 
HIV (hALHIV). The majority of current contraceptive users relied on injectables (60.5%), followed 
by condoms alone (27.7%), then long-acting reversible contraceptives [LARC](9.1%) and 
hormonal pills (2.7%). Almost 1 in 5 (18.8%) female ALHIV had an unintended pregnancy. When 
contraceptive use consistency was restricted to the three months preceding the survey, levels of 
consistent condom use and dual-method use were 37.9% and 20.6%, respectively. Also, the 
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quantitative data shows multiple barriers and facilitating factors for contraceptive uptake among 
female ALHIV. Overall, both the quantitative and qualitative data generally found that the receipt 
of contraceptive provision and use are similar between female pALHIV and hALHIV; however, the 
quantitative data suggest that pALHIV were more likely to experience unintended pregnancies 
compared to hALHIV. Though the quantitative data lack information on the particular hormonal 
method associated with HIV-specific safety concerns, there is evidence suggesting that the 
concern about HIV-specific hormonal contraceptive-related risks does not impact hormonal 
contraceptive uptake among ALHIV. Furthermore, adolescent-friendly services (AFS) appear to 
have been reasonably well-mainstreamed into routine care in the Cape Town context at least, to 
the extent that standalone youth clinics do not appear to provide significant added value to 
contraception-related outcomes among female ALHIV. The qualitative data highlighted 
preponderance of injectable contraception, inconsistent contraceptive use, fears about the 
intrauterine device (IUD) use, positive and negative provider attitudes to contraceptive services 
for ALHIV, and provider competency and training, among others.  
 
Conclusion: Overall, the thesis supports socioecological-based approaches to contraceptive care 
for female ALHIV as well as mainstreaming AFS within public sector facilities. Moreover, potential 
risk-reducing interventions, such as a client-centred approach to contraceptive care, are needed 
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Glossary of terms 
 
Adolescents refer to individuals between ages 10 and 19. 
 
Antiretroviral therapy (ART) consists of multiple antiretroviral (ARV) drugs to maximally suppress 
the HIV or halt the progression of HIV disease. 
 
Antiretroviral adherence: For this study, ARV adherence refers to the use of ARVs at the right 
frequency and dosing over the 4 days preceding a client interview. ALHIV who adhered to their 
antiretroviral therapy schedule 100% of the time are considered adherent to their ART.  
 
ART Naïve in this study refers to ALHIV who did not initiate ART before participation in the survey.  
 
Contextual factors: means the context in which an individual is embedded, and this context 
includes relational/interpersonal, institutional, community, and societal factors.  
 
Contraceptive prevalence rate: This is defined as the per cent of women of reproductive age (15-
49) who are using (or whose partner is using) a contraceptive method at a given point in time 
(WHO., 2020). 
 
Dual method use: Describes the use of an effective contraceptive method for pregnancy 
prevention (hormonal contraception, intrauterine device, or sterilization) plus consistent use of 
male or female condoms to prevent STI and HIV transmission. 
 
Dual protection: Refers to the use of a method or methods that can protect against unintended 
pregnancy as well as STI and HIV transmission. This can be achieved through single method use 




General PHC clinics: In this study, it refers to health facilities that offer PHC services for patients 
of various age groups.  
 
HIV-reinfection: refers to either (i) co-infection with another HIV viral strain at the same time or 
within a month of the initial HIV-infection or (ii) super-infection- infection with another strain of 
the virus in a person with an established HIV infection (Shapiro & Ray, 2007). 
 
Horizontally infected ALHIV refers to adolescents with behaviourally acquired HIV (e.g., through 
sexual intercourse, injection drug use, etc). 
 
Hormonal contraception: Includes oral contraceptives (OCs), injectables, implants, patches, 
rings, and levonorgestrel intrauterine devices (IUDs).  
 
Key informants: Include healthcare providers (doctors, nurses, clinic managers, and counsellors), 
and system-level policymakers working in the township communities selected for this research 
study. 
 
Long-acting reversible contraception: Includes intrauterine devices and implants.  
 
Mature Minor: Refers to adolescents within the age group 14-17 years. The matured minor 
concept is premised on the evidence that adolescents aged 14 years and above have the cognitive 
capacity to make informed decisions.  
 
Minor: The South African Children’s Act (2005) defines any person under the age of 18 years as 
a minor.  
 
Modern contraceptive methods in this thesis apply to sterilization, intrauterine devices, 
subdermal implants, oral contraceptives, condoms (male and female), Injectables, emergency 
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contraceptive pills, patches, diaphragms and cervical caps, spermicidal agents (gels, foams, 
creams, etc.), vaginal rings and sponge. 
 
Models of HIV care: In this thesis, it apply to stand-alone youth clinics providing HIV services and 
general PHC clinics providing HIV services. 
 
Non-hormonal contraception: Comprises male and female condoms, diaphragm, cervical cap, 
sponge, sterilization, and withdrawal.  
 
Ph.D candidate: Refers to the doctoral student responsible for this dissertation. 
 
Peri/postnatally infected ALHIV refers to adolescents who acquired HIV via maternal-to-child 
transmission routes.  
 
Primary caregiver: A person who assumes the most responsibility for the care, and upbringing of 
an HIV-infected adolescent minor aged 12 years and above are considered as the primary 
caregiver in the context of this research. Primary caregivers may include parents, grandparents, 
other relatives, or legal guardians. 
 
Standalone youth clinics refer to health centres that provide health care services to young 
people, and may also offer and recreational facilities. 
 
Self-efficacy refers to people’s judgements about their capabilities to execute behaviours 
necessary to produce designated levels of performance (Bandura., 1986). In this study, self-
efficacy applies to ALHIV skill to hesitate sexual vaginal intercourse without the use of condom 
and/or any other modern contraceptive method.  
 
Sexually active adolescents: In the context of this study, adolescents who have had sexual 




Unintended pregnancy: “Unintended pregnancies are pregnancies that are reported to have 
been either unwanted (i.e., they occurred when no children, or no more children, were desired), 
mistimed (i.e., they occurred earlier than desired), or unplanned (i.e., one that occurred when 
the woman used a contraceptive method or when she did not desire to become pregnant but did 
not use a method)” (Santelli et al., 2003). 
 
Townships: In South Africa, townships “refer to the urban (often underdeveloped) living areas 
that, under Apartheid, were reserved for black Africans and coloureds, but also working-class 
Indians. Townships are on the periphery of towns and cities. Townships sometimes have large 
informal settlements nearby” (Setswe, 2010). 
 
Unmet need for contraception: describes women who are fecund and sexually active, not using 
any method of contraception, and who report not wanting any more children or wanting to delay 
their next birth” (WHO., 2020). 
 
Youth or young adults are considered those individuals between the ages 15 and 24. 
 
Young people refer to individuals between ages 10 and 24. 
 
Youth- and adolescent-friendly service-provision models refers to service delivery models that 
are adolescent/youth friendly. Models to provide youth/adolescent friendly services include 
standalone clinic, separate space co-located in public or private health facilities, mainstreamed 
services within existing services, mobile outreach services, drug shops and pharmacies, and 
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1.  Introduction 
 
1.1   Background 
1.1.1  Overview of the contraceptive needs of ALHIV 
Globally, four out of five ALHIV, defined by the United Nations as persons aged 10-19 years 
(UNICEF, 2013), live in sub-Saharan Africa (Idele et al., 2014). Like in most of the United Nations 
Children’s Fund (UNICEF) regions, HIV infection rates among adolescents in sub-Saharan Africa 
are higher among girls than among boys (Idele et al., 2014). Recent HIV/AIDS data published by 
the South African National AIDS Council (SANAC) suggest approximately two-fifths of new HIV 
infections in South Africa occur among young women and adolescent girls (SANAC., 2017). 
Furthermore, it is estimated that over 240,000 new HIV infections occurred in 2018, ranking 
South Africa first in terms of the global HIV incidence (UNAIDS., 2019).  
 
Contraception, either dual method or dual protection, remains the cornerstone of the global 
strategy to prevent unintended pregnancy, vertical HIV transmission and sexual transmission of 
HIV in women living with HIV (WLHIV), including female ALWH (Haddock et al., 2008, p.84). 
Several different simulation models have demonstrated the potential impact of contraceptive 
services on preventing HIV transmission and unintended pregnancies among WLHIV (Stover et 
al., 2003; Sweat et al., 2004; Reynolds et al., 2004; Reynolds et al., 2008). One such simulation 
model evaluated the role of contraception in avoiding unintended pregnancies and HIV-positive 
births among WLHIV in President’s Emergency Plan for AIDS Relief (PEPFAR) focus nations. The 
study also examined the cost savings to these nations. The results showed that, annually, the 
estimated number of such unintended pregnancies avoided through contraceptive use ranged 
from 595 in Guyana to 400,854 in South Africa (Reynolds et al., 2008). Additionally, HIV-positive 
births averted ranged from 178 in Guyana to as high as 120,256 in South Africa (Reynolds et al., 
2008). The estimated cost savings associated with averting these births were substantial, ranging 




Despite such benefits, female ALHIV have a continuing risk of infecting an uninfected partner, 
unintended pregnancy and HIV superinfection (Carter et al., 2013). Within South Africa, female 
ALHIV in urban townships seem particularly vulnerable. These socio-economically disadvantaged 
townships bear the highest burden of HIV infection, and the proportion of unintended 
pregnancies is higher than the rest of the country (Shisana et al., 2014; Jewkes et al., 2001; Myer 
et al., 2004). This suggests that female ALWH in urban townships in South Africa have critical 
contraceptive needs that are made more challenging not only by their HIV status but also by the 
context in which they live. The current literature offers little insight into HIV-positive adolescent 
girls’ broader contraceptive needs, such as counselling, method choice, service preferences and 
the extent to which services are friendly to adolescents. 
 
The assessment of the contraceptive needs of female ALHIV has been proposed as an important 
step in the development of strategies to address their contraceptive needs and improve their 
access to and use of contraceptive services in HIV care and treatment services (Birungi et al., 
2008). Moreover, as a socio-ecological intervention approach has been found particularly useful 
in addressing adolescent reproductive health (DiClemente et al., 2005), this is an important way 
to assess female ALWH contraceptive needs. 
 
A specific focus of the Western Cape Department of Health is on integrating contraceptive 
services into HIV care and treatment programs to improve health outcomes for WLHIV in 
Western Cape Province (Van Esch et al., 2014). Many factors may limit the contraceptive needs 
of female ALHIV in townships. Therefore, exploring the factors that impact the provision and 
utilisation of contraceptive services at multiple levels such as individual, interpersonal, 
community, institutional (including structure and processes of care) and societal for female 
ALHIV, as well as their contraceptive experiences, can help to address their specific contraceptive 






1.1.2 Contraceptive non-use and reproductive health outcomes  
in ALHIV 
Without contraception, WLHIV including adolescent girls face a significant risk of adverse 
consequences including unintended pregnancies and associated perinatal HIV transmission as 
well as HIV-reinfection and HIV transmission to uninfected partners (Raifman et al., 2014). 
Indeed, making access to contraceptive services widely available to WLHIV is recognized by 
UNAIDS as a critical strategy to preventing unintended pregnancies, and holds the prospects for 
eliminating paediatric HIV infections and enhancing health outcomes for WLHIV and their 
children (UNAIDS|World Health Organisation., 2011). 
 
WHO and UNAIDS consider contraceptive use to avert unintended pregnancies among HIV-
positive women as one of the four key strategies to prevent maternal-to-child transmission of 
HIV (UNAIDS|World Health Organization, 2011). A simulation model that included data from 15 
countries (mainly sub-Saharan African nations) supported by President’s Emergency Plan for AIDS 
Relief (PEPFAR) demonstrated that the numbers of unintended pregnancies and HIV-positive 
births averted to HIV-positive South African women by contraceptive use per year were 400,854 
and 120,256, respectively (Reynolds et al., 2008). 
 
Studies from developed and developing country settings have found high rates of unintended 
pregnancy among female ALHIV; ranging from 74% in Kenya to 83% in United States (Elgalib et 
al., 2011; Kenny et al., 2012; Koenig et al., 2007; Obare et al., 2010a; Obare et al., 2012). These 
results are not surprising, as over 50% of adolescents in HIV care in sub-Saharan Africa have 
reported inconsistent condom use, and nearly 50% have reported non-use of any contraceptive 
method (Birungi 2008; Birungi et al., 2009; Olivera & Makumbi., 2013). In the United Kingdom, a 
study shows that two-thirds of female ALHIV were not using contraception prior to conception 
(Elgalib et al., 2011). The study also found that female ALHIV used condoms as their sole method 
of contraception, and a vast majority of pregnancies within 12 months of delivery were 
unintended (Elgalib et al., 2011). One study from sub-Saharan Africa demonstrated a substantial 
level of recurrent unintended pregnancies among female ALHIV (Obare et al., 2011). Empirical 
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evidence from sub-Saharan Africa has also suggested high levels of unintended pregnancies 
among female ALHIV (Obare et al., 2010a; Obare et al., 2012).  
 
One study conducted in Kenyan among female ALHIV reported that the occurrence of adverse 
pregnancy outcomes (miscarriage, stillbirth, or abortion) was more likely in pregnancies that 
were unintended as compared to pregnancies that were intended (OR 1.3; 95% CI 0.5-3.3) (Obare 
et al., 2012). In South Africa, empirical data on the burden of unintended pregnancies among 
female ALWH are not available; however, the evidence that unintended pregnancies remain high 
among adolescent girls (HIV status unknown, HIV positive or negative) may point to high levels 
of unintended pregnancies among female ALWH (Christofides et al., 2014). This study 
underscores the vulnerability of ALHIV in South Africa to unintended pregnancy. However, no 
data to inform how to better the delivery and utilization of effective contraceptive services for 
this group of young women. 
 
In summary, the levels of unintended pregnancies among female ALHIV are incredibly high, and 
the fact that female ALHIV included in the above studies were in HIV care and treatment 
programmes suggests that barriers to accessing contraceptive services exist for adolescent girls 
in HIV care. Thus, a better understanding of adolescent-friendly contraceptive services in HIV care 
and treatment programmes is needed to tailor services to the needs of female ALHIV.  
 
1.2   Research context 
1.2.1  Burden of HIV in South Africa 
In South Africa, HIV/AIDs remains an epidemic and a major national health challenge (Simbayi et 
al., 2017; UNAIDS., 2019). Not only is South Africa the country with the largest number of people 
living with HIV (PLHIV) globally (UNAIDS, 2019), but there has also been a marked upward trend 
in HIV prevalence in the country (Shisana et al., 2002; Shisana et al., 2005; Shisana et al., 2009; 
Shisana et al., 2012; Shisana et al., 2014; Simbayi et al., 2017). This upward trend in HIV 
prevalence is expected as people are living longer with antiretroviral therapy (ART). The national 
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population-based surveys have shown that the estimated overall national HIV prevalence had 
risen from 11.4% in 2002 to 14% in 2017 (Shisana et al., 2002; Shisana et al., 2005; Shisana et al., 
2009; Shisana et al., 2014; Simbayi et al., 2017). These prevalence estimates suggest that the 
number of persons living with HIV (PLHIV) in South Africa rose from 5.1 to 7.9 million over the 12 
years covered by the national surveys. The over 50% increment in the country’s HIV-positive 
population between 2002 and 2017 indicates explosive positive population growth among PLHIV 
in the country. According to UNAIDS Data 2019, there were 7.7 million PLHIV in South Africa in 
2018 and 20.4% HIV prevalence among persons within the ages 15 – 49 years (UNAIDS., 2019).  
South Africa accounted for approximately one-fifth of the 37.9 million PLHIV globally in 2018 
(UNAIDS., 2019), despite accounting for just less than 1% of the world’s population. In the same 
year, the country also accounted for over 14% of the total 1.7 million people with newly acquired 
HIV infections and about 10% of the 770,000 global AIDS-related deaths.  
 
Based on data from previous national population-based HIV surveys from 2002 to 2017, Simbayi 
and colleagues draw important conclusions regarding substantial differences in HIV infection 
levels by epidemiological profile, including age, gender, race, province and locality type (Shisana 
et al., 2002; Shisana et al., 2005; Shisana et al., 2009; Shisana et al., 2012; Shisana et al., 2014; 
Simbayi et al., 2017). In terms of gender, the epidemiological curve continues to show higher HIV 
prevalence among women than among men (Shisana et al., 2002; Shisana et al., 2005; Shisana et 
al., 2009; Shisana et al., 2012; Shisana et al., 2014; Simbayi et al., 2017; UNAIDS, 2019), and young 
women (ages 15 – 24) are disproportionally affected (UNAIDS, 2019).  
 
Analysis of data from the last national HIV surveys suggests that KwaZulu-Natal, Eastern Cape 
and Free State were the provinces with the highest HIV prevalence, followed by Mpumalanga, 
North West, Gauteng, and Limpopo, and then by Northern Cape and Western Cape (Simbayi et 
al., 2017). Also, the UNAIDS Data 2019 revealed that adolescent girls constitute groups most 
affected by HIV/AIDS in South Africa (UNAIDS., 2019).   Data from the 2012 national HIV surveys 
showed that HIV prevalence was nearly twice as high among residents in informal settlements 
than among those informal settlements (Shisana et al., 2014). Similarly, an analysis of HIV 
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prevalence among youth by locality in 2005 found that prevalence was highest among 
adolescents and young adults in informal settlements within urban areas (Shisana et al., 2005).   
 
Adolescents living with HIV are a uniquely vulnerable subset of HIV-positive populations. In South 
Africa, studies have suggested that ALHIV experience additional challenges that put their health 
at risk. These challenges – such as neurocognitive deficits, ART adherence, stigma and disclosure 
challenges, and orphanhood (Hoare et al., 2012; Cloete et al., 201Madiba & Mokgatle., 2016) - 
also have implications for healthcare utilisation. Along with the factors that increase adolescents’ 
risk of HIV infections (including sexual coercion and age-disparate sexual relationships) (Shisana 
et al., 2014), these additional challenges put them at risk of sexual risk-taking behaviour and 
consequent teenage pregnancy. 
 
 
1.2.2  Current contraception policy and profiles in South Africa 
Since the early 2000s, South Africa has established a national policy on contraception, released 
in two complementary documents, within the framework of reproductive health, rights and 
equity aimed at improving access to contraception in the general population (Department of 
Health., 2001). Due in part to HIV prevalence, development of new contraceptive technologies 
and findings from contraceptive research (specifically, the link between HIV acquisition and 
hormonal contraception), the scope of the contraception policy launched in the early 2000s has 
been expanded in the new national contraception policy launched in 2013 (Department of 
Health., 2012a). The revised policy which was also released in two documents (The National 
Contraception and Fertility Planning Policy and Service Delivery Guidelines and its companion, the 
National Contraception Clinical Guidelines) includes an emphasis on strategies to address the 
contraceptive needs of WLHIV (either on ART or ART-naive) (Department of Health, 2012a, 
2012b). These strategies include the inclusion of contraception within the context of HIV and 
appropriate integration of contraceptive and HIV services. Furthermore, the contraceptive policy 
documents acknowledge the high burden of unintended pregnancies among women living with 
HIV, and the emphasis is also placed on HIV testing in contraception program, pregnancy 
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prevention and provision of comprehensive and accessible contraceptive services as crucial 
strategies for preventing unintended pregnancies in this sub-group of women. 
 
Besides promoting access to contraceptive method mix, specifically expanding contraceptive 
choices to include longer acting reversible contraceptives (Copper IUD, intrauterine systems and 
implants), the use of dual method among WLHIV is also a key feature of the new contraception 
policy. Further, provision of high-quality contraceptive services is also highlighted in the policy, 
and key areas for high-quality contraceptive service delivery include effective procurement and 
supply, management systems, rights, the environment of care, accessibility and acceptability, 
with special emphasis on confidentiality, privacy, contraceptive choices, and technical 
competence for WLHIV. 
 
Furthermore, consider adolescents among certain groups of clients that should be offered special 
contraceptive needs (defined as “making contraceptive services accessible, and dismantling 
barriers that would prevent service utilization”). The policy documents also promote adolescent 
access to contraception on the ground that young age is not a barrier to using any form of 
contraception. Unfortunately, the policy documents have no separate recommendations for 
ALHIV. Despite the evidence on adolescent-friendliness of the National policy documents on 
contraception, critical gaps exist in terms of contraceptive service provision to adolescents. 
Hoope and colleagues used the "WHO Contraception-Specific Guidance and Recommendations" 
as an analytic framework to determine how current South Africa's contraception policy 
addressed the needs of adolescents (Hoopes et al., 2015). This analysis revealed that there are 
gaps with respect to informed decision making, availability and adolescents' involvement in 
program developments that can create barriers to accessing quality contraception service for 
adolescents. 
 
Another policy that is geared towards improving South African adolescents’ access to 
contraception is the integrated school Health Policy launched in 2012. The integrated policy 
considers contraceptive counselling, and methods or referral for sexually active adolescent 
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learners by an on-site nurse; with emphasis on dual contraception, as part of the Primary Health 
care reengineering programme (Department of Health., 2012c). In Western Cape, nurses at the 
public-sector primary health care system provide school health services. To enhance access to 
contraception for ALHIV, including both in-school and out-of-school ALHIV, there is need to 
explore the understandings of key informants involved in both HIV and contraception services 
(e.g. system-and service delivery-level providers) in primary health care (PHC) facilities. 
 
Adolescents’ access to contraception is also promoted by the current Children’s Amendment Act 
(No. 41 of 2007). Section 134 (“Access to contraceptives”) “states that no person may refuse to 
sell condoms to a child over the age of 12 years; or refuse to provide a child over the age of 12 
years with condoms on request, where such condoms are provided or distributed free of charge”. 
The act also states that a child over the age of 12 years may independently access contraception 
other than condoms. Concerning the quality of care perspective, the act highlights confidentiality 
in the provision of contraceptive services to young people (Children’s Amendment Act., 2007). 
 
On the contraception profile side, DHS studies conducted in South Africa and two other Southern 
African countries (Zimbabwe and Lesotho) in the past decade suggest similarity in the levels of 
current contraceptive prevalence, however, the mix of contraceptive methods vary across the 
three southern African countries (Ministry of Health [Lesotho] and ICF International., 2016; 
Zimbabwe National Statistics Agency and ICF International., 2016; National Department of 
Health., 2019). In the 2016 South Africa DHS (SADHS) data, the current contraceptive prevalence 
rate (CPR) is 48.2% among all women age 15 - 49 years, close to 48.6% in the 2015 Zimbabwe 
DHS data and 48.9% in the Lesotho 2014 DHS data (Ministry of Health [Lesotho] and ICF 
International., 2016; Zimbabwe National Statistics Agency and ICF International., 2016; National 
Department of Health, 2019). In South Africa, current CPR among all women of reproductive age 
has declined from 50.2% in 2003 to 48.2% in 2016, probably because of decline in the prevalence 
use of norethisterone enanthate (NET-EN) injectable, pills and female sterilisation (Department 
of Health., 2007; National Department of Health., 2019). In contrast, current CPR has generally 
increased over time among all women of reproductive age in Zimbabwe (from 40.1% in 2005-
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2006 to 48.9% in 2015) and Lesotho (from 29% in 2004 to 48.6% in 2014) (Ministry of Health 
[Lesotho] and ICF International., 2016; Zimbabwe National Statistics Agency and ICF 
International., 2016). Concerning the mix of modern contraceptive methods, recent DHS 
evidence suggests current use of injectable contraceptives is higher among all women of 
reproductive age in South Africa (23%) than Zimbabwe (7%) and Lesotho (17%). The proportion 
of current users of condoms was higher among women in South Africa (12%) than in Zimbabwe 
(4%), whereas women in Lesotho had an approximately twofold increase in current condom use 
compared to women in South Africa (19% vs. 12%, respectively). The current use of pills was 
lower among South African women (5%) than Zimbabwean (27%) and Lesotho women (9%). By 
comparison, uptake of long-acting reversible contraception, including implants and intrauterine 
device (IUD), was lower in South Africa (4%) than in Zimbabwe (9%), but higher than in Lesotho 
(2%). More women in South Africa relied on female sterilization (4%) than women in Zimbabwe 
(0.6%) and Lesotho (1%) (Ministry of Health [Lesotho] and ICF International, 2016; Zimbabwe 
National Statistics Agency and ICF International, 2016; National Department of Health, 2019). 
 The results of the recent SADHS indicate that CPR varies with age, rising from 60.4% 
among sexually active adolescents age 15 – 19 to 63.4% among sexually active women age 35 – 
39, before decreasing to 42.9% among sexually active women age 45 – 49 (National Department 
of Health, 2019). The survey showed that male condoms and hormonal contraceptives were the 
methods currently used by adolescents. The most common contraceptive method currently used 
by adolescents was male condoms (24%), followed by injectable contraceptives (27%), then 
implants (5%) and pills (4%). Among adolescents reporting injectable contraceptives, injectable 
DMPA was higher, at 59%. There was a notable difference in the contraceptive method mix 
between adolescents and older women, with older women reporting current use of male and 
female sterilization, IUD, and female condoms, in addition to male condoms and hormonal 
contraceptives.  
 
Given that the recommendations on adolescent contraception in the above policies are not 
explicit for ALHIV, there is the potential for the policies to be prone to diverse interpretations 
and implementations in the way they are applied to female ALHIV. There is no doubt that a focus 
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on ALHIV needs to be incorporated into all contraceptive policies, given the safety concerns 
around hormonal contraception in HIV-positive populations (e.g., HIV-disease progression, HIV-
transmission to sexual partners). Thus, there is a need for understanding the issues of access to 
contraception for HIV-positive adolescent girls through the existing policies from the views of the 
diverse range of stakeholders [female ALHIV, system-level providers (i.e., sub-district health 
managers) and service-delivery level providers (facility managers, HIV clinic operational 
managers, doctors, nurses and adherence counsellors] whose perspectives can inform the 
provision of optimal health services. Furthermore, available DHS data suggest there are unique 
differences in the general contraceptive method mix by country within Southern Africa, and the 
only South Africa study that has explored contraceptive practices among ALHIV failed to explore 
their mix of specific contraceptive methods (Sadeghi et al., 2015). Thus, additional South Africa-
specific data on the contraceptive method mix of ALHIV is required to guide policies and 
programmes to promote contraception in HIV services for adolescents.  
 
 
1.2.3  Sexual and reproductive health and HIV services and  
the primary public healthcare system in Western Cape, 
South Africa 
Under South Africa’s National Health Act (61 of 2003), which sets a framework for a unified health 
system and universal health coverage via PHC system, Western Cape Province has a publicly 
funded, publicly managed, not-for-profit PHC system. In addition to the recognition of the right 
of every South African to have access to healthcare services, including reproductive healthcare, 
the National Health Act makes provisions for citizens who do not hold private medical 
insurance/Aids to be eligible for free primary care services, including, but not limited to, sexual 
and reproductive health services (National Health Act., 2003). The PHC service component of 
Western Cape’s health system is the most critical, as it serves as the entry point into the care 
continuum and caters to the vast majority of healthcare needs (Western Cape Government 




In the Western Cape, the management of PHC services falls under two types of health authorities: 
local (City Health) and provincial (Provincial Department of Health (DoH)). Apart from Cape Metro 
Health District with a dual public PHC system management (City Health and Provincial DoH), all 
Western Cape districts have a unified health management system under the jurisdiction of the 
Provincial DoH. The nature of PHC services is ambulatory, and public PHC services are provided 
across a range of healthcare facilities (Western Cape Government Health, 2014). These include 
clinics (including mobiles and satellites), Community Day Centres and Community Health Centres. 
Within the Cape Metro Health District, most clinics are operated by the local (City Health) health 
authority. The Provincial DoH operates Community Day Centres and Community Health Centres. 
Some public PHC facilities in the Cape Metro Health District are owned by both local and 
provincial authorities. Public PHC facilities are managed at the district level and are supported by 
a network of district hospitals. 
 
The Western Cape Province has 479 publicly funded PHC centres, including 237 general PHC 
centres that provide HIV/AIDS treatment and care services. In Western Cape, approximately 35% 
of the HIV/AIDS-treatment centres are in the Cape Metro Health District. Moreover, Site B Youth 
Centre and Site C Youth Centre, both located in the Khayelitsha Health sub-district of the Cape 
Metro and administered by City Health, are the only publicly funded youth-only PHC clinics 
providing HIV treatment and care services in Western Cape. These youth centres are dedicated, 
stand-alone reproductive health clinics for youth aged 13–24 years. In addition, these youth 
centres deliver sport (snooker) and audio-music activities, along with information about life skills, 
provided by a youth mentor from a non-governmental organisation within the community. The 
operating hours of all public PHC facilities, as well as standalone youth clinics, are between 8:00 
am and 16:30 pm, Monday through Friday. The facilities are closed on weekends and all public 
holidays.  
 
The PHC service component of the Western Cape health system consists of three discrete but 
interrelated service delivery platforms, including home- and community-based care, primary care 
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services at health facilities and intermediate care (i.e., in-patient transitional care) (Western Cape 
Government Health, 2014). PHC facilities provide a broad range of preventative and curative 
services, together with services such as rehabilitation and palliative care services, to ensure one-
stop service for patients (Western Cape Government Health, 2014). Besides the range of services, 
including maternal and child health services, described in the provincial primary care package 
(Western Cape Government Health, 2014), the public primary care facilities provide a full range 
of sexual and reproductive health services, such as termination of pregnancy, family planning 
services, sexually transmitted infections (STI) management, cervical cancer screening, HIV 
prevention and care, and antiretroviral therapy (ART). Although South Africa’s PHC system is 
designed to be nurse-driven in terms of service delivery at healthcare facilities (Western Cape 
Government Health, 2014), HIV care and treatment services are delivered mainly by both medical 
and nursing personnel in most PHC facilities. The nursing personnel include staff nurses (diploma 
in nursing), professional nurses (Bachelor of Nursing) and clinical nurse practitioners (advanced 
diploma in primary clinical healthcare with infectious disease expertise). Medical personnel who 
provide HIV care and treatment services at PHC facilities include medical officers and family 
physicians. Other personnel involved in HIV care include adherence counsellors and community 
care workers (non-professional care workers, such as community health workers and home-
based carers). 
 
Youth clubs (peer support groups) are another critical feature of the HIV service delivery platform 
in South Africa. These are meant to ensure retention in care and adherence to treatment 
(Adherence Guidelines for HIV, TB, and NCDs, 2016). However, not all PHC facilities offering 
HIV/ART services have youth clubs. Youth clubs are lay healthcare worker-driven and have a 
nurse and/or a doctor to provide clinical support. Each youth club consists of approximately 20 
members (including both ART-naïve and ART clients) who come together voluntarily. In terms of 
composition, youth clubs vary slightly within and between facilities in the Cape Metro district. 
The group may be a mixed-age group (adolescents and young adults), adolescents only, young 
adults only with mixed-gender, or gender-specific (only male or only female). Club meetings are 
held in a private space in the facilities, usually once a month during the first six months and bi-
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monthly after that. Services such as ART refills, routine check-ups, laboratory services, clinical 
consultations and structured interactive group sessions are integrated into youth clubs. 
 
The integration of family planning into HIV care/treatment services at PHC facilities has been an 
essential priority in the Western Cape Province, which has been encouraged by the success of 
the provincial Family Planning Integration Project into HIV services. The Family Planning 
Integration Project has increased client satisfaction and improved access to and uptake of 
contraception services among WLHIV attending PHC facilities (Van Esch et al., 2014). The project, 
initiated in September 2012, offers an opportunity for the roll-out of the integration of family 
planning and HIV services throughout the Western Cape Province. It also provides a framework 
and programmatic guidance for delivering integrated family planning and HIV services to the 
entire country. The integration approach is a combination of provider- and room-level integration 
(i.e., the simultaneous provision of HIV and family planning services by one provider within one 
consultation room) (Bradley et al., 2008). In Western Cape, as in other South Africa’s provinces, 
HIV services have also been expanded to include other SRH services such as cervical cancer 
screening and STI care (SANAC., 2011). 
 
 
1.2.4  Urban townships in Cape Town, Western Cape, South Africa  
In South Africa, townships or locations refer to often underdeveloped urban living settlements, 
located as far from the economic city centres as possible and designated for non-white residents, 
including blacks, coloureds and Indians, during the apartheid era (Statistics South Africa., 2012a). 
In post-apartheid South Africa, the term ‘township’ is used for both legally defined residential 
and industrial areas. Historically, townships were created during the apartheid era as a 
mechanism for controlling the influx of non-whites into the cities (Mahajan, 2014). It is important 
to emphasise that the focus of this research is on townships that were established under 
apartheid. Townships are usually built on the outskirts of big towns and cities and sometimes 
have large informal settlements (defined as illegal dwellings generally constructed with wood 
and iron) located both within and around it (Mahajan, 2014). Most of the legal dwellings in the 
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townships have backyard shacks (Mahajan, 2014). In many ways, these historically established 
townships are synonymous with the slums in much of the developing world, except that 
townships were designed for residential purposes and in compliance with planning and building 
code norms (Mahajan, 2014).).  
 
Data from South Africa’s 2011 census demonstrated that 18 million people (approximately 35% 
of South Africa’s total population) were residing in townships and informal settlements (Statistics 
South Africa, 2011). Approximately 50% of South Africa’s urban population resides in townships 
and informal settlements, representing 38% of the working-age population (15 - 64 years of age). 
Nearly 60% of persons not employed in South Africa’s labour force dwell in townships and 
informal settlements due to economic migration from rural areas and neighbouring nations 
(Mahajan, 2014). Among the reasons why many new internal and external migrants to South 
Africa settle in the townships include the low cost of living and affordable housing.  Access to 
public health services, education, and other infrastructure, such as water, sewerage and 
electricity connections, remains highly problematic in the townships and informal settlements 
(Mahajan, 2014). 
 
Data from the national statistical service of South Africa rank three of Cape Town’s townships 
(Khayelitsha, Mitchell Plain and Gugulethu) among the 50 largest townships in the country 
(Statistics South Africa, 2011). These three townships account for over 20% of the population of 
the City of Cape Town Metro District (Statistics South Africa, 2011; City of Cape Town., 2011a; 
City of Cape Town., 2011b; City of Cape Town., 2011c). Table 1.1 illustrates the profiles of Cape 
Town’s townships. All three are predominantly black people (99%), except for Mitchell Plain, 
which is predominantly coloured people (91%) (City of Cape Town., 2011a; City of Cape Town., 
2011b; City of Cape Town., 2011c). Data from the City of Cape Town’s district planning profiles 
provide evidence of the human development indicators - the Human Development Index (HDI) 
and the City Development Index (CDI) – in the city’s townships. The HDI is the average of the 
following vital socio-economic indicators: health, education and income. The CDI is an indicator 
of city development concerning infrastructure, waste, education, city product and health. In 
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addition to these indicators, the CDI also includes infrastructure. These townships are among the 
city's most poorly developed areas, with HDIs and CDIs far below the city's averages of 0.82 and 
0.83, respectively (Socio-economic Profile: City of Cape Town, 2006). Additionally, criminal 
activities (including rape) within Cape Town are concentrated in townships such as Gugulethu, 
Khayelitsha, Nyanga and Mitchells Plain (Kagee & Frank., 2005; Silber & Geffen., 2009).  
 
As in other townships across South Africa, spontaneous protests are prevalent in Cape Town's 
large townships. These are mostly due to demand for better social infrastructure (including 
health services) and access to essential services. Issues related to HIV infection are also 
problematic in townships (Shisana et al., 2005).  
 
Table 1.1: Profile of three of the largest townships in Cape Town 
 






















HIV prevalence (antenatal prevalence)a 18.4% 34.3% 22.3% 
 
Public sector HIV & treatment clinics 8 12 8 
Youth only services’ facilitiesb 1 2 1 
Completed education beyond Grade 12c 5.9% 4.9% 8.6% 
Economic profile 
Not economically active 















5.1% 55.4% 23.7% 
 
 
Source: City of Cape Town – 2011 Census Suburb; aData from Western Cape Department of Health; 
bOnly Khayelitsha Youth services’ facilities offer reproductive health services, including HIV care and 
treatment  services (the remaining two youth centres offer reproductive reproductive health services, 
except HIV care and treatment); cProportion of persons aged 20 and above. 
 
 
1.3   Research questions, aims and objectives  
This thesis focusses on understanding the contraceptive needs of female ALHIV in South 
Africa’s largest urban townships in Western Cape by exploring multiple perspectives from a 
broad range of key actors, including female ALHIV clients, system-level providers and service-
level providers. In a relatively high HIV-burden country like South Africa, the HIV burden 
seems to be concentrated in urban townships, with adolescent girls disproportionately 
affected by HIV, coupled with a high risk of unintended pregnancy. In this light, there is a need 
to understand the full range of female ALHIV contraceptive needs, as well as the factors 
associated with access to and use of contraception. 
 
 
1.3.1  Research questions 
The research questions guiding this thesis include: 
1. How do contraceptive behaviours and related outcomes among female ALHIV relate to 
contextual factors?  
2. How do hormonal contraceptive-related safety considerations specific to HIV-positive 
populations’ impact on female ALHIV contraceptive use behaviours? 
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3. How do the contraceptive practices, preferences, and needs of adolescent girls differ by 
route of HIV acquisition? 
4. How do female ALHIV clients’ contraceptive behaviours, service provision, quality 
perceptions and satisfaction with services, and unmet need for contraception vary with 
age-dedication of access sites for HIV treatment and care services, that is, youth-only or 
all-ages access sites? 
5. How do HIV-related service providers describe their knowledge, perceptions, and 
experiences of contraceptive service provision for female ALHIV in HIV care? 
 
1.3.2  Overall research aims and specific objectives and  
hypotheses 
This thesis aims to explore the contraceptive behaviours and needs of female ALHIV in urban 
townships in Western Cape, and identify the contextual factors affecting access to and utilisation 
of contraceptive services from both providers’ and female ALHIV clients’ perspectives, as well as 
make recommendations for optimal contraceptive services in HIV programmes. 
 The specific objectives are as follows: 
1. To describe the demographic, psychosocial, inter-personal, socio-cultural, and socio-
economic factors that influence contraceptive behaviours and related outcomes among 
female ALHIV. 
2. To investigate whether hormonal contraceptive-related safety considerations specific to 
HIV-positive populations impact female ALHIV contraceptive use behaviours. 
3. To investigate how the contraceptive practices, preferences, and needs of horizontally 
infected female ALHIV (hALHIV) compare and contrast with peri/postnatally female 
infected ALHIV (pALHIV).  
4. To investigate whether models (access sites) of HIV-related services that serve only youth 
lead to greater contraceptive service uptake and provision, perceptions of higher quality 
18 
 
and greater satisfaction, and lower rates of unmet needs for contraception and 
unintended pregnancy among female ALHIV. 
5. To describe the knowledge, perceptions, and experiences/practices of HIV-related service 
providers, in terms of contraceptive service provision and utilisation for adolescent girls 
in HIV care. 
6. To use research findings related to the objectives mentioned above to make policy and 
programmatic recommendations to provide female ALHIV clients with optimal access to 
contraceptive services.  
 
The specific hypotheses to be tested using quantitative analysis are:  
1. H1: The following factors will be significantly associated with contraceptive behaviours 
and related outcomes among female ALHIV: individual, psychosocial, interpersonal, 
community and societal factors. 
2. H2: Female ALHIV that consider themselves at risk of hormonal contraceptive related side 
effects are less likely to use hormonal contraceptive compared to their peers that do not 
consider themselves to be at risk. 
3. H3: There will be a significant difference between female pALHIV and hALHIV in terms of 
contraceptive practices, preferences, and needs. 
4. H4: Female ALHIV accessing HIV care services at stand-alone youth clinics are more likely 
to have higher contraceptive use, receipt of contraception services, service quality 
perceptions and satisfaction, and lower unmet needs for contraception compared to their 
peers accessing HIV care services at general PHC clinics for all ages. 
 
 
1.4   Conceptual framework 
Two theoretical frameworks guided this study: 1) the Socio-Ecological Model (SEM) and 2) 
Donabedian's Quality framework (Bronfenbrenner., 1979; Donabedian., 1980). The Socio-
Ecological Model (Figure 1.1) is the overarching framework used here because it reflects the 
multiple factors (e.g., individual, relational, community and societal) that must be considered 
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when investigating access to healthcare and in designing interventions to improve access to 
health services. However, the SEM does not account for structure and process variables within 
the healthcare delivery system. To better understand these multidimensional influences on 
access to and use of health services, Donabedian’s Quality framework (Figure 1.2) will be used as 
well. This framework provides a guide for the evaluation of the impact of institutional (here, 
healthcare facility) structures and processes on health outcomes. 
 
The central precept of Bronfenbrenner’s (1977, p. 518) ecological perspective is that human 
development occurs within a multileveled set of nested and changing social contexts and that 
the interactions within and between these contexts influence behaviours. One problem that 
limits the utility Bronfenbrenner’s original ecological conceptual framework is its lack of 
specificity regarding which specific social context attributes should be measured (McLeroy et al., 
1988). Borrowing from Bronfenbrenner’s work on ecological models, McLeroy et al. (1988) 
developed a conceptual framework to guide researchers’ understanding of the factors associated 
with health problems. Like Bronfenbrenner's model, McLeroy et al.'s SEM framework also 
conceptualise human behaviour as influenced by multiple levels of social contexts. 
 
Toska et al. (2017) demonstrated the relevance of the ecological model as a framework in 
accounting for influences on sexual health and behaviour among HIV-positive adolescents and 
young adults (Toska et al., 2017). Using data from published studies related to sexual risk-taking 
among young people living with HIV, Toska et al.’s (2017) variant of Bronfenbrenner’s ecological 
model identifies factors related to sexual risk-taking among HIV-positive adolescents and young 
adults at multiple levels, each of which can be targeted through intervention. The SEM model 
was also used by Hagey et al. (2015) to conceptualise barriers to and enablers of contraception 
use among HIV-positive adolescent girls as a multidimensional construct including individual, 
interpersonal, institutional and societal/public policy factors.  
 
The conceptual model for this research (see Figure 1.3) was developed by drawing upon a 
modified version of the SEMs described by McLeroy et al. (1988), DiClemente et al. (2005), Hagey 
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et al. (2015), Toska et al. (2017) and constructs from Donabedian’s Quality Framework. This 
combination allowed for the creation of an appropriate model for this research.  
 
Within the proposed research framework, access to and the use of contraception among HIV-
positive adolescent girls are considered to be influenced by: 
1. Individual-level factors: Socio-demographic, psychosocial, behavioural factors, HIV-
related factors (e.g. HIV-acquisition route, CD4 lymphocyte count, ART use and adherence 
as well), knowledge, attitudes and perceptions. 
2. Interpersonal-level factors: family, peer, provider and partnership factors. HIV-related 
factors (e.g. serostatus disclosure to sexual partners and serodiscordant partnerships). 
3. Community-level factors consist of societal or cultural norms and stigma. 
4. Structural-level factors: structures (setting) and processes (quality dimensions) of care, 
broader political and socio-economic issues, including laws and policies related to 



















1.5   Structure of the thesis 
 This thesis comprises ten chapters as follows: 
1.  Chapter 1: Introduction. This chapter presents the background information; research 
context; research questions, hypotheses, and objectives; and conceptual framework for 
the study.  
2. Chapter 2: Literature review. This chapter summarises and synthesises the relevant 
literature related to the burden of HIV, contraceptive practices, and the determinants 
of contraceptive access and utilisation.  
3. Chapter 3: Methodology. This chapter covers study setting and population, research 
design, data collection and analytic procedures, as well as data triangulation, and ethical 
considerations. 
4. Chapter 4: Response rates and profile of cross-sectional study participants. This results 
chapter covers the survey response rate, item response rates, and profile of cross-
sectional study participants. 
5. Chapter 5: Factors influencing contraceptive practices among female ALHIV attending 
PHC services. This chapter presents the study’s results on the multilevel factors affecting 
indicators of contraceptive utilisation among female ALHIV. 
6. Chapter 6: The relationship between mode of HIV acquisition, contraceptive service 
uptake and service delivery. This chapter presents the study's results on the 
independent association between mode of HIV acquisition and the measures of access 
to and use of contraceptive services, and service delivery preferences among female 
ALHIV.  
7. Chapter 7: Hormonal contraceptive-related safety considerations and contraceptive use 
among female ALHIV. This chapter presents the study results of the independent 
association between perceived hormonal contraceptive-related safety considerations 




8. Chapter 8: Contraceptive service quality, uptake, and models of HIV care. This chapter 
presents the study results of the independent association between the measures of 
contraceptive uptake, service quality perceptions, satisfaction and clinic model. 
9. Chapter 9: Provider perceptions of contraceptive service delivery in the context of HIV. 
This chapter presents the response rate and the background characteristics of Individual 
In-depth Interview (IDI) respondents (providers), and the findings from the qualitative 
interviews.  
10. Chapter 10: Discussion and conclusions. This chapter presents the key research findings 
and the implications of the research findings for contraception programs for ALHIV in 
urban townships in South Africa, as well as the relative strengths and limitations of the 




















2.   Literature review 
 
Introduction 
This literature review covers topics related to the burden of HIV, contraceptive practices, and the 
determinants of contraceptive access and utilisation among female ALHIV (mainly females), 
including individual, socio-cultural and community, and structural factors. Where no information 
is available on ALHIV, the literature review draws insights from relevant groups, such as the 
general population of adolescents, and the general population of youth and WLHIV (see Appendix 
1 for the literature search strategy).  
 
2.1   Burden of HIV in adolescents  
Adolescents aged 10–19 years constitute approximately one-fifth (18%) of the world’s population 
(United Nations., 2011). According to a UNAIDS report, people aged 10–14 and 15–19 are 
considered younger and older adolescents, respectively (UNAIDS., 2013). In 2012, there were an 
estimated 1.2 billion adolescents globally (United Nations Population Division., 2012), and 
around 600 million (50%) were female (UNFPA., 2014). Worldwide, of the estimated 36.7 million 
PLHIV in 2016, about 2.1 million (6%) were adolescents between the ages of 10 and 19; these 
data included hALHIV and pALHIV (UNAIDS., 2017). Among the 2.1 million ALHIV, 770,000 were 
younger adolescents older (age 10 – 14 years) and 1.3 million older  (age 15 – 19 years) were 
older adolescents (UNAIDS., 2017). Ninety per cent of the estimated 770,000 younger ALHIV lived 
in sub-Saharan Africa (UNAIDS., 2017). The cohort of older ALHIV has expanded with an 
increasing population of pALHIV surviving (UNAIDS., 2017).  
 
About 260,000 older adolescents (between the ages of 15 and 19) were newly infected with HIV 
in 2016 alone (an average of approximately 712 per day); accounting for over 12% of new HIV 
infections globally (UNAIDS., 2017). The absolute number of ALHIV has increased from 2.0 million 
in 2009 to 2.1 million in 2016, an increment of approximately 5% over six years (UNAIDS., 2017). 
The estimated number of younger ALHIV increased by about 300% from 2001 to 2012, from 
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250,000 to 900,000 (UNAIDS., 2013), suggesting that the vast majority of pALHIV children in the 
era of ART are surviving into adolescence. In contrast, there was an estimated 8% decline in the 
number of older ALHIV  (15–19 years)  during the same period (UNAIDS., 2013). Globally, AIDS-
related deaths among adolescents increased by about 200% between 2001 and 2012 (from 
38,000 to 107,000) (UNAIDS., 2013). 
 
The global aggregate data on the adolescent HIV epidemic masks regional and national 
differences (Idele et al., 2014). The UNAIDS global data on HIV and AIDS among adolescents by 
region found that sub-Saharan Africa accounted for the highest-burden of HIV epidemics among 
adolescents; accounting for more than 80% (1.7 million) of the world's 2.1 million ALHIV and 
approximately 75% of new HIV infections globally (UNAIDS., 2017). Within sub-Saharan Africa, 
Eastern and Southern Africa have the highest burden of ALHIV, accounting for about three out of 
four (76.5%) ALHIV in the region (Idele et al., 2014). Table 2.1 shows the estimated number of 
ALHIV by United Nations Children's Fund Regions and gender. As illustrated in Table 2.2, the 
gender-specific prevalence rates of the disease vary by region. In 2012, the percentage of female 
ALHIV ranged from 43% to 58%, with Eastern and Southern Africa having the highest proportions. 
Although the burden of the disease is much lower in high-income countries, the non-inclusion of 
data from these nations probably underestimates the actual global burden of HIV among 
adolescents in 2012. The burden of new HIV infections among older female adolescents was 
calculated by UNICEF region, including high-income countries, in 2016 (UNAIDS., 2017) (Table 
2.2). Table 2.2 shows a pattern similar to that in 2012, with Eastern and Southern Africa having 
the highest percentages of new HIV infections among older female adolescents (UNAIDS., 2017). 
 
The UNAIDS 2017 data reported that 61% of ALHIV are females. Also, females disproportionately 
accounted for 67% of new infections among older ALHIV (UNAIDS., 2017). In Sub-Saharan Africa, 
female adolescents are disproportionately infected with HIV compared to their male 
counterparts. These sex-based differences in HIV infections among ALHIV are linked to horizontal 
HIV infections. In Eastern and Southern Africa, where sex-based differences in HIV infections 
among ALHIV are particularly pronounced, the estimated number of horizontally infected older 
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ALHIV is over two-fold higher in females than males (UNAIDS., 2017). The factors that make 
female adolescents disproportionately vulnerable to HIV in most low- and middle-income 
countries include gender discrimination, gender-based violence, limited knowledge about HIV 
transmission and ability to negotiate condom use, and limited access to sexual and reproductive 
health services (SRH) (Idele et al., 2014; UNAIDS., no date). 
 
In contrast, the HIV infection rate in most countries outside sub-Saharan Africa is considerably 
higher among adolescent males (Idele et al., 2014; UNAIDS., 2017). These gender disparities in 
nearly all countries with low and concentrated HIV epidemics are linked to the heightened risk of 
HIV among key adolescent populations, such as adolescent men having sex with men and 
injection drug use (Idele et al., 2014). The Demographic and Health Survey data from high-burden 
countries such as Ugandan, Swaziland, South Africa and Botswana revealed apparent disparities 
in gender-specific prevalence rates of HIV during adolescence and young adulthood: female 
youth had higher prevalence rates than their male peers (UNFPA., 2014; Idele et al., 2014). For 
instance, data from the 2012 South African national survey of HIV burden suggested that HIV 
prevalence among older female adolescents (5.6%) was up to eight times the rate among their 
male counterparts (Shisana et al., 2014).  
 
In South Africa, data on the burden of HIV among the general adolescent population are lacking. 
Aside from the information on gender-specific HIV prevalence previously described among older 
adolescents, age-disaggregated data from South African-based surveys have typically aggregated 
HIV among the general adolescent population in the age groups 0–14 and 15–24 years, which 
makes it difficult to refine the data on the disease burden among the general adolescent 
population. Data from the South African National Antenatal Sentinel HIV survey, conducted in 
2011, revealed that the HIV prevalence among older female adolescents was approximately 13% 
(Department of Health., 2011). In 2010, the estimated HIV prevalence among pregnant younger 




In summary, the population of older ALHIV is growing as more pALHIV are surviving into 
adulthood. Sub-Saharan Africa bears the highest burden of HIV among adolescents, particularly 
among female adolescents. A better understanding of female adolescents' contraceptive 
behaviours and the distinct needs of hALHIV and pALHIV is needed to reduce the rates of HIV 
transmission and unintended pregnancy. 
 
Table 2.1: Estimated number of adolescents aged 10-19 years living with HIV by United Nations 
Children’s Fund regions, 2012(Source: Idele et al; 2014). 
 
UNICEF Regions Estimated number of 
adolescents living with HIV 
aged 10-19 years in 2012 
Percent of the estimated number 
of females adolescents living 
with HIV (aged 10-19) in 2012 
Sub-Saharan Africa 1,700,000 58 
Eastern and Southern Africa 1,300,000 59 
West and Central Africa 390,000 56 
Middle East and North Africa 17,000 52 
South Asia 130,000 49 
East Asia and the Pacific 110,000 51 
Latin America and the Caribbean 81,000 43 
Central and Eastern Europe and 
the Commonwealth of 
Independent States 
22,000 52 





Table 2.2: Proportion of the estimated new HIV infections among adolescents (aged 15-19) that 
are among girls, by UNICEF region, 2016 (Source: UNAIDS 2017 estimates) 
 
UNICEF regions Percent of the estimated number of new 
HIV infections among adolescents (aged 15-
19) that are among girls 
Eastern and Southern Africa 78 
West and Central Africa 69 
Middle East and North Africa 49 
South Asia 47 
Eastern Europe and Central Asia 70 
Western Europe 42 
Latin America and the Caribbean 41 
East Asia and the Pacific 38 




2.2   Contraceptive practices of ALHIV 
A sizeable body of literature has explored the contraceptive practices of ALHIV, mainly pALHIV 
adolescents and the general ALHIV population; however, little research has examined the 
contraceptive practices of ALHIV by HIV acquisition route. Thus, a rigorous insight into the 
contraceptive behaviours and needs of the distinct groups of ALHIV - pALHIV and hALHIV- is 
essential given the evidence base on their differing sexual behaviours. Also, understanding the 
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context of contraceptive behaviours and needs of female ALHIV, in general, is essential to address 
their needs. Contraceptive practices, including method use consistency, method mix, dual 
contraception, contraceptive prevalence rates and the unmet need for contraception of female 
ALHIV, are reviewed in this section.  
 
Studies conducted in the United States have generally found that over half of ALHIV in care had 
engaged in sex without a condom after learning of their HIV serostatus (Murphy et al., 2001; 
Koenig et al., 2010). Data from the Reaching for Excellence in Adolescent Care and Health 
(REACH) cohort study of adolescents in HIV care (conducted at 15 clinical sites in the United 
States), which included repeat measures of the sexual behaviours of 323 sexually-active ALHIV 
(aged 13–18) across six study visits, showed that approximately 43% of the study sample 
consistently reported sex without a condom at last heterosexual intercourse (Murphy et al., 
2001). One small study in the United Kingdom included pregnant ALHIV aged 13–19 and 
demonstrated the same trend (Elgalib et al., 2011). The study, which attempted to provide 
demographic information by the HIV-acquisition route failed to disaggregate data on 
contraceptive use. The same United Kingdom's study reported conception in over 25% of 
pregnant ALHIV within a year of having given birth (Elgalib et al., 2011). The percentage of 
inconsistent condom use is substantial, as low as 27% among ALHIV in the United States who 
used condoms as their sole contraceptive method and 61% among ALHIV in Zambia (Belzer et al., 
2001; Ndongmo et al., 2017). Perhaps the most probable explanation for the inconsistent 
condom use among adolescents in different countries has been related to the perception of 
sexual pleasure loss associated with sex without a condom (Ahmed et al., 1990; Buck et al., 2005; 
Versteeg et al., 2008; Lucea et al., 2013). In Spain, 75% of ALHIV were not on contraception 
despite not wanting to conceive (Echenique et al., 2017). In Zambia, McCarraher and colleagues 
(2018) found that approximately three-fifths of female ALHIV used contraception at last sex; and 
a vast majority of female ALHIV who used contraception at last sex used male condoms. 
Additionally, studies have still found relatively inconsistent use of effective contraceptive 
methods among female ALHIV across developed and developing countries; the estimated rates 
have been between 44% and 56% (Belzer et al., 2001; Birungi et al., 2008). One such study 
31 
 
reported substantial differences in the use of effective forms of contraception between hALHIV 
female adolescents and their HIV-negative counterparts (56% vs 44%, p < 0.0001) (Belzer et al., 
2001). Overall, the little research that examined contraceptive use consistency among female 
ALHIV failed to disaggregate data by HIV-acquisition route, and the only review on the 
reproductive health behaviours, including contraceptive behaviours, of ALHIV and young adult 
WLHIV, did not identify any studies that disaggregated findings by HIV-acquisition route (Carter 
et al., 2013), a fact probably explained by the lack of such data.   
 
Studies comparing female ALHIV to their HIV-negative counterparts in terms of the contraceptive 
methods have shown unequivocal results about the frequency, or consistency, of condom use 
and contraceptive pills. However, the findings on other contraceptive methods were mixed. 
Studies have consistently found condom use to be higher and more consistent in ALHIV compared 
to their HIV-negative counterparts (Studentvart et al., 2001; Belzer et al., 2001; Obare et al., 
2010b; Robinson et al., 2014; Sadeghi et al., 2015). Studies have also generally found that the use 
of pill contraception alone was lower among female ALHIV compared to their HIV-negative 
counterparts (Belzer et al., 2001; Robinson et al., 2014; Sadeghi et al., 2015). Wayenze et al. 
(2013) revealed that the lower intake of pills among both HIV-positive adult and adolescent 
women was influenced by concerns regarding additional pill burden (i.e. antiretroviral therapy 
[ART]) (Wayenze et al., 2013). Based on self-reported contraception use rates gathered at study 
visits, Belzer et al.'s (2001) longitudinal study in the United States suggested that female ALHIV 
(when compared to their HIV-negative peers) used injectable contraceptives (21% vs 15%, 
respectively) and either implants or tubal ligation (2% vs 0%) at higher rates (Belzer et al., 2001). 
In contrast, data from the only South Africa-specific study to describe the contraceptive 
behaviours of female ALHIV (including HIV-negative female adolescents) in urban townships in 
Western Cape, South Africa demonstrated lower rates of injectable contraceptive use in ALHIV 
(compared to HIV-negative peers) (3% vs 8%, respectively) (Sadeghi et al., 2015). 
 
In terms of sexual behaviour, ALHIV do not constitute a homogeneous group. Koenig et al. (2010) 
reported significantly higher current sexual activity for hALHIV than for pALHIV (Koenig et al., 
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2010), suggesting that these two groups differ in their contraceptive practices and needs. In a 
single-centre, cross-sectional study of 33 female ALHIV (ages 15–25 years; 46% hALHIV) in the 
United States, the use of some method of modern contraception was higher among female 
hALHIV (93% vs 83%, respectively) (Atrio et al., 2013). While the use of condom and injectable 
contraceptives alone (precisely DMPA) was greater among female pALHIV, female hALHIV were 
more likely to use long-term reversible contraceptives (either implants or intrauterine hormonal 
devices). Additionally, contraceptive pills were used infrequently by both groups, and the 
proportion of females using contraceptive pills was similar among hALHIV and pALHIV (Atrio et 
al., 2013). Atrio et al.'s study was the only study that compared the contraceptive practices of 
ALHIV by HIV-acquisition route and also suggested that hALHIV have a significantly higher 
number of lifetime pregnancies than pALHIV. 
 
For WLHIV, dual method protection with both a male or female condom and another effective 
contraceptive rather than dual protection with condom alone is the standard and most effective 
contraceptive option because it minimizes HIV transmission risk and is more effective in 
preventing pregnancy (Kancheva Landolt et al., 2011). For sexually active female ALHIV, in 
particular, the need to prevent HIV transmission risks such as HIV-reinfection, transmission to 
uninfected partners and perinatal transmission, as well as, consequences associated with 
unintended adolescent pregnancy is an important motivation for dual-method use (Kancheva 
Landolt et al., 2011). There is limited evidence on dual method contraception among female 
ALHIV (Belzer et al., 2001; Oliveras & Makumbi., 2013; Robinson et al., 2014). Research from U.S 
based studies suggest relatively low uptake of dual method contraception among female ALHIV, 
and findings on dual method contraception use by HIV-status were mixed (Belzer et al., 2001; 
Robinson et al., 2014). One longitudinal U.S study demonstrated that female ALHIV (compared 
to HIV-negative female adolescents) were slightly more likely to use dual method contraception 
(male condom and injectable or oral contraceptives) during their study visits (16% vs 12%)(Belzer 
et al., 2001). The second and more recent U.S based study, carried out using a cross-sectional 
design, found that female ALHIV (aged 13-21) reported lower use of dual method contraception 
than their HIV-negative counterparts (OR 0.58, 95% CI 0.17-2.03); however, the study failed to 
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explain the reasons for the differential uptake of contraception by HIV status. Also, based on the 
proportion female ALHIV and HIV-negative female adolescents who relied on condoms alone 
(75% vs 29%, P=0.005), it can be argued that less than a quarter of female ALHIV in care use dual 
method contraception (Robinson et al., 2014). In Uganda, 69% of female ALHIV reported dual 
contraception use (no detailed information on condom subtypes, male or female type) (Oliveras 
& Makumbi., 2013); however, this finding from the quantitative study in Uganda should be 
interpreted with caution, because dual contraception use was evaluated among 13 female ALHIV 
and may not be generalizable to the general population of ALHIV in the country. Furthermore, 
based on the relatively low rates of condom use or any contraceptive method use noted in the 
earlier mentioned Ugandan studies of ALHIV (Birungi et al., 2008; Birungi et al., 2009a; Olivera & 
Makumbi., 2013), the reported rate of dual method contraception (69%) might be by chance. The 
relatively low rate of dual method contraception in female ALHIV, perhaps suggesting a need for 
better understanding of the contraceptive use behaviours among this sub-group of adolescents. 
 
Available research findings on contraceptive prevalence rate and unmet contraception needs 
among female ALHIV further suggest the need for strategies for holistically addressing 
contraception for ALHIV. The CPRs have been documented to be as low as 35% among female 
ALHIV in Uganda (Oliveras & Makumbi., 2013), and as high as 66% among their counterparts in 
Kenya (Obare et al., 2010a). The findings from the Ugandan study should be interpreted with 
caution, given the tiny sample of ALHIV in the study. The same  Ugandan study also suggest that 
female ALHIV encounter more difficulties in accessing and using contraceptive services in HIV 
care, compared with older WLHIV. Female ALHIV have a lower CPR (ranging from 23% to 34%) 
than WLHIV in the older five-year age groups (ranging from 39% to 43%), except for women who 
were 40 or more years of age (Obare et al., 2010a). 
 
Moreover, the unmet need for contraception (24%) is also higher in female ALHIV than their 
counterparts aged 20 years and above (14% to 20%) (Olivera & Makumbi., 2013). Aside from the 
paucity of data specific to the contraceptive behaviour of ALHIV, the typical descriptive study 
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design of existing studies limits information on the contextual factors that influence 
contraceptive uptake and the unmet needs for contraception among female ALHIV 
 
In summary, the data above suggest a clear unmet needs for contraception among ALHIV, and 
further understanding of contraceptive behaviours and needs of ALHIV is needed to increase 
contraceptive uptake and utilisation.  Strengthening health systems for ALHIV contraception data 
by mode of HIV acquisition –pALHIV and hALHIV – may shed further insight into the distinct 
contraceptive behaviours and needs pALHIV and hALHIV and contribute to the development of 
differentiated models of contraceptive care for the above separate groups of ALHIV.  
 
 
2.3   Determinants of contraceptive access and utilisation 
The wide range of determinants of youth access to and utilisation of sexual and reproductive 
health (SRH) services, including contraception, have been categorised into three overall 
categories: individual, socio-cultural and structural factors (Simon et al., 2015).  
 
 
2.3.1  Individual-level factors 
This section describes the influence of demographic, behavioural and HIV-related factors on 
contraceptive access and utilisation, including the influence of HIV-related safety concerns 
regarding hormonal contraception.  
 
Demographic, behavioural and HIV-related factors 
Research on the determinants of contraceptive service access and utilisation has addressed 
demographic and psychosocial factors such as age, education, parity, self-efficacy, substance use 
and knowledge about contraception. Only one previous study indicated the influence of age on 
the utilisation of contraception among female ALHIV. This study, conducted in Uganda, included 
pALHIV and found that a lower proportion of younger female pALHIV (15–17 years) used 
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contraception than their older peers (18–19 years) (55% vs 37%, respectively). The same 
Ugandan study reported higher sexual activities among older adolescents, which is a possible 
explanation for the age difference in contraceptive utilisation between younger and older pALHIV 
(Birungi et al., 2009b). Studies have even documented increased contraceptive use with 
increased age among the general adolescent and young adult population (Katz et al., 2000; 
Nsanya et al., 2019). In comparing adolescents who used condoms, Van Horne et al. (2009), found 
no significant differences in condom by age. Also, a mixed-methods study conducted in Kenya 
demonstrated no significant variation in contraceptive use by age among adolescents (Kinaro et 
al., 2015). 
   
Multiple studies revealed that providers imposed restrictions on adolescent and young adults' 
access to contraception based on parity status (Chilinda et al., 2014; Schwandt et al., 2017). In 
addition, one study based on the recent DHS and multiple indicator surveys conducted in Low-
and middle-income countries explored the link between parity, marital status and contraceptive 
uptake, and found that contraceptive prevalence was particularly low among married female 
adolescents without children compared to their counterparts who were not married or married 
with children (de Vargas et al., 2019). Atrio et al. (2013) found that compared to female pALHIV, 
female hALHIV were more likely to have had one live birth (93% vs 17%, respectively) (Atrio et 
al., 2013). In addition, Atrio et al. (2013) revealed non-significant higher rates of DMPA or condom 
use among female pALHIV compared to their hALHIV counterparts, who had non-significant 
higher rates of long-acting reversible contraceptives or DMPA; suggesting that parity may not be 
associated with contraceptive use among ALHIV (Atrio et al., 2013). Atrio et al. (2013) concluded 
that the non-significant differences in contraceptive use were because of the small sample size 
(Atrio et al., 2013). 
 
Several studies have described the relationship between contraceptive use and the education 
level of adolescents and young adults, but the findings have been mixed. An analysis of 
representative data on first-year high school students in two Swedish cities found that 
contraceptive use is higher among participants attending 'academic' (college preparatory study 
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programmes) than their peers attending 'practical' (vocational-educational) study programmes 
(Haggstrom-Nordin et al., 2002). In a mixed-gender of sample of adolescents aged 15–19 years 
in Ethiopia, Feleke et al. (2013) found that those with formal education (i.e. at least primary 
education) were more likely to utilise family planning services than their peers with no formal 
education; this association was statistically significant for secondary education and above in the 
multivariate analysis (AOR = 9; 95% CI: 1.45–54.14) (Feleke et al., 2013). Similar findings were 
demonstrated among adolescents and young adults in different contexts, including Uganda, 
Tanzania, Spain and Britain (Wellings et al., 2001; Martin et al., 2005; Nsanya et al., 2019). Obare 
et al. (2012) demonstrated a positive dose-gradient relationship between postpartum 
contraceptive use and educational attainment among female ALHIV; however, it found no 
statistically significant association on multivariate analysis (Obare et al., 2012). Similarly, several 
researchers have found that condom or contraceptive use is not significantly associated with 
adolescent and young adult education level (Adih & Alexander., 1999; Meekers & Klein., 2002; 
Van Horne et al., 2009), nor has currently being in or out of school been found to be associated 
with condom utilisation (Van Horne et al., 2009; Meekers & Klein., 2002). 
 
Self-efficacy, defined as one's beliefs about his or her abilities to execute a particular task or 
behaviour in a specific situation (Bandural., 1986), can also influence contraceptive behaviour. 
One United States-based, multi-site sample of HIV-positive youth demonstrated that self-efficacy 
for safer sex directly predicted condom use (Outlaw et al., 2010). Several studies, conducted 
within and outside sub-Saharan Africa, have found that self-efficacy was positively associated 
with contraceptive use among the general population of adolescent and young adult women 
(Levinson., 1982; Richard & van der Pligt., 1991; Heinrich., 1993; Crosby et al., 2001; Miller et al., 
2001; Meekers & Klein., 2002; Longmore et al., 2003; Wang et al., 2004; Nsanya et al., 2019). 
Richard and van der Pligt (1991) and Levinson (1982) also found self-efficacy to be the most 
significant positive determinant of condom and contraceptive use among adolescents and 




Results from studies examining the link between substance abuse and contraceptive use among 
adolescents have been mixed, and the links are yet to be explored among HIV-positive youth. 
Studies from Taiwan and the United States have found no association between substance use 
and contraceptive use and consistency (Wang et al., 2004; Hacker et al., 2000). However, other 
studies have shown that substance use may impact contraceptive utilisation in adolescence and 
young adulthood. For example, Khadr et al. (2016) revealed a strong positive association between 
substance use (defined as frequent binge drinking at least once a week or recent drug use within 
the past four weeks) and non-condom use (i.e. unprotected sex) at the first sexual exposure to 
one or more new partners; however, emergency contraceptive use was also strongly associated 
with substance use. Similar non-condom use was observed in other studies on substance use 
(alcohol or marijuana) among female adolescents and young adults (Hingson et al., 1990; 
Cooper., 2002; Hensel et al., 2011), which may be due to the reduced inhibitions and impaired 
judgement resulting from substance use (Khadr et al., 2016). 
Fertility desire has been demonstrated in several studies to impact contraceptive use, but the 
findings of the studies consistently point to a negative association between fertility desire and 
contraceptive use (De Silva., 1991; Roy et al., 2003; Schoemaker et al., 2005). One rare large 
example draws on health service data among women with unknown HIV status in Kenya. The 
Kenyan study, a cross-sectional evaluation, found LARC use varied significantly with fertility 
desire; while the odds of LARC use decreased by 70% among women wanting another child within 
two years compared to those who wanted no more children, the odds of LARC use decreased by 
22% among women who desired another child after two years compared to those who wanted 
no more children (Omo-Adjei et al., 2019). Also, a secondary analysis of DHS data of Kenya has 
found not having the desire for more children was positively associated with contraceptive use 
(Anand et al., 2009). While studies show that a considerable proportion of ALHIV expressed a 
desire for pregnancy at one point in the future (Ezeanolue et al., 2006; Finger et al., 2012; 
Finocchario-Kessler et al., 2012), there remains a dearth of information on the impact of 




Access to and use of contraception among ALHIV may also be influenced by several individual 
HIV-related characteristics, such as mode of infection, time since HIV diagnosis, adherence to 
ART, time on ART treatment and CD4 count (Toska et al., 2017). A few studies reported 
relationships between condom use/safer sex and the above-mentioned individual HIV-specific 
factors, but information on the links between these factors and use of contraceptives other than 
condoms was not provided (Kaggwa & Hindin., 2012; Mhalu et al., 2013; Toska et al., 2015). 
Kaggwa and Hindin (2012) and Toska et al. (2015) explored the determinants of safe sex among 
ALHIV and HIV-positive young adults. They concluded that time since HIV diagnosis, adherence 
to ART and time on ART were not significantly associated with condom use among ALHIV and 
young adults (Kaggwa & Hindin., 2012; Toska et al., 2015). Findings on the relationship between 
mode of infection (i.e. HIV acquisition route) and condom use have been inconsistent (Kaggwa & 
Hindin., 2012; Mhalu et al., 2013; Toska et al., 2015). For example, Toska et al. (2015) analysed 
multicentre data from Eastern Cape, South Africa and found that a vertical mode of infection was 
associated with an increased rate of unsafe sex. However, the mode of infection was not 
associated with condom use among HIV-positive youth in Uganda (Kaggwa & Hindin., 2012). No 
previous studies have examined the relationship between CD4 lymphocyte count and 
contraceptive behaviour among ALHIV and HIV-positive young adults. 
 
Adolescents’ knowledge, attitudes and perceptions towards contraception may also impact their 
access to and use of contraception. The results of the data from the Demographic and Health 
Surveys conducted in developing nations, mainly Asia, Latin America, and northern and southern 
Africa, found a weak association between adolescents' knowledge about modern contraceptives 
and the utilisation thereof (Curtis et al., 1996). This inverse association was also reported by 
Williamson et al. (2009). However, some studies showed that knowledge about contraception is 
positively related to its use among adolescent population (Wang et al., 2004; Kinaro et al. 2015; 
Nsanya et al., 2019). Qualitative interviews conducted among adolescents in South Africa 
highlighted that a lack of knowledge about contraception was one of the barriers to obtaining 
contraceptives (Wood & Jewkes., 2006). Very few studies evaluated the contraceptive knowledge 
of HIV-positive adolescents, and none tested the association between contraceptive knowledge 
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and use. Furthermore, findings on contraceptive knowledge and use among ALHIV suggested an 
inverse relationship between contraceptive knowledge and use: one mixed-method Kenyan 
study showed a mismatch between relatively high overall knowledge about contraceptive 
methods and actual use among ALHIV (Birungi et al., 2008). Similarly, a recent study in Botswana 
found that the use of contraception was low among female ALHIV, despite their relatively high 
knowledge about contraception (Adeyemi et al., 2014). This variation has been attributed to 
misconceptions about the side effects of contraceptives, infrequent sex, the perception of low 
pregnancy risk and a lack of information about how to use a given contraceptive method (Birungi 
et al., 2008; Adeyemi et al., 2014; McCarraher et al., 2018). The literature on perceptions towards 
contraception is described further in the following subsection. 
 
Perceptions of contraception and safety concerns 
Concerns about safety are fundamental to contraceptive uptake and are reported to be one of 
the reasons for contraceptive discontinuation among adolescents (Bellizzi et al., 2019., Cohen et 
al., 2019). In addition to experiencing the same physical and emotional side effects of hormonal 
contraception as HIV-negative women, such as menstrual disorders, weight gain, depression and 
anxiety (Laher et al., 2009; Imbuki et al., 2010; Laher et al., 2010, Todd et al., 2011; Bengtson et 
al.,  2013), WLHIV may also have safety concerns that stem from epidemiological and 
pharmacokinetic/biological evidence, such as HIV progression, HIV transmissibility (i.e. female-
to-male HIV transmission) and specific drug-drug interactions between hormonal contraceptives 
and ART (Curtis et al., 2009). 
 
Published systematic reviews synthesised the findings of studies that assessed the direct or 
indirect effects of hormonal contraception on HIV progression or sexual transmission of HIV. In 
2013, Phillips et al. published a systematic review of 11 observational studies and one 
randomized controlled trial (RCT) to assess the association between hormonal contraceptive 
methods and measures of HIV disease progression, including progression to AIDS, death, or ART 
initiation, or composite outcome consisting progression to AIDS, death, or ART initiation among 
postpartum WLHIV in Zambia. The observational studies were designed to assess the association 
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between the measures of HIV disease progression and hormonal contraceptive methods 
including injectable contraception, oral contraceptive pills (OCPs), or levonorgestrel (LNG) IUDs. 
None of the observational studies found a significant association between the use of any 
hormonal contraceptive method and measures of HIV disease progression. The RCT assessed the 
relationship between the measures of HIV disease progression and injectable DMPA, combined 
OCPs and copper IUD (Phillips et al., 2013). The results of the RCT show that DMPA was associated 
with statistically significant elevated risks of HIV disease progression to AIDS or ART initiation 
compared to copper IUD in both intention to treat (ITT) and actual use analysis. Oral 
contraceptives were also statistically significantly associated with HIV disease progression to AIDS 
or ART initiation compared to copper IUD use in only the ITT analysis. Both injectable DMPA and 
OCPs were significantly associated with elevated risks of the composite measure of HIV disease 
progression in both the ITT and actual use analysis (Stringer et al., 2007). Phillips et al. (2016) 
updated the earlier systematic review with one prospective cohort data from 2269 WLHIV in 
seven Eastern and Southern African countries (Heffron et al., 2013). The multi-country study of 
2269 WLHIV found that injectable contraception was associated with significantly reduced risks 
of a composite measure of HIV disease progression, defined as ART initiation, progression to AIDS 
or nontraumatic death, while OCPs were not associated with any statistically significant 
difference. Like most epidemiological or laboratory studies within whether hormonal 
contraception alters WLHIV’s elevated risks of HIV disease progression or female-to-male HIV 
transmission, the study by Heffron et al. (2013) failed to disaggregate data by the sub-types of 
injectable contraception or OCPs.  
A published systematic review of the effects of hormonal contraception on sexual HIV 
transmission from WLHIV to un-infected male partners demonstrated mixed results, among 12 
studies, some indicated increased sexual HIV transmission risk with the use hormonal 
contraception, while others identified no difference by hormonal contraception status (Polis et 
al., 2013). Of the 12 studies included in the systemic review, only one direct study examined the 
association between OCPs or injectable contraception and HIV transmission showed a higher risk 
with injectable contraception. Of the remaining 11 indirect studies, three specifically addressed 
the association between measures of female-to-male HIV transmission and a particular type or 
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dose of hormonal contraception, including injectable DMPA, high- and low-dose OCPs, or 
Norplant (Mostad et al., 1997; Graham et al., 2010; Morrison et al., 2010). Results of the Mostad’s 
study demonstrates a greatest increased risk of measures of female-to-male HIV transmission 
with high-dose OCPs use, followed by low-dose OCPs use, then injectable DMPA; however, 
injectable DMPA was not associated with significantly increased risk of measures of female-to-
male HIV transmission (Mostad et al., 1997). In Morrison et al’s multi-country study, no 
association was found between either OCPs or injectable DMPA use and measures of female-to-
male HIV transmission (Morrison et al., 2010). Phillips et al. (2016) also updated the prior 
systematic review by Polis et al. (2013) and included three new studies (Lutalo et al., 2013; Low 
et al., 2014; Day et al., 2014). While the two studies that assessed the association between OCPs 
or injectable DMPA use and HIV transmission measures found a greater increased risk of 
measures of female-to-male HIV transmission with OCPs use than injectable DMPA use compared 
to non-use of hormonal contraceptives (Lutalo et al., 2013; Low et al. 2014), the remaining one 
new study assessing HIV transmission risk among injectable DMPA users and non- hormonal 
contraception users indicated an increased risk of measures of female-to-male HIV transmission 
(Day et al., 2014). In general, the three new studies found no evidence of significantly increased 
risks of measures of female-to-male HIV transmission with any hormonal contraceptive method 
evaluated (Lutalo et al., 2013; Low et al., 2014; Day et al., 2014). Although the findings of many 
studies conflicted, much of the evidence suggests that hormonal contraception may be used by 
WLHIV without the risk of HIV progression (Phillips et al., 2013; Polis et al., 2013; Phillips et al., 
2016). However, there is no conclusive evidence on the impact of hormonal contraception on 
HIV transmission from WLHIV to uninfected male sexual partners (Polis et al., 2013; Phillips et al., 
2016).  
Several epidemiological and pharmacokinetic studies also provided data on the effects of drug 
interactions between ART and hormonal contraception. Two large prospective cohort studies in 
East and Southern Africa found that pregnancy rates were slightly higher among OCP users taking 
efavirenz-based ART compared with OCP users taking nevirapine-based ART (Patel et al., 2015, 
Pyra et al., 2015). One small clinical trial in Australia, Netherland and Thailand found higher 
ovulation rates among concurrent users of desogestrel/ethinyl estradiol (DSG/EE) containing COC 
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and efavirenz-based ART than the concurrent users of DSG/EE containing COC and nevirapine-
based ART (Landolt., 2013), and another larger clinical trial in South Africa and Uganda found that 
pregnancy and ovulation rates did not significantly differ between DSG/EE users taking 
nevirapine-based ART and those yet to initiate ART treatment (Nanda et al., 2013). One small 
pharmacokinetic study in the US also point to decreased bioavailability of levonorgestrel in 
healthy HIV–seronegative women after exposure to levonorgestrel-only pills and efavirenz-based 
ART (Carten et al., 2012). The literature shows that data regarding the impact of ART on injectable 
contraception are exclusively on injectable DMPA. While pharmacokinetic studies did not 
demonstrate a clinically significant effect of efavirenz-, nelfinavir-, and nevirapine-based ART on 
the contraceptive effectiveness of injectable DMPA (Cohn et al., 2007; Nanda et al., 2008Watts 
et al., 2008), the largest cohort study of WLHIV using injectable DMPA found that pregnancy rates 
were higher among users of efavirenz-based ART and those yet to initiate ART than those on 
nevirapine-based ART (Patel et al., 2015). Two studies, including one pharmacokinetic study and 
one epidemiological study, found that the contraceptive effectiveness of levonorgestrel implants 
is lower among efavirenz-based ART users compared to nevirapine-based ART users (Perry et al., 
2014; Scarci et al., 2016). One pharmacokinetic study found that, while efavirenz-based ART 
reduced the bioavailability of etonogestrel implants, lopinavir-based ART increased the 
bioavailability of etonogestrel implants (Vieira et al., 2014). In contrast to the inconsistent effects 
of ART regimens on hormonal contraceptive effectiveness, a recent systematic review by Nanda 
et al. (2017) shows that nine studies, evaluating data on whether the efficacy of ART regimens is 
influenced by hormonal contraception, consistently found that ART efficacy was not significantly 
affected by any method of hormonal contraception. 
 
In 2012, the World Health Organization (WHO) held a technical consultation to review the 
systematic reviews prepared by Phillips et al. (2013) and Polis et al. (2013) and to determine 
whether WLHIV were eligible for hormonal contraception (Phillips et al., 2013; Polis et al., 2013; 
WHO., 2012). The WHO then recommended that WLHIV may use any hormonal contraception 
method without restriction (Medical Eligibility Criteria (MEC) Category 1) (WHO., 2012). This 
guidance laid the groundwork for South Africa's current recommendations on the eligibility 
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criteria for contraceptive use for those with HIV (Department of Health., 2012a; Department of 
Health., 2012b). These recommendations, which were provided in the 2012 South Africa's 
National Contraceptive Guidelines, affirmed the WHO recommendations (Department of Health., 
2012a; Department of Health., 2012b). Though WLHIV are eligible for any method of hormonal 
contraception, in fact evidence suggests HIV-specific safety concerns among WLHIV using 
hormonal contraception. Very little information is available on hormonal contraception and HIV-
specific safety concerns. Multi-country qualitative research by Todd et al. (2011) on contraceptive 
use by WLHIV found that concerns about the efficacy of ART due to interactions with hormonal 
contraception influenced some women's contraceptive choices (Todd et al., 2011). The concerns 
may have led to an increase in unintended pregnancies among WLHIV. The qualitative data from 
a mixed-methods study of WLHIV aged 15–43 years in Kenya showed that WLHIV were concerned 
about ART drug interactions with hormonal contraception. However, this information was not 
delineated by age group (Akelo et al., 2015). Thus, it is unknown whether the perceived risk of 
drug interactions between hormonal contraception and ART impacted the use and delivery of 
hormonal contraceptives among female ALHIV. Imbuki et al. (2010), using both focus groups and 
one-on-one interviews, interviewed WLHIV of reproductive age (18–45 years) living in western 
Kenya and found that they had a common perception that hormonal contraception would 
exacerbate their HIV due to amenorrhoea, because of the myth that the virus is lost through 
menses (Imbuki et al., 2010). Cross-country, qualitative interviews of WLHIV aged 15–45 years in 
Brazil, Kenya and South Africa also uncovered the myth that hormonal contraception-induced 
amenorrhoea affects HIV progression; this misconception was most common among the 
youngest interviewees (Todd et al., 2011). This same multi-country study also highlighted that 
WLHIV's contraceptive choices were guided by concerns about the efficacy of ART due to 
interactions with hormonal contraception (Todd et al., 2011). The concerns could have led to an 
increase in unintended pregnancies among WLHIV. Although Akelo et al. (2015) did not directly 
report WLHIV (aged 15–43 years) HIV-specific concerns regarding hormonal contraception, they 
found that the women were deterred from using hormonal contraception due to their partners' 
concerns; however, this information was not provided by age group (Akelo et al., 2015). Thus, it 
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is not known whether, for female adolescents, the perceived risk of drug interactions between 
hormonal contraception and ART impacts their use of hormonal contraception. 
 
 
2.3.2  Socio-cultural factors 
This section describes the influence of dyad, peer, family and provider factors on contraceptive 
use. It also reviews norms and stigma around adolescent/youth contraception. 
 
Dyad, peer and family factors 
HIV-specific dyad factors that may influence sexuality and contraception include a serodiscordant 
relationship (defined as one in which one partner is HIV-positive, and the other is not), knowledge 
of a partner’s HIV status and disclosure of HIV status to a partner (Toska et al., 2017). Findings on 
the association between disclosing HIV status to partners and contraceptive use among 
adolescents have been inconsistent. One U.S. study within HIV care and treatment services 
conducted in the United States found that disclosure of HIV status to male partners by female 
adolescents and young adult women was significantly associated with increased condom use 
(Sturdevant et al., 2001). In contrast, a U.S. study of ALHIV of both genders showed that 
disclosure of HIV status to partners was associated with unprotected sex (D’ Angelo et al., 2001). 
Furthermore, Toska et al. (2015) found no significant association between the disclosure of HIV-
positive status to partners and unprotected sex among adolescents in HIV care in Eastern Cape, 
South Africa (Toska et al., 2015). However, no studies have examined how serodiscordant 
relationships shape the contraceptive behaviours of ALHIV. One study addressed this issue 
among serodiscordant couples in which the women were HIV-positive and found that 
contraceptive use increased significantly during follow-up, that the use of contraceptive methods 
other than condoms was associated with the non-use of condoms, and that the most frequently 
used method of contraception was the injectable method (Hefron et al., 2010). Only two studies 
examined the relationship between knowing a partner’s HIV status and contraceptive use among 
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ALHIV; these studies showed no relationship between knowing a partner’s HIV status and 
contraceptive use (Mhalu et al., 2013; Toska et al., 2015).  
 
Contraceptive use among adolescents can also be influenced by non-HIV-specific dyad factors 
such as multiple sexual partnerships, having a child with a partner, living with a partner, marital 
status, partner age, relationship quality, partner support and child sexual abuse. Studies in Kenya 
and Zimbabwe attributed higher unintended pregnancies among ALHIV and HIV-positive youth 
to living with a partner, having biological children with a partner and gender-based violence 
(Birungi et al., 2011; Nhamo et al., 2013). Marital status can also shape contraceptive use among 
female adolescents. Using data from Demographic and Health Surveys (DHS) gathered between 
1986 and 2006 in 40 developing countries, Blanc et al. (2009) concluded that contraceptive use 
was higher among unmarried adolescents than married adolescents (Blanc et al., 2009). Using 
data from the 2008 Ghana DHS, Marrone et al. (2014) restricted analysis to 162 sexually active 
adolescents and showed that the likelihood of contraceptive use was higher among unmarried 
female adolescents than for their married counterparts (Marrone et al., 2014). Data from the 
same 2008 Ghana DHS and 2010/2011 Zimbabwe DHS also revealed that the likelihood of 
contraceptive use was higher for female adolescents who were married or had ever been married 
(married, separated, divorced, or widowed) than for unmarried female adolescents (Ngome & 
Odimegwu, 2014; Nyarko, 2015). Similar findings were noted in a mixed-method study of 
adolescents in Kenya (Kinaro et al., 2015). Though studies reporting the association between 
marital status and contraceptive behaviour among HIV-positive young people are lacking, HIV-
positive youth who lived with partners were more likely to have unintended pregnancy (Nhamo 
et al., 2013).  
 
Qualitative studies of female adolescents also highlighted that partner disapproval of 
contraceptive use was a key barrier to the use of contraception among female adolescents 
(Wood & Jewkes., 2006; Brown & Guthrie., 2010). For example, Wood and Jewkes (2006) 
reported that male partners used manipulative tactics such as using physical violence and tearing 
clinic cards to stop female adolescents from using contraception to prove their fertility or have a 
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baby (Wood & Jewkes., 2006). On the other hand, several studies also found positive associations 
between female adolescents’ contraceptive use and dyad attributes such as sexual partner 
communication, longer relationship duration, partner support for contraception and romantic 
relationships (Kenyon et al., 2009; Feleke et al. 2013; Kinaro et al., 2015; Nsanya et al., 2019). In 
South Africa, there is mixed evidence on the effects of past experiences of child sexual abuse on 
an indicator of contraceptive non-use. While forced sexual initiation has been found to increase 
the risk for teenage pregnancy in township areas of Cape Town (Jewkes et al., 2001), there is 
contrasting evidence that unintended pregnancies were not associated with first sexual initiation 
or coerced sex among a cohort of female adolescents in Eastern Cape, South Africa (Christofides 
et al., 2014). The mismatch between the research questions and secondary data may be a 
probable explanation for the lack of association between child sexual abuse and unintended 
pregnancy in the latter study. Koenig et al. (2010) conducted a study among pALHIV and hALHIV 
in the US and found a positive association between experience of sexual abuse and sex without 
a condom.  
Peers can also influence adolescents’ access to and the use of contraception, but the findings  
have been mixed. Studies have suggested that peer influence can have a profound positive 
impact on contraceptive use among female adolescents (Adedimeji et al., 2008; Fallon et al., 
2010; Ali et al., 2011; Feleke et al., 2013). For example, Fallon (2010) observed that female friends 
assumed important supporting roles, such as confidante, motivator and advisor, with respect to 
the use of contraception (Fallon., 2010). In some instances, these crucial supporting roles 
included physically accompanying hesitant peers to SRH services to negotiate contraceptive 
provision with service-providers (Fallon., 2010). Ali et al.’s (2011) nationally representative 
longitudinal study of adolescents in the United States reported that peer social networks played 
an important role in contraceptive use: a 10% rise in the proportion of peers (classmates) who 
used contraceptive was associated with a 5% increase in individual adolescent contraceptive use 
(Ali et al., 2011). In contrast, peer pressure to conceive, peers’ experiences of failed contraception 
and peers’ perspectives on side effects were acknowledged by female adolescents as reasons for 
the non-use of contraceptives (Wood & Jewkes, 2006; Chernick et al., 2015). Meekers et al. found 
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that peer support was not associated with high levels of condom use among youth in urban cities 
in Cameroon (Meeker et al., 2002). 
 
Several studies have found that adolescents' contraceptive behaviours can be strongly influenced 
by family process variables, such as parent-child communication, parent-child connectedness, 
parental support and family intactness. Parents, especially mothers, may have a significant 
influence on their female adolescents' contraceptive decision making by either promoting or 
hindering contraceptive use (Commendador., 2010; Rubin et al., 2016). Wang et al. (2015) 
evaluated the impact of a brief parent-adolescent sexual communication intervention among 
2,564 Bahamas adolescents aged between 13 and 17 years, and they reported that the 
intervention led to higher condom use skills and self-efficacy among adolescents. In a recent 
meta-analysis of 52 studies from three decades of research, Wildman et al. (2016) concluded that 
the association between parent-adolescent communication about sex and adolescent safe sex 
behaviour, including contraception and condom use, was positive and significant; however; this 
association was mediated by both adolescent and parental sex/gender, with a stronger 
association for adolescent females than for males and for mothers than for fathers. Wildman 
surmised that the association between parent-adolescent communication and adolescents' safe 
sex was positive across more than 50 studies, regardless of study design and communication 
topic (Wildman et al., 2016). 
 
The availability of parental support is also a protective factor for adolescents’ contraceptive use 
(Meekers et al., 2002; Wilson et al., 2011; Kinaro et al., 2015). For example, the results of a 
quantitative analysis of a mixed-method study in Kenya revealed that contraceptive use 
significantly increased from 6.2% among adolescents whose parents disapproved of 
contraception to 17.7% among their peers who had parental approval for contraception (Kinaro 
et al., 2015). This positive association between parental approval and adolescents' contraceptive 
use is supported by findings from the qualitative component of the same mixed-method study 
(Kinaro et al., 2015). Likewise, in-depth interviews with key informants highlight the lack of 
parental support as one of the barriers to adolescent mothers' post-partum contraceptive use 
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(Wilson et al., 2011). Studies also mention that parent-child connectedness and family intactness 
strongly influence adolescents' contraceptive use, including the consistency of such usage 
(Jaccard et al.,1996; Hogan et al., 1985). A more recent study conducted in Nicaragua found 
discussing contraception with family members or a health care provider to be positively 
associated with adolescents’ contraceptive use (Parker et al., 2019). 
 
Family members other than parents can play an influential role in adolescents' contraceptive use. 
Wood and Jewkes observed, for example, that in Limpopo, South Africa, family members, 
specifically grandmothers, encouraged female teenagers to have a baby (Wood & Jewkes., 2006). 
In a qualitative study in Rangpur district, Bangladesh, Shahabuddin et al. (2016) found that aside 
from husbands, mothers-in-law and sisters-in-law played an essential role in restricting married 
adolescent girls from using contraception for the sake of having a baby in the family, son in 
particular (Shahabuddin et al., 2016). 
 
Providers’ knowledge, attitudes, and practices  
Providers' knowledge, attitudes, beliefs and practices strongly impact the utilisation, provision 
and quality of SRH services (Jonas et al., 2017). Within clinical practice, it has been argued that 
providers' attitudes, beliefs and practices related to contraception, including the safety thereof, 
are significant influences on access to contraception for adolescents (Morgan et al., 2019; 
Onukwugha et al., 2019). This may be particularly true for ALHIV, because providers may 
discriminate against them and equate contraceptive care-seeking with sexual promiscuity (Fair & 
Beck., 2018; Hagey et al., 2015). Recent Systemic reviews have extensively documented the 
attitudes and practices of healthcare providers in contraceptive service-provision for female 
adolescents, without disaggregating the data by HIV status (Chilinda et al., 2014; Onukwugha et 
al., 2019). However, only few studies documented providers' attitudes towards contraception for 
ALHIV patients (FHI 360., 2013; Wayenze et al., 2013; Hagey et al., 2015; McCarraher et al., 2018). 
Due to the dearth of literature on the subject, this section presents the literature on providers’ 
attitudes towards contraceptive service-provision and care-seeking among female ALHIV and 




Contraceptive utilisation, including method choice, continuation and switching among female 
HIV-positive populations, may be strongly influenced by providers' attitudes, practices, 
knowledge and skills (Blanchard et al., 2014; Imbuiki et al., 2010). Research has shown varied 
results regarding provider attitudes and practices, including those of programme managers and 
policy-makers, towards contraception for WLHIV. Using nationally representative cross-sectional 
data from settings where HIV is endemic in South Africa and Zimbabwe, Blanchard et al. (2014) 
found that the majority of clinicians offered hormonal contraception; however, less than half 
considered hormonal contraception appropriate for WLHIV and most relied on condoms for 
contraceptive protection (Blanchard et al., 2014). In Argentina, Gogna et al. (2009) performed 
qualitative interviews of health professionals (including HIV service-providers and programme 
coordinators). They found that the majority recommended only condom use, while a few 
encouraged other contraceptive options (Gogna et al., 2009). However, an earlier qualitative 
study conducted in Cape Town, South Africa before the introduction of contraceptive service-
provision guidelines for HIV-positive populations found that providers placed higher reliance on 
injectable contraceptives than other contraceptive methods for WLHIV (Harries et al., 2007). 
Additionally, the results suggested that the lack of specific guidelines and training around 
contraception for HIV-positive populations were determining factors (Harries et al., 2007). In 
addition to its lack of data specific to female ALHHIV, the findings from the South Africa study 
may not be generalisable to the present era of service-provision guidelines on contraception for 
HIV-positive populations. 
 
Influenced by perceived safety concerns, such as the interaction between hormonal 
contraceptives and ART, and the increased risk of adverse effects with hormonal contraceptives 
or intrauterine devices, providers may have negative attitudes towards providing contraception 
other than condoms to WLHIV and ALHIV (Hagey et al., 2015; Imbuki et al., 2010; Gogna et al., 
2009). Thus, they may offer limited contraceptive options to their HIV-positive patients (Laher et 
al., 2009; Gogna et al., 2009). As demonstrated by Hagey et al. (2015) in a qualitative study of 
contraceptive service barriers and facilitators in Kenya, providers’ concerns about the adverse 
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effects of hormonal contraceptives for female ALHIV influenced their provision of non-hormonal 
contraception methods, such as abstinence or condoms (Hagey et al., 2015). Moreover, providers 
resisted offering hormonal contraception methods to female ALHIV because they believed it 
would deter condom use (Hagey et al., 2015). This is consistent with the findings of another study 
from Argentina that explored clients’ and providers’ perspectives on reproductive health needs 
of PLHIV (Gogna et al., 2009). Furthermore, stigmatised attitudes around sexual promiscuity for 
ALHIV seeking contraception exist among providers (FHI., 360). 
 
The few studies that reported providers’ behaviours around contraceptive service-provision for 
ALHIV have not disaggregated their findings by ALHIV gender (FHI., 360; Wayenze et al., 2013., 
Parker et al., 2013), therefore, how providers perceive contraception service for female ALHIV  is 
unclear. According to the gender-mixed studies of ALHIV, providers have less favourable attitudes 
towards ALHIV seeking contraceptive services, as indicated by mandated parental 
involvement/permission (i.e. providers expect that adolescents speak with their parents prior to 
seeking contraceptive services), the provision of incomplete information or non-provision of 
information about contraception, and feeling uncomfortable providing contraception to 
adolescents because they perceive them as children and too young to participate in sexual 
activity) (FHI 360., 2013; Wayenze et al., 2013., Parker et al., 2013).  
 
In Zambia, a mixed-method study on HIV care and the SRH needs of ALHIV found that providers 
(e.g. doctors, nurses, adherence counsellors and pharmacy technologists) wanted to offer 
contraception for ALHIV and to be trained in how to do so (FHI., 360). A more recent Zambian 
mixed-method study mentioned above suggests that providers' poor foundational knowledge of 
counselling about non-condom methods of contraception for ALHIV influences providers' 
reliance on condoms for ALHIV contraception (McCarraher et al., 2018). Banda et al. (2004) also 
found that many service-providers in Zambia, despite the existence of clear policy guidelines 
favouring dual contraception for WLHIV, withheld information about dual contraception from 
WLHIV. Banda et al. (2004) also reported that, for WLHIV, providers’ lack of technical knowledge 
or up-to-date information on appropriate contraceptive methods was a barrier to their access to 
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contraception (Banda et al., 2004); this was also true for providers in some other African 
countries and Argentina (Harries et al., 2007; Gogna et al., 2009; Adamchak et al., 2010). Finally, 
Orner et al. (2008) found that WLHIV described ‘bad answers from clinic staff’ as a barrier to 
accessing contraception (Orner et al., 2008).  
 
Social norms and stigma 
Social disapproval of contraceptive use also limits adolescent women's use of contraception. For 
instance, concern over being recognized in the family planning clinic by family members was 
illustrated as a common factor that deterred adolescents from using contraception (Ritcher & 
Mlambo, 2005). In Kenya, a recent multi-centre qualitative study of service providers highlighted 
female ALHIV fear of being seen in the contraceptive clinics by peers, parents and providers as a 
significant barrier to accessing contraceptive services (Hagey et al., 2015). Specifically, providers 
reported that female ALHIV were afraid of being viewed as sexually promiscuous by community 
members (peers, parents and providers) when seeking contraceptive services (Hagey et al., 
2015). One qualitative study conducted among  Swazi adolescents aged 16 -18 years revealed 
that cultural norms that reinforce the minority status of women, childbearing to deepen a 
relationship, and preference for boys to use contraceptives were strong influences that 
motivated adolescent women for not using contraception (Ziyane et al., 2006). One recent 
qualitative study of U.S Latino adolescents has documented cultural factors, including family 
dishonour and sexual taboo, as barriers to contraception access (Barral et al., 2020). 
 
 
2.3.3  Structural-level factors 
Structural factors include laws, policies and access considerations, including service quality, 
parental education, unemployment and economic factors such as access to grants, poverty and 
food security (Toska et al., 2017; Simon et al., 2015). A recent systematic review of the literature 
on the sexual risk behaviours of ALHIV and HIV-positive young adults in sub-Saharan Africa 
highlighted ART access/use, ART care type and group counselling/support group as HIV-specific 
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factors that influence SRH behaviours at the structural level (Toska et al., 2017). This thesis 
focuses on the following structural factors: service quality dimensions/youth friendliness of 
service, access site/youth-friendly services (YFS) model, socio-economic factors (including 
proxies such as parental education and household income) and HIV-specific factors. 
 
Contraception service quality, friendliness and satisfaction  
Quality of care or service is a concept that includes multiple dimensions (Donobedian., 1980; 
Bruce., 1990; Sofaer & Firminger., 2005; Becker et al., 2007, WHO., 2006 & 2009), and it provides 
the basis for defining adolescent-friendly sexual and reproductive health services (SRH) (WHO., 
2006; WHO., 2009). Service quality has also been linked to contraception provision, utilisation 
and continuation (Ramarao et al., 2003; Do & Koenig 2007; Dehlendorf et al., 2016). Patient 
satisfaction, which is usually evaluated through a range of service quality dimensions, has also 
been linked to the uptake and continued utilisation of contraception services (Bruce., 1990; 
Williams et al., 2000). Additionally, service quality has consistently been found to impact patient 
satisfaction with contraception (Rosenberg et al., 1998; Agha et al., 2009; Hutchinson et al., 
2011;).  
 
Studies of contraception service quality have typically included the general populations of 
adolescent or adult women (without disaggregating data by HIV status), and very few have 
attempted to provide information on HIV-positive populations (FHI., 360; Wayenze et al., 2013). 
For this reason, this thesis reviews those studies that provided information on the quality of 
contraception service provided to adolescent women or HIV-positive female populations. The 
various dimensions of contraception service quality include accessibility, communication and 
information, provider-patient interactions, the efficiency and effective organisation of care, 
technical competence, structure and facilities, method choice and patient-centredness (Becker 
et al., 2007). 
 
Method choice refers to whether patients are offered the full contraceptive method mix and can 
choose those that are most suitable (Bruce., 1990; Becker et al., 2007). Studies have suggested 
53 
 
that the contraceptive options commonly offered to WLHIV in South Africa and Argentina are 
injectable methods and condoms, respectively (Harries et al., 2007; Gogna et al., 2009). In 
Zambia, a recent mixed-method study found that the contraceptive options for ALHIV are limited 
to condoms (McCarraher et al., 2018). As previously discussed, providers generally advise WLHIV 
against hormonal contraception despite its safety (Imbuiki et al., 2010; Todd et al., 2011). 
Furthermore, a review of studies in low- and middle-income countries showed that contraceptive 
options for adolescents are limited to condoms due to provider misconceptions about methods 
other than condoms (Chandra-Mouli et al., 2014). Similarly, in a qualitative study of adolescent 
contraceptive use in South Africa, Wood and Jewkes (2006) found that provider refusal to allow 
adolescents to switch from injectable methods to another method, even when there are medical 
indications, is a common reason for discontinuation of contraception (Wood & Jewkes., 2006). 
One study using simulated patients specifically assessed contraceptive service quality from the 
perspective of youth and found that the choice of contraceptive methods had the highest service 
quality rating score among the dimensions of quality assessed. On the ‘choice of contraceptive 
methods’ index (ranging from 0 to 9), the average reported quality score being 5.3 (SD = 2.5). 
These results suggest a poor- to moderate-level of contraceptive service quality in this dimension 
(Nalwadda et al., 2011).  
 
Provider–patient interactions refer to providers' verbal and nonverbal behaviours towards 
patients. This dimension of service quality reflects friendliness, empathy, courtesy and respect, 
including provider respect for patient privacy (Becker et al., 2007). Across studies, adolescents 
and young adults have consistently emphasised privacy, confidentiality and respectful treatment 
by providers as the most important aspects of SRH service quality (Senderowitz., 1999; Erulkar et 
al., 2005; Ambresin et al., 2013). Studies have found that provider unfriendliness, rudeness, 
judgement, discrimination and problems with confidentiality are significant barriers to access to 
contraception among adolescents (Donovan et al., 1997; Mmari & Magnani., 2003 Wood & 
Jewkes., 2006; Baxter et al., 2011; Chilinda et al., 2014). In one study that evaluated contraceptive 
service quality disparities by patient age, female adolescents reported a lower quality of 
provider-patient interactions compared to young adult women (Darney et al., 2016). In South 
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Africa, a mixed-method simulated patient study of 22-year-old male and female patients found 
friendly and respectful treatment by providers as the more positive experiences of service quality 
(Geary et al., 2015). On the other hand, the simulated patients identified provider disrespect for 
patient privacy and negative opinions on contraceptive-seeking as reasons for less positive 
contraceptive experiences (Geary et al., 2015). 
 
The dimension of communication and information includes making available to patients 
sufficient and understandable information about the contraindications, advantages, side effects 
and effectiveness of different contraceptives, and how to use these method(s), during 
consultations for contraceptive services (Bruce et al., 1990; Becker et al., 2007). Little is known 
about the quality of contraceptive information given to adolescents and HIV-positive populations 
and its possible impact on contraceptive behaviours. In a qualitative study in Sri Lanka, 
adolescents felt that providers did not provide sufficient information on contraception 
(Agampodi et al., 2008). The South African simulated patient study described above revealed that 
youth reported receiving insufficient information as a less positive experience (Geary et al., 
2015). Another South African study by Wood and Jewkes (2006) evaluated the perspectives of 
adolescent patients on contraceptive service quality as part of a broader qualitative exploration 
of barriers to adolescent contraceptive use and found that service-providers offered female 
adolescents low-quality care in the dimension of provider-patient interaction (Wood & Jewkes., 
2006). A facet of the dimension of communication and information is consultation time, and 
insufficient consultation time was reported as a reason for adolescents being provided with 
inadequate contraceptive information (French., 2002). This is consistent with findings from in-
depth interviews with a mixed-gender sample of ALHIV in Uganda (Wayenze et al., 2013). In 
countries without age restrictions on contraceptive service-provision, the refusal of healthcare 
providers to offer contraceptive information to unmarried adolescents has been noted as an 





Accessibility, one of the central dimensions of adolescent-friendly sexual and reproductive health 
services (SRH), can be considered a multidimensional construct consisting of economic, 
administrative, cognitive, psychosocial, and geographic or physical access factors (Bertrand et al., 
1995), and denotes the extent to which patients are able to obtain available health services 
(WHO., 2009). Marital status, parity and/or age have been reported as barriers to contraceptive 
utilisation among adolescents and youth in several studies (Speizer et al., 2000; Mmari & 
Magnani., 2003; Baxter et al., 2011; Chilinda et al., 2014; Sidze et al., 2014, Schwandt et al., 2017). 
Mmari and Magnani (2003) found that unnecessary medical procedures (in addition to age and 
marital status) deter adolescents from seeking SRH (including contraception) across non-YFS and 
YFS clinics in Zambia (Mmari & Magnani., 2003). Distance, inconvenient opening hours and delay 
in securing clinic appointments have also been reported as obstacles to contraceptive care-
seeking among youth (Baxter et al., 2011; Donovan., 1997). As demonstrated in a quasi-
experimental study of a YFS approach in London, extended clinic operating hours and 'no 
appointment required' enabled youth use of contraceptive services (Baraister et al., 2002). 
 
The efficiency and effective organisation of care can include waiting time to be seen, follow-up, 
seeing the same provider at each consultation, and billing and referral (Becker et al., 2007). 
However, there is limited research on the impact of this dimension of service quality on youth 
contraceptive use. Providers of ALHIV care and treatment services in Zambia described long 
queues, understaffing and heavy workload as obstacles to high-quality SRH counselling with 
ALHIV (Hodgson et al., 2012). While waiting to be seen is one of the indicators of contraceptive 
service quality that adolescents in Central London considered to be important (Nwokolo et al., 
2002), feeling dissatisfied with clinic waiting time during contraceptive clinic visit was frequently 
reported among female adolescents and adult women in the District of Columbia (Sonenstein et 
al., 1997). Short follow-up visits (i.e. less than one month from the initial appointment) have been 
found to increase contraceptive use among adolescents (Brindis et al., 1994).  
 
Technical competence refers to a provider's competence and skills in providing safe and effective 
care and adhering to clinical guidelines or protocols (Bruce., 1990; Becker et al., 2007). An aspect 
56 
 
of this dimension, technical skills of provider, has been investigated in a few studies regarding 
adolescents: Burrack et al. (2000) and Geary et al. (2014) found that some providers lacked the 
skills to provide SRH services to adolescents. A mixed-method study in Zambia reported low 
technical competence of providers in modern contraceptive methods other than condom, and 
this probably explains ALHIV reliance on condoms (McCarraher et al., 2018). The limited evidence 
suggests that although clinical practice guidelines regarding contraception for HIV-positive 
populations are available, adherence to these guidelines are somewhat poor (Adamchalk et al., 
2010; Banda et al., 2004). Providers' misconceptions about the safety of hormonal contraception 
in WLHIV also suggest poor technical competence (Laher et al., 2009; Gogna et al., 2009; Imbuki 
et al., 2010; Newmann et al., 2013; Hagey et al., 2015). Providers’ lack of updated information 
about the interactions between hormonal contraceptives and ART has also been negatively 
associated with the provision of hormonal contraception to HIV-positive women (Banda et al.,  
2004; Harries et al., 2007; Gogna et al., 2009).  
 
Youth-and adolescent-friendly service-provision models 
As previously described, a wide range of individual, socio-cultural and structural barriers prevent 
youth from using SRH services (including contraception). YFS, also known as adolescent-friendly 
services, are generally considered important in addressing these barriers and are a strategy for 
increasing youth access to and uptake of SRH services (Simon et al., 2015; Zuurmond et al., 2012). 
YFS can be delivered through non-health settings (e.g. schools, prisons and workplaces); non-
static health settings (including mobile clinics, satellite clinics and community-based outreach 
services); completely separate static settings; separate spaces co-located in facilities; and 
integrated/mainstreamed into existing health facilities, drug shops and pharmacies) (Simon et 
al., 2015; Zuurmond et al., 2012). In the context of YFS models, completely separate static 
settings for adolescents and youth have been categorised as youth centres, which are 
‘multipurpose centres that offer SRH services, educational, recreational and/or vocational 
activities’ (Denno et al., 2015; Simon et al., 2015;) or standalone ‘health centres/clinics dedicated 
to serving adolescents and youth with a range of clinical services, including SRH services’ (Simon 




Many developing countries have emphasised youth centres as an important YFS model for 
promoting youth uptake of SRH services (Senderowitz., 1997; Denno et al., 2015); however, there 
has been limited comparative research examining the effectiveness of youth centres in increasing 
the uptake SRH services. The findings are mixed. The literature evaluating youth centres has 
exclusively focused on the general adolescent population, and data on more vulnerable 
adolescent subpopulations, including those living with HIV, are lacking. A Togolese longitudinal 
study evaluated the impact of a youth centre in Lome and demonstrated a significant increase in 
contraceptive uptake and use consistency among adolescents who visited the centre during the 
follow-up period (Speizer et al., 2004). In South Africa, Erulkar et al. (2001) evaluated public and 
private sector youth centres and found that condom use and dual protection were higher among 
female (but not male) adolescents and young adults who had visited youth centres, compared to 
their peers who had not visited (Erulkar et al., 2001). Additionally, some aspects of provider-
patient interactions have been noted as problematic among patients attending South African 
youth centres. For example, about 14% of patients reported embarrassing treatment by 
providers; the proportion reporting judgemental treatment was particularly high at about one-
third of patients (Erulkar et al., 2001). In addition to negative, judgemental or moralistic attitudes 
on the part of providers, inconvenient hours of operation and lack of contraceptives were also 
highlighted in an evaluation of youth centres in Kenya (Erulkar & Mensch., 1997). 
 
Townsend et al. (1987) utilised a quasi-experimental design to evaluate the efficacy of two YFS 
strategies (Integrated Youth Centres and Community-Based Programmes) and found that, 
compared to youth residing in control communities, contraceptive uptake was higher for youth 
in Integrated Youth Centre communities (44% vs 2%). A striking percentage of 98% uptake was 
reported for Community-Based Programme communities (Townsend et al., 1987). In Rwanda, 
while youth centres significantly and positively impacted HIV test uptake, they had no positive 
effect on contraceptive use (Neukom & Ashford., 2003; Plautz & Meekers., 2003). A recent 
systematic review of peer-reviewed and grey literature on youth centres and the uptake of SRH 
services, including contraception, concluded that youth centres were not likely to be an effective 
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strategy for promoting the utilisation of SRH services (Zuurmond et al., 2012). Distance issues 
concerning cost of transport, privacy and confidentiality issues, attendance by youth for whom 
recreation was the key reason to use the centres, and gender issues, including predominantly 
male users, were identified in the systematic review as the obstacles to the utilisation of youth 
centres for SRH services (Zuurmond et al., 2012). 
 
Other studies have also evaluated the mainstream YFS model (i.e. ‘all (or most) health providers 
and support staff in the health facility offer high-quality services to youth as part of their routine 
service-delivery’), with mixed findings. In a study of the quality of sexual and reproductive health 
services for adolescents in the context of HIV care, Mathew and colleagues demonstrated that 
simulated adolescent patients seeking HIV testing services at public sector primary healthcare 
clinics across Cape Town, South Africa, experienced negative attitudes from healthcare providers 
in both youth-friendly and general clinics. Additionally, this study, which included a mixed-gender 
sample of HIV-infected and uninfected adolescents (no information on perception of service 
quality by HIV status) showed that confidentiality breaches were prevalent in both clinics 
(Mathews et al., 2009). Compared to health facilities not providing YFS, Geary et al. (2015) found 
that non-standalone health facilities offering YFS did not deliver higher-quality contraceptive 
services (Geary et al., 2015).  
 
Research with adolescents has suggested that they prefer dedicated youth clinics and standalone 
clinics (Smith., 2001; Baraister et al., 2002; Agampodi et al., 2008). Although the effectiveness of 
standalone youth clinics is yet to be rigorously evaluated, the clinics are considered an effective 
strategy to increase youth access to SRH services (Baraister et al., 2002). Using data from a 
nationally representative survey of school-linked health centres (SLHC), defined as ‘adolescent 
health care facilities located beyond school property but with formal or informal relationships to 
one or more schools in the community’, in the United States, Fothergill and Ballard (1998) argued 
that the SLHC are a promising model with great potential for promoting adolescent access to 




Other structural-level factors  
As noted above, HIV-related structural factors include ART treatment/access, ART care type (e.g. 
hospitals vs clinics) and support group (Toska et al., 2017). The literature on the influence of HIV-
related structural factors on the contraceptive behaviour of HIV-positive adolescents/youth is 
sparse and has focused on condom use/unprotected sex (Toska et al., 2015; Kaggwa & Hindin., 
2013; Mhalu et al., 2013). A cross-sectional study of HIV-positive adolescents and young adults 
in Tanzania found that ART treatment was not associated with condom use (Toska et al., 2015). 
A similar result was found in a case study in Uganda (Mhalu et al., 2013). Likewise, ART access 
site (receiving care at hospitals vs primary clinics) was not associated with unprotected sex 
(Kaggwa & Hindin., 2012). Only one study aimed to evaluate the impact of access to a support 
group on the safe sex behaviour of HIV-positive adolescents and youth (Snyder et al., 2014). This 
study, which is a longitudinal one and involves a mixed-gender sample (95% females), found that 
support group sessions increased condom use significantly by 12% (Snyder et al., 2014).  
 
Socio-economic status (SES) can also influence adolescents’ access to and use of contraception. 
In Hogan et al.’s study in Chicago, the US, higher levels of social class, defined as living in 
neighbourhoods with a high SES, were associated with significantly greater use of contraception 
among unmarried Black adolescents, as opposed to lower levels of social class, defined as residing 
in ghetto neighbourhoods (Hogan et al., 1985). When parental education and income are applied 
as a proxy for SES, Miller et al. (2001) found that adolescents’ contraceptive use increased with 
parental education attainment and income (Miller et al., 2001). Parental education alone was 
also positively associated with adolescents’ contraceptive use (Feleke et al., 2013). The greater 
tendency of individuals from a higher SES to overcome economic and geographic/physical access 
barriers to contraception is a possible explanation for the positive association between SES and 
contraceptive use (Prince & Hawkins., 2007). By contrast, a Finnish study of 16-year-old females 
found that oral contraceptive use was greater among adolescent females from less-affluent 
backgrounds than among those from more affluent backgrounds (Kosunen et al., 1995). 
Gebreselassie et al. (2013) analysed multiple DHS data collected in Ethiopia during 2000-2011 and found 
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wealth status was not a significant predictor of contraceptive use among adolescents and young 
women.  
 
Policies and regulations can dissuade ALHIV from using contraceptives. For example, in a recent 
Zambian multi-site study conducted in clinics providing HIV treatment and care to ALHIV, service 
providers emphasized that they would require authorization to provide contraception to ALHIV 
(FHI., 360). One qualitative study among providers highlighted that parental consent (for 
adolescents) for receiving contraceptive services was a barrier to contraceptive access for female 
ALHIV (Hagey et al., 2015).  
 
In summary, there remained limited data on the determinants of contraceptive behaviours 
among ALHIV. Future research on determinants of access to and use of contraception among 
ALHIV is crucial and should include a multilevel analysis.  
 
 
2.4   Summary of findings and knowledge gaps  
The literature indicates substantial gaps in contraception research around ALHIV. The findings 
suggest a need to understand the distinctive needs of female ALHIV regarding contraception at 
multiple levels to promote female ALHIV optimal access to and utilisation of contraception, 
impacting their well-being. Most studies of issues regarding contraception in ALHIV focused on 
pALHIV or general female ALHIV populations, with little or no specific information on hALHIV who 
may have contraceptive needs different from those of their pALHIV peers. The majority of these 
studies involved mixed genders, with little details on gender-specific profiles related to 
contraceptive behaviours. Also, the existing literature is biased towards North America and East 
Africa. Information is lacking on other aspects of contraceptive needs among ALHIV in general, 
including consistency of use of contraceptives other than condoms.  
 
Given the inadequate exploration of ALHIV contraceptive service preferences, particularly 
method choice, access site, provider profiles and clinician continuity, the types of services that 
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work best for this group remain unknown. The few studies that have attempted to explore 
contraceptive service preferences among female ALHIV have been limited to the sources of 
contraceptive information or method choice. Establishing the impact of the route of HIV 
acquisition on female ALHIV's contraceptive behaviours and needs has also proved challenging 
because of the lack of data for comparability in existing studies. The fact that pALHIV and hALHIV 
vary in terms of sexual activity (Carter et al., 2013) suggests that further research is needed to 
isolate the contraceptive behaviours and needs of both groups. Knowing the similarities and 
differences in the ALHIV's contraceptive behaviours and needs by HIV-mode of acquisition girls 
would help further identify the peculiar contraceptive needs of each sub-group of ALHIV. 
  
A socio-ecological intervention approach rather than an individual-level one has been proposed 
as a useful strategy to increase the accessibility to and acceptability of sexual and reproductive 
health services for adolescents (Diclemente et al., 2005). Adolescents make behavioural 
decisions, including contraceptive-related behaviours, within a broad social context. No studies 
on the application of a socio-ecological model to evaluate the enabling or constraining factors for 
contraceptive use from female ALHIV perspectives have been identified in the literature. Only 
one published used a socio-ecological model to explore provider perspectives on the 
determinants of contraceptive use among female ALHIV. The design of the study, a structured 
qualitative interview of service-delivery providers, may have limited the diversity of its findings. 
Given that studies demonstrate that contraceptive use among WLHIV aged 18 years and above 
is influenced by HIV-specific factors, generalising or transfering findings from studies of 
adolescents with unknown HIV status is challenging.  
 
Research has begun to show the role of hormonal contraceptive-related safety considerations 
among WLHIV; such concerns include the risk of HIV disease progression and reduction in the 
efficacy of either ART or hormonal contraceptives. Inconsistencies in the existing literature may 
exacerbate these concerns. Indeed, no studies have explicitly evaluated the perspectives of 
clients and providers on the HIV-specific safety issues regarding hormonal contraception. With 
the potential for misinterpretation and concerns over the effect of hormonal contraception on 
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HIV disease and ART efficacy, more research is needed. In particular, exploring both how 
providers interpret such guidelines for female ALHIV and how female ALHIV themselves perceive 
hormonal contraceptive-related safety issues, may provide further insight into the constraints on 
contraceptive service provision and utilisation.    
 
South Africa's National Contraception Policy and Service Delivery Guidelines also recognise the 
importance of quality in contraceptive care services. As noted in the literature, only one study 
explored young people's experiences in the quality of contraceptive services in youth-friendly 
clinics compared with clinics that did not provide youth-friendly services in the context of South 
Africa (Mathews et al., 2009). However, this study included only HIV-negative participants (males 
and females) aged 22 years to evaluate clinic services. Adolescents living with HIV were not a part 
of the evaluation process, so the findings from the study may not be generalisable to ALHIV. 
Furthermore, the study assessed only one dimension of contraceptive service quality, which was 
the method chosen, and a conceptual framework did not guide the research. Moreover, the 
design of the study – simulated client approach- might have limited the opportunity to capture 
more abundant data. Given the current interest of the Western Cape Provincial Department of 
Health/City Directorate of Health in improving young persons’ access to integrated contraceptive 
and HIV care services, evidence is urgently needed on the impact of the standalone youth clinic 













3.   Methodology 
 
Introduction 
This chapter outlines the research design and methodology used to address the hypotheses and 
research questions of this dissertation. Firstly, the study setting and population are described, 
followed by the justification for the mixed-method study design. The next section describes 
exploratory meetings with stakeholders, data collection and analytic procedures for both the 




3.1   Research Design 
 
3.1.1  Study setting and population 
Western Cape, one of nine South African provinces, is located in the southwestern part of the 
country and the southernmost part of the African continent. It is the fourth-largest province in 
South Africa in terms of population and land area, as well as in population density (Statistics 
South Africa, 2012). The province has six districts: one metropolitan district (city of Cape 
Town/Cape Metro) and five rural districts. In 2011, Western Cape had an estimated population 
of 5.8 million (Statistics South Africa, 2012). Western Cape was selected for this case study 
because it was the only province in South Africa to have integrated family planning services into 
all public-sector HIV care clinics. Moreover, three of South Africa’s largest townships in Western 
Cape, Khayelitsha, Gugulethu and Mitchell’s Plain, have HIV prevalence rates above both the 
overall provincial and national rates. 
 
The city of Cape Town, which contains the setting for the study, is the capital of Western Cape 
Province and the largest city in the province. Within Cape Town, three sub-districts were 
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purposively selected – 1) Khayelitsha and Eastern; 2) Mitchells Plain and Southern; and 3) 
Klipfontein and Tygerberg – as three of South Africa’s largest townships (Khayelitsha, Gugulethu 
and Mitchells Plain) are located in these sub-districts (Statistics South Africa, 2011). As noted 
above, the HIV prevalence rate in each of these three sub-districts (ranging from 18.4 to 34.3%) 
is estimated to be higher than the overall provincial rate (17.8%) (Shisana et al., 2005; Shisana et 
al., 2014).   
 
 Data from South Africa's most recent national HIV seroprevalence survey suggested that HIV 
prevalence was highest in the townships (Shisana et al., 2014), indicating that this context would 
offer the best option in terms of the recruitment of a sufficiently diverse sample of study 
participants, including healthcare providers and the hard-to-reach population of ALHIV. Fifteen 
high-volume general PHC clinics providing HIV services (ranked by the number of HIV-positive 
clients) were selected for this research because it was not feasible to recruit participants from all 
28 facilities. These health facilities were selected from the three aforementioned townships to 
maximise participant recruitment and diversity in terms of geographic location. Also, two stand-
alone youth clinics providing HIV services were also purposively chosen for comparison with the 
general PHC clinics providing HIV services to answer the fourth research question (see chapter 
one subsection 1.3.1). These stand-alone youth clinics, located in Khayelitsha, were the only 
stand-alone youth clinics providing HIV services in Western Cape at the time of the study.  All 17 
study clinics are in townships within these three sub-districts, and these clinics serve over 90% of 
PLHIV in these sub-districts. The townships included in the study are Khayelitsha, Mitchells Plain, 
Gugulethu, Nyanga, Phillipi, Crossroads and Heldeveld. These are black townships, except for 
Mitchells Plain and Heldeveld, which are coloured townships.  
 
 
3.1.2  Mixed methods study design  
A concurrent mixed methods design (i.e., simultaneous implementation of quantitative and 
qualitative methods during a single data collection phase, with one method serving as a primary 
method guiding the study and the other playing a supporting role was utilised. The study design 
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is preferred when one needs to use different modes (qualitative and quantitative) of inquiry, with 
unequal weighting/priority, to gain perspectives from two different groups/levels.  In this study, 
predominantly quantitative data were obtained from the survey of female ALHIV, and an 
additional qualitative component was also obtained from interviews with health care providers. 
 
In-depth interviewing of adolescents by the candidate, who is of different gender, native 
language and cultural background and considerably older than the research adolescent 
participants, could pose a threat to the reliability, validity and analysis of the data on sensitive 
phenomena under evaluation in this research. Against this potential effect of an interviewer's 
social position (i.e., aforementioned characteristics) and the necessity for the candidate to play 
a substantial role in the qualitative data collection and analysis, interviews with a broad range of 
health care providers were considered as the most appropriate data source for the qualitative 
research methodology. Furthermore, integrating findings from two different data collection 
approaches for different population groups – female ALHIV and health care providers- would 
likely provide more insight from different levels, and consequently yields a better understanding 
of the research phenomena than either population group alone. 
 
The main components of this study are as follows: 
1. Exit interviews with female ALHIV in HIV care and treatment (quantitative method)  
2. In-depth interviews (IDIs) with key informants – system- and service-levels health care 
providers (qualitative method) 
 
 
3.1.3  Exploratory meetings with stakeholders  
During the development phase of the research proposal, the candidate communicated with 
various key stakeholders in both local and provincial department of health in Western Cape, 
including health facility managers, HIV operational managers, health care providers, and relevant 
system-level managers and directors involved in HIV and SRH services. The staff of non-
governmental organisations involved in HIV/SRH services in Western Cape was also engaged. The 
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stakeholder engagement process provided the primary researcher with the opportunity to gain 
broader access to HIV/AIDS burden estimates in both the study settings and clinics as well as 
obtain contextual information about contraception issues among ALHIV and ultimately improved 
the research approach. Meetings were also held with the Community Advisory Boards or health 




3.2   Quantitative cross-sectional survey 
The quantitative research objectives and their respective dependent/outcome variables are 
displayed in Table 3.1. This section provides an overview of the quantitative methodology 
component of the research and outlines the rationale for the application of the 
procedures/techniques used. First, sample size determination and sampling technique are 
described. Next, the section details the survey tool, data collection planning, fieldwork 
procedures and data collection. Last, the section concludes with a description of the data 
management and statistical analysis methods employed.   
 
Table 3.1: Quantitative research objectives and outcome variables 
Research objectives Dependent/outcome variables 
1. To describe the demographic, 
psychosocial, inter-personal, socio-
cultural, and socio-economic factors 
that influence modern contraceptive 
uptake and unmet needs for 
contraception among female ALHIV. 
2. To investigate whether hormonal 
contraceptive-related safety 
considerations specific to HIV-positive 
1.1 Current contraceptive use 
1.2  Consistent contraceptive use 
1.3 Unmet needs for contraception 
1.4 Unintended pregnancy 
 
 





populations impact female ALHIV 
contraceptive use behaviours. 
3. To investigate how the contraceptive 
practices, preferences, and needs of 
female pALHIV compare and contrast 
with female hALHIV. 
4. To investigate whether models (access 
sites) of HIV-related services that serve 
only youth lead to greater 
contraceptive service uptake and 
provision, perceptions of higher quality 
and greater satisfaction, and lower 
rates of unmet needs for contraception 





3.1 Receipt of contraceptive services 
3.2 Current contraceptive use 
3.3 Service delivery preferences 
 
4.1 Receipt of contraceptive services 
4.2 Current contraceptive use 
4.3 Client satisfaction with services 
4.4 Service quality perceptions 
 
 
Respondents who reported the current use of one modern method of contraception were 
classified as current contraceptive users, and those who reported using condoms and another 
modern contraception method were categorised as dual-method users. Consistent users are 
defined as respondents who reported that they had used condoms or any other modern method 
of contraception every time they had intercourse during the past three months before 
participation in the survey. Respondents were categorised as consistent dual-method users if 
they reported use of both a condom and any other modern contraceptive method every time 






3.2.1  Sample size  
The sampling frame for the quantitative research component was drawn up to allow for a 
representative sample and generalizable results. In this study, several outcome variables were 
evaluated, and there was no overriding primary outcome. Sample size computations were based 
on the CPR. Data on CPR are unavailable for female ALHIV in South Africa. Though two studies in 
Kenya and Uganda have documented the CPRs among female ALHIV (Obare et al., 2010a; Oliveras 
& Makumbi., 2013), the rate from either of these two studies was not used to estimate the 
study’s sample size because the levels of contraceptive uptake in these East African countries 
contrasted with that of South Africa (Department of Health., 2007; Kenya., 2014; Uganda., 2016). 
Thus, the required sample size was based on the South Africa DHS (SADHS) data on the CPR (69%) 
among sexually active adolescent girls between 15 – 19 years of age (with unknown HIV status) 
(Department of Health, 2007), and assuming a similar level in sexually active female ALHIV in 
South Africa, the estimated sample size for this survey was 329. The sample size was based on 
2003 SADHS published in 2007 and drawn before the 2017 SADHS results came out. The 
assumption of similarity in the CPRs between female ALHIV and their counterparts not living with 
HIV was based on the existing literature which suggests that WLHIV and female ALHIV in urban 
townships in Cape Town area have same levels of current contraceptive uptake as their HIV-
negative counterparts (Crede et al., 2012; Sadeghi et al., 2015). Assuming a 95% confidence level, 
the formula n=1.962 x [p (1–p)/d2] was used to estimate the sample size (Pourhoseinqholi et al., 
2013), where n is the required sample size, p is the assumed prevalence (0.69), and d is the level 
of precision (0.05)].  
 
The sample size required to compare contraceptive related outcomes (e.g., current use, service 
quality perception measures) by mode of service delivery (stand-alone youth vs general PHC 
clinics providing HIV services was also based on CPR. The estimated minimum sample size needed 
to demonstrate a CPR difference of 10% between access sites that serve only youth and those 
that serve all ages, with 80% power, a 95% confidence interval and a 5% significance level, is 301 
individuals per group (i.e., a total sample of 602 subjects for both stand-alone youth and general 
PHC clinics. As the ALHIV client loads are generally low across health facilities, approximately 500 
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female ALHIV were retained in care in the selected study centres (unpublished data from the 
Centre for Infectious Disease Epidemiology and Research), a finite population correction (fpc) 
factor was applied to the initial required sample size (nr=602) so that a difference of 10% 
contraceptive uptake between the two groups can be reliably detected with a realistic sample 
size at 80% power with 95% confidence (National Academies of Sciences, Engineering, and 
Medicine., 2018). Since nr=602 is >5% of the population size (i.e., ALHIV retained in HIV care at 
the study sites) and sampling is without replacement, the assumptions of the finite population 
factor are met (Susan et al., 2015). The fpc factor reduces the sample size to achieve an 
appropriate size for a survey and corrects for standard error. The equation employed to calculate 
the adjusted sample size was (Susan et al., 2015): na  = nr  /(1 + (nr – 1)/N), where na= the adjusted 
sample size, nr = the initial required sample size and N = population size. Using the fpc factor with 
nr = 602 and N=800 (i.e., estimated population of female ALHIV in HIV care in Western Cape PHC 
clinics based on unpublished data from the Centre for Infectious Disease Epidemiology and 
Research) in the equation above, the estimated total adjusted minimum sample size required to 
contraceptive related outcomes by clinic group would be 273 – indicating a minimum sample size 
of 137 individuals per group.   
 
 
3.2.2  Sampling strategy 
Purposive sampling of sub-districts and facilities was carried out instead of multistage sampling 
because ALHIV can be hard to reach in healthcare facilities. As an initial step in the research 
process, after gaining approval from local and provincial authorities to access the selected 
facilities, the PhD candidate visited all the selected PHC facilities to ascertain the adolescent client 
load in the HIV care and treatment clinics and their respective peer/youth support groups. These 
visits revealed that the client load was below the estimated sample size for each clinic due to loss 
during follow-up in a sizeable proportion of this young sub-population of PLWH.  
 
To achieve representativeness for female ALHIV in the study setting, a consecutive case selection 
technique was utilised so that all female ALHIV retained in care at the selected clinics had an 
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equal chance of being selected. Poudel et al. (2016), based on an in-depth analysis of the 
challenges of conducting research among PLHIV, along with possible solutions, identify sampling 
and recruitment of participants as a significant issue in HIV/AIDS research. For such research, the 
authors recommend employing a non-probability sampling technique instead of probability 
sampling techniques due to the difficulty of obtaining a realistic sampling frame (Poudel et al., 
2016). 
 
To be eligible for questionnaire administration or an interview, participants had to be a female 
ALHIV between 14-19 years of age, be enrolled in HIV care and treatment services at the 
respective study clinics where interviews were conducted, had to have had sex, be willing to 
participate in the research, feel comfortable with questions on sexual and reproductive 
behaviours, currently living in Khayelitsha, Klipfontein or Mitchell’s Plain sub-district, and be able 
to speak English, Afrikaans, or Xhosa. Potential participants between 14-17 years who met these 
criteria were given a parental/guardian permission form (see Appendixes 2 & 3), and 
participation in the study required parental/guardian consent. Potential participants who self-
reported they had never had sex, who were too ill to be willing or feasible for interviews, and 
who were receiving treatment for cognitive impairment were excluded from the study. The age 
group of 14 to 19 years was chosen because it was thought that these individuals' experiences 
with contraceptive issues would contribute significantly to this research. A reason for choosing 
14 years as the age threshold for inclusion in the study is that adults and minors aged 14 years 
and above (i.e., mature minors) are similar concerning their cognitive capacity for making 
informed decisions (Weithom & Campbell, 1982). 
 
 
3.2.3  Data collection  
A structured paper-based questionnaire (see Appendixes 4 & 5) was used to gather research 
data. The questionnaire design was guided by the research objectives and conceptual framework, 
and the wording was chosen to be age-appropriate for the sample population. To enhance the 
quality, and particularly reliability and content, criterion and construct validity, of the study’s 
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questionnaire, existing survey instruments previously used in populations that included 
adolescents were utilised. The items on the questionnaire were either taken verbatim or adapted 
from the following national/international survey tools: 
1. WHO Global School-based Student Health Survey 2013; 
2. UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and 
Research Training in Human Reproduction’s Illustrative Core Instruments 2001; 
3. South African National Health and Nutritional Examination Survey 2011/2012; 
4. U.S National Health and Nutrition Examination Survey 2013-2014; 
5. South African Demographic and Health Surveys Questionnaire 2003; 
6. South African National HIV Prevalence, HIV incidence, Behaviour and Communication Survey 
2008; and 
7. Family Health International (FHI) Behavioural Surveillance Survey 2000 (Behavioural 
Surveillance Surveys, 2000). 
Furthermore, the following existing validated scales were also utilised in the design of the 
questionnaire: 
8. Contraceptive self-efficacy for teenagers; 
9. Antiretroviral medication adherence; 
10. Service satisfaction;  
11. Stigma; and 
12. Quality of family planning services. 
 
A review of the literature also led to the inclusion of other measures in the questionnaire. For 
example, items on partnership factors, parent-adolescent communication, cultural norms, and 
HIV-specific factors. In addition, the relevant literature on the evaluation of sexual health and 
reproductive health services was evaluated extensively. To further the content validity of the 
questionnaire and ensure its wording was appropriate for the study population, the 
questionnaire was reviewed by the research supervisors and committee, with additional 
oversight by the institutional review board (IRB). The questionnaire was available in English, 
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Xhosa and Afrikaans (see Appendixes 4 & 5). It was translated and back-translated by professional 
translators, with emphasis on conceptual and cultural equivalence. 
 
The items (questions) on the questionnaire progress from not sensitive to more sensitive and 
particular attention was paid to the questionnaire wording to ensure that the questions were 
understandable and devoid of misinterpretation. Single item or multiple item Likert-type 
questions, with five response options (mostly from strongly agree to strongly disagree), were 
used to measure participants' opinions or attitudes towards safety concerns, self-efficacy, dyadic 
perceptions, service quality and satisfaction, and clinic stigma related to contraception. Carifio 
and Perla (2007; 2008) argue that a multi-item measuring scale (also known as Likert scale) yields 
a unified result or summative assessment and allow maximization of internal consistency-
reliability and improved reflection of the underlying latent construct of interest. Vickers (1999) 
demonstrated the same trend with a single-item measure in the Likert scale format and 
concluded that the single-item Likert-type response provided an excellent, responsive measure. 
The PhD candidate also used equivalent smiley faces alongside text response Likert-options as 
visual primes to help participants process their answers to the questions. One recent study shows 
that survey response options containing text labels with smiley faces result in less fixation times 
on question stems (Stange et al., 2016). 
 
The questionnaire was divided into sub-sections that covered the following: demographic profile; 
HIV service use; pregnancy experiences; contraceptive behaviours; safety concerns around 
hormonal contraception in PLHIV; dyadic perceptions; sexual behaviour; receipt of contraception 
services; and contraceptive preferences, service quality and satisfaction. Dependent and 
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¥Dual-method use refers to the simultaneous use of condoms and another modern method of 
contraception. 
ƗBased on the adapted DHS definition, female ALHIV with unmet need for contraception included 
sexually experienced female ALHIV (i.e have had sexual vaginal intercourse) who either not 
currently using any modern contraceptive method or inconsistently used condoms as a primary 
contraceptive method and did not want any more children or intend to become pregnant in the 
next two years, or included currently pregnant women for whom the index pregnancy was 
mistimed or unintended.  
 
Pilot testing questionnaire 
A pilot test of the questionnaire was undertaken in one clinic with a high volume of HIV-positive 
youth to check comprehensibility, sensitivity, response burden/problems, skip pattern 
compliance and coding errors with a sample of three female ALHIV. The questionnaire was pilot 
tested in its English-, Xhosa- and Afrikaans- version. The pilot testing techniques included 
conventional pretesting method (interviews conducted by trained bilingual fieldworkers on real 
respondents using the questionnaire), as well as cognitive interviewing (see Appendix 6 for 
cognitive interviews’ excerpts) to check the acceptability and comprehensibility of survey 
questions, and to assess the feasibility of the survey questions and the question-answer process 
(Aicken et al., 2013).  
 
3.2.4  Recruitment, selection, and training of fieldworkers 
Before the administration of the questionnaire, a team of fieldworkers comprising seven female 
data collectors (between 20 and 25 years of age) was trained to attain proficiency in the relevant 
research techniques. Individuals with a minimum of matriculation certificate working towards a 
bachelor’s degree or who have had a bachelor degree had experience as field interviewers with 
adolescents, and worked in youth/adolescent HIV prevention programs were recruited as field 
workers. Other requirements such as bilingualism, with fluency in English and Xhosa or Afrikaans, 
and being of a similar racial or cultural background as interviewees were considered in the 
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recruitment process. The training of the survey fieldworkers was conducted by an adolescent 
psychologist, an individual with experience interviewing in both Xhosa and Afrikaans, and the 
candidate with oversight from the primary PhD research supervisor. 
 
 
3.2.5  Participant recruitment and fieldwork procedures 
As described in section 3.2.2, a census of the study target population was undertaken across all 
the study clinics. A daily clinic attendance register was used to identify potential participants for 
study eligibility and enrolment. Fieldworker-administered explanations and information sheets 
as well as comprehension sheets (see Appendixes 7 - 9) were utilized to help potential 
participants to give informed consent (see Appendixes 10 & 11). To ensure the privacy of 
potential participants and avoid social desirability bias, fieldworkers were assigned to study 
clinics outside their neighbourhood.  
 
Interviews were held after the day’s consultations and activities at the clinics and support groups. 
Only potential participants who demonstrated an understanding of the information about the 
study and consent to participate were interviewed. To ensure that a participant was not enrolled 
twice into the study, participants were asked to respond to a filter phrase (see Appendix 9: item 
13). Interviews were conducted in the respondents' language of choice (English, Xhosa or 
Afrikaans) in private and convenient spaces within the clinics, and each interview lasted between 
30 and 45 minutes. Participant recruitment and interviewing were conducted every day of the 
week during clinic operational hours (8 am to 4 pm), except during one afternoon per week for 
quality assurance meeting with the candidate. 
 
In two instances, participants self-reported child neglect or a traumatic event following a sexual 
assault that occurred three years ago (and had been investigated by the police). For these cases, 
the interviewers completed a child abuse report (see Appendixes 12 & 13) and/or provided 
psychosocial support (see Appendix 14). Copies of the report of child neglect or traumatic event 
were immediately transmitted by the lead researcher to clinical social workers for support 
87 
 
services to be provided to the victims and for mandatory reporting (to the relevant agency), as 
set out in the Child Services Act. 
 
 
3.2.6  Data management and analysis 
Statistical analyses were conducted using STATA version 15.1.  
 
Missing data 
Descriptive analysis was used to determine the frequency of missing data. Based on the scientific 
knowledge of the variables with missing values and the statistical analysis (for example, chi-
square-based tests) for missing data mechanisms and patterns, values for each of the variables 
with missing data were assumed to be missing completely at random (MCAR) (Heitjan, 1997; 
Patrician, 2002). Thus, single imputation methods, such as mean (median) substitution and hot-
deck imputation method(s) were used to handle missing data. Although multiple imputation is 
the gold standard for handling missing data, the hot-deck and mean substitution methods were 
employed for several reasons. Single imputation methods are unbiased if data is MCAR or missing 
at random (MAR) (Bennet., 2001). Additionally, mean imputation has been proven to yield 
unbiased estimates of regression coefficients and standard errors when values are missing for 
less than 10% of subjects in a multi-item instrument (Ekhout et al., 2014). Aside from allowing 
only plausible values to be imputed from observed values in the respondent pool, hot-deck 
imputation generates estimates of missing values with values from respondents with matching 
co-variates (Andridge & Little., 2010).   
 
For each ordinal independent variable that had missing values below 5%, the average median 
value from respondents with matching covariates was imputed. For continuous variables such as 
“time to the clinic”, the median values from patients attending the same clinic was imputed. 
Missingness for dependent variables was ignored for the following reasons. First, the missingness 
on data for the dependent variables was too small to determine its mechanism and patterns. 
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Second, complete case analysis with covariate adjustment has been shown to yield similar and 
unbiased model estimates compared with other methods of missing data imputation in 
circumstances of missing outcome data in observational studies (Groenwold., 2012).  
 
Data reduction  
The first step in the data analysis after data cleaning and handling missing data was exploratory 
data analysis. For inferential statistics, quantitative variables, both continuous and discrete, were 
reduced into ordinal categorical variables that made sense conceptually or statistically so that 
results may be more readily translated into practice, policy, and public health improvements. 
Furthermore, the number of groups for certain categorical variables with a rare or redundant 
group(s) was reduced, based on exploratory data analysis or empirical data, to avoid biased 
estimates and make possible comparison with findings from existing research. For categorical 
variables where "Not Applicable" is a response option, I decided to leave "Not Applicable" as a 
separate response category for a better or easier interpretation of results. 
 
For this analysis, principal component analysis (PCA) was employed for the dimensional reduction 
of highly correlated items into a single variable and to construct scales from several items that 
represent the same concept in the questionnaire. Additionally, factor analysis (i.e. exploratory 
and confirmatory factor analysis) was used to investigate the dimensionality of scale items. 
Further scale development was not considered because the results from factor analysis 
suggested a unidimensional factor structure for each scale. 
 
Descriptive and bivariate analysis 
Descriptive analyses, including frequency distributions, cross-tabulations, measures of central 
tendency (such as mean, median, and mode) and dispersion (such as range and standard 
deviation) were used to describe the variables in the data set. In addition, bar charts were used 




To assess differences between groups, Pearson's chi-square test (or Fisher's exact test) was used 
for categorical variables and t-tests or ANOVA used for continuous variables. Pearson's chi-
square was also used to determine whether there was sufficient overlap of potential confounders 
in the dependent variables' categories before conducting a multivariable analysis. Furthermore, 
univariate logistic regression was used to estimate the unadjusted effects (crude odds ratio and 
95% confidence interval) of covariates on binary dependent variables. 
 
Multivariate analysis 
The multivariate analysis consists of two parts. First, a descriptive-analytic model tests the first 
research hypothesis that contextual factors (including individual, interpersonal, community, and 
structural contexts) influence specific contraceptive behaviours and outcomes (e.g., current use, 
consistent use and unmet needs). In the second part pertaining to the remainder of the research 
hypotheses, an explanatory analytic model was used to explore the association between some 
specific exposure variables and client outcomes.  An important point of concern before the 
multivariable analysis in this thesis, particularly analysis about the first research objective, is the 
small number of events per variable (EPV). In the literature, a popular rule of thumb, based on 
two simulation studies, is that EPV should be ten or more in both logistic and cox regression 
models of observational data to obtain unbiased estimates (Peduzzi et al., 1995; 1996). However, 
the rule of 10 or more EPV may be too conservative, not a well-defined threshold and 
inappropriate in observational data, and performance measures in models with 5 to 9 EPV are 
comparable to those with more than 10 EPV (Vittinghof et al., 2007). Thus, EPV was considered 
to be at least five in this analysis because invalid estimates can occur when there are too many 
covariates in a logistic regression model (Vitinghoff & Mccullock., 2007; van Domburg et al., 
2014). The coefficients and variances of the regression models are within reasonable limits, 
validating the outputs from the logistic regression analyses. 
 
To further ensure the reliability of the regression models, the variance inflation factor was used 
to explore multicollinearity among the covariates in the regression model. In cases where two or 
more covariates were highly correlated, only the one that was more scientifically or statistically 
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significant was retained in the model. A general rule of the thumb is that a VIF>10 indicates 
multicollinearity. To account for clustering at the clinic level, cluster-robust standard errors’ 
command (“vce (cluster clustvar)”) was employed (Kirwood & Sterne., 2003). Lastly, the Hosmer-
Lemeshow test was used to assess the goodness of fit of the final regression model (Hosmer & 
Lemeshoe., 1982). All statistical tests were two-sided 95% confidence intervals, interpreted at a 
5% level of significance for the final regression models.  
 
Analysis for identifying factors influencing outcome and rationale for the use of the 
multivariate model 
This analysis pertains to the first research hypothesis (H1) stating that following factors will be 
significantly associated with contraceptive behaviours and related outcomes among female 
ALHIV: individual, psychosocial, interpersonal, community and societal factors. Given that the 
inadequacies of the small numbers of EPV and large numbers of parameters in multivariable 
models pose a big challenge to the estimates of the model (Vitinghoff et al., 2007; van Domburg 
et al., 2014), both background knowledge and the purposive selection algorithm (PSA) (Bursac et 
al., 2008; Hosmer & Lemeshow., 2000) were used to reduce a large number of the initial set of 
covariates in this study (n=30) to an order of magnitude relative to the number of outcome events 
in the logistic regression models. Based on simulation studies, PSA has been shown to retain 
significant covariates in logistic regression modelling compared with other well-known variable 
selection algorithms such as forward, backward and stepwise methods, resulting in a more 
parsimonious and accurate model (Bursac et al., 2008).  Furthermore, PSA yields robust estimates 
for sample sizes in the range of 240-600, such as this study. Moreover, model building based on 
PSA made it possible to treat all the covariates in this thesis as equally important (Bursac et al., 
2008). For these reasons, PSA was considered a particularly well-suited method for the 
multivariable model building pertaining to the first research objective in this thesis using the 
steps described below:    
Step 1: Univariate analysis of the association between each independent covariate and each 




Step 2: Any variable that had a significant univariate test with an outcome event of interest at 
the 0.05, 0.1, or 0.25 alpha level was selected for inclusion in the full multivariate analysis. For 
the models including contraceptive use consistency as the outcome, significance was evaluated 
at 0.1 alpha level instead of a lower cut-off point to avoid the elimination of essential covariates 
(Mickey & Greenland., 1989). Furthermore, 0.1 probability level was chosen as a variable entry 
criterion for the multivariate modelling instead of the more commonly used level, 0.25, to avoid 
model inadequacies due to a small number of EPV with a broad set of covariates. For the models 
including current contraceptive use or unintended pregnancy as the outcome, 0.05 probability 
level was chosen as a variable entry criterion for the initial variable selection to avoid breaking 
the statistical rule of 5 or more EPV pertaining to the analysis in this thesis. Furthermore, 
variables that were not significant based on the abovementioned empirical criteria, and 
identified to be clinically significant based on background knowledge were included in the original 
multivariate model. 
 
Step 3: A new, smaller model following the elimination of non-significant variables at p<0.1 in the 
full multivariate model in Step 2 was fitted and when a variable with p≥0.1 was taken out one at 
a time from the full multivariate model, the parameter estimates of any remaining variables in 
the model did not change by >20%. A change in the parameter estimate of any variable in the full 
model shows that the excluded variable was a confounder and should be added back to the new, 
smaller model.  Furthermore, the reduced model was compared with the larger, full multivariate 
model using the partial likelihood ratio test (LRT).  
 
Step 4: To avoid the elimination of variables that made a significant contribution in the presence 
of other variables, each non-significant variable in Step 1 was added, one at a time, to the model 
obtained after Step 3. Any variable that was significant at p<0.1 either by the Wald test for 
categorical variables with two levels or the partial LRT for categorical variables with three or more 




Step 5: Following the conclusion of Step 4, potential interacting variables in the model was 
performed. Here, a priori' interactions include a) Does proximity to an HIV-care and treatment 
clinic modify the effect of household SES on any of the above-mentioned outcome event of 
interest?; b) Does mode of HIV acquisition modify the effect of age on any of the above-
mentioned outcome event of interest?; and c) Does having a child/children modify the effect of 
age on any of the outcome event of interest as mentioned earlier?. Because there were no 
potential interacting variables in the model obtained after Step 4 for each of the outcome events 
of interest, the PhD candidate did not test for interactions. All the Individual, relational, 
community and structural factor included in the final multivariate model are potential 
confounders for other factors.  
  
Analysis of the relationship between an exposure and an outcome, and the rationale for the 
use of the multivariate or multinomial model 
This analysis pertains to the second research hypothesis through the fifth research hypothesis 
(H2-4).  
1. H2: Female ALHIV that consider themselves at risk of hormonal contraceptive related side 
effects are less likely to use hormonal contraceptive compared to their peers that do not 
consider themselves to be at risk. 
2. H3: There will be a significant difference between female hALHIV and pALHIV in terms of 
contraceptive practices, preferences, and needs. 
3. H4: Female ALHIV accessing HIV care services at stand-alone youth clinics are more likely to 
have higher contraceptive use, receipt of contraception services, service quality perceptions 
and satisfaction, and lower unmet needs for contraception compared to their peers 
accessing HIV care services at general PHC clinics for all ages. 
 
Since the aim of the analysis about H2-4 was not to determine prognosis or diagnosis but the 
independent association between the exposure and outcome, a multinomial or multivariate 
regression model adjusting for potentially confounding variables were employed (Kaltz., 2006). 
A multinomial regression model was used for both the bivariate and multivariable analyses of H2 
93 
 
to allow for the dependent (outcome) variable with three categories: non-current use of 
contraception; current use of barrier contraception; and current use of hormonal contraception. 
Perceived hormonal contraceptive-related safety considerations were investigated as a 
composite exposure variable, and two categories of the exposure ('low' and 'high') were 
generated as described in Chapter 3 (see Table 3.2). All variables associated with an outcome and 
causally associated with a primary exposure variable as well as those that change the coefficient 
of association between the exposure and outcome by >=10% were considered confounders for 
model building.  
 
A multivariate logistic regression modelling approach adjusting for confounders was fitted for the 
analyses relating to H3-4. Regarding H3, the independent effects of mode of HIV acquisition 
(perinatal/postnatal and horizontal transmission routes) on the following contraceptive/client 
outcomes were evaluated: receipt of services, current contraceptive use, consistent 
contraceptive use, unmet needs and unintended pregnancy, service delivery preferences 
including provider continuity, provider age, provider gender. For H4, the independent effects of 
clinic model (standalone youth clinics and general PHC clinics) on the following 
contraceptive/client outcomes were assessed: receipt of services, current contraceptive use, 
consistent contraceptive use, unmet needs and unintended pregnancy and service quality 
perceptions. 
 
To minimise the potential bias due to unmeasured confounders, the 0.25 probability level was 
chosen as a statistical criterion for the identification of a confounder (Kaltz., 2006). Furthermore, 
any variable that changed the unadjusted coefficient of an exposure variable by ≥ 10% when  
added to a crude regression model was also selected as a confounder (Lee., 2014). However, to 
avoid violating the EPV criterion guiding variable selection in this thesis, only variables associated 
with the exposure and causally related to the outcome were selected as confounders in the 
multivariate analyses assessing the independent association between an exposure and the 




The identification of effect modifiers was guided a priori by the conceptual framework, empirical 
findings, and both theory and prior research guided by the literature review. Subsequently, a 
stratified analysis, using Mantel-Haenszel tests of the association was used to decide which 
interaction term to include in the multivariable model. To assess the significance of the 
interaction term(s), the Wald for the null that all interactions in the multivariate regression model 
were zero was employed. For the multinomial regression model, the joint test was used to assess 




In certain instances, sensitivity analyses were conducted to compare the regression results from 
the complete case analysis and the missing data analysis (listwise deletion) after simple 
imputation. Given that the outputs from the regression models with imputed means and list-wise 
deletion are more or less comparable, the results from the model based on the imputed means 
are presented in this dissertation. 
 
 
3.3   Qualitative component – in-depth interviews  
This section provides an overview of the qualitative component. First, the rationale for using a 
qualitative research approach was described. Then, data sources, data collection and instrument, 
and fieldwork procedures are discussed. Lastly, the data analysis techniques and methodological 
rigour are described. 
 
 
3.3.1  Participant types and data collection method  
Qualitative in-depth interviews were conducted with a purposively selected sample of key 
informants with diverse professional roles in healthcare service delivery in the three study sub-
districts. These key informants included: sub-district health managers; healthcare facility 
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managers; HIV clinic managers; doctors and nurses in HIV clinics; and ART adherence counsellors. 
As system-level key informants, sub-district health managers are likely to offer insight on the 
potential challenges to and opportunities for policy-making with regards to contraceptive 
services. Service-level key informants (including healthcare facility managers; HIV clinic 
managers; doctors and nurses in HIV clinics; and ART adherence counsellors) are directly involved 
in policy implementation, programme planning or service delivery in their work environment, 
and are more likely to have a deeper understanding of the health system challenges as well as 
promising approaches and interventions related to contraceptive service delivery to adolescents 
than adolescents themselves (Hagey et al., 2015). Initially, a representative from a non-
governmental organization who was knowledgeable in contraception service provision to HIV-
positive adolescents was contacted for an interview; however, the interview was not possible 
because the individual was on maternity leave and out of town during the study period. 
 
In-depth interviewing (IDI) was the only data collection method employed in the qualitative 
component of this study.  There are clear advantages to this method for gathering data in health 
service research. It is particularly suitable for exploring sensitive topics (Liamputtong., 2007; Elmir 
et al., 2011). In addition, this method yields thick, detailed, holistic and deeper understandings 
of a phenomenon as there are no effects from pressure dynamics that sometimes characterise 
the focus group data collection (Pope et al., 2002). For these reasons, focus group interviews 
were not considered for this study.  
 
 
3.3.2  Development of Interview guide  
A semi-structured interview guide (see Appendix 15), including open-ended/indirect, structuring, 
non-directing probing and interpreting questions, was developed for in-depth interviews with 
participants. The questions on the interview guide were developed based on the literature 
review, the research questions and objectives, and the conceptual framework. The interview 
questions follow a logical sequence, beginning with warm-up questions and ending with sensitive 
questions, to allow for a comfortable flow of discussion. Pilot testing of the interview guide was 
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conducted on two health care providers, and further refinement of the guide was based on 
participants’ responses from the pilot test.  
 
The interview guide, developed in English, includes questions related to the following themes: 
1. Knowledge of adolescent contraception;  
2. Attitudes towards adolescent contraception; 
3. Client’s contraceptive attitudes; 
4. Contraceptive policy and guidelines; 
5. Client’s contraceptive practices, preferences and needs; 
6. Perspectives on hormonal contraceptive-related safety considerations;  
7. Experiences of adolescent contraception; 
8. Perceptions of contraceptive service quality; 
9. Pathway to contraceptive decision making  
10. Contraceptive care-seeking and clinic stigma; 
11. Contextual factors related to contraceptive service provision and utilization; and  
12. Recommendations on improving contraceptive services. 
 
 
3.3.3  Fieldwork procedures and sampling 
Interview participants were purposely selected from the three sub-districts based on several 
factors, including professional roles, involvement in care for ALHIV, and ALHIV client load in their 
healthcare facilities. During the IDIs with the health facilities’ managers and ART clinic managers, 
the participants were asked to recommend other participants in their facilities who they believed 
were knowledgeable about HIV-care for ALHIV. 
 
Potential participants were invited to participate in the study via e-mail or face-to-face contact 
and were provided with information about the study. At the study facilities, key informants who 
were currently working and who had worked at the HIV clinics for three months were purposely 
recruited for IDIs. The interviews were conducted at a time and location that were convenient 
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for the participants. All the interviews took place face-to-face in a secluded space, either in a free 
consulting room or an office, within their worksite. Before each interview, participants were 
given a copy of the study information sheet (see Appendix 15) to read and two copies of the 
informed consent form to sign (see Appendix 17). Each participant was given a copy of the 
informed consent form signed by him/her and the PhD candidate, and a copy was retained by 
the interviewer. 
 
Participants' demographic information and interview data were collected using the participant's 
demographic sheet (see Appendix 15) and the digital audio-recordings, respectively, with the 
participants' permission. The duration of the interviews ranged between 45 mins to 90 minutes. 
Notes (memos) were written immediately after each interview.  After each round of interviews, 
verbatim transcripts were submitted to the primary supervisor on this project. Comments from 
the supervisor informed the interview process for the subsequent round of interviews. This 
process was carried out for several rounds of interviews. The PhD candidate transcribed all the 
interviews to have a deeper knowledge of how to reflect on the views of participants and to 
reformulate the interview questions. 
 
 
3.3.4  Data analysis methods 
Analysis of in-depth interview data from healthcare providers was guided by an iterative and 
recursive six-phase thematic analytic method proposed by Braun and Clark (2006). Thematic 
analysis –defined as a “method for identifying, analysing, and reporting patterns (themes) within 
data”- has the advantage of yielding rich, detailed account of the various aspects of the research 
phenomena (Boyatzis., 1998; Braun & Clark., 2006).  Its flexible approach to data analysis makes 
it usable within different theoretical frameworks and across the epistemological and ontological 





i. Data familiarisation: This began with conducting and transcribing of the interviews 
immediately after each round of interview. Transcripts were read and re-read to develop 
familiarity with the data further, make memos and summaries, and identify relevant meanings 
and patterns.   
 
ii. Generation of codes: Coding was performed using NVivo 11 software. Semantic and latent 
codes were generated both deductively and inductively for several potential themes, subthemes 
and patterns. An initial coding framework was developed based on a random sample of 
interviews with healthcare providers in different professional categories. The following coding 
methods were employed: holistic, descriptive, structural, magnitude, attribute, values, theming 
and sub coding (Saldana., 2015). The coding process was iterative and recursive. 
 
iii. Searching for themes: After the initial coding of all data in a data set, all conceptually related 
codes and their extracts were collated into a broader level of potential themes, which were then 
refined into candidate themes and sub-themes.  
 
iv. Reviewing themes: Candidate themes were reviewed and refined to ensure that the data 
within each theme were coherent and conceptually related. When necessary, data were 
recorded from the dataset. A thematic map was devised to aid in the refinement of candidate 
themes and sub-themes.    
 
v. Defining and naming themes: Themes were defined, and initial themes/sub-themes were 
further refined within the thematic map by reviewing the data extracts for each theme. This led 
to the formation of a coherent, conceptually related account, resulting in final themes and sub-
themes.  
 
vi. Producing the reports- interpretative analysis and write-ups: Using thematic matrices, the 
meaning and implications of each theme/subtheme as well as their underpinning assumptions 




3.3.5  Trustworthiness in qualitative data collection and analysis 
To ensure the quality of the qualitative inquiry and to avoid potential doubts or biases that might 
arise during and after the qualitative research process, qualitative methodological researchers 
have proposed trustworthiness criteria. These consist of four features: credibility, transferability, 
dependability, and confirmability (Lincoln & Guba., 1985). The measures employed in this study 
to combat the potential limitations of trustworthiness throughout the data collection process 
and analysis are as follows:     
 
Credibility: validity of the findings 
Through meetings with stakeholders (including potential interview participants) prior to data 
collection, as well as extended interaction with the IDI participants (providers), a sense of trust, 
rapport and familiarity was developed between the respondents and myself. Two types of 
triangulation, data source triangulation and method triangulation were utilised. Denzin (1978) 
and Patton (1999) mention triangulation as a key element in ensuring a comprehensive 
understanding of a research problem and testing the validity of research findings. Member 
checks (i.e. providing participants with summaries of their responses at various intervals during 
interviews and at the end to elicit clarifications) were also utilized to minimise the potential for 
researcher bias during data analysis and interpretation. Also, regular debriefing of the study 
supervisors during the data collection and analysis enhanced the interview technique and 
ensured that findings were crosschecked with feedback. Furthermore, data analysis (coding) was 
conducted on an ongoing basis, as the data were collected, to understand and explore 
unexpected findings, thereby adding depth to the results. 
Transferability: the applicability of the findings of qualitative inquiry in 
another context 
In-depth details/thick description regarding the research methodology and context helps to 
ensure that the study is replicable in other possible contexts (Lincoln & Guba., 1985; Li., 2004). 
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The multisite design of this study may give its findings significant potential in terms of 
transferability to other similar contexts. 
 
Dependability: reliability of the findings at another time 
A detailed, step-by-step description of the approach to the qualitative inquiry as well as the 
evaluation of the codes and extracts of data by the study supervisors ensured the stability of the 
findings over time.  
 
Confirmability: objectivity of the researcher during the research 
process 
In addition to the audit trail/thematic mapping described above, confirmability was established 
in part by a reflexive journal I kept during the research process. Several qualitative 
methodologists asserted that confirmability could be achieved through an audit trail, 
triangulation and reflexive journal (Bowen, 2009; Koch, 2006; Lincoln & Guba, 1985). The PhD 
candidate researcher conducted all the interviews and analysed the data. This may have 
introduced bias to his interpretation of the qualitative findings. Examination of the research 
process and findings by the research supervisors helped to minimise bias to the PhD candidate's 
interpretation of the findings. 
 
 
3.4   Data triangulation 
The integration of quantitative and qualitative data helps leverage the findings of mixed-methods 
research (Fetters et al., 2013). In this thesis, quantitative and qualitative data were obtained and 
analysed separately, and then findings from both data sources were merged in the interpretation 
of the results in the discussion chapter, thereby integrating the quantitative survey and 
qualitative interview results in a narrative. This allows for findings from both data sources to be 




In the context of concurrent mixed methods design, as exemplified by this present study, 
integration of both quantitative and qualitative data usually occurs during the analysis or 
discussion phase of the study (Cresswell, 2003; Cresswell & Plano, 2007). Beck et al. (2009) 
provide an illustration of the integration of qualitative and quantitative results at the 
interpretation level. The qualitative findings are useful in clarifying and explaining some findings 
from the quantitative survey data. For example, the qualitative data provide explanations for the 
heavy reliance of female ALHIV on injectable contraception. 
 
 
3.5   Ethical considerations  
 
3.5.1  Ethical issues specific to minors 
The ethical issues around a parent's/legal guardian's permission were considered. Under the 
Children's Act (2005), a parent or legal guardian must permit a child to participate in research. 
Thus, an adolescent minor (14 – 17 years of age) participated in this research only where a proper 
written parent’s or legal guardian’s permission had been obtained (see Appendixes 2 & 3). The 
assent and parental consent forms included explicit information on reporting obligations for 
abuse and neglect and the procedures to be followed in cases where abuse or neglect was 
reported by the minor or parent, or suspected by a fieldworker. Further, all adolescent minors 
were required to sign an assent form before participation in the study (see Appendixes 10 & 11). 
 
3.5.2  Informed consent 
Fieldworkers were required to confirm that the adolescent demonstrated an understanding of 
the information sheet and consent form before conducting the actual interview. To ensure that 
the female ALHIV had an adequate understanding of the study's purpose and the potential risks 
and benefits of participation, as well as the voluntary nature of participation, an information 
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sheet and consent form were reviewed orally using the adolescent's language of choice (English, 
Xhosa or Afrikaans).  For the key informants, the consent form was available only in English, and 
it was reviewed with the participants before the start of the interview. Written consent was 
required from every participant before participating in actual interviews. 
 
 
3.5.3  Anonymity and confidentiality  
Several measures were taken to address anonymity and confidentiality issues both during 
and after the research process. Participant recruitment was done discretely. Female ALHIV that 
the information they provided during the interviews would be kept confidential. However, 
adolescent minors (and their parents) were informed that there is a mandatory requirement by 
law to report cases of child sexual abuse or maltreatment to the relevant authority. Personal 
identifiers were not attached to the research data. Fieldworkers were required to sign an 
agreement to protect the confidentiality of identifiable information. Verbatim quotations from 
qualitative research participants and the study clinics are anonymised in this dissertation. The 
anonymity of all study participants (adolescents and key informants) was ensured on the consent 
forms. 
 
3.5.4  Beneficence and non-malfeasance 
To avoid the minimal risks, including discomfort, associated with the participation of ALHIV in the 
interview process, the questionnaire began with general questions, progressing from less 
sensitive to more sensitive questions. Fieldworkers were trained on effective communication 
techniques for discussing sensitive issues with female ALHIV, including non-judgemental 
attitudes and how to ensure that all interviewees were comfortable during the interview. 
 
In order to ensure that ALHIV who experienced psychological discomfort from the interview 
process were identified early on and properly managed, fieldworkers were trained by a clinical 
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psychologist (with expertise in adolescent psychology) in the detection of psychological 
discomfort and support skills for managing psychological discomfort or traumatic events. At the 
end of the interview, each participant was asked whether she had felt uncomfortable while 
participating in the research. Moreover, all adolescent participants were given a phone number 
through which they can contact a member of the research team if they had any questions or 
problems related to participation in the interview after they left. Furthermore, an arrangement 
was also made to refer all instances of child abuse or maltreatment, criminalised by the law, for 
sexual abuse services per the Western Cape’s guidelines.  
 
 
3.5.5  Right to withdraw from the research 
Potential participants were made to understand that they could withdraw at any time during the 
interviews, or refuse to respond to some or all questions and that such withdrawal or refusal 
would have no consequences for them. This information was provided during the recruitment 
and before the actual interviews began. Whether a potential adolescent participant agreed or 
declined to participate in the study would not affect care. The participation of key informants in 
the research was voluntary, and refusal to participate would not affect their job security. 
 
 
3.5.6  Other ethical considerations 
The reimbursement of research participants, particularly adolescents, is another important 
ethical issue. To avoid the possibility of coercion and desirability bias, adolescents were provided 
with light refreshments or gift vouchers where applicable, and they were reimbursed if they had 
incurred travel costs. However, key informants were not reimbursed or given any gift, to prevent 
social desirability bias. 
 
All paper-based records were stored in a locked filing cabinet. Moreover, computer-based 
records were in a password-protected file on a computer. The password-protected file was also 
used to store the audio files of the interviews. Additionally, the UCT REDCap -a password-
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protected, web-based and secure application- was also used for data storage. The audio 
recordings were erased from the tape recorders, and the field notes were destroyed after the 
transcription was finalised. All of the signed consent forms are kept under lock and key in a 
cabinet in the postgraduate students' office at the School of Public Health and Family Medicine, 
University of Cape Town, and these will be destroyed three years from the date the research was 
concluded. At this time, all audio files will also be destroyed. 
 
Ethics approval was obtained from the Human Research Ethics Committee (HREC) at the 
University of Cape Town, and facility approval was acquired from the City and Western Cape 
Department of Health. Approval was also sought from the management committees at 




















4.0   Quantitative datasets description  
This chapter, divided into three subsections, presents the survey response rate, item response 
rates, and profile of cross-sectional study participants. In the first subsection, the response rate 
among the sampled participants is described. The second subsection provides the summary 
statistics of missing data occurring on the dependent and independent variables. The third 
subsection outlines the descriptive statistics for background characteristics of the study 
population in the quantitative dataset, organised by multiple levels of determinants of health 
(described in Chapter 3), including individual, relational, community, and structural factors. The 




4.1   Participation rate  
The survey was conducted between March and July 2017. Data collection was discontinued by 
the end of July 2017 when it seemed that most eligible participants retained in HIV care across 
the clinics had been interviewed. Figure 4.1 illustrates the recruitment process flow chart. In 
total, 394 individuals between 14-19 years of age were approached to participate in the study. 
Of the total 316 eligible to participate in the survey, 303 were included in the data analysis; giving 
a 95.9% response rate. Thus, the survey results likely represent the views and experiences of the 
population of female ALHIV in care across the three sub-districts.  
 
The majority of ALHIV in care who were excluded from participating in the survey were ineligible 
because they had never had sex (97%; 76/78). Also, two individuals were ineligible due to mental 
challenges. Three individuals who were 20 years of age at the time of participation in the survey 
were interviewed erroneously. The inconsistency between the date of birth and the age given on 
the questionnaire helped to identify these three individuals. Unfortunately, there is no further 























    






  Female ALWA approached to participate in the survey 
n=394 
Ineligible to participate        n=78 
-Never had sex                n=76 
-Mental health challenge     n=2 
   Eligible to participate in the survey 
n=316 
Chose not to participate  
n=10 
 Participated in the survey 
         n=306 
Excluded from data analysis after validating 
age (age>19 years) 
          n=3 




4.2   Missing data 
Some independent and dependent variables included in the analysis had missing values; these 
ranged from less than 1% to approximately 15% (see table 4.1 below). The variable with the most 
common missing values is CD4 cell count (32.7%), followed by the length of enrolment into the 
clinics since testing positive for HIV (14.5%). Because the CD4 cell count had more than 20% of 
its values missing, this variable was not included in the missing data analysis (see the rationale in 
Section 3.2.6). There was significant missing data for CD4 cell count and length of enrolment into 
the clinics since testing positive for HIV due to the inability of respondents to recall the absolute 
values for these two variables. There was no way to retrieve missing values for the two variables 
mentioned above from the client’s health records during questionnaire administration because 
permission to access client medical record or chart was not sought in the application for facility 
approval to conduct the research.  
 
Table 4.1: Proportions of missing data 
 
Independent variables n % 
Household wealth index 1  0.3 
Time to clinic 14  4.6 
Length of enrolment (into clinics)  44 14.5 
Perceived mother-child communication 4 1.3 
Perceived peer influence 1 0.3 
Perceived community attitudes 1 0.3 
Age at sexual debut 9 3 
Partner age-gap 2  0.7 
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CD4 cell count 99 32.7 
Contraceptive self-efficacy 2 0.7 
HIV-status disclosure 1 0.3 
Felt stigma 1 0.3 
Dependent variables   
Consistency of condom use (past 3 months) 1 0.3 
Receipt of dual-method contraception (at any public 
health facility) 
6 2.0 
Receipt of dual-method contraception (at current HIV 
care clinic) 
10 3.3 
Hormonal contraception safety issues   
Risk of HIV disease progression 2 0.6 
Risk of reduced ART efficacy 1 0.3 
Service quality perception   
Friendliness of staff 6 2.0 
Provider continuity 4 1.4 
Being treated with respect 6 2.0 
Privacy of consultation 1 0.3 
Waiting time 4 1.4 
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Availability of preferred contraceptive method in 
clinic 
5 1.7 




4.3.   Background characteristics of the study population 
Background characteristics of the study population are presented according to multiple levels: 
(1) individual-level factors; (2) relationship-related factors; (3) community factors; and (4) 
structural factors (Table 4.2). First, individual factors are described. In the total sample (n = 303), 
the ages of the female ALHIV range from 14 – 19 years old, with 59.4% of participants between 
18 and 19 years old. Most female ALHIV (94.4%) had completed at least grade 7 level of 
education. Fifteen per cent of the total sample had delivered at least one child. HIV-infection was 
acquired through behavioural transmission routes (rather than perinatal routes) in 203 (67%) 
female ALHIV. In terms of the time since first enrolled into HIV care, approximately 56% of the 
participants had been in HIV care and treatment for less than one year. Of the 278 female ALHIV 
who had access to ART, 66.7% self-reported adherence to their ART doses in the past four days, 
while 33.5% reported that they missed taking any of their ART medications on at least one day 
during the same time frame (56.9%, 23.7%, 7.5% and 11.8% missed ART doses in the past one, 
two, three and four days, respectively). The aggregate median hormonal contraceptive-related 
safety considerations’ score using four dimensions, including HIV disease progression, ART 
effectiveness, sexual HIV transmission, and contraceptive failure, was 2.5 (out of 5) (see Appendix 
2: items 501a – d). Approximately two-thirds of the sampled participants reported higher levels 
of perceived hormonal contraceptive risks specific to HIV-positive populations. Regarding client 
satisfaction with contraceptive services, slightly more than half (52.8%) of female ALHIV reported 




At the relational level, around 60.1% of participants had less than five-year age gaps with their 
current male sexual partners. Of the 35% who had five-or-more year age gaps with their current 
partners, there was no case where the male partner was five or more years younger. Fifty-one 
per cent of female ALHIV reported higher perceived partner influence on contraceptive use. 
Seventy-one per cent of female ALHIV perceived high positive parent communication about 
contraception. The primary caregivers for most females ALWH were parents (62.1%) or relatives 
(32.3%). Approximately 54% of female ALHIV reported disclosing their HIV-status to their current 
regular male sexual partners. 
 
In terms of community characteristics, self-reported travel times from home to the clinics were 
less than or equal to 30 minutes for the majority of female ALHIV (81.9%). High HIV-related felt 
stigma was reported by 57.8% of female ALHIV. About a third of the sampled participants (64.0%) 
perceived that their community would agree to contraceptive use among female ALHIV. 
 
Regarding structural characteristics, slightly less than three-fifths (58.1%) of the sampled 
participants had secondary education. A lower proportion (45.9%) of the survey population 
attended standalone youth clinics providing HIV services. Slightly less than half (46.9%) of female 
ALHIV belonged to households in the middle wealth index tertile, with 36% belonging to 
households in the wealthiest tertile, and 17.2% belonging to households in the poorest tertile. 
Most of the female ALHIV (94.7%) in the sample were unemployed. Over 68% of female ALHIV 
reported receipt of contraceptive counselling from any public health facility since testing positive 
for HIV. In terms of HIV-specific factors, the majority of female ALHIV were currently taking ART 








Table 4.2 Background characteristics of study participants 
Variable Category N % 
Individual characteristics  
      Age group 
  
     Mean  
     Median (range) 
 
 
      Education 
 
 





      Cigarette smoking 
 
 
     Time enrolled at clinic 
   
 
 
      Mode of HIV infection 
 
 























  1-2 years 










123       
180    
17.5 
18 (14-19)   
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286     
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56      
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77      
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      Age at sexual debut 
 
 
       Mean  
       Median (range) 
         
 
 






      Self-efficacy to use     
       Contraception 
 
      Client satisfaction with    
       contraceptive service¥ 
 
      Perceived hormonal  
      contraceptive risks specific to    
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     Median (range) 
 
Less than 15 years 
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5 years and above 
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      No. sex partners in past 12  
      months 
 
 
     Mean 
     Median (range) 
 
      Disclosure of HIV-status to  
      Partner 
  





      Perceived peer influence on  
      contraceptive use 
 
       Parent-adolescent   
       Communication 
 
       Perceived partner influence  
       on contraceptive use 
 






        Distance from clinic  
 
None 
1 sex partner 
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158  
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215 
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        Median (range) 
 
 
        Perceptions of community  
        acceptance of contraceptive  
        use 
 




Structural characteristics    
       Household SES 
 
 




       Current membership of HIV  
       support group 
 
        Employment 
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194     
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109 
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176       
 59 
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        Current ART use 
 
 
         Ever received contraception  
         counselling at any public  
         clinic since testing positive  
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ƗEver drank alcohol 
ǂMissed taking ART during the past four days 
¥During last clinic visit 




















5.   Factors influencing contraceptive practices among female  
ALHIV attending PHC services 
This chapter presents study’s results on the multilevel (individual, interpersonal, community and 
structural) factors affecting indicators of contraceptive utilisation, including current 
contraceptive use, consistency of contraceptive use, unmet needs for contraception and 
unintended pregnancy among female ALHIV. For each indicator of contraceptive utilisation, a 
description of the quantitative dataset, organised by outcome measures and independent 
variables – individual, relational, community, and structural factors is presented first, followed 
by a presentation of the multilevel factors from the regression analysis.  
 
5.1   Current contraceptive use 
 
5.1.1  Descriptive analysis 
Table 5.1 displays the current contraceptive behaviours and practices of female ALHIV. 
Overall, 83.5% of female ALHIV reported current contraceptive use, and the methods used were 
exclusively modern methods of contraception. A total of 86.8% (n=190) of female ALHIV who 
have had sexual intercourse within the three months preceding the survey (n=219) reported 
current use of any modern method of contraception. Among current contraceptive users, the 
majority used injectable contraceptives (60.5%), followed by those who used condoms alone as 
a primary contraceptive (27.7%), implants (5.9%), IUDs (3.2%) and hormonal pills (2.7%). In total, 
85% (n=130) of the current injectable contraceptive users reported using a particular injectable 
contraceptive method, and of those, the majority were norethisterone enanthate (NET-EN) 
injectable contraceptive users (57.7%). Female condom use among those who reported condoms 
alone as a primary contraceptive was very low (n = 1). Overall, 48.6% of current contraceptive 
users (n=253) reported using dual-methods. Among current dual-method users, in addition to 
condoms, 79.7% used injectable contraceptives, followed by implants (8.8%), then IUDs (5.7%) 




Table 5.1 Frequency and distribution of current contraceptive use 
Characteristics N % 
Any current contraceptive use 
    Using modern method  
    Using traditional method 
    Not using any method  
 
 
Current use by primary method typeƗ  
 
    Condoms (only) 
    Injectable 
        NET-EN 
        DMPA 
        Not known** 
    Implants 
    IUD 
    Pills 
 
 
Method mix among current dual-method 
users  
     Injectable 
        NET-EN 
        DMPA 
        Not known** 
     Implants 
     IUD 
     Pills 
 
                      253 
                      0 
                      50 




                       70 
                       153 
                            75* 
                            55* 
                            23 
                        15 
                         8 
                         7 





    52 * 
    34 * 




Total            123 
 
83.5 








       57.7* 










     
      60.5* 
 








*Percentage of injectable method mix, exclude those who reported not knowing their particular 
injectable methods 
**Injectable method used not known 
ƗPercentage of method mix, excluding non-current contraceptive users 
 
Table 5.2 presents the distribution of the current contraceptive status by multiple levels: (1) 
individual-level factors; (2) relationship-related factors; (3) community factors; and (4) structural 
factors. Significantly more female ALHIV who had at least secondary education were current 
contraceptive users compared to those who had primary education or never attended school 
(p=0.03). Female ALHIV who had late first sexual intercourse were significantly more likely to be 
current contraceptive users compared to female ALHIV who had early first sexual intercourse 
(87.7 vs. 75.0, p=0.01). Seventy-six percent of female ALHIV who reported low perceived partner 
influence on contraceptive use were currently using a contraceptive method, compared with 90% 
of female ALHIV with higher perceived partner influence on contraceptive use (p=0.001). Female 
ALHIV who had a primary caregiver with at least secondary education most frequently used 
contraception currently (88.1%), followed by those who had a primary caregiver with primary/no 
education (77.9%) and those who were unaware of the educational status of their primary 















Table 5.2 Background characteristics of study participants by current contraceptive use 




  x2 
Individual factors  
      Age group 
  
 
      Education 
 
 
      Alcohol useƗ 
 
 
      Cigarette smoking 
 
 




      Mode of HIV infection 
 
 




      Age at sexual debut 
 




Grade 7 and above 








































































      Living children 
 
 
      Self-efficacy to use  
      Contraception 
 
      Client satisfaction with  
      contraceptive service¥ 
 
      Perceived hormonal  
      contraceptive risks  
      specific to HIV-positive  
      populations 
 
Relational factors  




      No. sex partners in past  
      12 Months 
 
     Disclosure of HIV-status to  
     partner  
 
     HIV concordance 
 
15 years and above 
 
No children 














5 years and above 
Below 5 year 
No partner 
 
None/1 sex partner 
>1 sex partners 
 
Disclosed status 



































































     Perceived peer influence on   
     contraceptive use 
 
     Parent-adolescent  
     Communication 
 
     Perceived partner influence  
     on contraceptive use 
 





Community characteristics     
     Distance from clinic 
 
 
     Perceptions of community  
     acceptance of   
     contraceptive use 
 
     HIV-felt stigma 
 
 


































































































     Current membership of    
     HIV support group 
 
      Employment 
 
 





      Current ART use 
 
 
      Receipt of contraceptive  









































































ƗEver drank alcohol 
ǂMissed taking ART during the past four days 
¥During last clinic visit 
∞Household SES (socio-economic status) calculated using principal component analysis 




5.1.2  Factors associated with current contraceptive use 
Table 5.3 displays the results of the unadjusted odds of current contraceptive use along with the 
adjusted odds of variables included in the baseline and final multivariate models. In the final 
multivariate analysis, alcohol consumption (aOR 2.23 CI 95% [1.08, 4.63]) and late first sexual 
intercourse (aOR 2.39 CI95% [1.18, 4.84]) were significantly associated with current 
contraceptive use at the individual level. Of the relational factors, having high perceived partner 
support for contraception (aOR 2.97 CI 95% [1.50, 5.87]) was associated with significantly higher 
odds of current contraceptive use in the adjusted analysis. After adjusting for other factors, no 
community factors had significant effects on current contraceptive use. At the structural level, 
belonging to households in the middle wealth index tertile was associated with significantly lower 
odds of current contraceptive use (aOR 0.25 CI 95% [0.07, 0.91]).  
 
 
Table 5.3: Multivariate correlates of current contraceptive usea 
Variables Category  cOR (95%CI) aOR (95%CI) ‡  
Individual characteristics   
      Age group 
 
 
      Alcohol useƗ 
 
 
      Age at sexual debut 
 
 
Relational characteristics    
      Perceived partner  
      influence on  
 
14 – 17 













1.74 (0.95 – 3.21) 
 
1.00 
1.93 (0.97 – 3.82) 
 
1.00 




2.89 (1.50 – 5.56) 
 
1.00 
1.36 (0.68 – 2.72) 
 
1.00 
2.23 (1.08 – 4.63) 
 
1.00 




2.97 (1.50 – 5.87) 
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      contraceptive use 
 
 
Structural characteristics  













0.26 (0.08 – 0.90) 






0.25 (0.07 – 0.91) 
0.29 (0.08 – 1.06) 
 
ƗEver drank alcohol 
‡ Variables included in the final model; significant associations (p<0.05) highlighted  
aInclude condoms as well as other forms of contraception 
 
 
5.2  Consistent contraceptive use 
 
5.2.1  Descriptive analysis: consistent condom use 
This analysis excluded female ALHIV who reported they had not had sexual intercourse during 
the three months preceding the survey. Overall, 72% (219) of the sample participants were 
sexually active during the three months preceding the survey, and of those, 67.1% reported that 
they used condoms during their last sexual intercourse (see Table 5.4). Slightly less than two-
fifths reported consistent condom use, 47.5% were inconsistent condom users and 11% did not 










Table 5.4 Frequency and distribution of indicators of consistent condom use 
 
Characteristics N % 
     
Condom useⱡ 
    Condom use at last sex 
    Condom used 
    Condom not used 
    No response+ 
 
 
Condom use in the past 3-months 
    Consistent user 
    Inconsistent user 
    Never used condoms 




                       147 
                         72 
                           0 
Total             219 
 
 
                       
                      83 
                    104 
                      24 
                        8 
















ⱡData analysis restricted to respondents who self-reported sex within 3-months before 
participation in the survey (data on self-report of sex within past 3-months are missing for only 
two participants in the entire data set N=303)  
 
 
Table 5.5 displays the bivariate data on condom use consistency by multiple levels: (1) individual-
level factors; (2) relationship-related factors; (3) community factors; and (4) structural factors. 
More than two-fifths of female ALHIV who were adherent with their ART medications used 
condoms consistently, while about one-third of those not adherent with their ART medications 
used condoms consistently and 13% of those that were ART naïve used condoms consistently 
(p=0.01). Significantly more female ALHIV who had late first sexual used condoms consistently 
compared with their peers who had early first sexual intercourse (p=0.04). Female ALHIV who 
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reported less than five –year age gaps in a current relationship most frequently used condoms 
consistently (45%), while 30% of their counterparts who reported five-or-more year age gaps in 
a current relationship used condoms consistently and 33% of those who had no sexual partners 
at the time of the survey reported consistent condom use (p=0.01). Female ALHIV reporting 
multiple sexual partnerships had a lower percentage of consistent condom use compared to 
those without multiple sexual partnerships (26% vs. 44%, p=0.01). Consistent condom use was 
significantly higher among female ALHIV reporting current use of ART compared to those who 
reported non-current use of ART (p=0.01). Also, the proportions of female ALHIV reporting 
consistent condom use vary across the tertile of wealth index (p=0.01).  
 
 
Table 5.5 Background characteristics of study participants by condom use consistency 
Variable Category Consistent condom use 
%(n) 
p-value 
  x2 
Individual factors 
    Age group    
     
 
    Education 
 
 
    Alcohol useƗ 
 
 
    Cigarette smoking 
 
 








Grade 7 and above 













































    Mode of HIV infection 
 
 




    Age at sexual debut 
 
 
    Living children 
 
 
    Self-efficacy to use  
    Contraception 
 
    Client satisfaction with  
    contraceptive service 
 
    Perceived hormonal  
    contraceptive risks specific 
    to HIV-positive populations 
 
 
Relational factors  




    No. sex partners in past 12  









Less than 15 years 
15 years and above 
 
No children 














5 years and above 
Below 5 year 
No partner 
 
None/1 sex partner 




































































    Disclosure of HIV-status to  
    partner  
 





    Perceived peer influence on  
    contraceptive use 
 
     Parent-adolescent  
     Communication 
 
     Perceived partner influence  
     on contraceptive use 
 






    Distance from clinic 
 
 
    Perceptions of community  
    acceptance of contraceptive  
    use 
 
    HIV-felt stigma 
 
Disclosed status 












































































































    Current membership of HIV  
    support group 
 
    Employment 
 
 





    Current ART use 
 
 
    Receipt of contraceptive  





















































































ƗEver drank alcohol 
ǂMissed taking ART during the past four days 
¥During last clinic visit 
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∞Household SES (socio-economic status) calculated using principal component analysis 
 
 
5.2.2  Factors associated with consistency of condom use 
Unadjusted odds and adjusted odds of consistency of condom use are summarized in Table 5.6.  
None of the individual-level factors was significantly associated with condom use consistency in 
the final adjusted analysis. At the relational level, age-disparate partnerships with age gaps of 
fewer than five years were significantly associated with consistency of condom use (aOR 1.75 CI 
95% CI [1.19, 2.57]). Female ALHIV with two or more sexual partners were significantly less likely 
to use condoms consistently compared to those with one sexual partner (aOR 0.51 CI 95% [0.26, 
0.97]). None of the community factors was significantly associated with condom use consistency 
in both unadjusted and adjusted analyses. At the structural level, belonging to households in the 
high wealth index tertile was associated with significantly lower odds of condom use (aOR 0.30 


















Table 5.6: Multivariate correlates of condom use consistency 
Variables Category cOR (95%CI) aOR (95%CI) ‡  
Individual characteristics  
    Self-efficacy 
 
 
Relational characteristics  




    No. sex partners in past 12  
    Months 
 
    Living arrangement 
 
 
Structural characteristics   




     HIV support group 
 
 







5 years and above 
Below 5 year 
No partner 
 
None/1 sex partner 





















1.93 (1.09 – 3.41) 
1.20 (0.10 – 13.70) 
 
1.00 
0.45 (0.24 – 0.84) 
 
1.00 
1.38 (0.43 – 4.46) 
1.17 (0.38 – 3.61) 
 
1.00 
0.39 (0.18 – 0.86) 
0.28 (0.12 – 0.64) 
 
1.00 
1.75 (0.96 – 3.18) 
 
1.00 
4.60 (1.32 – 15.99) 
 
1.00 




1.75 (1.19 – 2.57) 
0.81 (0.07 – 9.84) 
 
1.00 
0.51 (0.26 – 0.97) 
 
1.00 
0.91 (0.32 – 2.58) 
0.77 (0.28 – 2.09) 
 
1.00 
0.48 (0.16 – 1.48) 
0.30 (0.10 – 0.87) 
 
1.00 
1.57 (0.97 – 2.53) 
 
1.00 
3.44 (0.90 – 13.23) 
 
‡ Variables included in the final model; significant associations 




5.2.3 Descriptive analysis: consistent use of other contraceptive 
methods and dual-methods 
Also, this analysis (Table 5.7) excluded female ALHIV who reported they had not had sexual 
intercourse during the three months preceding the survey. More than two-thirds (66.7%) of 
sexually active female ALHIV reported using a contraceptive method other than condoms for 
their last sexual intercourse, with considerably fewer (46.3%) relying on the contraceptive 
methods consistently; slightly more than a fifth (21.0%) and fewer than a third (31.7%) reported 
inconsistent contraceptive method use or ‘contraceptive-method non-use’, respectively, during 
the three months preceding survey. About half (49.3%) of female ALWH who were sexually active 
during the three months preceding the survey relied on dual-methods for their last sexual 
intercourse, while only 20.6% consistently used dual methods.  
 
 
Table 5.7 Frequency and distribution of indicators of consistent use of other contraceptive 
methods and dual-methods  
 
Characteristics N % 
     
Contraception use (other than condoms) ⱡ 
    Other methods use at last sex 
    Other methods used 
    Other methods not used 
    No response+ 
 
 
   Other methods use in the past 3-months 
   Consistent user 
   Inconsistent user 
   Never used  
 
 
                       
                   146 
                     73 
                       0 
Total          219 
 
 
                    101 
                      46 















   No response+ 
 
 
Dual method useⱡ 
    Dual method use at last sex 
    Dual method used 
    Dual method not used 
    No response+ 
 
 
Dual method use in the past 3-months 
    Consistent user 
    Inconsistent user 
                        2 




                   108 
                   111 
                       0 
Total         219 
 
 
                     45 
                   173 
Total          218 







  0.0 








Table 5.8 displays the bivariate data on dual-method use consistency by multiple levels: (1) 
individual-level factors; (2) relationship-related factors; (3) community factors; and (4) structural 
factors. Compared to female ALHIV reporting higher levels of perceived partner influence on 
contraceptives, female ALHIV reporting low perceived partner influence on contraceptive use 
had a lower percentage of dual-method use consistency (p=0.01). Dual-method use consistency 
is significantly different across the strata of partner age-gap (p=0.001), with the lowest 
percentage among female ALHIV in age-disparate partnerships involving an age gap of five or 
more years higher (13%). Significantly more female ALHIV reporting current use of ART used dual-







Table 5.8 Background characteristics of study participants by dual-method use consistency 
Variable Category Consistent dual-method use 
%(n) 
p-value 
  x2 
Individual factors  
    Age group        
 
 
    Education 
 
 
    Alcohol useƗ 
 
 
    Cigarette smoking 
 
 
  Time enrolled in the clinic 
 
 
     
     Mode of HIV infection 
 
 




    Age at sexual debut 
 
 
    Living children 
 























Less than 15 years 































































    Self-efficacy to use  
    contraception 
 
    Client satisfaction with  
    contraceptive service 
 
    Perceived hormonal  
    contraceptive risks  
    specific to HIV-positive  
    populations 
 
 
Relational factors    
    Partner age-gap 
 
 
 No. sex partners in  
    past 12 months 
 
    Disclosure of HIV- 
    status to partner  
 





   Perceived peer  
   influence on  
   contraceptive use 














5 years and above 
Below 5 year 
No partner 
 
None/1 sex partner 
>1 sex partners 
 
Disclosed status 













































































   Parent-adolescent  
   communication 
 
   Perceived partner  
   influence on  
   contraceptive use 
 




Community factors     
   Distance from clinic 
 
 
   Perceptions of  
   community acceptance   
   of contraceptive use 
 




Structural factors     
   Household SES∞ 
    
 
 
   Parental education 





































































































   Current membership of   
   HIV support group 
 
   Employment 
 
 





   Current ART use 
 
 
   Receipt of contraceptive  




















































ǂMissed taking ART during the past four days 
¥During last clinic visit 
∞Household SES (socio-economic status) calculated using principal component analysis 
 
 
5.2.4  Factors associated with consistent use of dual-methods 
Unadjusted odds and adjusted odds of consistency of condom use are presented in Table 5.9.  
Controlling for all other factors, the only individual-level factor that significantly increased the 
likelihood of consistent dual-method use include late first sexual intercourse (aOR 1.83 CI 95% 
[1.10, 3.04]). At the relational level, age-disparate partnerships with age gaps of fewer than five 
years were significantly associated with dual-method use (aOR 2.41 CI 95% [1.14, 5.11]). 
Furthermore, higher levels of perceived partner influence on contraceptive use were significantly 
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associated with dual-method use consistency (aOR 2.69 CI 95% [1.30, 5.52]). None of the 
community or structural factors was significantly associated with dual method use consistency in 
both unadjusted and adjusted analyses.  
 
 
Table 5.9: Multivariate correlates of dual-method use consistency 
Variables Category cOR (95%CI) aOR (95%CI) ‡ 
Individual characteristics  




Relational characteristics     





    Perceived peer influence on  
    contraceptive use 
 
 
    Perceived partner influence  








5 years and above 

















2.46 (1.19 – 5.09) 








2.40 (1.20 – 4.83) 
 
1.00 





2.41 (1.14 – 5.11) 








2.69 (1.30 – 5.52) 
 




5.3 Unmet need for contraception 
 
5.3.1  Descriptive analysis 
Overall, unmet need for contraception was higher among the sampled female ALHIV when 
condom use consistency was taken into account compared to when assessed based on the 
standard DHS definition (23.8%; n=72 vs 10.6%; n=32). Among female ALHIV who were sexually 
active within the three months preceding the survey (n=219), a total of 17.4% (n=38) had an 
unmet need for contraception when condom use consistency was taken into account. Table 5.10 
displays the bivariate data on unmet needs for contraception when condom consistency was 
taken into account, by multilevel characteristics: (1) individual-level factors; (2) relationship-
related factors; (3) community factors; and (4) structural factors. Unmet need for contraception 
varied significantly across the duration of enrolment in the clinic, with female ALHIV who had 
been in HIV care and treatment for more than two years having the lowest frequency of unmet 
need for contraception (10.5%). Unmet need for contraception was significantly higher among 
female ALHIV reporting lower satisfaction with contraceptive service compared to those who 
reported high satisfaction with contraceptive service (p=0.01). Female ALHIV reporting lower 
peer influence on contraceptive use had a higher unmet need for contraception compared to 
their peers who reported high peer influence on contraceptive use (p=0.004).  Compared to 
female ALHIV who reported higher partner influence on contraception, unmet need for 
contraception was significantly higher among female ALHIV who reported low partner influence 










Table 5.10: Background characteristics of study participants by an unmet need for contraception  
 
Variable Category Unmet needs 
%(n) 
p-value 
  x2 
Individual factors  
    Age group 
 
 
    Education 
 
 
    Alcohol useƗ 
 
 
    Cigarette smoking 
 
 




    Mode of HIV infection 
 
 




    Age at sexual debut 
 














































































    Living children 
 
 
    Self-efficacy to use  
    Contraception 
 
    Client satisfaction with  
    contraceptive service¥ 
 
    Perceived hormonal  
    contraceptive risks  
    specific to HIV-positive  
    populations  
 
Relational factors  




    No. sex partners in past  
   12 months 
 
    Disclosure of HIV-status  
    to partner  
 
    HIV concordance 
 
15 years and above 
 
No children 














5 years and above 
Below 5 year 
No partner 
 
None/1 sex partner 
>1 sex partners 
 
Disclosed status 



































































    Perceived peer influence  
    on contraceptive use 
 
 
    Parent-adolescent  
    Communication 
  
    Perceived partner  
    influence on  
    contraceptive use 
 




Community factors  
   Distance from clinic 
 
 
   Perceptions of community  
   acceptance of   
   contraceptive use 
 





























































































Structural factors   








   Current membership of  
   HIV support group 
 
    Employment 
 
 





     Current ART use 
 
 
     Receipt of contraceptive  















































































ƗEver drank alcohol 
ǂMissed taking ART during the past four days 
¥During last clinic visit 
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∞Household SES (socio-economic status) calculated using principal component analysis 
 
5.3.2  Factors associated with unmet need for contraception 
Table 5.11 displays unadjusted odds of unmet need for contraception when condom consistency 
was taken into account along with the adjusted odds of unmet needs for contraception by 
independent variables included in the baseline and final multivariate models. Individual factors 
associated with unmet need for contraception after adjusting for confounders include: age, with 
the age group 18 -19 having reduced odds of unmet need than the age group 14 – 17 (aOR 0.55 
95% CI [0.32, 0.95]); duration of enrolment in the clinic, with those who had enrolled more than 
two years in the clinic having reduced odds than those who enrolled in the clinic less than one 
year (aOR 0.23 95% CI [0.11, 0.48]); adherence to ART, with those who were not adherent to ART 
having increased odds of unmet need than those who were ART naïve (aOR 3.76 95% CI [1.29, 
10.99]). At the relational-level, female ALHIV reporting higher perceived partner influence on 
contraceptive use had reduced odds of unmet need for contraception compared with those 
reporting low partner influence on contraceptive use (aOR 0.43 95% CI [0.25, 0.72]). Those who 
reported not having current sexual partners were significantly more likely to have an unmet need 
for contraception compared to those with age-disparate partnerships with age gaps more than 
five years (aOR 2.77 95% CI [1.07, 7.21]). None of the community factors was significantly 
associated with unmet need for contraception in the adjusted analysis. At the structural-level, 
female ALHIV who had a parent with at least a secondary education had reduced odds of unmet 
need for contraception than those who had parents with lower educational status (aOR 0.54 95% 









Table 5.11: Multivariate correlates of unmet need for contraception 
Variables Category cOR (95%CI) aOR (95%CI) ‡ 
Individual characteristics    
   Age group  
 
 








   
Client satisfaction with  
    contraceptive service¥ 
 





Perceived peer influence  
      on contraceptive use 
 
Perceived partner influence  





14 – 17 
18 - 19 
 
< 1 year 
  1 – 2 years 
  Over 2 years 
 









5 years and above 














0.60 (0.35 – 1.03) 
 
1.00 
1.03 (0.56 – 1.90) 
0.32 (0.13 – 0.81) 
 
1.00 
2.50 (0.79 – 7.93) 








1.04 (0.59 – 1.83) 
2.59 (0.82 – 8.21) 
 
1.00 
0.46 (0.26 – 0.79) 
 
1.00 







0.55 (0.32 – 0.95) 
 
1.00 
0.75 (0.43 – 1.30) 
0.23 (0.11 – 0.48) 
 
1.00 
3.76 (1.29 – 10.99) 








1.16 (0.63 – 2.11) 
2.77 (1.07 – 7.21) 
 
1.00 
0.53 (0.29 – 0.97) 
 
1.00 























0.60 (0.32 – 1.12) 





1.24 (0.73 – 2.11) 
1.00 
0.54 (0.34 – 0.84) 





1.67 (0.93 – 2.98) 
 
‡ Variables included in the final model; significant associations (p<0.05) highlighted 
ǂMissed taking ART during the past four days 
¥During last clinic visit 
∞Household SES (socio-economic status) calculated using principal component analysis 
 
5.4           Unintended pregnancy  
 
5.4.1  Descriptive analysis 
A total of 58 female ALHIV reported ever being pregnant, and 18.8% (n=57) reported ever having 
an unintended pregnancy since testing HIV positive. Only 0.3% (n=1) of the sample participants 
reported having a planned pregnancy since testing HIV positive. Of the 57 participants reporting 
unintended pregnancies, 89.5% said the pregnancies were unwanted or mistimed and failed 
contraception was responsible for 24.6% of the total unintended pregnancies. Unintended 
pregnancies vary significantly across some multilevel characteristics (Table 5.12).  
 
Significantly more female ALHIV who smoked cigarettes reported unintended pregnancy 
compared to those who did not smoke cigarettes (32.1 vs. 15.8, p=0.05). A significantly higher 
proportion of hALHIV reported unintended pregnancy compared to pALHIV (p<0.001). 
Unintended pregnancy varies across the strata of ART adherence, with the lowest percentage 
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among female ALHIV who were not adherent to ART (11.8%). Compared to female ALHIV who 
had no living children, unintended pregnancy was significantly higher among female ALHIV who 
had one or more living children (<0.001). The reported rate of unintended pregnancy was higher 
among female ALHIV who did not disclose their HIV status to a partner compared to those who 
disclosed their HIV status to a partner (24.5% vs. 14%, p=0.02). The rates of unintended 
pregnancy vary across the strata of the variable ‘HIV concordance’, with female ALHIV in sero-
concordant relationships having the highest frequency of unintended pregnancy (32.1%). Female 
ALHIV reporting higher parent-child communication had higher unintended pregnancy compared 
to their peers reporting low parent-child communication (p=0.03).    
 
Table 5.12: Background characteristics of study participants by unintended pregnancy  




  x2 
Individual factors  
    Age group        
 
 
    Education 
 
 
    Alcohol useƗ 
 
 
    Cigarette smoking 
 
 






















































    Mode of HIV infection 
 
 




    Age at sexual debut 
 
 
     Living children 
 
 
     Self-efficacy to use  
     contraception 
 
     Client satisfaction with   
     contraceptive service¥ 
 
      Perceived hormonal  
      contraceptive risks  
      specific to HIV-positive  

















Less than 15 years 
15 years and above 
 
No children 















5 years and above 
Below 5 year 
No partner 
 



































































     12 months 
 
     Disclosure of HIV-status  
     to partner  
 
 





      Perceived peer influence  
      on contraceptive use 
 
      Parent-adolescent  
      Communication 
 
      Perceived partner  
      influence on  
      contraceptive use 
 






    Distance from clinic 
 
 
    Perceptions of community  
    acceptance of  
>1 sex partners 
 
Disclosed status 































































































    contraceptive use 
 





    Household SES∞ 
 
     
 
     Parental education 
 
      
 
     Current membership of  
     HIV support group 
 
      Employment 
 
 





      Current ART use 
 
 
     Receipt of contraceptive  

































































































ƗEver drank alcohol 
ǂMissed taking ART during the past four days 
¥During last clinic visit 
∞Household SES (socio-economic status) calculated using principal component analysis 
 
5.4.2  Factors associated with unintended pregnancy 
Table 5.13 displays the odds of unintended pregnancy by the background characteristics included 
in the unadjusted and adjusted models. Of the individual-level factors, cigarette smoking (aOR 
4.24 CI 95% [2.03 – 8.87]) and having one or more living child (aOR 31.21 CI 95% [12.18 – 80.02]) 
were significantly associated with increased likelihoods of unintended pregnancy after the final 
multivariable adjustment. Furthermore, enrolment in HIV care for 1-2 years at the current clinics 
(aOR 0.18 CI 95% [0.07 – 0.45]) was associated with reduced likelihoods of unintended 
pregnancy. 
 
At the relational level, being unaware of a partner’s HIV status (aOR 0.41 CI 95% [0.25 – 0.69]) 
and higher levels of perceived parent-child communication about contraception (aOR 2.76 CI 95% 
[1.16 – 6.58]) were associated with unintended pregnancies in the final multivariate model. At 
the structural level, belonging to households in the high wealth index tertile (aOR 3.70 CI 95% 
[1.27, 10.77]) and receipt of contraceptive counselling (aOR 2.92 CI 95% [1.29, 6.63]) were 










Table 5.13: Multivariate correlates of unintended pregnancy 
Variables Category cOR (95%CI) aOR (95%CI)‡ 
Individual characteristics       
   Cigarette smoking 
 
 




   No. of living children 
 
 
Relational characteristics      





   Parent-adolescent  
   communication 
 





Perceptions of community 







< 1 year 
 1 – 2 years 
 Over 2 years 
 
No children 






















2.53 (1.31 – 4.87) 
 
1.00 
0.26 (0.11 – 0.65) 
0.66 (0.31 – 1.43) 
 
1.00 




1.81 (0.84 – 3.90) 




2.18 (1.05 – 4.54) 
 
1.00 
0.30 (0.10 – 0.90) 









4.24 (2.03 – 8.87) 
 
1.00 
0.18 (0.07 – 0.45) 
0.56 (0.20 – 1.60) 
 
1.00 




0.90 (0.16 -5.04) 




2.76 (1.16 – 6.58) 
 
1.00 
2.15 (0.29 – 15.94) 





































1.56 (0.60 – 4.06) 
2.52 (0.97 – 6.56) 
 
1.00 
1.54 (0.80 – 2.97) 
1.00 





3.01 (0.95 – 9.61) 
3.70 (1.27 – 10.77) 
 
1.00 
2.92 (1.29 – 6.63) 
 














6.   The relationship between mode of HIV acquisition,  
contraceptive service uptake and service delivery  
This chapter evaluates the independent association between mode of HIV acquisition and the 
measures of access to and use of contraceptive services, and service delivery preferences among 
female ALHIV after testing positive for HIV. Here, the focus is on the differences in access to 
contraceptive services, current contraceptive use, unmet needs for contraception, and 
unintended pregnancies between two distinct groups of female ALHIV, hALHIV and pALHIV, after 
adjusting for potential confounders. Also, results are presented on how the measures of service 
delivery preferences, including provider age, gender, and continuity as well as access site, vary 
depending on the mode of HIV acquisition after adjusting for potential confounders. For each 
measure of contraceptive utilisation and service delivery preferences, the descriptive statistics 
are described first, followed by multivariable regression results. 
 
 
6.1        Participant characteristics across hALHIV and pALHIV groups 
In total, 303 sampled participants were included in the analysis. Based on participants’ reports, 
HIV-infection was acquired through horizontal and perinatal/postnatal transmission routes in 
203 (67%) and 100 (33%) female ALHIV, respectively (see Table 5.2). Of the female hALHIV, 72.4% 
reported that they contracted HIV via sexual intercourse, 5.9% via rape, 2.5% via caring for an 
HIV-infected family member, and 19.2% via an unknown behavioural route.  
 
Table 6.1 displays the selected characteristics (i.e., considered potential confounding variables) 
of the participants, by the reported mode of HIV acquisition. Female hALHIV were more likely to 
be older, consume alcohol, smoke cigarettes, adherent to ART, have one or more child, and living 
with a male partner or alone, but were less likely to enrol in HIV care for less than one year, 
engage in late first sexual intercourse, have partner age-gaps fewer than five years, disclose HIV 
status to a partner, be in serodiscordant relationships, higher perceived HIV-felt stigma, current 
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Table 6.1: Demographic characteristics of study participants, by mode of HIV acquisition 
 


















Time enrolled at the 
clinic                                   
 
 




















Not on ART 







































































































No. sex partners in 
past 12 months            
 
Disclosure of HIV-
status to partner 
 






Less than 15 years                                                          
15 years and above 
 
No children                                                            









5 years and above
Below 5 years 
No partner 
 
None/1 sex partner 
>1 sex partners 
 
Disclosed status                                      
Status not disclosed 
 
Sero-discordant                               
Sero-concordant 




























































































































Distance from clinic         
                 













membership of HIV 
support group 
 





















None/primary                                   

















































































































































ƗEver drank alcohol 
ǂMissed taking ART during the past four days 
¥During last clinic visit 
∞Household SES (socio-economic status) calculated using principal component analysis 
*significance at p<0.05 
 
 




6.2.1  Descriptive statistics  
Table 6.2 displays data on the receipt of contraceptive services, including contraceptive 
counselling, condom provision, and dual-method provision, by mode of HIV acquisition. 
Significantly higher receipt rates of contraceptive counselling and condom were noted among 
female pALHIV compared to their hALHIV counterparts (76.0% vs 64.5%, p=0.04). In contrast, a 
relatively higher percentage of female hALHIV received dual-method provision (36.9% vs 31.3%, 








Table 6.2: Frequency and proportion of participants reporting receipt of contraceptive 






 % (N) 
Mode of HIV acquisition P-value 
(x2) 
hALHIV 
% (n)  
pALHIV 














     
Yes 
 








35 (100) 36.9 (73) 31.3 (31) 
 
0.34 
      
      








6.2.2  Association between mode of HIV acquisition and receipt of  
contraceptive services 
Table 6.3 shows the results of the crude and adjusted analysis of the association between the 
mode of HIV acquisition and the receipt of the following contraceptive services: contraception 
counselling, condom, and dual-method contraception. The unadjusted analysis revealed that 
female pALHIV had a 74% significant increase in the odds of receiving contraception counselling 
(cOR 1.74 95% CI [1.01, 2.99]). In the Mantel-Haenszel stratified analysis of the association 
between the mode of HIV acquisition and the receipt of contraception counselling, there was no 
evidence of effect modification across the potential confounders. Adjusting for the potential 
confounders, there was no evidence of an association between the mode of HIV acquisition and 
the receipt of contraception counselling (aOR 0.90 95% CI [0.59, 1.38]).  
 
The association between the mode of HIV acquisition and the receipt of condoms after testing 
positive for HIV is shown in Table 6.3. In the crude analysis, there was evidence of an association 
between mode of HIV acquisition and the receipt of condoms, with female pALHIV having lower 
odds of the receipt of condoms compared to their hALHIV (cOR 0.52 95% CI [0.31, 0.87]).  The 
Mantel-Haenszel stratified analysis revealed evidence of effect modification by participants’ age 
status or receipt of contraception counselling. In the final multivariate analysis, adjusting for 
confounding and effect modification, there was no evidence for an association between mode of 
HIV acquisition and the receipt of condoms (aOR 0.14 95% CI [0.01, 1.80]). However, the effect 
of ‘mode of HIV acquisition’ on the receipt of condoms differed by age status or receipt of 
contraception counselling (interaction p<0.05); with higher odds of receipt of condoms among 
older ALHIV and those reporting receipt of contraception counselling compared to young ALHIV 
and those who did not report receipt of contraception counselling, respectively. Results from the 
Wald test conducted on the final multivariate model demonstrated statistical evidence for 
interaction and was thus considered appropriate to include interaction terms in the final model.  
 
Turning to receipt of dual-method contraception (Table 6.3), there were no significant 
differences in the receipt of dual-method contraception across hALHIV and pALHIV in the crude 
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analysis (cOR 0.78 95% CI [0.48, 1.31]). The Mantel-Haenszel test for the homogeneity of the 
odds revealed that the effect of the mode of HIV acquisition on the receipt of dual-method 
contraception was modified by the age status or access to HIV support groups (p<0.05). In the 
final multivariate model including potential confounders and interaction terms, pALHIV had non-
significant lower odds of receiving dual-method contraception compared to hALHIV (aOR 0.02 
95% CI [0.00, 0.38]). The Wald statistic showed evidence of an interaction. Additionally, the effect 
of mode of HIV-acquisition differed by participants’ age status or access to a youth support group 
(p<0.05). 
 
Table 6.3: Crude and adjusted association between mode of HIV acquisition and receipt of 
contraceptive services 
 
Mode of HIV 
acquisition 




     hALHIV 






































































0.02 (0.00 – 0.38)3 
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*Adjusted model without interaction 
**Adjusted model with an interaction term(s) 
1Adjusted for individual factors (duration of enrolment in HIV care, Art adherence, client 
satisfaction score), relational factor (partner age-gap) and structural factors (household wealth 
status, access to HIV support group, clinic model).  
2Adjusted for individual factors (age, cigarette smoking, duration of enrolment in HIV care, ART 
adherence, sexual debut, client satisfaction score), relational factors (partner age-gap, HIV 
concordance) and structural factors (access to HIV support group, receipt of contraception 
counselling) 
3Adjusted for individual factors (age, education, alcohol consumption, duration of enrolment in 
HIV care, sexual debut, living child, client satisfaction score), relational factors (partner age-gap, 
number of sex partners, HIV concordance, living arrangement), community factors (perception 
of community acceptance of contraception, HIV felt-stigma) and structural factors (parental 
education, access to HIV support group, employment status, clinic model, receipt of 
contraception counselling) 
Significant variables at p<0.05 highlighted  
 
aInclude condoms as well as other forms of contraception 
 
bFrom public health service 
 
 
6.3 Mode of HIV acquisition and contraceptive usage 
 
6.3.1  Descriptive statistics 
Table 6.4 shows the results of the indicators of contraceptive usage by the mode of HIV 
acquisition. The percentage of current contraceptive users was higher among female pALHIV 
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compared to their hALHIV counterparts (87.0 % vs. 81.8%, p=0.27). Among both distinct groups 
of female ALHIV, the majority of current contraceptive users reported using injectable 
contraceptives, followed by condoms alone, then implants, IUDs and hormonal pills. When 
injectable method mix is considered, a higher proportion of both distinct groups of female ALHIV 
reported NET-EN injectable contraception. Current contraceptive method mix did not vary across 
mode of HIV acquisition, except dual method use (p=0.007). Regarding the unmet need for 
contraception after accounting for condom use consistency, 24.6% of female hALHIV had unmet 
need, compared to 22% of pALHIV counterparts (p=0.61).  A relatively higher percentage of 
female hALHIV reported experiencing unintended pregnancies after testing positive for HIV 
(24.6% vs. 7.0%, p<0.001).  The percentages of female ALHIV reporting experience of mistimed 
(86.4% vs. 13.6%, p=0.52) or unwanted pregnancy (82.9% vs. 17.1%, p=0.14) were greater among 
female hALHIV compared to female pALHIV. 
 
 
Table 6.4: Current contraceptive use, by mode of HIV acquisition 
Characteristics All female 
ALHIV 
 % (N) 
Mode of HIV acquisition P-
value 
(x2) 
hALHIV % (n) pALHIV % (n) 
Current use (all 
modern methods)  
(N=253) 

















Current use by 
primary method 
typeƗ (N=253) 
    Condoms (only) 
    Injectable 
        NET-EN 





60.5 (153)  
        57.7 (75)* 






      54.4 (49)* 






      65.0 (26)*  










        Not known** 
    Implants 
    IUD 
    Pills 
   
                 (23) 
   5.9 (15) 
   3.2 (8) 
   2.7 (7) 




                (10) 
  5.6 (5) 
  2.3 (2) 























     Injectable 
        NET-EN 
        DMPA 
        Not known** 
     Implants 
     IUD 






       60.5 (52) * 
       39.5 (34) * 
                (12) 
  8.8 (11) 
  5.7 (7) 






      57.1 (32) * 
      42.9 (24) * 
                 (6) 
 7.7 (6) 
 6.5 (5) 






      66.7 (20) * 
      33.3 (10) * 
                (6) 
11.2 (5) 
  4.4 (2) 












Unmet need for 
contraception     






































**Injectable method used not known 
ƗPercentage of method mix, excluding non-current contraceptive users 
 
6.3.2  Association between mode of HIV acquisition and  
contraceptive usage 
Crudely, the odds of current contraceptive use were significantly higher in female pALHIV 
compared to female hALHIV (cOR 1.49 95% CI [0.75, 2.95]; Table 6.5). Although there was 
evidence of effect modification by participants’ age status, alcohol consumption or household 
wealth status (p<0.05), the inclusion of the interaction terms in the final regression model would 
violate the EPV criterion guiding the statistical analysis in this thesis. Therefore, I considered it 
appropriate to exclude the interaction terms from the final regression model. The odds of current 
contraceptive use were not significantly higher in female pALHIV compared to their hALHIV 
counterparts (aOR 1.23, 95% CI [0.52, 2.92]); Table 6.5), adjusting for potential confounders. 
 
Unadjusted models indicate that female pALHIV had lower odds of unmet need for contraception 
(cOR 0.93 95% CI [0.57, 1.51]) and unintended pregnancies (cOR 0.23 95% CI [0.10, 0.53]) 
compared to their hALHIV counterparts (Table 6.5). The stratified analysis revealed that 
household wealth status modified the effect of the mode of HIV acquisition on unmet needs for 
contraception, with the wealthiest households having lowest odds of unmet needs (p<0.05), but 
there was no evidence of effect modification of the relationship between unintended pregnancy 
and mode of HIV acquisition. Mode of HIV acquisition was not associated with unmet needs for 
contraception, after adjusting for potential confounders and the interaction term (aOR 2.83 95% 
CI [0.26, 30.65]); Table 6.5). Wald test assessing the significance of the interaction between the 
mode of HIV acquisition and household wealth status indicated statistical evidence for 
interaction (p<0.05). Thus, the final multivariate model including the interaction term was 
considered appropriate. For unintended pregnancy, female pALHIV had statistically significant 
slightly higher odds of unintended pregnancies compared to female hALHIV (aOR 1.02 95% CI 





Table 6.5: Crude and adjusted association between mode of HIV acquisition and contraceptive 
usage 
 
Mode of HIV 
acquisition 
































































1.02 (0.39 – 2.67)3 
 











             - 
 
*Adjusted model without interaction 
**Adjusted model with an interaction term(s) 
1Adjusted for individual factors (age, alcohol consumption, cigarette smoking, sexual debut), 




2Adjusted for individual factors (age, duration of enrolment in HIV care, Adherence to ART, living 
child/children, client satisfaction with contraceptive service, sexual debut, living child/children, 
client satisfaction with contraceptive service), relational factors (partner age-gap), and structural 
factors (household wealth status)  
3Adjusted for individual factors (age, education, cigarette smoking, duration of enrolment in HIV 
care, ART adherence, living child/children), relational factors (partner age-gap, disclosure of HIV 
status to partner), community factors (HIV felt-stigma) and structural factors (clinic model) 
Significant variables at p<0.05 highlighted  
 
aInclude condoms as well as other forms of contraception 
 
 
6.4 Mode of HIV acquisition and service delivery preferences 
 
6.4.1  Descriptive statistics 
Horizontally HIV infected female adolescents, compared to female pALHIV, displayed relatively 
higher percentages of participants reporting preferences for clinician continuity (69.8% vs. 30.2%, 
p=0.11), female providers (63.5% vs. 33.5%, p=0.10) and stand-alone youth clinics (69.8% vs. 
30.2%, p=0.48) across visits for contraceptive services, respectively. In terms of preferences for 











6.4.2  Association between mode of HIV acquisition and service  
delivery preferences 
Table 6.6 displays the unadjusted and adjusted odds of the associations between the mode of 
HIV acquisition and the measures of female ALHIV service delivery preferences. The Mantel-
Haenszel stratified analysis of the association between the mode of HIV acquisition and the 
female ALHIV preference for clinician continuity across contraceptive service visits by potential 
effect modifiers revealed no significant effect modification. Results from the crude analysis 
showed that there was no evidence for an association between mode of HIV acquisition and 
preference for clinician continuity at contraceptive service visits (cOR 0.66 95% CI [0.39, 1.10]). 
After adjusting for potential confounders, female pALHIV showed a lower likelihood to consider 
clinician continuity at contraceptive service visits important, but this finding was not statistically 
significant (aOR 0.89 95% CI [0.52, 1.54]).  
Crudely, mode of HIV acquisition was not associated with preference for female providers among 
female ALHIV (cOR 1.54 95% CI [0.93, 2.56]). In the Mantel-Haenszel stratified analysis, there was 
significant evidence that the association of the mode of HIV acquisition with the female ALHIV 
preference for female providers differed depending on the travel times from their homes to the 
clinic (p<0.05).  Results from the final multivariate model including potential confounders and the 
interaction term showed that female pALHIV had a significant increased likelihood to prefer a 
female provider for contraceptive services after (aOR 5.11 95% CI [1.25 – 20.91]). The interaction 
between the mode of HIV acquisition and the travel times from home to the clinic was significant 
in the final regression model (p<0.05). Wald test assessing the significance of the interaction term 
indicated statistical evidence for interaction (p<0.05).  
 
In the unadjusted analysis, female pALHIV had a significantly increased likelihood to report 
preferences for youth contraceptive service providers between 15 – 24 years of age compared 
to female hALHIV (cOR 2.40 95% CI [1.36, 4.24]). This association was stronger after adjusting for 
potential confounders (aOR 4.45 95% CI [2.84, 6.97]). The final regression model did not include 





In the unadjusted analysis, female ALHIV preferences for stand-alone youth facilities for 
contraceptive services did not significantly differ between hALHIV and pALHIV (cOR 0.84 95% CI 
0.52, 1.38). There was evidence of effect modification by clinic model or household wealth status 
(p<0.05). Perinatally/postnatally HIV infected female adolescents had significantly increased 
odds to report preferences for stand-alone youth facilities compared to female hALHIV (aOR 7.01 
95% CI [2.39, 20.55]), after adjusting for potential confounders and the interaction terms. The 
interaction between the mode of HIV acquisition and clinic model or household wealth status 
were significant in the final multivariate model (p<0.05), and Wald test demonstrated statistical 
evidence for interaction (p<0.05). 
 

























































4.45 (2.84 – 6.97)3 
 
 





































7.01 (2.39 – 20.55)4 
 
*Adjusted model without interaction 
**Adjusted model with an interaction term(s) 
1Adjusted for individual factors (alcohol consumption, duration of enrolment in HIV care, ART 
adherence), relational factor (partner age-gap, number of sex partners, disclosure of HIV status 
to partner, HIV concordance) and structural factors (household wealth status) 
2Adjusted for individual factors (age, duration of enrolment in HIV care, ART adherence, living 
child/children), relational factors (partner age-gap, number of sex partners, disclosure of HIV 
status to partner, HIV concordance, living arrangement), community factors (distance from the 
clinic, perceptions of community acceptance of contraception) and structural factors 
(household wealth status, clinic model) 
3Adjusted for individual factors (duration of enrolment in HIV care, living child/children), 
relational factors (partner age-gap, disclosure of HIV status to partner, HIV concordance), 
community factors (distance from the clinic, perception of community acceptance of 
contraception)  
4Adjusted for individual factors (age, duration of enrolment in HIV care, sexual debut, living 
child/children), relational factors (HIV concordance), community factors (distance from the 
clinic) and structural factors (household wealth status, access to HIV support group, clinic 
model, access to ART medications, receipt of contraceptive counselling) 




7.  Hormonal contraceptive-related safety considerations and 
contraceptive use among female ALHIV 
This chapter focuses on the independent relationship between perceived hormonal 
contraceptive-related safety considerations specific to HIV-positive populations and the current 
contraceptive method use among female ALHIV. First, the selected background characteristics of 
the study participants by the current contraceptive method use are presented. Thereafter, the 
perception of female ALHIV of hormonal contraceptive-related safety considerations in HIV-
positive populations is described. Finally, the associations between perceived hormonal 




7.1   Participant characteristics by contraceptive use 
The descriptive statistics of the study sample by contraceptive method use are summarised 
across the potential confounders of the relationship between perceived hormonal contraceptive-
related safety considerations and the current contraceptive method use (Table 7.1). This analysis 
included all the 303 female ALHIV included in the final quantitative analysis of this thesis (see 
Chapter 4). As emphasised in Chapter 4, 16.5% of female ALHIV reported not currently using any 
method of contraception. Approximately three-fifths (57.8%, n=175) of female ALHIV reported 
current use of any hormonal method of contraception – injectable contraception (50.5%, n=153) 
was the most commonly reported hormonal method, followed by implants (5%, n=8) and oral 
pills (2.3%, n=7), and the remaining 25.7% (condoms alone [23.1%, n=70] and IUD alone [2.6%, 
n=8]) reported current use of barrier contraception (condoms or IUD) alone. The mean age of 
female ALHIV was comparable across contraceptive method use (p=0.67). Contraceptive use 
varied significantly by participant age status, age at sexual debut, perceived peer influence on 
contraceptive use, perceived partner influence on contraceptive use, perceptions of community 




7.1 Demographic characteristics of study participants, by current contraceptive method   
      use.  
 
























Age at sexual 










14-17                                                                 
18-19 
 





Grade 7 and 
above 
 
Less than 15 
years                                                              

























































































































































None/primary                                                                     
Secondary 





















































































































7.2   Perception of hormonal contraceptive-related safety  
considerations  
The aggregate mean perceived hormonal contraceptive-related safety considerations’ scores 
were slightly higher among female ALHIV reporting current use of barrier contraception (2.73, SD 
0.81) or non-current use of any modern contraception (2.66, SD 0.82) than female ALHIV 
reporting current use of hormonal contraception (2.53 SD 0.79). Data not shown. The aggregate 
mean scores were not significantly different between the three groups of contraceptive method 
use (p=0.92).  
 
Table 7.2 displays the responses of female ALHIV to a series of statements regarding hormonal 
contraceptive-related safety considerations specific to HIV-positive populations. The majority of 
respondents disagreed or strongly disagreed with the series of statements regarding the 
hormonal contraceptive related safety issues in HIV positive populations. Interestingly, the 
minority of respondents strongly perceived that hormonal contraceptive use would accentuate 
HIV-disease progression (4.9%) or reduce the efficacy of antiretroviral medications (8.3%). 
Appreciable proportion (19.5%) of respondents strongly believed that hormonal contraceptive 
use would increase the risk of heterosexual transmission of HIV, and a similar proportion (21.4%) 
strongly perceived that hormonal contraceptive failures would increase in women living with HIV 












Table 7.2:  Perception of female ALWH on hormonal contraceptive-related safety 
considerations in HIV-positive populations 
 
Specified statement 
preceded by: “In your 
case:” 
                                                      Agreement 
Strongly 
agree 
    % 
Agree 
    % 
Intermediate 





   % 
Using hormonal 
contraceptive could 
make HIV disease 
progression to occur 
quickly?  
4.9 11.6 16.5 39.3 27.7 
Hormonal contraceptive 
use could make passing 
HIV to an uninfected 
male sexual partner to 
be more able? 
19.5 19.8 11.9 27.7 21.1 
The ability of HIV 
treatments/medications 
to fight HIV /AIDS could 
be reduced with 




8.3 12.9 16.2 32.3 30.3 
Birth control failure (i.e 
a possibility of getting 
pregnant) could be 
more if hormonal 
21.4 17.2 12.9 27.1 21.4 
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contraceptive is used 
concurrently with HIV 
medications because of 
the possible alterations 
in its ability to prevent 





7.3  Associations between perceived hormonal contraceptive-
related safety considerations and contraceptive uptake 
Table 7.3 displays the unadjusted and adjusted results of the multinomial regression analysis of 
the association between contraceptive method use and hormonal contraceptive safety 
considerations specific to HIV-positive populations among female ALHIV. In the unadjusted 
analysis, the relative risk of non-use of contraception versus current use of hormonal 
contraception was higher in female ALHIV with higher perceived hormonal contraceptive-related 
safety scores, but not statistically significant (cRR 1.22 95% CI [0.65, 2.30]). The likelihood of the 
current use of barrier contraception versus current use of hormonal contraception was 
significantly higher for female ALHIV with higher perceived hormonal contraceptive-related 
safety scores (cRR 1.76, 95% CI [1.01, 3.08]).  
 
In the adjusted analysis, the relative risk of non-use of contraception versus current use of 
hormonal contraception remained non-significantly higher for female ALHIV with higher 
perceived hormonal contraceptive-related safety scores relative to those with low scores (aRR 
1.13 95% CI [0.63, 2.05]). Likewise, the adjusted relative risk of the current use of barrier 
contraception versus current use of hormonal contraception was non-significantly higher for 
female ALHIV with higher perceived hormonal contraceptive-related safety scores relative to 
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those with low scores (aRR 1.69 95% CI [0.97, 2.96]). The final regression model did not include 
interactions because the joint test for the null that all ‘perceived safety considerations and 
education status interactions’ were zero (p>0.05).  
 
 
Table 7.3: Multinomial logistic regression models of current contraceptive method use, 




Non-use vs. Hormonal method use  Barrier method use vs. Hormonal 
method use  








1.22 (0.65 – 2.30) 
1.00 
1.1(0.63 - 2.05)  
 
1.00 
1.76 (1.01 – 3.08) 
1.00 
1.69 (0.97 – 2.96) 
 
*Adjusted model without interaction: adjusted for individual factors (age, education, sexual 
debut), relational factor (peer influence on contraceptive use, partner influence on 
contraceptive use), community factor (perceptions of community acceptance of contraception) 










8.   Contraceptive service quality, uptake, and models of HIV  
care 
This chapter evaluates the independent relationship between the measures of contraceptive 
uptake, service quality perceptions, satisfaction and clinic model. First, the characteristics of the 
participants according to the models of HIV care, including standalone youth- and general PHC -
clinics providing HIV services, are described. Then the results pertaining to variation in 
contraception use, unmet needs for contraception, unintended pregnancies, receipt of 
contraceptive services and client satisfaction by the aforementioned distinct models of care are 
presented. And finally, the rating of the quality of contraceptive service are compared across the 
two distinct models of HIV care, and only four domains/measures of service quality perceptions- 
client-staff interaction, information and communication, provider continuity and contraceptive 
method counselling - that meet the EPV criterion considered in developing the regression models 
for this thesis are presented here (see Chapter 3).  
 
 
8.1   Participant characteristics across standalone youth clinics  
and general PHC clinics  
Overall, a cross-sectional sample of 303 female ALHIV was included in the analysis. Over half 
(54.1%) of the participants attended general PHC clinics providing HIV care, with 45.9% attending 
standalone youth clinics providing HIV care. Table 8.1 presents the background characteristics of 
the participants by the clinic model- stand-alone youth clinics and general PHC clinics- across the 
potential confounders of the relationship between clinic model and the dependent variables. 
Female ALHIV at stand-alone youth clinics were less likely to be adherent to ART, enrol in the 
clinic for HIV care for more than one year, pALHIV, perceive community acceptance of 
contraception and stigma as high, attend HIV support group and currently use ART, but were 
more likely to have a partner with age-gap more than five years, engage in multiple sexual 
partnerships and report higher levels of perceived partner influence on contraceptive use than 
female ALWH at general PHC clinics (Table 8.1). 
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Table 8.1: Demographic characteristics of study participants, by clinic model 
 
Variable Category Total  
%(N) 








                                                       







Time enrolled at the 
clinic                                   
 
 




















No. sex partners in 
 past 12 months 
 
      
Disclosure of HIV-
status                               










<1 year                                                                      








Not on ART                                                                     










5 years and above                                                                      
Below 5 year                                                
No partner 
 
None/1 sex partner                                                                   
>1 sex partners 
 
 
Disclosed status                                                                     





















































































































































































































Low                                                                  
Medium                                                                 
High 
 
None/primary                                                                  
Secondary above                                                                  
unknown 
 




No                                                                      
Yes 
 

















































































































































ƗEver drank alcohol 







8.2   Models of HIV care and receipt of contraceptive services 
 
8.2.1  Descriptive statistics 
Overall, 61% of respondents received contraceptive counselling at their last clinic visit for HIV 
care at all-ages or standalone youth clinics, and 66% had access to condoms. The receipt of 
contraceptive counselling varied significantly across the clinic model (p=0.02), with 67% of female 
ALHIV at general PHC clinics receiving contraceptive counselling at their last clinic visit for HIV 
care, compared to 54% of female ALHIV at standalone youth clinics. Data not shown A higher 
receipt rate of condoms was also demonstrated among female ALHIV at general PHC clinics 
compared to their peers at stand-alone youth clinics (70.1% vs. 61.9%, p=0.13). Dual-method 
contraception was less widely accessed. Among female ALWH at stand-alone youth clinics, the 
receipt rate of dual-method contraception was 34.5%, whereas, in general, PHC clinics, the 
receipt rate was lower at 23.8% (p=0.04).  
 
 
8.2.2  Association between Models of HIV care and receipt of  
contraceptive services 
Table 8.2 displays the unadjusted and adjusted analysis of the association between the clinic 
model and the measures of the receipt of contraceptive services. In the unadjusted analysis, 
female ALHIV at standalone youth clinics had 42% lower odds of receiving contraception 
counselling than those at general PHC clinics (cOR 0.58 95% CI [0.36, 0.92]). In the final model 
adjusting for confounders, the association between the clinic model and the receipt of 
contraception counselling was attenuated, but this was non-significant (aOR 0.84 95% CI [0.55, 
1.26]). The interaction involving the clinic model and age status was omitted in the final adjusted 
analysis due to collinearity. As noted above (Chapter 3), the coefficients and variances of the 




Receipt of condoms after testing positive for HIV was not crudely associated with clinic model 
(cOR 0.69 95% CI [0.43, 1.12]). Mantel-Haenszel test of homogeneity of odds ratios revealed 
evidence of effect modification between the association of clinic model and the receipt of dual-
method contraception by the receipt of counselling (p<0.05), with higher odds of the receipt of 
condoms among female ALHIV reporting receipt of contraception counselling compared to those 
who did not report receipt of contraception counselling. Compared with female ALHIV at general 
PHC clinics, those at standalone youth clinics had non-significant reduced odds of receiving 
condoms after controlling for confounders (aOR 0.54 95% CI [0.26, 1.16]). The interaction 
involving the clinic model and the receipt of contraception counselling was omitted in the final 
adjusted analysis due to collinearity. 
 
Female ALHIV at standalone youth clinics had a significantly greater odds of receiving dual 
contraception compared to those at general PHC clinics (cOR 1.69 95% CI [1.02, 2.79]). The 
Mantel-Haenszel test for homogeneity of odds showed no evidence for effect modification across 
the strata of baseline covariates.  In the adjusted analysis, female ALHIV at stand-alone youth 
clinics demonstrated higher odds of accessing dual-method contraception compared to their 




Table 8.2: Crude and adjusted relationship between clinic model and receipt of contraceptive 
services 
Mode of HIV acquisition %(n) cOR (95% CI) aOR (95% CI)* 
 Ever received contraception 
counselling 
  Stand-alone youth clinics 














0.84 (0.55 – 1.26)1 
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Ever received condoms 
  Stand-alone youth clinics 







0.69 (0.43 – 1.12) 
 
1.00 
0.54 (0.26 – 1.16)2 
Ever received dual-method  
  Stand-alone youth clinics 







1.69 (1.02 – 2.79) 
 
1.00 
1.80 (0.81 – 3.99)3 
*Adjusted model without interaction 
1Adjusted for individual factors (duration of enrolment in HIV care, mode of HIV acquisition, 
ART adherence, client satisfaction score), community factor (HIV-felt stigma) and structural 
factors (access to HIV support group, access to ART).  
2Adjusted for individual factors (age, mode of HIV acquisition, ART adherence), relational 
factors (partner age-gap, number of sex partners, disclosure of HIV status to partner) and 
structural factors (access to HIV support group, access to ART, parental education, employment 
status, receipt of contraception counselling) 
3Adjusted for individual factors (age, education, alcohol, mode of HIV acquisition, client 
satisfaction score), relational factors (number of sex partners, partner influence on 
contraceptive use), community factors (perception of community acceptance of contraception, 
HIV felt-stigma) and structural factors (parental education, access to HIV support group, 
employment status, receipt of contraception counselling) 









8.3   Models of HIV care and contraceptive usage 
 
8.3.1  Descriptive statistics 
Table 8.3 displays the distribution of indicators of contraceptive usage by clinic model. Among 
female ALHIV at all-ages clinics, 82.9% were current contraceptive users; this was true for 84.2% 
of female ALHIV at standalone youth clinics. There was no evidence of variation in the current 
use of contraception across the clinic model (p=0.76). Among female ALHIV at general PHC clinics 
who reported current contraceptive use, the proportion of current users of injectable methods 
was 58.8% compared with 62.4% among female ALHIV at stand-alone youth clinics (p=0.56). Also, 
there was no evidence of variation in the proportion of current users of other contraceptives, 
including, implants, IUDs, and hormonal pills among female ALHIV who reported current 
contraceptive use across the clinic model (p=0.64, 0.82 and 0.09, respectively), with 8.5% of 
female ALHIV at general PHC clinics being current users of LARC, compared to 9.5% among their 
peers at stand-alone youth clinics. A similar proportion of female ALHIV reporting current use of 
contraception at stand-alone youth and general PHC clinics reported current use of condoms as 
a primary method of contraception (28.2% vs. 27.2%, p=0.86); however, a higher proportion of 
female ALHIV currently using any method of contraception at standalone youth clinics reported 
current use of dual-method contraception than in general PHC clinics (53.0% vs. 44.9%; p=0.20). 
The great majority of female ALHIV reporting current dual-method contraception at each clinic 
model used injectable contraceptives, with higher proportion at standalone clinics compared to 
the general PHC clinics (82.3% vs. 77.0%, p=0.47). 
 
Overall, the levels of unmet need for contraception among female ALHIV at standalone youth 
clinics and general PHC clinics after accounting for condom use consistency were similar (25.9 % 
vs. 22%, p=0.42). The rates of unintended pregnancy since testing positive for HIV were lower 
among female ALHIV at general PHC clinics compared to their counterparts at standalone youth 
clinics although the difference was not statistically significant (15.2% vs. 25.0%, p=0.08). A higher 
proportion of female ALHIV at stand-alone youth clinics considered their pregnancy unwanted as 
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compared to their counterparts at general PHC clinics (15.0% vs. 8.0%, p=0.05), but the difference 
did not reach statistical significance. A similar trend is seen regarding mistimed pregnancy (9.0% 
vs. 6.0%, p=0.32).  
 
Table 8.3: Current contraceptive use, by clinic model 
Characteristics All  clinics  
% (N) 







Current use (all 
modern methods)  
(N=253) 

















Current use by 
primary method 
typeƗ (N=253) 
    Condoms (only) 
    Injectable 
        NET-EN 
        DMPA 
        Not known** 
    Implants 
    IUD 





60.5 (153)  
        57.7 (75)* 
        42.3 (55)* 
                 (23) 
   5.9 (15) 
   3.2 (8) 






      60.0 (39)* 
      40.0 (26)* 









      55.4 (36)*  
      44.6 (29)* 
                 (8) 
  5.1 (6) 
  3.4 (4) 









































     Injectable 
        NET-EN 
        DMPA 
        Not known** 
     Implants 
     IUD 




       60.5 (52) * 
       39.5 (34) * 
                (12) 
  8.8 (11) 
  5.7 (7) 




      71.8 (28) * 
      28.2 (11) * 
                 (8) 
 8.2 (5) 
 4.9 (3) 




      51.1 (24) * 
      48.9 (23) * 
                (4) 
 9.7 (6) 
  6.5 (4) 











*Percentage of injectable method mix, exclude those who reported not knowing their particular 
injectable methods 
**Injectable method used not known 
ƗPercentage of method mix, excluding non-current contraceptive users 
 
 
8.3.2  Association between models of HIV care and  
contraceptive usage 
Table 8.4 shows the unadjusted and adjusted analysis of the association between the clinic model 
and the measures of contraceptive usage.  Female ALHIV attending standalone youth clinics had 
similar odds of current contraceptive use relative to their counterparts attending general PHC 
clinics in the unadjusted regression analysis (cOR 1.09 95% CI [0.60, 2.02]). A stratified analysis 
of the relationship between clinic model and current contraceptive use demonstrated no 
evidence for effect modification among baseline independent variables on the association 
between clinic model and current contraceptive use. In the multivariable analysis adjusting for 
confounders, the association between the clinic model and current contraceptive use was 




 In the unadjusted analysis, a female ALHIV odds of having an unmet need for contraception were 
similar across clinic models- stand-alone youth clinics and general PHC clinics (cOR 1.24 95% CI 
[0.73, 2.11]. The Mantel-Haenszel test for homogeneity of odds of the association between clinic 
model and unmet need for contraception, stratified by other key covariates, did not identify an 
effect modifier. There was no association between clinic model and unmet needs for 
contraception (aOR 1.64 95% CI [0.90, 2.98]), adjusting for potential confounders.  
 
The crude association between unintended pregnancy and clinic model was not significant (cOR 
1.66 95% CI [0.93, 2.97]). The Mantel-Haenszel test for homogeneity of odds revealed that the 
effect of the clinic model on unintended pregnancy did not vary across strata of the potentially 
modifying variables (p>0.05). The adjusted analysis shows that female ALHIV at stand-alone 
youth clinics and general PHC clinics had similar odds of unintended pregnancy (aOR 1.06 95% CI 
[0.57, 1.98]).  
 
 
Table 8.4: Crude and adjusted relationship between clinic model and contraceptive usage 
Clinic model n(%) cOR (95% CI) aOR (95% CI)* 
Current contraceptive usea 
    Stand-alone youth clinics 
    General PHC clinics 
 
Unmet need for contraception 
    Stand-alone youth clinics 
    General PHC clinics 
 
Unintended pregnancy 
    Stand-alone youth clinics 






















1.66 (0.93 – 2.97) 
 
1.00 












*Adjusted model without interaction 
1Adjusted for individual factors (age, education, duration of enrolment in HIV care, self-efficacy, 
client satisfaction score), relational factors (partner age-gap, partner influence on contraceptive 
use), community factor (HIV-felt stigma) and structural factors (access to HIV support group, 
receipt of contraceptive counselling) 
2Adjusted for individual factors (age, duration of enrolment in HIV care,Adherence to ART), 
relational factors (partner age-gap, partner influence on contraceptive use), community factors 
(perceptions of community acceptance of contraceptive use) and structural factors (parental 
education) 
3Adjusted for individual factors (age, education, duration of enrolment in HIV care), relational 
factor (disclosure of HIV status to partner), community factor (HIV felt-stigma) and structural 
factors (parental education, employment status, access to ART) 
significant variables at p<0.05 highlighted  
 
aInclude condoms as well as other forms of contraception 
 
 
8.4   Models of HIV care, client satisfaction and service  
quality perceptions 
 
8.4.1  Descriptive statistics 
The aggregate mean satisfaction score among all female ALHIV was 4.0 (SD 0.55). Standalone 
youth clinics had a higher aggregate mean satisfaction score, which differed statistically from 
general PHC clinics (4.04, SD 0.53 vs. 3.89, SD 0.55, p=0.01). Regarding service quality perception 
measures, the proportion of female ALHIV reporting optimal rating of client-staff interaction was 
non-significantly higher in standalone youth clinics compared to general PHC clinics (25.2% vs 
17.7%, p=0.11). Also, the proportion of female ALHIV reporting optimal rating of information and 
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communication regarding contraception was non-significantly higher in stand-alone youth clinics 
compared to general PHC clinics (36.7% vs. 29.9%, p=0.17). In contrast, a significantly lower 
proportion of female ALHIV at standalone youth clinics (compared to general PHC clinics) 
reported ever being informed about multiple contraceptive methods (73.8% vs. 61.2%, 0.02). In 
terms of provider continuity, the rates were similar between female ALHIV at standalone youth 
and general PHC clinics (51.2% vs. 42.2%, p=0.13).  
 
 
8.4.2  Association between Models of HIV care, client satisfaction, 
and service quality 
The unadjusted and adjusted odds of client satisfaction (score >=4) with contraceptive services 
by clinic model are presented in Table 8.5. In the unadjusted analysis, there was no association 
between client satisfaction and clinic model (cOR 1.42 95% CI [0.90, 2.24]). There was evidence 
of effect modification by the receipt of contraception counselling (p<0.05). In the final 
multivariate analysis adjusting for potential confounders, the clinic model was not associated 
with client satisfaction (aOR 1.25 95% CI [0.87, 1.81]). The interaction term was excluded from 
the final model due to collinearity.   
 
 
Regarding client perception of service quality, female ALHIV at stand-alone youth clinics had non-
significant higher odds of reporting optimal rating of client-staff interaction in the unadjusted 
analysis (cOR 1.57 95% CI [0.90, 2.73]; Table 8.4). Mantel-Haenszel test of homogeneity of odds 
revealed that there is no evidence of effect modification between the association of clinic model 
and optimal rating of client-staff interaction. In the adjusted analysis, the direction of the 
association between the clinic model and optimal rating of client-staff interaction is reversed 




In terms of information and communication (Table 8.4), the unadjusted odds of optimal rating 
were not significantly different for female ALHIV at standalone and general PHC clinics (cOR 1.40 
95% CI [0.87, 2.27]). Mantel-Haenszel test of homogeneity of odds showed that none of the 
potential effect modifiers significantly modified the effects of the clinic model on the optimal 
rating of information and communication. In the adjusted analysis, the odds of information and 
communication remained non-significantly different for female ALHIV at standalone and general 
PHC clinics (aOR 0.92 95% CI [0.59, 1.46]).  
 
Results from the unadjusted and adjusted analyses of the association between clinic model and 
having being informed about multiple contraceptive methods are displayed in Table 8.4. Bivariate 
analysis of the association between having being informed about multiple contraceptive 
methods and clinic model, across potential effect modifiers, revealed no evidence of effect 
modification. In the unadjusted analysis, female ALHIV at standalone youth clinics had 
significantly lower odds of having being informed about multiple contraceptive methods 
compared to female ALHIV at general PHC  (cOR 0.56 95% CI [0.34, 0.91]), and this association 
remained statistically significant in the adjusted analysis (aOR 0.41 95% CI [0.22, 0.76]). 
 
Table 8.5: Crude and adjusted relationship between mode of clinic model, client satisfaction with 
services and perceptions of service quality 
 
Clinic model n(%) cOR (95% CI) aOR (95% CI)* 
Client satisfaction (score >=4.0) 
   Standalone youth clinics 
   General PHC clinics 
 
Optimal rating of client-staff 
interaction 
    Standalone youth clinics 































Optimal rating of information and 
communication 
   Standalone youth clinics 
   General PHC clinics 
 
Methods variety discussed 
   Standalone youth clinics 
























0.41 (0.22 – 0.76)4 
 
*Adjusted model without interaction 
1Adjusted for individual factors (education, duration of enrolment in HIV care, mode of HIV 
acquisition, ART adherence, self-efficacy), relational factor (partner influence on contraceptive 
use), community factor (perception of community acceptance of contraception, HIV-felt stigma) 
and structural factors (parental education, access to HIV support group, receipt of 
contraceptive counselling, employment status, access to ART) 
2Adjusted for individual factors (age, mode of HIV acquisition, self-efficacy), relational factors 
(partner influence on contraceptive use), community factors (perceptions of community 
acceptance of contraception, HIV felt-stigma) and structural factors (access to HIV support 
group, employment status) 
3Adjusted for individual factors (age, education, mode of HIV acquisition, self-efficacy), 
relational factor (partner influence on contraceptive use, number of sex partners), community 
factor (perception of community acceptance of contraception, HIV felt-stigma) and structural 
factors (access to HIV support group) 
4Adjusted for individual factors (age, education, mode of HIV acquisition), relational factors 
(partner age-gap, HIV concordance, partner influence on contraceptive use), community factors 
(HIV felt-stigma) and structural factors (access to HIV support group, receipt of contraception 
counselling) 


































9.   Provider perceptions of contraceptive service delivery  
in the context of HIV 
 
This chapter presents the findings from the qualitative interviews that took place between April 
and June 2017. The response rate and the background characteristics of Individual In-depth 
Interview (IDI) respondents (providers) are described first. Then, the qualitative findings are 
presented under the themes that emerged: (1) preponderance of injectable contraception, (2) 
inconsistent contraceptive use, (3) views on IUD use, (4) provider gender preference,  (5) peer, 
partner and child grant influence on contraceptive use, (6) factors promoting ALHIV 
contraceptive use, (7) provider attitudes to contraceptive services for ALHIV, (8) provider 




9.1   Participant profile   
Of the total 20 sampled healthcare providers, 19 were available for interviews. As emphasised in 
Chapter 3 (see subsection 3.3.1), an interview with one provider was not possible because the 
individual was out of town during the qualitative study period. Table 9.1 captures the background 












Table 9.1 In-depth interviews participant background profile (N=19) 
 
Characteristics Category  













Median Years working in                                                        
current clinic (IQR)  
 
Median Years working in 
HIV-programme (IQR) 
 
Median Years of experience 



























4 (3 – 8.5)  
 
 
7 (4.5 – 10)  
 
 





*computed for 16 respondents because three respondents declined to disclose their ages. 
195 
 
 9.2   Provider views on ALHIV contraceptive preference and  
use 
This section presents the themes that emerged in providers’ perspectives of female ALHIV 




9.2.1  Preponderance of injectable contraception  
Even though the access provided by clinics to a range of free contraceptives other than condoms 
such as pills, injectables, implants, and IUDs, the general sense across all interviews was that 
female ALHIV relied heavily on the use of injectable contraceptives, especially the two-monthly 
injectable, Nuisterate. There was little use of other longer-acting methods such as implants or 
IUDs. A female provider said: “At the moment, most of them use the injectables - they use any 
injectable” (Nurse, female, 29 yrs.). Another female provider noted the heavy reliance on 
injectable contraception seems to indicate client preference in the view of providers: “They like 
to come for the injectables- the Nuristerate and Petogen ...there is a problem of believing in the 
IUD, we teach them about the IUD, but most of them are on (Nuristerate)...I think I have got a 
higher rate of patients on Nuristerate” (Doctor, female, 43 yrs.).  
 
Providers in this sample mentioned influences on ALHIV heavy reliance on injectable 
contraception with respect to the following issues:  (1) ease of compliance, and (2) perceived 
increased pill burden for ALHIV with the oral contraceptive pill. Providers generally described 
their concerns about ALHIV client compliance with HIV/ART clinic visits as a key reason they 
promote injectable contraception among female ALHIV. In general, providers noted that 
injectable contraception appeared to them as the most feasible option for female ALHIV due to 
ease of compliance, given the coinciding of ART visits with a two-month contraceptive injection. 
These views are exemplified in the following responses: “Normally we give them 2 month supply 
of ARVs. We preferably use the 2 months injection so that when they come for their drugs (ARVs) 
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they get the 2-month injection as well” (ART operation manager, male, 34 yrs.). “Our follow-up 
visits are every 2 months so the injections coincide with the follow-up visits here ..so what it 
basically means – one-stop shop…everything is under one roof where it is a reminder when they 
come here ..you actually have to do that” (Doctor, female, 43 yrs.). 
 
The issue of compliance with clinic visits due to the long lifespan of IUDs was also cited by some 
providers. They felt the long lifespan of IUDs with no need for regular clinic visits for maintenance 
is linked to non-adherence to HIV care and treatment among female ALHIV. These views are 
captured below: “For me, I recommend the injectables because the injectables make them come 
to the clinics. If we give them five-year contraception (IUDs) …. they won’t come to take their 
treatment in the clinics” (Counselor, female, 36 yrs.). 
  
Providers also thought that the reliance of female ALHIV on injectable contraception stemmed 
from the issue of pill burden. As noted in the quote below from an HIV clinic manager, it seems 
that both that clients and providers are concerned about pill burden resulting from medications 
for HIV-related and –unrelated indication: “I think the reason for that [heavy reliance on 
injectable contraception]  is that the country has a high rate of poor adherence to the ARV tablets 
so adding one tablet to the ARV medication and with the adolescent also forgetting to come and 




9.2.2  Inconsistent contraceptive use 
Providers’ perspectives on inconsistent use of condoms and other contraceptive methods are 
collapsed into five subthemes: (1) erratic condom use, (2) side effects of injectable contraception, 






Erratic condom use 
Most providers who shared their views on the consistency of condom use mentioned that many 
female ALHIV who were willing to use condoms and had condoms provided at the clinics often 
used condoms inconsistently. Some providers reported that many female ALHIV who were 
regularly offered condoms present with sexually transmitted infections. “We have a problem 
here. We have a problem. Most of the youth here they don’t use condoms whether they are 
positive or they are negative. Whenever you ask them are you using a condom then they will say 
‘No” sister I use it part-time. All of them, whether they are positive or negative there is no specific 
that because they are HIV-positive then they use it. They don’t” (Nurse, female, 29 yrs.). 
 
Providers also reported that erratic condom use among female ALHIV stemmed from clients’ 
perception of reduced risk of HIV infection transmission with adherence to ART medications. This 
perception among female ALHIV was attributed to how information is communicated. A female 
nurse said: “I think sometime it is how all of this information is communicated to them. For 
example, they are told if you are taking your ARV daily, you don’t miss taking them, your chances 
of your partner contracting HIV are very little. So these kids take that and decide if I don’t use 
condom my partner is not gonna get HIV. It is how it is being communicated that actually I think 
sometime is what is misleading them. So they decide not to use the condom because of that..” 
(Nurse, female, 30 yrs.). 
 
Side effects of injectable contraception  
Concerns about the side effects of injectable contraceptives was a common reason providers 
cited for contraception discontinuation among female ALHIV, however, information about 
whether clients changed to another method or stop using contraception altogether was not 
elicited. The perception of the providers is captured in this response: “Sometimes the others say 
this method [injectables] is making me fat ….this is making me to have breakthrough 
bleeding…..another thing the amenorrhoea,,…No I want to have my menses this injection 





Providers highlighted the issue of fertility concerns as a barrier to consistent use of contraception 
among female ALHIV. In particular, providers noted that female ALHIV are concerned about their 
fertility potential and often discontinue contraception in order to conceive. The responses below 
demonstrate this: 
“Yes, they discontinue if they are getting older using contraceptives and they try to fall pregnant 
just to see if they are able to. I have heard quite a few cases saying Sister I think I am getting 
old…..let me just see if I can get pregnant……then they discontinue their contraceptive method” 
(Nurse, female, 30 yrs.). 
“One of the reasons is that they want babies ….they want children…. I asked them last year to 
write out the burning questions that they have anonymously…..and all of them wanted to know 
about babies…. they are more concerned about conceiving …..they are scared they will be left 
alone somewhere and not have a normal life like any other ….so they want to have children 
because they don’t want to be stranded” (Nurse, female, 49 yrs.). 
 
Service-related obstacles  
Providers described service-related obstacles to ALHIV consistent contraceptive with respect to 
two key issues: limited service hours; and long waiting times. Feedback from providers suggests 
that the current clinic operating hours (08.00 – 16.30 hrs on Mondays through Fridays) hinder 
sustained use of contraception among in-school female ALHIV. One female provider said: “the 
only problem is after-hours services for the ones (female ALHIV) in grade 12 or the ones that are 
doing after school classes because the clinics close half past 4 so the ones that come leave the 
schools around 4’O clock … may be they get to the clinic 20 past 4’Oclock and they stay in line 
..so by the time they enter the consultation room it is half past 4 so by half past 4 you must close 
out” (Nurse, female, 29 yrs.). Another provider said: “Because they are in schools they will say 
sometime they don’t have time to come to the clinics because they finish late in schools, they are 




Some providers recognized the limited-service hours as a barrier and suggested they are trying 
to address this. For example, a health-system level service provider mentioned access to after-
hours’ services as an important component of patient-centeredness of contraceptive care for 
female ALHIV: “We are providing more and more extended hours services after 4pm when the 
adolescents are available after school…the nurses are expected to run adolescent services and 
we are also training our school nurses in the art (Sub-district area manager, female, 57 yrs.). 
A female nurse noted long waiting time for female ALHIV to be seen by service providers in clinics 
hindered consistent use of contraception in this group of PLHIV: “If they are going to wait for too 
long that discourages them from continued use of contraception” (Nurse, female, 30 yrs.).   
 
   
9.2.3  Views on LARC use 
Providers identified possible fears underpinning ALHIV reluctance to use LARC. These are 
collapsed into three sub-themes: (1) fear of IUD entering the womb; (2) fear about IUD causing 
infertility and IUD translocation;  (3) fear of fetal abnormalities caused by IUD; (4) concerns about 
the concomitant use of ART and implanon; and (5) fear of implanon being robbed.   
 
Fear of IUD entering the womb 
Providers mentioned that ALHIV clients’ concerns about the IUD being a method that entails 
insertion into the uterus seem to be a key reason ALHIV prefer injectable contraception to the 
IUD. An ART adherence counsellor says: “Sometimes when we tell them about the loop they are 
afraid of it because we tell them that they are gonna open their legs and we put it in the womb 
…so they are afraid of it and they prefer the injectables” (Counsellor, female, 38 yrs.). 
 
Fears about IUD causing infertility and IUD translocation  
Providers described two main issues of concern with respect to the community perception of the 
effect of IUD on ALHIV client. These include fertility concerns and IUD translocation. These are 
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captured in the response of a female physician: “Because of the community telling them IUD is 
going to be lost in your tube …..you are not going to conceive ….those are the myths they talk 
about in the community” (Doctor, female, 43 yrs.).  
 
Fear about babies being born with IUD in the hand  
Some providers also mentioned that female ALHIV feel they would deliver babies with IUD in the 
hand if they became pregnant while using IUD. As one provider put it:  “First of all they are afraid 
to use IUD …they will tell lot of story that the baby will come out carrying it in the hand” (Nurse, 
female, 30 yrs.). 
 
Concerns about the concomitant use of ART and Implanon 
Providers generally considered the relative effectiveness of contraceptive implants in clients on 
efavirenz-based ART as a critical reason they stopped providing ALHIV with implantable 
contraceptives despite ALHIV clients’ interest in the method. Many participants reported that the 
provincial guidelines indicated that the ARV efavirenz use reduces the efficacy of implants to 
prevent unintended pregnancies when using concomitantly. Before this, the insertion of 
contraceptive implants among female ALHIV had been popular. A response from a female 
physician captures the views of many respondents: “At the time the implanon came it was the 
best for them.. they  all wanted the implanon  ..unfortunately we have to face the problem of 
drug interaction…..unwanted pregnancy…. and stop the implanon but they all wanted the 
implanon” (Doctor, female, 43 yrs.).  
 
According to a female nurse, providers promote injectable contraception over implanon because 
of the perceived reduction in the efficacy of implanon when used concomitantly with ART:  
“...there are certain methods you cannot use when you are on ART because ART decreases the 
efficacy of those methods, so they are contraindicated in people living with HIV …. For example, 
If they are using Implanon or combined oral contraceptive pills, then they need to use a 
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secondary protective measure so that they don’t fall pregnant. Hmm…….So most of them are left 
with two options- IUD and Petogen- we are offering in the clinic..” (Nurse, female, 30 yrs.)  
 
According to a sub-district manager at the Western Cape DOH, providers are reluctant to provide 
implants to WLHIV, despite government’s efforts to dispel the inaccurate information around 
ART and implants: “Things like unintended pregnancy and drug interactions with the implanon 
that was a major issue that was brought to our attention and we had to have a medical officer 
going around to make sure …and also the MSF providers…with the articles and evidence to dispel 
the inaccurate information that implants cannot be used by women with HIV… but  some of the 
providers are not convinced that implanon should be given with some ARV medications” 
(Subdistrict manager, female, 57 yrs.). 
 
Fear about implanon being robbed  
Though the available qualitative data precluded information on the reasons behind implant 
robberies, one provider who was not included in the IDI said that drug addicts were robbing 
women of the implantable contraceptives to make a potent cocktail. It seems this is a myth and 
doesn’t in fact happen. A female nurse said: “….there was a story that was going around that 
Implanon get robbed. Somebody would come and stab you and take out the implanon. So that 
thing influences a number of our patients. Something that come from the community and they 
bring to our awareness. Unfortunately, we are still stocked with the consequences of whatever 
it is that is preached out there because they still believe even till today that Implanon get 
robbed… that is why they are not considering it. They would rather prefer injectable” (Nurse, 
female, 29 yrs.). 
 
  
9.2.4  Provider gender preference 
When asked about female ALHIV gender preference of providers during contraceptive care, 
providers consistently reported that female pALHIV would prefer female providers to male 
providers because they are shy at showing their body to a male provider. This is captured in the 
202 
 
response of an adherent counselor: “Sometimes the girls say I am not going to the boetie (male) 
because I cannot show that man my boms (buttock) ..I always tell them that man is nurse …he 
does not care about their nums.. .but he always want to give them the contraception only….then 
they run away to the other rooms with female providers” (Counselor, female, 36 yrs.). 
 
 
9.3   Perceptions of influences on contraceptive use 
 
 
9.3.1  Peer, partner and child grant influences on  
contraceptive use 
Providers also mentioned they believed that peers negative perspectives dissuaded female ALHIV 
from using injectable contraception. A response from a female ART adherence counsellor 
summarises the extent to which they believed interpersonal relations between peers may 
prevent female ALHIV from obtaining injectable contraception and using it: “The peers are 
discouraging them from using family planning (injectables) by saying if you have the family 
planning you gonna be fat…if you put the family planning you gonna be ugly…telling them mixed 
things that you gonna be ugly…..you gonna be fat….then you must stop the family planning..that 
is what they always tell each other when they are sitting (in waiting room)” (Counselor, female, 
36 yrs.). 
 
Some providers felt child support grants discouraged female ALHIV from using contraception 
altogether. When discussing the reasons for the reluctance of female ALHIV to use contraception, 
a facility manager said:  “We have got unemployment now, these girls want to be pregnant for 
social grant because once they have a child they can take money from the government. Secondly, 
they need something to hold their boyfriends or sugar daddies (blessors) because they will look 




In general, providers felt that older male partners play an ambiguous or divided role in female 
ALHIV contraception – some deterring contraceptive use and other older male partners 
promoting contraceptive use. Some providers thought that female ALHIV who engage in sexual 
relationships with older male partners who exchange some amounts of money for sex are not 
likely to use condoms. This is captured in the response of a male nurse: “If the sugar daddy is 
providing money and is not willing to use condoms….of course they dictate whether to use 
condoms or not” (ART operational manager, male, 36 yrs.). In contrast to the role played by male 
sexual partners in dissuading female ALHIV from using condoms, some providers attributed 
female ALHIV contraceptive access to the support received from older male partners. “ We found 
in some of our services that the older boyfriends would actually bring them to the clinics for 
contraceptives….so with family members, and especially mothers and aunties they want the 
children to complete their education” (Sub-district manager, female, 57 yrs.). 
 
 
9.3.2   Factors promoting ALWH contraceptive use 
Providers commonly described some female ALHIV receiving support and encouragement from 
family, partners, peers, and social workers in the health system to access and use contraception. 
The views of providers on support for female ALWH contraceptive access are collapsed into two 
broad sub-themes: (1) personal, interpersonal and social factors, and (2) health service-related 
factors.  
 
Personal, interpersonal and social factors 
Client fears of pregnancy 
Providers reported how the society views teenage pregnancy and negative consequences of 
being a young mother as something that has encouraged female ALHIV to utilise contraception. 
One respondent, male ART operational manager stated: “The fear of what people will say or the 
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reactions from the parents and the community ……the fear of having a child and not sleeping 
because the baby is crying are some reasons they use contraception” (ART operational manager, 
male, 36 yrs.).  
 
Parent fears of pregnancy 
Providers reported that female ALHIV vulnerability to pregnancy seemed to be an important 
concern to parents, and female ALHIV are often brought to the clinics for contraception by the 
family members, even when they were not aware of their HIV-positive status. “Most of our HIV-
positive adolescent girls are sent by their parents. Sometime may be the parents won’t know 
because they hide their status but they are sent by their parents to come for contraception due 
to the fact that they (parents) come late home and because they don’t stay at home and they go 
out partying and all of that” (Nurse, female, 29 yrs.). 
 
Family desire for education completion 
In some cases, providers thought that aspirations for female ALHIV to complete their education 
underpinned family’s support for contraception: “Family members, and especially mothers and 
aunties they want the children to complete their education....they kind of encouraging them to 
come and use contraceptives…. they don’t want them to be pregnant” (Sub-district manager, 
female, 57 yrs.). 
 
Peer influence and support groups 
Some providers noted the important motivating role of peer social networks in access to and 
utilisation of contraception among female ALHIV. This is captured in the responses below:  
 
“Peers….Peer influence is what actually bring us numbers ….is what bring everyone else actually 




“We have got this thing what we called peer pressure and now the group that are using family 
planning or they are on contraceptives everybody should be on a family planning method so they 
come as a group so those are the things that are making them to use contraceptives” (Facility 
manager, female, 42 yrs.). 
 
Another respondent suggested that the negative effects of teenage pregnancy by others could 
influence female ALHIV to utilise contraception: “May be a close relative or friend that have got 
pregnant and they see the difficulty and they don’t want to have that same life” (Doctor, female, 
44 yrs.). 
 
Health service-related factors 
As highlighted below, one provider discussed the girl empowerment programme in some clinics 
as a key facilitator of female ALHIV access to contraception. However, this was not probed 
further. “We have this girl power initiative offering Youth Friendly services..they form a 
relationship with the adolescents..they have group sessions with them..they come more now for 
contraception  via the girls power program” (ART operational manager, female, 34 yrs.). 
 
HIV-support groups/clubs seem to be an important component of health system support for 
contraceptive uptake among female ALHIV through peer-counsellors.  
“We have got what we called the youth focus team that has a young counsellor and a young 
professional nurse that attend to our adolescents….we are doing this in their own space where 
they can freely express themselves and this is where the youth team gets a chance to explain to 
the adolescent females that are infected with HIV the different contraceptives” (ARV operation 
manager, Male, 34 yrs.). 
 
“The other linkage we have done now is that with the ARV service we have got adolescent clubs 
so those needs (contraceptive services) are also important and so the adolescent contraceptive 




9.4   Provider perceptions of ALHIV contraceptive services 
Provider views about ALHIV contraceptive services are collapsed into three themes: (1) provider 
attitudes to contraceptive services for ALHIV, (2) provider competency and training, and (3) 
challenges and recommendations for improving contraceptive services. 
 
 
9.4.1  Provider attitudes to contraceptive services for ALHIV 
Provider attitudes toward female ALHIV seeking contraception are collapsed into three sub-
themes: (1) positive provider attitude, (2) negative provider attitudes, and (3) views on hALHIV 
and pALHIV. 
 
Positive provider attitudes 
Positive provider attitudes included friendliness, the privacy of care/confidentiality and client-
centred care, with a minority also describing respectful care and empathy. Regarding friendly and 
respectful interpersonal interactions between providers and female ALHIV, rapport-building 
behaviour more likely with female pALHIV was described as an important factor and was related 
to the length of time since enrolment in HIV care that facility. A provider from a general PHC clinic 
summarised how the mode of HIV acquisition or length of time since enrolment in HIV care 
promoted friendly and respectful interpersonal interactions between providers and female 
ALHIV: “I think friendliness and respect also the fact that we accommodate them and again the 
rapport that develops over the years and a number of them have been with us from the times 
they have been babies and that relationship has grown and blossom over the years. So is the 
mutual trust and the safety” (Doctor, female, 43 yrs.). 
 
Providers also considered positive provider attitudes to be a key reason for the lack of differential 
preference for provider gender among ALHIV. One ART operational manager from a general PHC 
clinic acknowledged the importance of provider attitude stressing that positive provider attitudes 
would mean that there would be unlikely to be a preference for female providers among female 
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ALHIV: “I don’t think they have any preference I think the most important part here is the attitude 
of the health provider you can be older person but if you have the ways/skills of approaching the 
younger ones they can be comfortable..I think it can be more about the providers and not the 
clients” (ART Operational Manager, male, 34 yrs.). 
 
Some providers sometimes reported youth-friendly programming characteristics, specifically 
clients calling providers by nicknames or first names and providers giving warm smiles during 
contraceptive care visits, as qualities that suggest friendly interpersonal interactions between 
providers and female ALHIV. A facility manager from a stand-alone youth clinic said: “They 
(providers) have got good relationship with them because you will find that they even know the 
providers by their first names because only the surnames that are on those doors ..you will see 
that they call the sisters by nicknames that means they have got good relationship with them” 
(Facility manager, female, age not given). 
 
Providers mentioned client privacy as an attribute of positive provider attitudes during 
contraceptive care for ALHIV. Most providers felt that patient privacy was achieved during 
contraceptive provision for female ALHIV. The response of a female physician from a general PHC 
clinic captures the views of most providers: “Privacy is not even a discussion. This is part of our 
training. We work with privacy. We work with …the correct term is confidentiality and I don’t 
need the mother if the child wants to have it” (Doctor, female, 43 yrs.). Providers also mentioned 
friendliness as a positive attribute of provider attitudes. When discussing positive provider 
attitudes during contraception consultations, a young provider from a stand-alone youth clinic 
noted: “One, you have to put a smile on your face...The mere fact that we are placed in youth 
clinic I think we are chosen specifically for this place. Yeah….we do tend to be friendly…..we are 
friendly” (Nurse, Female, 29 yrs.).  
 
Interviewed providers generally felt that providers showed empathy to female ALHIV during 
contraception consultations; this could be explained by the narratives expressing provider 
commitment to shortening waiting times for female ALHIV along with female ALHIV openness in 
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discussing personal challenges with providers. One female provider from a general PHC clinic 
noted: “We want to help them first…..we don’t want them to wait in the queue” (Nurse, female, 
, 43 yrs.). In a standalone youth clinic, a female provider said: “We give more support to the HIV 
positive adolescent girls because most of the times they have personal problems we talk about 
it” (Nurse, female, 29 yrs.). 
 
Negative provider attitudes 
Although a substantial number of interviewed providers believed that positive attitudes towards 
ALHIV seeking contraception were the norm, they still described the negative attitudes expressed 
by their colleagues towards this sub-group of females living with HIV. Providers’ views suggest 
that some providers have negative judgemental attitudes regarding contraception towards 
younger female ALHIV in particular. Some providers equated older provider age with negative, 
judgemenatl provider attitudes. The quote below from a system-level provider summarises the 
responses from many interviewed providers: “Provider age definitely matters because we find 
especially in our experience with the younger providers …..I would say in most facilities we do 
have attitude problems…I would say it is also link to the older providers” (Sub-district Area 
Manager, female, 57 yrs.). 
 
The perception of parental figures among older providers seem to be connected to their negative, 
judgemental attitudes regarding contraception for female ALHIV. A female physician from a 
general PHC clinic said: “Okay we are human and I know for mothers (providers) that we have 
here who are staff you wouldn’t like your child to be given contraception that means the child is 
involved in sexual activities …I wouldn’t like my 15 year old to start having sex..I know about that 
feeling..I have got children and sometime it is the community…that stigma around ..that myth 
around sex for the younger age because it is condemned” (Doctor, female, 43 yrs.). The same 
female physician had this to say about female ALHIV client reactions in response to a provider’s 
judgemental attitude about contraception: “I had reports from some children complaining about 
a certain doctor and I just had to speak to the colleague to understand the needs of the 




The provider’s description of female ALHIV perceived rude behaviour of providers not only 
reflects judgemental attitudes of providers toward female ALHIV during consultations for 
contraception but offers further insight into the negative attitudes of providers toward female 
ALHIV requesting contraception. One female noted: “they see the other sister as somebody that 
is rude, what do you want…things like that fell onto these children and it goes down  ..and this is 
not here and the children still feel we are the same....although they try utmost to be kind most 
person… ..for the contraceptives they still have that…they are fearful of the providers” (Nurse, 
female, 49 yrs.). 
 
When asked about the privacy of contraceptive service provision to female ALHIV, one 
respondent said this: “I think it is more sort of …may be shouting all over or may be joking a little 
bit inappropriately with the girls around….also you have come for… in a space or in a more public 
space …I think it is more in the treatment room where there may be other people in the 
treatment room so it might not be absolutely appropriate to be talking so openly” (Doctor, 
female, 49 yrs.).  
 
Views on pALHIV and hALHIV 
Providers discussed their views on contraception for pALHIV and hALHIV with respect to the 
following issues: (1) service delivery preferences, and (2) contraceptive uptake and method use.  
Though some providers saw mode of HIV acquisition coinciding with younger age of providers, 
another view was that pALHIV and hALHIV are similar with respect to provider age preference. A 
perceived lack of pALHIV and hALHIV differential preference for younger providers was seen as 
stemming from the positive attitudes of their providers rather than age. An ART adherence 
counsellor from a general PHC clinic said: “Those who got HIV infections from their mothers and 
those who got it through their behaviours like to see younger providers because they are still 
young” (Counselor, female, 43 yrs.). In contrast, a provider from a stand-alone youth clinic said: 
“They (pALHIV and hALHIV) are not different in terms of the type of provider (age) they would 
like to see” (Counselor, female, 36 yrs.). Another provider from a general PHC clinic believed that 
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positive provider attitudes underpin the perceived lack of differential preference for provider age 
between pALHIV and hALHIV: “.. for my place here is about the relationship…It is the way the 
health care provider builds relationship with the client. Age does not matter at all. I am quite 
older to them but because I have got that relationship. When you have the attitude and the 
relationship in attending to adolescents then age does not matter” (Doctor, female, 43 yrs.). 
 
Providers also emphasised that female pALHIV were more likely to prefer the continuity of care 
with a particular provider compared to their hALHIV counterparts. The preference of pALHIV for 
continuity of care may be explained by their attachment to these providers beginning at a young 
age, bound in issues of positive provider attitudes. A response from a female physician from a 
general PHC clinic captures what many providers reported:   “those who got it through their 
behaviours like to see any provider ….they don’t care about who saw them last week but those 
born with HIV they have got many issues …..they like to see the same person every time they 
come…....those are the babies that I raised and now they are 15, 16 and they would rather see 
me....they choose when they come..” (Doctor, female, 43 yrs.).  
 
Providers most often reported that they don’t distinguish between pALHIV and hALHIV in 
providing contraceptive services. Providers also viewed contraceptive method use to be similar 
between pALHIV and hALHIV because they perceived the two distinct groups of ALHIV as having 
similar sexual behaviours. The similarity in contraceptive method use between pALHIV and 
hALHIV was also attributed to their age category. These are captured by the responses of three 
providers:  
 
 “It is not like you really dig into how they (female ALHIV) acquire HIV during consultation…..you 
just deal with someone who is positive ..you just give the same service to female ALHIV ….as long 





“Once they get to the stage of needing a contraceptive it is the same....because it’s the same 
behaviours they gonna have whether they got HIV at birth or later  ….you (provider) will still 
provide the same talks with everybody else (Doctor, female, 44 yrs.). 
 
“They don’t differ. They use the same methods. ....It is because they are of the same group even 
if they contacted the HIV from their mothers or through their sexual behaviours…..they are of 
the same adolescent group …so we encourage them to use the injectable methods so that they 
cannot forget” (ART Operational manager, female, 56 yrs.). 
 
A smaller proportion of study participants described a situation in which they perceived female 
pALHIV and hALHIV as behaving differently in their uptake of contraception. For example, the 
views of one provider imply that female pALHIV and hALHIV may be different in terms of 
contraceptive uptake due to shyness to receive contraception on the part of female pALHIV: 
“They do tend to be different groups of people in the sense that the perinatally acquired HIV 
adolescents are often a little bit behind in their development by a year or two so they seem to 
be developing later. ...also they are shy to receive contraception” (Doctor, female, 49 yrs.). 
 
Some providers reported being uncomfortable giving contraception to female pALHIV due to 
their perception that this sub-group of female ALHIV should not be sexually active. The impact of 
this practice on the differential uptake of contraceptives between pALHIV and hALHIV is capture 
in the response of this provider: “Sometimes you as the provider feel uncomfortable to give it to 
the perinatal ones because sometimes you think that they are not sexually active- you 
understand- that is your perception whereas with the other groups you will just give it ” (Nurse, 








9.4.2  Provider competency and training  
 Although providers generally reported competence in the provision of short-acting 
contraceptive methods, they still generally emphasised low competence in LARC insertions and 
removals, with an increased potential risk of undesirable events in clients wishing to use LARC. A 
system-level provider discussed the complications accompanying IUD insertions within primary 
care: “We had a huge challenge very recently with regards to IUD insertion... because we had 
quite a lot of perforated uteri…in one clinic about seven …we then stopped the providers from 
providing and we are having a focus on training sessions and then we will start again” (Sub-district 
Area manager, female, 57 yrs.). A facility manager from a stand-alone youth clinic said about the 
competency of providers: “We have more experience with the injections and the pills because 
the ones like the implanon is a newly introduced contraceptive otherwise they are experience in 
all the other methods” (Facility manager, female, Age not given).  
 
Lack of a wide-spread provider training model in newer contraceptive methods was frequently 
mentioned as a factor in provider competence in LARC provision within primary care. A female 
nurse from a general PHC clinic noted: “There is only one provider that is trained on the long-
acting methods…I don’t know why it is only one provider….there is only one provider who can 
put in the Implanon…..there is only one provider who can put in the IUCD” (Nurse, female, 43yr.).  
 
Lack of familiarity with LARC among the few providers trained therein was also noted. As this 
provider noted at a stand-alone youth clinic, client preference for short-acting contraceptive 
methods over LARC was associated less hands-on-experience with the LARC methods: “We have 
less experience with IUD because we don’t insert it because there are no clients who want it ..we 
have the theory of it but we don’t have the practical because the client are not coming for 
it….then we will forget the skills” (Nurse, female, 30 yr.). 
 
Contraceptive stockouts were also tied to provider expertise. One provider from a stand-alone 
youth clinic described the stockout of the IUD method in her clinic due to the lack of a provider 
skilled in the administration thereof: “Well, the only information I have about that it was actually 
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the IUD- we didn’t have it because there was no one who was trained to put it. I think that was 2 
years ago, so we would write a referral letter to the clinic -day hospital- then if they want it they 
can go there and put it there because you can’t really put in an IUD if you were not trained in 
doing so ….that is the only contraception that was not available” (Nurse, Female, 29 yrs.). 
 
 
9.4.3  Challenges and recommendations for improving  
contraceptive services 
Providers listed several challenges for targets and suggestions for improvement in the provision 
of contraception to female ALHIV, and data analysis indicates that most factors mentioned by 
respondents were infrastructural or systemic: provider-level factors, facility procedures, safety 
concerns, physical structure and limited contraceptive options, time pressure during 
consultations, and loss to follow-up; these also came up during the qualitative sections described 
above.  
 
In addition to provider competence in the provision of contraception, LARC in particular, as is 
described in the previous sections, provider competence in adolescent-friendly services was also 
considered an important provider-level target for improving female ALHIV access to and use of 
contraception. Negative attitudes among certain providers also emerged as important provider-
level barriers to be overcome to improve contraceptive access among this sub-group of 
adolescents. One ART adherence counselor said: “…those providers of HIV-positive children must 
know how to treat the children ….they must know that the children are very sensitive .... …and 
they still have denial of HIV-status….so when they meet a child they must just explain why I must 
give you this family planning …..they must not give a child any family planning because there are 
family planning that those on ARVs must not use like the implanon…. ……..Efivarenz and Tenofovir 




As mentioned earlier, providers emphasized limited hours of operation at the clinics as a major 
clinic-level barrier to providing contraceptive services to female ALHIV Several providers 
suggested that placing reproductive health clinics in social spaces, such as shopping malls or train 
stations, might improve access to and uptake of contraception among female ALHIV.“I have 
always thought that the city should have a clinic for reproductive health in a mall or in a train 
station because that is where you get some of them (female ALHIV)… because in Nyanga they 
have a reproductive clinic every time when they get off the train they just go to the clinic” (Nurse, 
female, 29 yrs.). Providers reported they are concerned with safety when providing extended 
hours service, despite their suggestion that this would be a good idea. A facility manager 
mentioned that “The other thing is safety - especially our facility is in a residential area. We would 
like to go extended hours so that we can ensure that they have access after schools and running 
up to six O’çlock  ….because of the crime in the area and assault on the staff we actually have to 
close our facility at four O’çlock which is very sad” (Facility manager, female, Age not given) 
 
The issue of time pressure during consultations for HIV care was also an important infrastructural 
and systemic challenge to the provision of HIV care and treatment for female ALHIV. While the 
role of time pressure in contraceptive service provision was not explicitly stated, broader 
narratives pertaining to time pressure in HIV clinics suggest it can significantly undermine the 
provision of integrated HIV services as well as the quality of contraceptive services delivered, as 
exemplified by the response from this provider at a standalone youth clinic: “City Health is 
pushing numbers, they just want statistics. I don’t even think they care how we get those 
numbers. They are just pushing us to push numbers.  At times it appears to us that they have lost 
a plus to care for quality it is just about quantity.  Say for an example, there was a mandate that 
says that each and every clinician needs to see about 30 clients per day and they actually stated 
that you are supposed to spend less than 5 minutes with a patient. My question is… because of 
the age of the patients am dealing with and considering that these kids have social problems, If I 
pick up someone that really has a social problem, do you honestly believe I can spend 5 mins with 
that patient? It is not possible. So if you want me to spend 5 mins with a patient it means am not 




IDI data also suggest that the physical structure of a facility with respect to privacy was an 
important component of the challenges for targets in female ALHIV contraception. Providers at 
general primary health care clinics, in particular, reported privacy issues related to the physical 
layout of the facility, perhaps due to the implications of female ALHIV contact with older clients, 
notably stigma, during consultations for HIV and contraceptive services. One female provider 
noted: “The clinic is busy, there is lack of space and there is lack of kind of private space and 
sometimes we have to juggle up in the clinic rooms which makes talking about contraception 
very difficult when we are running the clubs - the clubs have to be run from the board rooms and 
sometimes that could make talking individually about contraception very difficult because you 
have got other people there. So yeah there are challenges just around private space” (Doctor, 
female, 49 yrs.). 
 
Regarding model of care, a female physician at a general PHC clinic providing HIV services to all 
groups suggested having a separate space for ALHIV would be a good strategy to overcome the 
perceived stigma related to HIV and contraceptive care among female ALHIV: “There should be 
a separate corner for them where they know or room where there is no stigma from people 
seeing adolescents coming around. They know they go to that room ..is set up for them. I think 
that should be the best if there is budget” (Doctor, female,43 yrs.). 
 
Providers talked about ALHIV limited contraceptive method choice; suggesting the need to 
expand contraceptive method choice for ALHIV. The quote from this provider at a stand-alone 
youth clinic sums up the responses of many interviewees on this issue: “Well! According to my 
understanding, if ever there is only two options out of the rest of the options that we have of 
contraceptives in this clinic where HIV positive clients cannot use the other methods, it means 
we are not giving them quite a lot of options. Say if they don’t want IUD, what else can they use? 
They can only use injectables and if they don’t want that too, what else is available for them? 
Nothing…..there is vaginal ring, spermicide….. I know in some NGOs clinics they do have these 
options. Some of our curious clients who have been to those clinics they would come here and 
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ask we would tell them we don’t have these options only because City of Cape Town cannot 



























10.   Discussion and conclusions 
This chapter highlights the key research findings and contextualises these findings within the 
existing literature on HIV and contraception services. The chapter also describes the implications 
of the research findings for contraception programs for ALHIV in urban townships in South Africa, 
as well as the relative strengths and limitations of the research design, recommendations for 
further research and concluding remarks.   
 
 
10.1   Main findings and interpretations 
 This section synthesises the main findings by client outcomes as well as by influences on these 
outcomes based on the four-level socio-ecological model described in Chapter one. Here, the 
findings are compared and contrasted with other relevant studies. The in-depth qualitative 




10.1.1  Contraceptive uptake 
Overall, a large proportion of female ALHIV (83.5%) was currently using modern methods of 
contraception, with an overall preponderance of injectable contraceptives (60%). The levels of 
modern contraceptive prevalence among sexually experienced female ALHIV population in this 
study (86.8%) are remarkably higher than the general population of sexually active adolescents 
derived from the 2016 SADHS data (60.4%) (National Department of Health., 2019). As 
highlighted in Chapter 3, reports from other sub-Saharan African countries have indicated a lower 
prevalence of current contraceptive use among ALHIV (Oliveras & Makumbi., 2013; Obare et al., 
2010b). While the overall prevalence of current contraceptive use was extremely high, what was 
also very interesting was that contraceptive prevalence was high among both female hALHIV 
(81.8%) and pALHIV (87%). The high prevalence of the current use of modern contraceptives in 
this population of female ALHIV enrolled in HIV-related care and treatment services is promising 
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and underscores the remarkable progress made by South Africa in strengthening adolescent-
friendly services across public-sector PHC clinics. The mix of methods reported among current 
contraceptive users in this study (Chapter 5) contrasts with the recent DHS data on the general 
population of sexually active adolescents in South Africa (40% condoms; 45% injectable 
contraceptives, the majority of whom were using injectable DMPA; 8% Implants; and 7% pills) 
(National Department of Health., 2019). Provider narratives validated the quantitative results, 
suggesting the preponderance of injectable contraceptives and, in particular injectable NET-EN, 
among ALHIV. Shedding light on the narratives of providers, it was clear that ALHIV’s heavy 
reliance on injectable contraception is related to ALHIV clients being offered limited 
contraceptive options. Furthermore, providers discussed reasons for the high reliance of female 
ALHIV on injectable contraception, some of which are related to providers and others are related 
to female ALHIV. Key provider issues attributed to the high reliance of female ALHIV on injectable 
contraception included providers’ limited technical skills in LARC insertion, perceived inefficacy 
of implantable contraceptives in the context of ART and perceived pill medication-related 
burden. Also, the qualitative data suggest that provider concerns about ALHIV complying with 
clinic visits is responsible for the greater on the two-monthly injectable contraceptive method 
(injectable NET-EN) noted among injectable contraceptive users in the quantitative data. Client 
issues relate to concerns expressed about other methods, such as rumours of contraceptive 
implant robberies and fears of IUD, including translocation and insertion procedures.  
 
In Chapter 5, the analyses partly aimed to explore the contextual influences of contraceptive 
uptake among female ALHIV in urban townships in Western Cape. For female ALHIV, alcohol 
consumption was significantly more likely to be positively associated with current use of 
contraception methods than non-consumption, a finding consistent with a recent report on 
alcohol consumption and contraceptive uptake, particularly hormonal contraception, among 
young adults in the United States (Jones et al., 2019). It is possible that female ALHIV who 
consume alcohol decide to have access to contraception to avoid pregnancy and childbearing to 
continue engaging in substance use. The data on the somewhat unexpected positive association 
between alcohol consumption and contraceptive uptake suggests further research on this topic 
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among young people, including ALHIV, given the consistent findings in the literature that alcohol 
abstention increases contraceptive uptake (Hingson et al., 1990; Cooper., 2002; Hensel et al., 
2011; Khadr et al., 2016). Similar to the findings from a South African study, the present study’s 
results show that a later age of sexual debut predicted current contraceptive use among female 
ALHIV (Seutlwadi., 2012); suggesting interventions to delay sexual debut may promote 
contraceptive use among female ALHIV.  
 
In Chapter 6, the association between the mode of HIV acquisition and contraceptive uptake 
among female ALHIV was further explored. It was hypothesised that there would be significant 
variation in contraceptive practices between hALHIV and pALHIV. Similar to findings in Chapter 
5, the analyses in Chapter 6 found no significant variation in the receipt of contraceptive services 
and current contraceptive use by mode of HIV-acquisition after adjusting for potential 
confounders. Though providers’ attempt to attribute pALHIV’s shyness to receive contraception 
and providers’ reluctance to provide them contraception to the relatively low utilization of 
contraception among female pALHIV are perceived self-reports, it was not clear from the 
qualitative data whether there are differences in contraceptive uptake between the two female 
ALHIV groups. However, some providers reported that they do not distinguish between female 
pALHIV and hALHIV in providing contraceptive services. The mixed findings on the mode of HIV 
acquisition and contraceptive uptake in the present study provide suggestions for future mixed-
methods research with female ALHIV to address this phenomenon. Nevertheless, the qualitative 
interviews suggest that differentiated contraceptive care models based on the mode of HIV 
acquisition may be a useful approach to client-centred contraceptive care for pALHIV.  
 
Furthermore, higher levels of perceived partner influence on contraceptive use were associated 
with current contraceptive use among female ALHIV. These findings align with the existing 
evidence that support from male partners can help increase contraceptive uptake among 
adolescents (Callegari et al., 2004; Lewis et al., 2013). In Chapter 9, we further explored the 
influences on female ALHIV contraceptive uptake. The quantitative data in this study further 
suggest that male partners, particularly older male partners, play an ambiguous role in female 
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ALHIV contraceptive uptake – some deterring contraceptive use and others promoting its use. 
The finding related to male partners’ disapproval of contraceptive uptake among female ALHIV 
confirms that of an earlier study conducted among the general population of South Africa’s 
adolescents (Pettifor et al., 2009).  
 
The issue of hormonal contraception-related safety concerns specific to pALHIV also arises in 
quantitative data. The diversity of responses to the safety concerns of hormonal contraception, 
as highlighted in Chapter 7, may imply that female ALHIV are more concerned about the risk of 
hormonal contraceptive failures and HIV heterosexual transmission risk than ART efficacy and 
HIV-disease progression. Given that HIV infection alone does not preclude WLHIV from using any 
sub-type of hormonal contraception (Kourtis et al., 2016), it is important to acknowledge the 
safety of hormonal contraception in contraception counselling for WLHIV. In Chapter 5, we 
explored whether the perception of hormonal contraceptive-related risks specific to PLHIV 
predicted contraceptive use among female ALHIV. In the analysis, the perception of hormonal 
contraceptive-related risks specific to PLHIV was not associated with current contraceptive use. 
In Chapter 7, the association between the perception of hormonal contraceptive-related risks 
specific to PLHIV and contraceptive use was further explored, adjusting for potential 
confounders. It was hypothesised that female ALHIV that consider themselves at risk of hormonal 
contraceptive-related side effects would be less likely to use hormonal contraceptives compared 
to their peers that do not consider themselves to be at risk. The results in Chapter 7 validated 
those of Chapter 5 by showing female ALHIV who reported higher levels of perceived hormonal 
contraceptive-related risks specific to PLHIV were not significantly more likely to use no method 
at all or currently use barrier methods. Provider narratives that female ALHIV reliance on 
injectable contraception probably reflects perceived hormonal contraceptive-related risks did 
not strongly influence female ALHIV’s contraceptive use. Alternatively, there remained limited 
contraceptive choices for female ALHIV. The link between clients’ concerns about HIV-specific 
safety considerations relating to hormonal contraception and contraceptive decision-making or 
method choice has been documented (Imbuki et al., 2010; Todd et al., 2011). Therefore, future 
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studies should consider exploring the perspectives of female ALHIV on issues around 
contraceptive use and HIV-specific safety considerations related to hormonal contraception.  
 
Also, the qualitative results from the present study suggest that providers’ concerns about 
contraceptive failures when implants are used concomitantly with Efavirenz-based ART 
influenced the promotion of injectable contraception. Furthermore, the qualitative data from 
this dissertation validated other quantitative and qualitative studies that WLHIV’s own concerns 
about physical side effects of hormonal contraception decrease their hormonal contraceptive 
uptake (Imbuki et al., 2010; Laher et al., 2010; Todd et al., 2011; Bengtson et al.,2013); the 
promotion of effective non-hormonal contraceptive methods, specifically condoms and IUDs, is 
vital to note for young women concerned with or experiencing the side effects of hormonal 
contraception. Nonetheless, the qualitative findings suggest that safer conception strategies for 
female ALHIV desiring pregnancy may be a relevant approach to reducing the HIV burden and 
requires further research. 
 
Among the structural-level factors, female ALHIV’s household socio-economic status appears as 
the most critical determinant of the current use of contraception. Compared to female ALHIV in 
the poorest household wealth tertile, female ALHIV from the middle or highest tertiles were 
significantly less likely to have used a contraceptive method currently. This finding contrasts with 
that of the only study that evaluated the association between poverty and sexual risk taking 
among ALHIV, which suggests no significant association between poverty and contraceptive use 
(Toska et al., 2015). Therefore, it is important for future studies to explore the association 
between poverty and contraception among ALHIV, as well as plausible explanations for the 
somewhat unexpected link between higher household socio-economic status and decreased 
uptake of contraception among ALHIV.  
 
Finally, the research results in this dissertation offer insight into whether contraceptive uptake 
vary by models of HIV care, including stand-alone youth and general PHC clinics. In addition to 
hypothesising that contextual factors, including clinic model, would significantly influence female 
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ALHIV contraceptive behaviours and related outcomes, It was further  hypothesised that female 
ALHIV at standalone youth clinics providing HIV services would be more likely to report 
contraceptive uptake compared to their peers at general PHC  clinics. Across Chapters 5 and 8, 
female ALHIV at standalone youth clinics demonstrated similar current contraceptive use and 
receipt of contraceptive services as female ALHIV at general PHC clinics. One study conducted in 
Rwanda also found similarity in current contraceptive use between users and non-users of youth 
centres (Plautz & Meekers., 2003). The present study support those reports, suggesting that 
stand-alone clinics may not be an effective and efficient approach to promoting SHR service use 
among young people (Senderowitz 1997; Zuurmond et al., 2012). One could argue that the 
reason stand-alone youth clinics did not outperform the general PHC clinics on current ALHIV 
contraceptive use in the present study is the implementation of NAFCI in public-sector clinics 
throughout South Africa. 
 
In Chapter 9, provider narratives were helpful in further establishing a range of contextual 
influences on female ALHIV contraceptive uptake, including individual, interpersonal and 
structural factors. On one hand, providers believed peers, parents, and child grants tend to 
dissuade female ALHIV from using contraception; on the other hand, facilitators of female ALHIV 
contraceptive use include the female ALHIV’s own and parent fears of pregnancy, family desire 
for education completion, and peer influence and support groups. The findings on the individual, 
interpersonal and structural influences on female ALHIV contraceptive use, either as barriers or 
facilitators, also support the literature identified in Chapter 2 (Wood & Jewkes, 2006; Fallon., 
2010; Hartman et al., 2013; Snyder et al., 2014; Chernick et al., 2015; Hagey et al., 2015; Rubin et 
al., 2016; Maly et al., 2017). 
 
 
10.1.2  Inconsistent contraceptive use 
In Chapters 5 and 9, multilevel influences on consistent contraceptive use among female ALHIV 
were explored. Quantitative and qualitative data suggest multiple levels of contextual influence 
affect female ALHIV’s consistent contraceptive use. Female ALHIV in age-disparate partnerships 
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with age gaps of fewer than five years have increased likelihoods of both consistent use of 
condom alone and dual-method contraception. This finding probably reflects the result of 
asymmetrical male-female power relationship in contraceptive decision-making or even higher 
contraceptive decision-making power in favour of female ALHIV in age-disparate partnerships 
with age gaps fewer than five years. This aligns with reports from that of other studies (Ryan et 
al., 2008; Volpe et al., 2013). Furthermore, the late sexual debut was positively associated with 
consistent dual-method use. This is important additional information on dual-method 
contraception among female ALHIV, as there is a paucity of data on the link between sexual debut 
and consistent use of dual-method contraception among ALHIV. 
 
In this study, consistent with Steffenson et al. (2011), female ALHIV reporting multiple sexual 
partnerships had diminished likelihoods of consistent condom use compared to their 
counterparts who did not report multiple sexual partnerships, although this previous study 
focused on the general population of adolescents in South Africa. Thus, this finding suggests that 
addressing the issue of multiple sexual partnerships could help promote contraception practices 
among female ALHIV. Also, quantitative results from this present study revealed a positive 
relationship between higher perceived partner influence on contraceptive use and consistent 
dual-method use, as another prior research has suggested (Kosugi et al., 2019). HIV programmes 
should thus highlight the importance of male partner involvement as a primary component of 
positive contraceptive behaviours of female ALHIV. 
 
Providers perceived the issue of fertility concerns and physical side effects of hormonal 
contraception as barriers to consistent contraception use, although the particular methods of 
contraception were not explicit. WLHIV have uncertainties regarding their future health, and 
having children is considered to give hope for the future (Upton & Dolan., 2011). A qualitative 
study conducted in Malawi indicates that the strong values female pALHIV in HIV care placed on 
childbearing precluded them from complying with contraceptive use; many of these adolescents 
got pregnant to meet society’s expectations and enhancing self-worth (Mwalabu et al., 2017). 
HIV-related fertility concerns and pregnancy intentions among female ALHIV must be addressed, 
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as they may have policy implications concerning educational interventions on fertility issues and 
safer conception in this young population of PLHIV. 
 
Among the structural-level factors, female ALHIV’s household socio-economic status and 
parental education appear as the most critical determinants of the current use of contraception. 
Quantitative data in this study revealed that female ALHIV in the middle or highest wealth tertiles 
of household wealth were significantly less likely to have used condoms consistently compared 
to female ALHIV in the poorest household wealth tertile. This somewhat unexpected finding 
warrants further research to clarify the relationship between household wealth status and 
contraceptive practice among ALHIV. The qualitative study revealed further some health service-
related factors influencing female ALHIV contraception: providers widely perceived limited 
service hours and long wait times in the clinics as crucial health system barriers to the consistent 
use of contraception among female ALHIV. These findings confirm what has been documented 
in a previous study of the general population of adolescents and older women (Silumbwe et al., 
2018). The issue of excessive wait times was perceived as frequent among female ALHIV 
attending clinics for HIV care and contraception on different days, suggesting that a provider-
level integrated HIV–contraception care (i.e. a provider providing HIV and contraceptive services 
to an ALHIV in the same room) may prevent contraceptive discontinuation among ALHIV. 
Providers also mentioned the girl empowerment programme in some clinics in Western Cape as 
a great facilitator of contraceptive access among female ALHIV, and this intervention helps to 
justify the use of trained peer providers in enhancing adolescents’ access to contraception.  
 
 
10.1.3  Unmet need for contraception 
Unmet need for contraception among sexually active female ALHIV (17.4%) was much lower than 
the rate derived from the recent SADHS data for sexually active women of that age (31.2%) 
(National Department of Health., 2019), and this underscores the importance of integration of 
HIV and contraceptive services at PHC clinics in Western Cape, South Africa. Part of the first study 
hypothesis (H1) was that multilevel characteristics would be significantly associated with 
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contraceptive-related outcomes, including the unmet need for contraception, among female 
ALHIV. This study revealed multilevel influences on unmet need for contraception among female 
ALHIV. Adjusted analyses demonstrated that age and duration of enrolment in the clinic were 
the individual determinants of unmet need for contraception among female ALHIV in this study, 
alongside adherence to ART; findings that have not been previously reported in the literature. 
Older age (18 – 19) was associated with lower reports of unmet need for contraception than 
young age (14 – 17), perhaps partly due to less negative reactions from providers when accessing 
contraceptive services, and the significantly higher proportion of older female ALHIV engaging in 
sex within the three months preceding the study survey than young female ALHIV (bivariate 
analysis not shown) could add to the understandings of the possible explanations for the negative 
association between older age and unmet need for contraception. Quantitative research in 
Uganda suggests that older pALHIV are more likely to use contraception at first sexual debut or 
currently use contraception probably, and higher sexual activities among older pALHIV is a 
possible explanation for the differential uptake in contraception by age (Birungi et al., 2009a); 
further supporting the finding from the present research. Providing client-centred contraceptive 
care to ALHIV may help to encourage the demand for contraception among young ALHIV. Unmet 
need for contraception also differed across strata of the length of enrolment in HIV care, and 
with unmet need for contraception significantly diminished with longer duration of enrolment in 
HIV care. It could be that longer duration of enrolment in HIV care leads female ALWH to practice 
contraception, presumably due to sufficient familiarity with service providers. Longitudinal 
contact of HIV care and treatment has been shown to have a profound positive impact on clients’ 
HIV needs, as well as reproductive health needs (Myer et al., 2005).This important finding has 
implications for contraception policy and programming in HIV care for female adolescents and 
suggests the need for future research on this topic, given that none of the existing studies 
assessed duration of enrolment in HIV care and issues of contraceptive access or use. Female 
ALHIV who were not optimally adherent to ART were more likely to have an unmet need for 
contraception than their counterparts who were ART naïve; finding that is surprising. It was not 
clear from both the quantitative and qualitative data to deduce the probable explanations for 
the observed surprising relationship between ART adherence and unmet need for contraception, 
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and further mixed methods research could clarify the relationship between adherence and 
unmet need for contraception among female ALHIV in the present study. 
In the analysis exploring the covariates that predicted female ALHIV’s unmet need for 
contraception (Chapter 5), mode of HIV acquisition was not associated with unmet need for 
contraception. In Chapter 6, part of the aim of the analysis was to compare the unmet need for 
contraception between female hALHIV and pALHIV, after adjusting for potential confounders. It 
was also hypothesised that contraceptive need would vary significantly between hALHIV and 
pALHIV. Results from the analysis in Chapter 6 suggest that there were no differences in unmet 
need for contraception when comparing hALHIV and pALHIV; further supporting the finding in 
Chapter 5. Such lack of differential in the contraceptive behaviours of female hALHIV and pALHIV 
have been highlighted in the qualitative arm of this study (Chapter 9), and indeed the views of 
providers suggest that contraceptive practices and provision, as well as sexual behaviours, are 
similar between female hALHIV and pALHIV. 
 
 
The present study has also demonstrated interesting relational determinants of unmet need for 
contraception among female ALHIV; namely around social networks. Quantitative data has 
demonstrated that female ALHIV who reported higher perceived peer influence on contraceptive 
use had decreased odds of unmet need for contraception compared to those who reported low 
perceived peer influence on contraceptive use. Qualitative data suggests peer social networks 
either dissuade or encourage female ALHIV to access and use contraception and peers’ negative 
perspectives on the physical side effects of hormonal contraception, injectables, in particular, 
was one of the reasons for female ALHIV’s contraceptive non-use that emerged from IDI with 
providers. As noted in Chapter 3, several studies in different contexts have documented the 
positive impact of peer social networks on access to and utilisation of contraception among the 
general population sample of adolescents (Adedimeji et al., 2008; Fallon et al., 2010; Ali et al., 
2011; Feleke et al., 2013). The finding demonstrating that peer pressure dissuaded female ALHIV 
from contraceptive use has also been documented in a qualitative study of adolescents and 
providers in South Africa (Wood & Jewkes, 2006). Female ALHIV who reported no current sexual 
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partners had greater odds of unmet need for contraception than those in age-disparate 
partnerships with age gaps more than five years, potentially suggesting the absence of support 
from male partners. This finding could also partly be explained by the likelihood of women with 
no current sexual partners to have had infrequent or no sexual intercourse while not using any 
method of contraception. Data from DHS conducted in 52 developing countries during 2005-2014 
indicated infrequent or no sex as a key reason for contraceptive non-use among sexually active 
women (Sedgh et al., 2016). Having a sexual partner may also be positively related to 
contraceptive uptake among female ALHIV; as the quantitative and qualitative data presented in 
chapter 5 and Chapter 9, respectively, demonstrated, partner support is attributable to 
contraceptive utilization. Also, higher levels of perceived partner influence on contraceptive use 
were associated with the report of diminished unmet need for contraception among female 
ALHIV (Chapter 5), further suggesting male partner involvement in contraceptive programmes 
for this population. The mixed findings regarding social networks and unmet need for female 
ALHHIV’s contraception in this present study imply the need to embed the evaluation of social 
networks during female ALHIV’s contraceptive consultation.  
 
Contrary to the report from the only study examining the link between maternal education and 
ALHIV contraception (Birungi et al., 2011), the present study indicates that unmet needs for 
contraception tend to be lower among female ALHIV when a parent or primary caregiver has 
secondary or tertiary education. This suggests that if preventive service interventions targeting 
parents of ALHIV emphasised improving contraceptive information and counselling needs of their 
ALHIV, then a reduction in ALWH’s unmet needs may be achieved. In Chapter 8, the analyses 
partly aimed to compare the unmet need for contraception by the model of HIV care, i.e. stand-
alone youth clinics vs. general PHC clinics, after adjusting for potential confounders. The 
hypothesis was that female ALHIV at stand-alone youth clinics would have a lower unmet need 
for contraception compared to their counterparts at general PHC clinics. Similar to the finding 
with the model of HIV care and unmet need for contraception in Chapter 5, the analyses in 
Chapter 8 found no association between the model of HIV care and unmet need for 
contraception. These findings add to the existing literature reports that stand-alone youth clinics 
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are not more effective and efficient than general PHC clinics in terms of SRH services, suggesting 
no need for a policy change from the general PHC clinic model of HIV-related care and services 
to the stand-alone youth clinic model. 
 
 
10.1.4  Unintended pregnancy 
The data presented in Chapter 5 revealed a lower overall rate of unintended pregnancy (18.8%) 
than rates demonstrated in the data from both developed and developing settings; ranging from 
74% to 83% (Elgalib et al., 2011; Kenny et al., 2012; Koenig et al., 2007; Obare et al., 2010a; Obare 
et al., 2012). Interestingly, the extent of unintended pregnancy in this study is similar to that of a 
larger study conducted among the general population of adolescents in Eastern Cape, South 
Africa (18%) (Christofides et al., 2014). A plausible explanation for the lower rate of unintended 
pregnancy in the Christofides et al’s study (2014), as in the present study, is the high proportion 
of contraceptive users. Also, in Chapter 5, the influences on unintended pregnancy at multiple 
levels were explored among female ALHIV. Part of the hypothesis was that unintended pregnancy 
among female ALHIV is influenced by multilevel factors. Quantitative results identified some 
individual-level predictors of female ALHIV’s unintended pregnancy, including having at least one 
living child, smoking, and duration of enrolment in HIV, after adjusting for all other factors. The 
relationship between unintended pregnancy and cigarette smoking, as well as the length of 
enrolment in HIV care among female ALHIV, has not been previously studied in PLHIV. The higher 
odds of unintended pregnancy among female ALHIV who smoked cigarettes compared to female 
ALHIV who did not is vital to note, as it may have policy implications concerning integrating 
behavioural intervention programmes into HIV and contraceptive services. Other studies also 
demonstrated increased odds of unintended pregnancy with cigarette smoking, although these 
studies were conducted in the general adolescent population (Ayoola et al., 2006; Adolescent 
substance use., 2011). The finding regarding the increased likelihood of unintended pregnancy 
with having a living child aligns with that of the quantitative research from Kenya reporting the 
increased likelihood of unintended pregnancy among female ALHIV who had biological children 
with their spouses (Birungi et al., 2011); however, the Kenyan study failed to provide the reasons 
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for the association. In Chapter 6, the link between the mode of HIV acquisition and unintended 
pregnancy was further explored. The results suggest that female pALHIV might have a higher risk 
of unintended pregnancy than female hALHIV. Furthermore, provider narratives on the lower 
rates of uptake of contraceptives in female pALHIV than female hALHIV provided evidence that 
the mode of HIV acquisition might influence unintended pregnancy in female ALHIV. To date, the 
link between the mode of HIV acquisition and unintended pregnancy has not been investigated. 
Therefore, further research is needed to shed light on this phenomenon.  
In this study, female ALHIV reporting partners with unknown HIV status were less likely to classify 
pregnancy as unintended compared to their counterparts in serodiscordant relationships. One 
probable explanation is that female ALHIV in serodiscordant relationships may be reluctant to 
have unprotected sex with un-infected sexual partners because of the risk of HIV-transmission 
and may consider their pregnancies unintended. A qualitative study of couples in Uganda found 
that participants acknowledged partners’ HIV status as a critical driver of unintended pregnancy, 
with women in serodiscordant relationships having increased unintended pregnancy (Grilo et al., 
2018). This makes knowing partners' HIV status a potential target for intervention to prevent 
unintended pregnancy in PLHIV. The quantitative findings also suggest that parent-child 
communication does not lead to better contraception access/uptake, as evidenced by the 
positive association between perceived parent-child communication and unintended pregnancy. 
There is evidence that the characteristics of parent-child communication itself are key to its 
effectiveness over adolescents’ reproductive outcomes (Rogers., 2017). Although the qualitative 
study suggests that parents/family also acted to support female ALHIV’s contraceptive access 
and uptake, the empirical evidence to explain the communication characteristics is lacking. Given 
that the survey tool did not include questions on how parents discuss issues relating to 
contraception for ALHIV, understanding how parent-child communication occurs in the context 
of contraception for ALHIV may hold answers to promoting parent communication skills. 
 
Female ALHIV in the highest household wealth group were more likely to report unintended 
pregnancy – the lower odds of current contraceptive use and consistent condom use may have 
impacted the increased risk odds of unintended pregnancy. The finding on the link between 
230 
 
household wealth status and unintended pregnancy is an essential issue for additional research 
since the only study testing for the influence of poverty on unintended pregnancy among ALHIV 
documented significant unintended pregnancies due to food insecurity (Nhamo et al., 2013). On 
the other hand, given that receipt of contraceptive counselling at health facilities was significantly 
associated with a higher rate of unintended pregnancy, strengthening the capacity of health care 
professionals on effective contraceptive counselling can further reduce contraceptive non-use as 
well as unintended pregnancy. Similar results were obtained by other studies concerning the link 
between unintended pregnancy and contraceptive counselling in clinical settings conducted in 
clinical settings (Winter et al., 1991; Kirby et al., 2010).  
 
 
10.1.5  Client satisfaction, preferences and service quality  
perceptions 
In Chapter 6, the association between mode of HIV acquisition and measures of contraceptive 
service delivery preferences was explored. Part of the fourth study hypothesis was that 
contraceptive service delivery preferences would vary significantly between female hALHIV and 
pALHIV. To the best of the PhD candidate’s knowledge, no studies have evaluated the link 
between the mode of HIV acquisition and SRH service delivery preferences among ALHIV. 
Quantitative results suggested that pALHIV were significantly more likely to express a preference 
for female providers, younger providers and stand-alone youth clinics, but there was no 
significant difference in preference for provider continuity between hALHIV and pALHIV. The 
qualitative interviews offer further insight into the similarities and differences in service delivery 
preferences between hALHIV and pALHIV. In general, provider narratives suggested that pALHIV 
showed a greater preference for continuity of care with a particular provider than hALHIV. Such 
differential preference between hALHIV and pALHIV was linked to the length of enrolment in HIV 
care in the health facilities, and the attachment of pALHIV to providers, beginning at a young age 




Provider views on female ALHIV’s preferences for provider age are mixed. This is the result of 
differing provider attitudes. Most providers felt that preferences for provider age did not vary 
among hALHIV and pALHIV, and the perceived lack of differential preference for provider age was 
seen as stemming from the positive attitudes of providers rather than age. Regardless of ALHIV’s 
mode of HIV acquisition, providers felt that some female ALHIV held a preference for younger 
providers – the judgemental attitude of older providers was mentioned frequently as a reason. 
Most providers mentioned pALHIV would feel more comfortable with a female provider during 
consultations for contraceptive care, perhaps because of shyness at revealing their body to a 
male provider. The issue of positive provider attitudes also figured highly in responses that there 
would unlikely be a preference for a provider of a particular/specific gender among female ALHIV.  
 
In Chapter 8, the analyses compared client satisfaction and service quality between general PHC 
and stand-alone youth clinics. It was hypothesised that client satisfaction and service quality 
perceptions would be higher at stand-alone youth clinics compared to their peers at general PHC 
clinics. Results from the quantitative analyses presented in Chapter 8 suggest that stand-alone 
youth clinics did not outperform general PHC clinics with regard to client satisfaction and in terms 
of some service quality dimensions, such as client-staff interactions and information and 
communication. Conversely, the quantitative results indicate stand-alone youth clinics 
outperformed general PHC clinics in terms of providing counselling about all available 
contraceptive methods. Presenting qualitative data on the service quality construct in 
contraception programmes for ALHIV was helpful in explaining nuanced aspects of service quality 
across study clinics; yet, it is hard to compare and contrast service quality between the two 
groups of clinics because the majority of providers interviewed had no work experience in both 
groups of clinics.  
 
Provider narratives indicate a mix of positive and negative provider attitudes toward female 
ALHIV seeking contraception. Similar experiences were reported in Hagey et al.’s qualitative 
study of healthcare providers’ perceptions of female ALHIV contraceptive services (Hagey et al., 
2015). Providers also described certain components of client-centred contraceptive care specific 
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to ALHIV, including method choice provision based on ART regimen, teen support clubs and the 
availability of HIV counsellors. For example, the HIV counsellors’ role was highly valued as a 
facilitator of contraception for ALHIV, as well as in identifying which contraceptive provider 
would best suit a given client. Consistent with the findings from Hagey et al.’s (2015) study, 
judgemental attitudes about sexual activity abound, particularly towards young adolescents, and 
it appears deeply rooted in providers’ attitude of equating contraceptive care-seeking with sexual 
promiscuity. Given the thoughts of providers about the physical structure of the clinics, it is not 
surprising that some providers breach the privacy of contraceptive care provision in clients 
seeking HIV care and treatment. Thus, the need for a physical clinic structure that could decrease 
the risk of privacy breaches during SRH care for adolescents should be considered.  
 
 
As highlighted in Chapter 2, provider competence and performance are values essential to 
providing quality services. The qualitative results suggest that heavy client reliance on injectable 
contraception and provider technical competence combined with explanations above about why 
other methods were not used or encouraged (e.g. views on HIV and Implanon) are strongly 
linked. Respondents also felt ALHIV access to LARC methods was restricted by providers’ limited 
technical skills, a result found in a similar study conducted in another high HIV prevalence setting 
in sub-Saharan Africa (Nawaldda et al., 2011). While providers felt that all providers have 
competencies necessary to provide short-acting contraception services, low competence of the 
majority of providers in LARC insertions and removals was frequently cited. Additionally, 
providers equated less hands-on experience with LARC methods to poor performance among 
some providers with high technical competence. Finally, future, broader studies are needed to 
provide sufficient evidence on the effectiveness of stand-alone youth clinics in promoting HIV-
related services for ALHIV, including contraception, given the limited literature on ALHIV client 






10.2    Evolving conceptual framework 
An important component of the overall aim of this research is to identify the contextual factors 
influencing female ALHIV’s contraceptive provision and uptake. As has been highlighted in 
Chapter 3, there is very little research on the influences of contraception derived from the data 
on ALHIV. Thus, the conceptual framework for this research (Figure 1.3) was based mainly on the 
different elements derived from the literature on the general population of female adolescents 
and adults. Figure 10.1 displays the evolving conceptual framework of influences on female ALHIV 
contraceptive service delivery and utilisation, which incorporates different factors, grouped into 
four contextual layers, derived from the data collected from both providers and female ALHIV 
included in this research, as well as the sparse literature on contraception among ALHIV. At the 
individual level, the quantitative data goes beyond the factors documented in the literature on 
ALHIV and it suggests that the duration of enrollment for HIV care in the clinic and adherence to 
ART impact on unmet need for contraception; that cigarette smoking, having a biological 
child/children and duration of enrollment in the clinic influences unintended pregnancy; and that 
alcohol consumption and timing of sexual debut impact on contraceptive uptake and consistency. 
Also, the qualitative data shows that fears of pregnancy and fertility concerns impact on 
contraceptive use among female ALHIV. New relational or interpersonal determinants emerged 
which have not been previously documented in the literature regarding measures of ALHIV’s 
contraception; namely around, family, partnership and provider factors. Specifically, the 
quantitative findings suggest that peer and partner support impact on unmet needs for 
contraception; that contraceptive use or consistency is also impacted by partner support, age-
disparate partnership and sexual partnership status; and that unintended pregnancy is impacted 
by parent-adolescent child and awareness of a partner’s HIV status. The qualitative data, in turn, 
provides new information on how peer social networks, parent fears about pregnancy and 
concerns for ALHIV’s education completion, partner support, and provider concerns about the 
efficacy of Implanon when used with ART play a role in access to and uptake of contraception for 
female ALHIV. At the community level, the qualitative data provide new evidence of a link 
between Implanon uptake and concerns about personal security. Lastly, the conceptual 
framework introduces new structural determinants of ALHIV’s contraception outcomes which 
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were not documented in the literature on ALHIV. Specifically, the effects of household 
socioeconomic status and gender-based empowerment on ALHIV client outcomes, including 
contraceptive uptake, contraceptive consistency, or unintended pregnancy; and the impact of 






10.3   Limitations 
A mixed methods research design offered information-rich data to answer the research questions 
guiding this thesis. However, both quantitative and qualitative data methodologies had some 
potential limitations. These constraints should be considered in terms of interpreting the findings 
resulting from this research. 
 
Quantitative data 
The quantitative data has some limitations. First, the sample size was drawn based on the 2003 
SADHS before the results of the 2016 SADHS survey were available. Though the 2016 SADHS 
survey would be more relevant for the time data was collected, the fact that all eligible female 
ALHIV retained in care at the study clinics were included in the study suggest that the precision 
in the estimates of the parameters of interest are reliable. The issue of generalization of research 
findings from quantitative data derived from a non-probability sampling technique is also a 
limitation. Nevertheless, the survey results are likely to adequately represent the views and 
experiences of female ALWH in the study setting, given the high participation rate (95.9%) of 
female ALHIV retained in care at the study facilities. Furthermore, the lack of probability sampling 
of study sub-districts and facilities could have introduced selection bias as female ALHIV in the 
high HIV volume sub-districts/facilities selected for this research may have different experiences 
and behaviours than those at the low volume HIV sub-districts/facilities excluded from this 
research. Additionally, the unavailability of data on the demographic profiles of potentially 
eligible participants not retained in care for comparison with those of the participants included 
in the data analysis is also another data limitation. Given that clients were not randomly allocated 
to the two broad categories of clinic models (standalone youth and general PHC clinics), there 
was the possibility of  
 
Cross-sectional studies by design are unable to reliably provide information on cause and effect. 
Nevertheless, findings regarding associations among different variables will help generate causal 
hypotheses that can then be investigated further if cause-and-effect relationships are needed. 
Also, there was a possibility of recall bias on the part of the respondents in terms of questions on 
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earlier reference periods, such as responses relating to contraceptive use consistency – for which 
the time frame extends up to 3 months or beyond. Regarding the assessment of recall bias 
relating to variables with responses on earlier reference periods, the candidate considered the 
risk to be low because there was no systematic missingness or unexpected pattern in response. 
The interviewer-administered mode of questionnaire administration for sensitive topics may 
have resulted in social desirability and non-response biases, particularly for sensitive questions. 
Attempts to reduce this included the administration of the questionnaire by trained fieldworkers 
with similar gender, racial and cultural. Also, a set of questions were used to evaluate the mode 
of HIV acquisition (hALHIV vs pALHIV) to allow for within-interview verification and eliminate 
misclassification (see Appendix 4: items 203-204). 
 
The quantitative data was insufficient to determine the relationships between clinic model and 
some service quality dimensions, including technical competence, structure and facility, and 
patient-centeredness between the two clinic models of HIV care. However, the qualitative data 
helped to provide insights into the quality mentioned above. The quantitative data also preclude 
information on the particular hormonal contraceptive that was associated with HIV-specific 
safety concerns. The fact that the sample size of the quantitative study was insufficient for 
multilevel regression modelling further points to a limitation of the quantitative data. Another 
quantitative data limitation relates to the exclusion of CD4 cell count from the final data analysis 
because more than 20% of its values were missing. As a result, information on the relationship 
between CD4 cell count and client outcomes is lost. Some variables may also have been measured 
with error. For example, contraceptive self-efficacy was assessed with a single item comprising 
four sub-items instead of 18-items in the original scale to avoid questionnaire burden. Future 
research would help to address these data limitations relating to scale modification.  
 
Qualitative data 
 The data source for the qualitative component could have a meaningful impact on the study 
findings. The exclusion of female ALHIV from the qualitative interviews about their experiences 
in a healthcare setting is a limitation as some aspects of their life experiences of contraception 
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care processes and the outcome could go undocumented. Therefore, the qualitative findings are 
susceptible to provider biases. Recruiting equal number of IDI participants from both types of 
service delivery models was not feasible because there were only two standalone youth clinics 
providing HIV services in the study setting. Thus, a higher number of participants were recruited 
from the general PHC clinics providing HIV services to all age groups, and this may mean biases 
in information. The majority of service delivery-level providers interviewed (16 out of 17 service 
delivery-level providers) only had work experience with the general PHC clinics. As a result, this 
further curtailed the analytic potential of the qualitative data by clinic type.  
 
Finally, researcher worldview and background shape the findings and conclusions from 
qualitative research. The qualitative findings from this research may have been limited by the 
influence of the candidate's professional familiarity or experience with the research phenomena. 
However, a thorough review of the entire data analysis process by the research supervisors may 
have contributed to explicating the effect of the candidate's lens of experience on the credibility 
of the findings. 
 
 
10.4   Strengths  
The mixed-method design of this thesis provided a platform for integrating quantitative and 
qualitative data to elucidate comprehensive information. For example, as noted above, the 
quantitative data was inadequate to elucidate the factors determining contraceptive method 
choice. However, emerging themes from the qualitative findings helped to explain the reasons 
for female ALHIV heavy or low reliance on specific contraceptive methods. Quantitative methods, 
on the other hand, allowed contextualization of hormonal contraceptive-related safety 
considerations and contraceptive method use among female ALHIV, which was impossible with 
the qualitative method because respondents declined knowledge of the research phenomenon.  
 
 Purposive variable selection approach helped reduce a large number of the initial set of 
covariates in this study to an order of magnitude relative to the number of outcome events in 
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the regression models, which therefore reduced the risk of over-adjustment of variables included 
in the multivariate regression models. Additionally, the approaches to confounders' 
identification, as noted in Chapter 3, helped limit the potential for unmeasured confounders in 
the regression models exploring the relationship between exposure and outcome. Finally, 
another strength of this thesis is the diversity of the qualitative interview respondents, which 
allowed the research questions to be addressed from various perspectives. 
 
 
10.5   Recommendations and policy implications  
 In addition to the recommendations described by providers above (see Chapter 9 sub-section 
9.4.3), this thesis points to several recommendations and policy implications. 
 
 
10.5.1  Ecological approaches to promoting female ALHIV 
contraception  
 
The findings reported from both the quantitative and qualitative research in this thesis 
underscore the need for programme planners and policy implementers to apply multi-level 
approaches to contraception-related programmes and policy for female ALHIV. Furthermore, 
advancing strides towards a multi-level approach to female ALHIV contraception would allow for 
more targeted interventions for this subgroup of vulnerable adolescents.    
 
 
10.5.2 Strengthening the capacity of PHC providers on LARC 
methods 
In the context of low LARC methods provision for female ALHIV, explicitly underscored by the 
lack of PHC providers' technical skills, provider competency in LARC provision is crucial to 
ensuring a high level of LARC uptake. LARC methods are the ideal contraceptive methods of 
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choice for female ALWH, because they provide a higher level of couple years of protection and, 
therefore eliminate the need for regular adherence or follow-up for effectiveness as well as 
lessen pill burden (Kourtis et al., 2016). Beyond sound training, providers' understanding of 
implantable contraception provision in the context of HIV is essential. The development of 
specific practice guidelines for the use of contraceptive implants in WLHIV, including adolescents, 
can serve as an aid to determine the appropriateness of contraceptive implants for a particular 
female ALHIV. The fact that LARC as a method of contraception is not usually the method of 
choice by adolescents with HIV needs to be examined by providers as to whether to and how to 
promote it as a serious option given that LARC eliminate the need for frequent clinic visits. 
 
 
10.5.3 Interventions to promote a wide range of contraception  
options  
As documented above, substantial evidence suggests that female ALHIV choice of contraception 
is restricted. Given that HIV-infection alone does not preclude the use of any contraceptive 
method (Kourtis et al., 2016), it might be worthwhile to promote evidence-based strategies that 
would expand contraceptive options for female adolescents in HIV care at the PHC settings. In 
particular, developing a technical manual that focuses on the appropriateness and concerns 
regarding each contraceptive method for female ALHIV may be vital. As some of the previous 
results sections demonstrate low uptake and utilization of dual-method contraception among 
female ALHIV, it is essential for programmers to orient service providers to recommend dual-
method contraception for female ALHIV.  
 
 
10.5.4  Consider the particular needs of female ALHIV 
Data from this study show that some female pALHIV have specific needs, including the preference 
for young providers, female providers, and clinician continuity of care. Furthermore, there is also 
evidence that female pALHIV have developmental issues. Given the preferences mentioned 
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above, programmes and policies should certainly consider age and gender diversity among 
providers of HIV care for adolescents. Also, there is a need to promote continuity of care with a 
particular clinician of choice. To the extent possible, providers should understand the cognitive 
abilities of female pALHIV and offer support in developing aspects of higher cognition on 
reproductive health issues. Furthermore, the qualitative data suggest that clinic hours need to 
be synced with school schedules so that female ALHIV can attend the clinic at the end of the 
school day.  
 
 
10.5.5  Making PHC services more adolescent-friendly 
Providers' suggestions on overcoming the challenges to contraceptive service provision and 
utilization, as noted in sub-section 9.4.3, can guide initiatives to ensure PHC services are more 
adolescent-friendly. Specifically, the NAFCI policy documents could be reviewed to include 
interventions that are specific to ALHIV. Both the quantitative and qualitative data suggest that 
mainstreaming adolescent-friendly health services in a separate space in existing facilities seems 
to be a more appropriate way to meet the SRH needs of female ALWH. This is further validated 
by the evidence that adolescents prioritise service quality over stand-alone youth clinic model as 




10.5.6         Encourage steps to avoid misperceptions about  
contraceptives 
The issue of contraceptive safety concerns, in particular, HIV specific safety concerns, 
underscores the need to encourage initiatives to address the concerns over the safety of specific 
hormonal contraception for PLHIV. The preponderance of evidence at present indicates that HIV-
positive populations can use any hormonal contraceptive method without concerns for increased 
risk of HIV acquisition, transmission and disease progression (Kourtis et al., 2016). Thus, providers 
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should discuss these concerns as early as possible when recommending hormonal contraception 
for ALWH. Myths and misconceptions also come to the forefront of constraints regarding 
contraceptive use among adolescents. Initiatives to promote uptake and utilization of 
contraception among adolescents, including ALHIV, should include approaches to address the 
perceptions around myths and misconceptions about contraceptives on an ongoing basis.  
 
 
10.6   Suggested areas for further research 
The findings and some limitations of this study speak to a need for further research. First, it might 
be worthwhile for future research to consider a longitudinal study design which will allow for the 
measurement of behavioural trends over time. This design, coupled with multimethod qualitative 
research exploring female ALHIV perspectives, could help to elucidate the processes involved in 
the changes in contraceptive behaviours of female ALHIV. Second, more extensive studies are 
needed to adequately address the best service delivery model for female ALHIV, given the 
insufficient data to evaluate the relationship between clinic model of care and some measures 
of contraceptive service quality.  
 
Studies on the relationship between contraceptive method use and hormonal contraceptive-
related safety concerns specific to PLHIV would benefit from a longitudinal design with large 
population-based sample size. Also, examining the relationship between each of the constructs 
of hormonal contraceptive-related safety concerns specific to PLHIV (e.g., HIV disease 
progression, drug interactions, contraceptive failure) and the particular contraceptive method 
use would allow for the identification of which of the components of hormonal contraceptive-
related safety concerns specific to PLHIV impact on contraceptive method use among ALHIV. 
Further work on the relationship between immune status (e.g. CD4 count, viral load) and 
contraceptive behaviours among female ALHIV is also needed, given that, in addition to being 
largely understudied, there is no clear relationship between ALHIV immune status and SRH 
outcomes. Finally, the interesting findings regarding partner influence, socio-economic 




10.7   Conclusions  
The findings from this dissertation suggest that factors at the individual, relational, community 
and structural levels impact female ALHIV’s access to and utilisation of contraception; 
highlighting the need for SRH programmes to continually address the contextual influences of 
contraceptive behaviours of ALHIV. Potential risk-reducing interventions, such as a client-centred 
approach to contraceptive care, may help to reduce pALHIV’s risk of unintended pregnancies. 
Though the thesis lack information on the particular hormonal method associated with HIV-
specific safety concerns, there is evidence suggesting that the concern about HIV-specific 
hormonal contraceptive-related risks does not impact hormonal contraceptive uptake among 
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Appendix 1: Literature search strategy 
Studies and conference proceedings published between June 1981 (since the first report of HIV 
in humans) and October 2017 were identified using databases such as Scopus, Web of Science, 
EBSCO (via Academic Search Premier, Africa-Wide Information, CINAHL, ERIC, PsycINFO and 
Health Source: Nursing/Academic Edition) and PubMed via Medline. Additional searches were 
conducted using Google Scholar. Combinations of the following search terms were used: HIV, 
HIV-infected, HIV-positive, acquired immune deficiency syndrome, AIDS, contraception, family 
planning, birth control, adolescent, teenager, youth, young adult and women. The bibliographies 
of the relevant articles were also examined. 
 
Appendix 2: (isiXhosa): Parent/legal guardian consent form: adolescent and pregnancy 
prevention study exit survey (uxwebhu lemvume lo mzali/mgcini ngokwasemthethweni) 
PARTICIPANT ID NUMBER: ……………….DATE…………………………. 
ISAZISI SOMTHATHI-NXAXHEBA:………………………..UMHLA………………………………. 
Investigator’s name: Biodun Olagbuji   Phone: 0717243901 
Igama lomphandi: Biodun Olagbuji 
Department: Women’s Health Research Unit, School of Public Health and Family Medicine, 
University of Cape Town. 
Introduction 
isiqalo 
 I am student at the University of Cape Town. I am requesting your permission to allow your 
daughter/ward take part in a research study. I am doing this research for the PhD degree.  
• Ndingumfundi kwi-Dyunivesithi yase Kapa. Ndicela imvume yakho yokuvumela intombi 




 Your daughter/ward is being asked to participate in a research study on pregnancy 
prevention. This study does not involve drawing blood from your child or giving her 
medications.  
• Intombi yakho/iwadi iyacelwa ukuba ithabathe inxaxheba kuphando olumalunga 
nokunqanda ukukhulelwa. Oluphando aludibenanga nokutsalwa kwegazi kumntwana 
wakho okanye anikwe amachiza. 
 She was identified as a possible participant because she is within the age group (14 – 19 years) 
of interest to this research.  
• Utyunjwe njengomthathi-nxaxheba kuba ekwiqela leminyaka ephakhathi kwe(14-19  
yeminyaka) 
 We ask that you read this form, attached information sheet, and ask any questions that you 
may have before allowing your daughter/ward to participate in the research study.  
• Sicela ukuba ufunde elixwebhu, uxwebhu lolwazi elidityaniswe apha, kwaye ubuze nayiphina 
imibuzo onganayo phambi kokuba uvumele intombi yakho/iwadi  ithabathe inxaxheba 
koluphando. 
Purpose of Study   
Injongo yoluphando 
 The purpose of this research is to better understand issues related to pregnancy prevention 
(including birth control/contraception) among young girls within the age group (14 – 19 
years) of interest to this research.  
• Injongo yoluphando kukufuna ukuqonda ngcono malunga nemiba enxulumelene 
kucwangciso/ukusetyenziswa kocwangciso ngamantombazana aselula abakwiminyaka ye 14-
19 ubudala.Uphando olunomdla kubo 
 Ultimately, the findings of this research would help to increase our understanding of the 
ways to improve access to contraceptive services. 
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• Ekugqibeleni, iziphumo zoluphando zizakunceda ekunyuseni izinga lokuqonda iindlela 
zokuphucula ukufumaneka kweenkonzo zocwangciso. 
Description of the Study Procedures 
Ingcaciso yemigaqo yoluphando 
 If you agree on your child/ward’s participation in the research study, she will be asked to 
provide answers to some questions about birth control services in the clinic.  
• Ukuba uyavuma ukuba umntwana wakho/iwadi ithabathe inxaxheba koluphando, 
uzakucelwa ukuba asinike iimpendulo kweminye iimibuzo malunga neenkonzo zocwangciso 
ekliniki. 
 The interview will take place in a comfortable location in the clinic where her privacy can be 
assured.   
• Udliwano-ndlebe luyakuqhutywa kwindawo ekhululekileyo apha ekliniki nalapho 
siyakuqinisekisa ukuba isecaleni. 
 The interview questions will be interviewer-administered.  
• Imibuzo yodliwani-ndlebe iyakubuzwa ngumbhexeshi wodliwano-ndlebe 
 We aim for an interview that will last approximately 40-45 minutes.  
• Sijonge ekubeni ukuba udliwano-ndlebe luthabathe into epha kwi 40-45 yemizuzu. 
 The information shared during the interview will be kept confidential, and only key members 
of the research team will have access to it. The information cannot be shared with the 
parent.  
• Ulwazi owabelene ngalo kudliwano-ndlebe luyakugcinwa luyimfihlelo, kwaye ngamalungu 
ophando aphambili odwa azakufikelela kulo. Ulwazi alusayi kwabelwana nalo nomzali. 
Risks/Discomforts of Being in this Study 
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Izichenge/Ukungaziva ukhululekilei xa ukuphando 
  There are no major risks to your child/ward.  
• Azikho izichenge ezikhulu kumntwana wakho/iwadi 
 She may feel uncomfortable talking about her personal life. She does not have to answer any 
question that may make her feel uncomfortable.  
• Ngahle angazive engakhululekanga ngokuthetha ngempilo yakhe. Akanyazelekanga 
ukuphendula nawuphina umbuzo onokuthi umenze azive engakhululekanga. 
 We will offer counselling for participants that feel the interview made them uncomfortable.  
• Siyakubanika iingcebiso abathathi-nxaxheba abathe baziva bengakhulekanga ngenxa 
yodliwani-ndlebe. 
Benefits of Being in the Study 
Inzuzo ngokuthatha inxaxheba 
 There is no direct benefit to your child/ward, but her involvement is likely to assist us to know 
more about how to tailor birth control services to meet the needs of young women.  
• Akukho nzuzo egqole ngqo kumntwana wakho/iwadi, kodwa ubukho bakhe kungasinceda 
ekwazini nzulu ngeenkozo zocwangciso ukuhlangabezana neemfuno zabafazi abaselula. 
Confidentiality  
Imfihlelo 
 The interview with your child/ward is confidential and the only thing that will be disclosed is 
any form of maltreatment (including physical ill-treatment, emotional maltreatment, sexual 
abuse or neglect), but this will be reported to the social development department, a child 
welfare agency, or a police official in terms of legislation.  
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• Udliwani-ndlebe nomtwana wakho/iwadi luyimfihlelo kwaye eyonanto iyakubangazwa kuxa 
kukho ukuhlukunyezwa(kuquka ukuhlukunyezwa ngokwasemzimbeni, emoyeni, ngokwesini 
okanye ukungakhathalelwa),kodwa kuyakuxelwa kwisebe lezoluntu, i-arhente ejongene 
nemfuno zabantwana, okanye ipolisa njengoko umthetho usitsho 
 If your child/ward tells us that she is experiencing some form of violence or maltreatment 
(including physical ill-treatment, emotional maltreatment, sexual abuse or neglect) or if a 
research staff reasonably suspects violence or maltreatment, and that this has not been 
reported to a relevant agency, we are required by law to report this to a child protection 
agency. Someone will then investigate and see what needs to be done to keep your 
child/ward safe. Your daughter’s confidentiality will be protected and we will provide 
counselling and manage expectations honestly. These actions are necessary to protect you 
and your child. 
• Ukubangaba umntwana wakho/iwadi usixelela ukuba ebeke wadibana nobundlobongela 
okanye ukungaphathwa kakuhle(kuquka ukungaphathwa kakuhle 
emzimbeni,emoyeni,ngesini okanye ukungakhathalelwa) okanye ukuba umqeshwa 
wophando uhlanela ubundlobongela okanye impatho embi, kwaye akuzange kuxelwe kwi 
arhente ezingqamane noku, siyagunyaziswa ngumthetho ukuba sikuxele oku kwi arhente 
ezijongene nokukhuselwa kwabantwana.Ukhona umntu ozakuphanda abone ukuba yintoni 
na enokwenziwa ukugcina umtwana/iwadi ikhuselekile. Imfihlelo yomntwana wakho 
iyakukhuselwa kwaye uyakucetyiswa  ngendlela enyanisekileyo. Lamanyathelo ayafuneka 
ukukhusela wena nomntwana wakho. 
 All the documents and records of this study will not be available to anyone outside the 
research team.  
• Onke amaxwebhu noko kushicelelweyo akusayi kufumaneka nakubani na ongaphandle  
kwiqela loluphando 
  Research documents and records will be kept in a locked file, and all electronic information 
will be coded and secured using a password protected file.  
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• Amaxwebhu ophando nook kushicelelweyo ayakugcinwa eluvalelweni, kwaye lonke ulwazi 
locwephesho luyakukhuselwa ngenombolo yokuvula. 
 Once we have completed the study and written the results, all study documents will be 
destroyed.  




 Your daughter/ward will receive a light refreshment on completion of the interview.  
• Intombi yakho/iwadi iyakunikwa amaqebengwana alula akugqiba udliwano-ndlebe 
Right to Refuse or Withdraw 
Igunya lokungavumi okanye urhoxe 
 The decision to involve your daughter in this study is entirely up to you and your child.  It is 
entirely voluntary. 
• Isigqibo sokubandakanya intombi yakho koluphando sixhomekeke kuwe nentombi yakho.  
Niyazikhethela. 
 If your child is uncomfortable about any of the interview questions she can choose not to 
answer or participate in that part of the question.  
• Ukuba umntwana wakho uziva engakhululekanga malunga nayiphina imibuzo yodliwano-
ndlebe unakho ukukhetha ukungaphenduli okanye angathathi inxaxheba kulombuzo. 




• Intombi yakho inalo igunya lokurhoxa kudliwano-ndlebe nakweliphina ixesha kudliwano-
ndlebe. 
 There will be no penalty if your daughter decides to quit at any time during the interview 
• Akusayi kubakho isohlwayo ukuba intombi igqibe ekubekeni phantsi  nangaliphi ixesha 
ukudliwano-ndlebe 
 Whether your daughter participates or not she will still get the same care as usual at the 
clinic.  
• Ukuba intombi yakho ithe yathabatha inxaxheba okanye akayithabatha uhleli ezakufumana 
lamphatho aqhelene nayo ekliniki. 
Right to Ask Questions and Report Concerns 
Igunya lokubuza imibuzo nokuxela iinxalabo 
 You have the right to ask any questions in relation to this research study, but the information 
your child has provided cannot be shared with you. 
• Unalo igunya lokubuza nayiphina imibuzo enxulumene noluphando, kodwa ulwazi ethe 
intombi yakho  yasinika lona asisayikwabelana nawe ngalo. 
 If you have any questions about this research study, you can contact me at 0717243901. 
• Ukuba unemibuzo malunga noluphando, unganxibelelana nam apha: 0717243901 
 If your daughter has any problem or concern that occurs as a result of her participation in 
the research study, you can contact me at 0717243901. 
• Ukuba intombi yakho iinazo naziphina iingxaki okanye iinxalabo ezithe zavela ngenxa 
yokuthatha inxaxheba koluphando, unakho ukunxibelelana nam apha: 0717243901 
 If you have any concern about your daughter’s right as a research participant that have not 
been adequately address by the research team, you can contact me at 0717243901 or  report 
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to Human Research Ethics Committee at the Faculty of Health Sciences University of Cape 
Town at +27214066346 
• Ukuba unenxalabo malunga namagunya omtwana wakho njengomthathi-nxaxheba 
koluphando athe akaphenduleka ngendlela, unganxibelelana nam apha 0717243901 okanye 




 Your signature/thumbprint below confirms that you have agreed to allow your daughter 
participates in the research study, and that you have read and understood the information 
provided in this form and information sheet. You will be given a signed/thumb printed copy 
of this form to keep. The lead researcher will keep a copy. 
• Umtyikityo wakho/ubhontsi ungqina ukuba uvumile ukuba intombi yakho ithabathe 
inxaxheba koluphando, kwaye ukufundile waqondisisa ulwazi olufumenaka kwelixwebhu. 
Uzakunikwa i-kopi etyikityiweyo/enobhontsi yelixwebhu. Umphandi oyintloko uzakugcina i-
kopi. 
Biodun Olagbuji (Lead Researcher) 
Biodun Olagbuji (Umphandi Oyintloko) 
Doctoral Candidate, School of Public Health 
Efundela Ubugqirha, kwi-Skolo se Mpilo  
University of Cape Town 
Mobile: 0717243901 
E-mail: biodun_olagbuji@yahoo.com 
Signature/thumbprint of parent/guardian…………………………   Date…………………….. 
Umtyikityo/ubhontsi womzali/mgcini…………………………………………Umhla………………………. 
Signature of research staff…………………………   Date…………………….. 




Appendix 3: (Afrikaans): Parent/legal guardian consent form to allow child‘s participation in a 
research ouer / voog toestemming vorm om kinderdeelname in 'n ondersoek toelaat. 
PARTICIPANT ID NUMBER: ……………….DATE…………………………. 
DEELNEMER ID NOMMER……………………DATUM………………………. 
 
Investigator’s name: Biodun Olagbuji 
Department: Women’s Health Research Unit, School of Public Health and Family Medicine, 




 I am student at the University of Cape Town. I am requesting your permission to allow your 
daughter/ward take part in a research study. I am doing this research for the PhD degree.  
 Your daughter/ward is being asked to participate in a research study on pregnancy 
prevention. This study does not involve drawing blood from your child or giving her 
medications.  
 She was identified as a possible participant because she is within the age group (14 – 19 years) 
of interest to this research.  
 We ask that you read this form, attached information sheet, and ask any questions that you 
may have before allowing your daughter/ward to participate in the research study.  
 
Inleiding 
 Ek is n student aan die Universiteit van Kaapstad. Ek vra u toestemming om toe te laat u 
dogter / saal  aan 'n navorsingstudie deel neem. Ek doen hierdie navorsing vir die PhD-graad. 
 U dogter / saal sal gevra om deel te neem aan 'n navorsingstudie oor geboortebeperking. 
Hierdie studie behels nie om bloed te trek uit u kind of gee haar medikasie. 
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 Sy is geïdentifiseer as 'n moontlike deelnemer, want sy is in die ouderdomsgroep (14-19 jaar) 
wat in hierdie navorsing belang stel. 
 Ons vra dat u hierdie vorm, aangeheg inligtingsblad lees, en enige vrae wat u mag hê te vra 
voordat u dogter /saal om deel te neem in die navorsingstudie. 
 
 
Purpose of Study   
 The purpose of this research is to better understand issues related to pregnancy prevention 
(including birth control/contraception) among young girls within the age group (14 – 19 
years) of interest to this research.  
 Ultimately, the findings of this research would help to increase our understanding of the ways 
to improve access to contraceptive services. 
Doel van studie 
 Die doel van hierdie navorsing is om kwessies wat verband hou met geboortebeperking / 
kontrasepsie gebruik onder jong meisies van 14-19 jare oud wat belang is vir hierdie navorsing. 
 Uiteindelik sal die bevindinge van die navorsing te help om ons begrip van die maniere om 
toegang tot voorbehoedmiddels dienste te verbeter verhoog. 
 
Description of the Study Procedures 
 If you agree on your child/ward’s participation in the research study, she will be asked to 
provide answers to some questions about birth control services in the clinic.  
 The interview will take place in a comfortable location in the clinic where her privacy can be 
assured.   
 The interview questions will be interviewer-administered.  
 We aim for an interview that will last approximately 40-45 minutes.  
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 The information shared during the interview will be kept confidential, and only key members 
of the research team will have access to it. The information cannot be shared with the 
parent.  
Beskrywing van die studie prosedures 
• As u saamstem oor deelname van u kind /saal in die navorsingstudie, sal sy gevra word om 
antwoorde op 'n paar vrae oor die geboorte beheer dienste in die kliniek verskaf. 
• Die onderhoud sal plaasvind in 'n gemaklike plek in die kliniek waar haar privaatheid kan 
verseker wees. 
• Die onderhoud vrae sal-onderhoudvoerder geadministreer word. 
• Ons streef na 'n onderhoud wat ongeveer 40-45 minute sal duur. 
• Die inligting gedeel tydens die onderhoud sal vertroulik hanteer word en slegs die 
belangrikste lede van die navorsingspan sal toegang daartoe het. Die inligting kan nie gedeel 
word met die ouer. 
 
Risks/Discomforts of Being in this Study 
  There are no major risks to your child/ward.  
 She may feel uncomfortable talking about her personal life. She does not have to answer any 
question that may make her feel uncomfortable.  
 We will offer counselling for participants that feel the interview made them uncomfortable.  
 
Risiko's / ongemak daarvan om in hierdie studie 
• Daar is nie 'n groot risiko's vir u kind /saal. 
• Sy kan ongemaklik voel as sy praat oor haar persoonlike lewe. Sy hoef nie enige vraag wat 
mag  haar ongemaklik laat voel beantwoord. 
• Ons bied berading vir deelnemers wat die onderhoud voel het hulle ongemaklik 
 
Benefits of Being in the Study 
 There is no direct benefit to your child/ward, but her involvement is likely to assist us to know 




Voordele van wat in die studie 
• Daar is geen direkte voordeel vir u kind /saal maar haar betrokkenheid is geneig om ons te 
help om meer oor hoe om op maat van geboorte beheer dienste aan die behoeftes van jong 
vroue te ontmoet weet. 
 
Confidentiality  
 The interview with your child/ward is confidential and the only thing that will be disclosed is 
any form of maltreatment (including physical ill-treatment, emotional maltreatment, sexual 
abuse or neglect), but this will be reported to the social development department, a child 
welfare agency, or a police official in terms of legislation.  
 If your child/ward tells us that she is experiencing some form of violence or maltreatment 
(including physical ill-treatment, emotional maltreatment, sexual abuse or neglect) or if a 
research staff reasonably suspects violence or maltreatment, and that this has not been 
reported to a relevant agency, we are required by law to report this to a child protection 
agency. Someone will then investigate and see what needs to be done to keep your 
child/ward safe. Your daughter’s confidentiality will be protected and we will provide 
counselling and manage expectations honestly. These actions are necessary to protect you 
and your child. 
 All the documents and records of this study will not be available to anyone outside the 
research team.  
  Research documents and records will be kept in a locked file, and all electronic information 
will be coded and secured using a password protected file.  




• Die onderhoud met u kind / saal is vertroulik en die enigste ding wat sal bekend gemaak word 
is enige vorm van mishandeling (insluitende fisiese mishandeling, emosionele mishandeling, 
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seksuele misbruik of verwaarlosing), maar dit sal gerapporteer word aan die departement 
van maatskaplike ontwikkeling, 'n kindersorg-agentskap, of 'n polisiebeampte in terme van 
wetgewing. 
• Indien u kind / saal vertel ons dat sy ervaar een of ander vorm van geweld of mishandeling 
(insluitende fisiese mishandeling, emosionele mishandeling, seksuele misbruik of 
verwaarlosing) of as 'n navorsing personeel vermoed geweld of mishandeling, en dat dit nog 
nie gerapporteer word aan 'n toepaslike agentskap, is ons deur die wet vereis om dit te 
rapporteer aan 'n kinderbeskermingseenheid agentskap. Iemand sal dan ondersoek en kyk 
wat gedoen moet word om u kind /saal veilig te hou .Vertroulikheid van u dogter sal beskerm 
en ons sal berading verskaf en eerlik verwagting te bestuur.. Hierdie optrede is nodig om u 
en u kind te beskerm. 
• Al die dokumente en rekords van hierdie studie sal nie beskikbaar vir iemand buite die 
navorsingspan wees. 
• Navorsing dokumente en rekords sal in 'n geslote lêer gehou word, en alle elektroniese 
inligting sal gekodeer word en verseker met behulp van 'n wagwoord beskermde lêer. 





 Your daughter/ward will receive a light refreshment on completion of the interview.  
 
Vergoeding 
• Jou dogter / saal sal 'n ligte verversings ontvang na afloop van die onderhoud. 
 
Right to Refuse or Withdraw 




 If your child is uncomfortable about any of the interview questions she can choose not to 
answer or participate in that part of the question.  
 Your daughter has the right to withdraw from the interview at any time during the interview 
process. 
 There will be no penalty if your daughter decides to quit at any time during the interview 
 Whether your daughter participates or not she will still get the same care as usual at the 
clinic.  
 
Reg om te weier of te onttrek 
• Die besluit om u dogter aan hierdie studie betrek is heeltemal aan u en u kind. Dit is 
heeltemal vrywillig. 
•  As u kind  ongemaklik is oor enige van die onderhoud vrae, sy kan kies om nie te antwoord 
of deel te neem in daardie deel van die vraag. 
• U dogter het die reg om te onttrek van die onderhoud te enige tyd gedurende die onderhoud 
proses. 
• Daar sal geen straf wees as u dogter besluit om op te hou te enige tyd gedurende die 
onderhoud 
• Of u dogter deelneem of nie, sal sy nog steeds dieselfde sorg soos gewoonlik by die kliniek 
kry. 
 
Right to Ask Questions and Report Concerns 
 You have the right to ask any questions in relation to this research study, but the information 
your child has provided cannot be shared with you. 
 If you have any questions about this research study, you can contact me at 0717243901. 
 If your daughter has any problem or concern that occurs as a result of her participation in 
the research study, you can contact me at 0717243901. 
 If you have any concern about your daughter’s right as a research participant that have not 
been adequately address by the research team, you can contact me at 0717243901 or  report 
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to Human Research Ethics Committee at the Faculty of Health Sciences University of Cape 
Town at +27214066346 
 
Reg om vrae te vra en Rapporteer Kommernisse 
• U het die reg om enige vrae wat betrekking het om hierdie navorsingstudie vra, maar die 
inligting  wat u kind voorsien kan nie gedeel word met u. 
• Indien u enige vrae het oor hierdie navorsingstudie, kan u my kontak by 0717243901. 
• As u dogter het 'n probleem of bekommernis wat plaasvind as gevolg van haar deelname 
aan die navorsingstudie, kan u my kontak by 0717243901. 
• Indien u enige kommernis oor regte van u dogter  as 'n navorsingsdeelnemer wat nie 
voldoende aan te spreek deur die navorsingspan, kan u my kontak by 0717243901 of verslag 
aan die mens Navorsingsetiekkomitee van die Fakulteit Gesondheidswetenskappe 
Universiteit van Kaapstad by + 27214066346 
 
Consent 
 Your signature/thumbprint below confirms that you have agreed to allow your daughter 
participates in the research study, and that you have read and understood the information 
provided in this form and information sheet. You will be given a signed/thumb printed copy 
of this form to keep. The lead researcher will keep a copy. 
toestemming 
• U handtekening / duimafdruk hieronder bevestig dat u ingestem het om toe te laat u 
dogter om aan die navorsingstudie deel te neem, en dat u het die inligting wat in hierdie 
vorm en inligtingsblad  gelees en verstaan. U sal 'n getekende / duim gedrukte afskrif van 
hierdie vorm gegee word om aan te hou. Die hoofnavorser sal 'n afskrif hou. 
 
Biodun Olagbuji (Lead Researcher) 
Doctoral Candidate, School of Public Health 





Signature/thumbprint of parent/guardian…………………………   Date…………………….. 
Signature of research staff…………………………   Date……………………..  
 
Appendix 4: Exit Interview Questionnaire for Adolescent Girl Clients (14-19 years) in HIV Services. 
 
 
1Instruction to field staff: Tick the appropriate consent form completed for this respondent.  
Please note that participation is voluntary and consent is a must. A parent’s/legal guardian’s written consent is 
required for all participants aged 14-17 years. Informed consent can only be completed after a participant has 
been informed about the facts of the study using the attached information sheet (see appendix 2), and 
demonstrated understanding of the information.  
Please tick the appropriate boxes below: 
Consent form for girl 18 or 19 years:  Yes             No   
Parent/Guardian consent for girl 14 to 17 years: Yes           No   




2Instruction to field staff: Please tell every participant that her opinion and views to the questions are very 
important. Inform participants to answer every question carefully and honestly. In addition, tell participants that 
their answers will help in the development of better health services.  
 
2Umyalelo kubasebenzi bophando lwangaphandle: Xelela omnye nomnye umthathi-nxaxheba ukuthi 
uluvo neembono zakhe kwimibuzo zibaluleke kakhulu. Xelela abathathi-nxaxheba ukuphendula 
omnye nomnye umbuzo ngononophelo nangokunyanisekileyo. Ngaphezu koko, xelela abathathi-
nxaxheba ukuba iimpendulo zabo ziya kunceda kuphuhliso lweenkonzo zempilo ezingcono.  
 
Interviewer ID number:  
Participant Study number:  
 
Study clinic’s code (please circle appropriate code below):  
 
01: Gugulethu CHC         02: Nyanga CHC            03: Heidveld CHC      04: Brown Farms CHC 
 05: Mitchells Plain            06: Cross roads CHC      07: Khayelitsha (site B)  08: Michael M. CHC 
 09: Site B youth clinic      10: Site C Youth Clinic   11: Nolungile CHC ]       12: Vuyani Clinic 
 13: Mzamomhle Clinic     14: Weltevreden Valley Clinic   15: Kuyasa Clinic   16: Mathew Goniwe Clinic 
17: Town 2 Clinic 
 
 
Language of interview (please circle appropriate box below) 
English             isiXhosa                Afrikaans           
 
Date of interview:  
                               Day         Month           Year 
 
 
No Questions Responses Cod-ing 
 
Skip 
Section 1: Socio-demographic  
101 How old were you at your last 
birthday? 
Ubuneminyaka emingaphi 















102 What is your date of birth? 





Day/Usuku   Month/Inyanga     Year/Unyaka 













































103 What is the highest level of grade 
you have completed or what level 
of school are you presently? 
 
Leliphi elona banga 
lomphakamo ophezulu 
oligqibileyo okanye ukowuphi 
umphakamo wesikolo ngoku? 
 
 

























































In the household/home where 
you currently live, do you have 
access to: 
 
Endlini/ekhaya apho uhlala 
khona ngoku, ingaba 
uyafikelela  kwezi: 
 
 
Interviewer: Please read all the response 
options to the respondent then tick the 




A television/Umabonakude/ iTV?     Yes       No 
 
A landline/Ifoni yasendlini?     Yes            No 
 
Own cellular phone/Iselifoni eyeyakho? Yes       No 
 
A computer/Ikhompyutha? Yes          No 
 
A refrigerator/Isibandisi/ifriji? Yes          No 
 
A car or truck/Imoto okanye ilori?  Yes      No  
                                                    
A motorcycle/scooter/Isithuthuthu/ isikuta?  
                                                              Yes          No          
A clothes washing machine/Umatshini wokuhlamba 
iimpahla? Yes         No 
                                                  
Piped water into house/Amanzi empompo angena 
endlini?  Yes       No 
                                                                  
Flush toilet not shared with other households/Igumbi 
langasese eligunxuzwayo elingadityanelwanga 
neminye imizi?    Yes        No 
                                                                          
 
Yes      No        
1             0 
 
1             0 
 
1             0 
 
1             0 
 
1             0 
 
1             0 
 
 
1             0 
 
1             0 
 
 





































Interviewer: Please note below: 
Atheism/Ateïsme:  disbelief in the 
existence of God or gods/I-Atheism: 
Ukungakholwa kubukho 
bukaThixo okanye oothixo 
 
Agnosticism/Agnostisisme: 
doubting whether or not God exists/ I-
Agnosticism: Ukungabaza 
nokuba ukhona okanye akekho 
uThixo.  
  
Interviewer: Tick only one that applies 
Protestant-Anglican, Methodist etc/IProtestanti- 
iTshetshi, iWesile njlnjl 
Afrikaanse/i-Afrikaanse 
Protestantse Kerk  
Traditional African belief/Inkolo yeSintu yaseAfrika 
Atheism/ I-Atheism: 
Agnosticism/I-Agnosticism: 















Interviewer: Please read all the response 
options to the respondent then circle only 
one that is applicable. 
 
Live alone/Uhlala wedwa  
Live with parent(s)/Uhlala nomzali (nabazali) 
Live with other relatives/Uhlala nezinye izizalwane 
Live with male partner or married/Ndihlala neqabane 
eliyindoda okanye nditshatile 
Live with others (i.e friends/peers, dormitory)/Ndihlala 























What is the highest level of 
education of the person who 
assumes the most responsibility in 
caring for you? 
 
Ngowuphi owona mphakamo 
uphezulu wemfundo womntu 






Never went to school/Akazange afunde kwaphela 
Primary (grade 7)/Iprayimari (ibanga 7) 



























109 If you come straight from the 
home where you currently live, 
how long does it normally take 
you to get to this clinic? 
 
Ukuba usuka ngqo ekhaya 
apho uhlala khona ngoku, 
ngesiqhelo kuthatha ixesha 








Have you ever had a glass of 
beer, wine, or a shot of liquor 
(not including while with your 
family at a banquet or 
celebration)? 
 
Ingaba sewukhe wasela iglasi 
yebhiya, yewayini, okanye 
isivuseleli sotywala (ungaquki 
xeshikweni unosapho lwakho 














111 Have you ever smoked cigarette?  












    
HIV service use 
 
201 What day, month and year did you 
enrol in this clinic for HIV care? 
 
Kungoluphi usuku, inyanga 
nonyaka owabhalisa ngalo kule 
kliniki yenkathalelo ye-HIV? 
 
Interviewer: Write approximate month 
and year if exact time not known 
 
     
Day/Usuku        Month/Inyanga            Year/Unyaka 
 









Why did you decide to choose this 
clinic for HIV care/services? 
 
Kutheni wathatha isigqibo 




Interviewer: Please read all the response 
options to the respondent then tick all the 




Availability of ARV/Ukufumaneka kweARV?                                     
                                           Yes/Ewe       No/Hayi 
Close distance to residence/Umgama omfutshane 
ukuya kwindawo yokuhlala? Yes/Ewe      No/Hayi 
                                     
Short waiting time/Ixesha lokulinda elifutshane? 
                                       Yes/Ewe       No/Hayi 
                             
Friendliness of providers/Ububele babanikeli 
benkonzo?   Yes/Ewe         No/Nee 
                                       
Attends to only youth/Ukuhoya ulutsha kuphela?                                         
                                           Yes/Ewe           No/Hayi                
Confidentiality and privacy/Imfihlo nobuwedwa?                           
                                       Yes/Ewe            No/Hayi 
Possibility to receive contraceptive services (counselling, 
contraception)/Ithuba lokufumana iinkonzo 
zothintelo lwenzala (ululeko, uthintelo lwenzala)? 
                                        Yes/Ewe         No/Hayi 
                                                            
Referred/transferred from other clinic/Ukuthunyelwa 
/ukugqithiselwa kwenye ikliniki?  
                                      Yes/Ewe         No/Hayi       
                                                   
Yes  No 
1        0 
 
1        0 
 
 
1        0 
 
 
1        0 
 
 
1      0 
 













Recommended by friend/parent/family/Ikhuthazwa 
ngumhlobo/umzali/usapho?  
                                          Yes/Ewe         No/Hayi                                                                
 
Others (specify)/Ezinye (cacisa)… 
 
 







203 Please can you tell me, when you 








Interviewer: Write approximate month 
and year if exact time not known.  
 
   
 
At Birth (mother to child): Yes             No  
 
If not at birth, Please tell me the date: 
 
                   
                                                                                     
     Day/Usuku         Month/Inyanga          Year/Unyaka 




204 Which of these best describes 
how you acquired HIV infection? 
 
Yeyiphi kwezi echaza ngeyona 
ndlela ingcono ukuba 
walufumana njani usulelo lwe-
HIV? 
 
Interviewer: Please read all the response 
options to the respondent then circle 
only one that is applicable 
 
Injecting drug use/Ukusebenzisa ukutofa 
ichiza/isiyobisi 
 
Sexual partner/Iqabane lezesondo 
 
Mother to child/Ukusuka kumama ukuya 
emntwaneni 
 
Others (specify)/Ezinye (cacisa)… 
 
 
































How many days have you missed 
taking all of your doses of HIV 
medications during the past four 
days? 
Zingaphi iintsuku oziphosileyo 
zokuthatha onke amayeza e-





One day/Usuku olunye 
Two days/Iintsuku ezimbini 
Three days/Iintsuku ezintathu 















Beluyintoni ubalo lwakho 
lokugqibela lwe-CD4?  
 
When was the date of this last 
CD4 count? 
 








Day/Usuku      Month/Inyanga       Year/Unyaka 









Are you currently attending HIV-
Youth Support Group/Club? 
Ingaba likhona iqela lenxaso 
lolutsha elinentsholongwane 






















                 Number/Inani  
 
302 a) Since you tested positive for 








b)How many of these pregnancies 
(including current pregnancy) 
occurred:  
 





 When no children, or no 






































 When you did not desire 
to become pregnant but 












        
                           
                          
303 a)Would you like any more 




Interviewer: this question is for 














b) In future would you like to have 
children? 
Kwixesha elizayo ungathanda 
ukufumana abantwana? 
Interviewer: this question is for 






N/A/Akusebenzi (for person who are physically unable 
to have children)/(vir persoon wat fisies nie kan 








304 How long would you like to wait 
before you become 
pregnant/next pregnancy? 
 
Ungathanda ukulinda ixesha 





                   Weeks/Iiveki 
   
                  Months/Iinyanga 
   
                   Years/Iminyaka 
 




Contraceptive behaviours: Now I would like to talk about family planning/contraception/preventer- the various 
ways or methods that a couple can use to delay or avoid a pregnancy. Iindlela zokuziphatha zokuthintela inzala: 
Ngoku ndingathanda ukuthetha ngocwangciso losapho /uthintelo lwenzala/isithinteli- iintlobo 
ngeentlobo zeendlela okanye iinkqubo ezinokusetyenziswa ngabalingane ukucothisa okanye ukuphepha 
ukukhulelwa. 
 
401 Have you ever heard of the 
following (METHOD)/ Ingaba 





b)2 months (Nur-Isterate) or 3 
months (Depo-provera) 
injectables/iinyanga ezi-2 (i-

























Udloliso lwendoda ngotyando 
lobugqirha/i-Vasectomy 
 
Interviewee: Please read all the response 
options to the respondent then circle all 
that are applicable 
 
Female sterilization: Surgical 
procedure to block fallopian 
tubes 






























































































Ufunde njani malunga 
nendlela yolawulo lwenzala 
/uthintelo lwenzala/uthintelo? 
 
Interviewer: Please read all the response 
options to the respondent then circle all 






Care provider (Doctors, nurses, etc)/Umnikeli 
weNkathalelo (Oogqirha, abongikazi, njlnjl) 











403 Are you or your partner currently 
doing something or using any 
method to delay or avoid getting 
pregnant? 
 
Ingaba wena okanye 
umlingane wakho ngoku 
nenza okuthile okanye 





















If Yes response to question 403, 
what methods are you currently 
using? 
Ukuba ngu-ewe kumbuzo we-
403, zeziphi iindlela 
enizisebenzisayo ngoku? 
 
Interviewer: Please read all the response 
options to the respondent then circle all 
that are applicable. Probe for use of 
condom with another method.  
 
  
Definition of terms: 
Rhythm Method: Sexual (vaginal) 
intercourse abstinence on days 12 
through 19 of the menstrual cycle i.e., 




Indlela yesingqi: Ukuzila 
ukwabelana ngesondo 
(kwilungu lobufazi) 
kwiintsuku ezili-12 ukuya 
kwezili-19 zomjikelo wokuya 
exesheni oko kukuthi., 
iintsuku xa ukukhulelwa 
Pills/birth control tablet/Iipilisi/ipilisi yokulawula inzala 
Male condom/Ikhondom yamadoda 
Female condom/Ikhondom yabasetyhini 
2 month (Nur-Isterate) or 3 month(Depo-provera) injectables/ 




Spermicide (chemical foam/jelly/cream)/Isibulala-madlozi 
(igwebu lechiza/ijeli/amafutha okuthambisa) 
Emergency contraception/morning after pill/Uthintelo 
lwenzala lwengxakeko/ipilisi yasemva kokwabelana 
ngesondo 
Female sterilization/tubal ligation/Udloliso lwabasetyhini 
ngotyando lobugqirha/ukubotshwa kwemibhobho 
Male sterilization/Udloliso lwendoda ngotyando lobugqirha 
Rhythm method/Indlela yesingqi 
Lactational amenorhhoea (Breastfeeding)/Ukuncancisa 
Standard days method/Indlela yemihla esesikweni 
Withdrawal/Urhoxiso 
Condom with another method/Ikhondom kunye nayiphi enye 
indlela engentla (Interviewer: Please write out the another 
method……………… 




































kukho ithuba lokuba 
kungenzeki. 
 
Standard Days Method: Sexual 
(vaginal) intercourse abstinence on days 
8 through 19 of the menstrual cycle i.e., 
(days when pregnancy is not likely to 
occur) by women with cycles consistently 
between 26 and 32 days. 
 
Indlela yemihla esesikweni: 
Ukuzila ukwabelana ngesondo 
(kwilungu lobufazi) 
kwiintsuku ezili-12 ukuya 
kwezili-19 zomjikelo wokuya 
exesheni oko kukuthi., 
iintsuku xa ukukhulelwa 
kukho ithuba lokuba 









     
     







If No to question 403, interviewer 
please ask this question:  
 
Since you tested positive for HIV, 
what family planning method(s) 
have you/your partner used to 
avoid getting pregnant? 
 
Ukuba nguHayi kumbuzo 
wama-403, mbuzi wodliwano-
ndlebe nceda ubuze lo mbuzo:  
Ukususela ekufumaneni 
uvavanyo lokuthi une-HIV, 








Interviewer: Please read all the response 
options to the respondent then circle all 





Pills/birth control tablet/Iipilisi/ipilisi yokulawula 
inzala 
Male condom/Ikhondom yamadoda 
Female condom/Ikhondom yabasetyhini 
2 month (Nur-Isterate) or 3 month(Depo-provera) 
injectables/ Iinyanga ezi-2 (i-Nur-Isterate) okanye 




madlozi (igwebu lechiza/ijeli/amafutha 
okuthambisa) 
Emergency contraception/morning after pill/Uthintelo 
lwenzala lwengxakeko/ipilisi yasemva kokwabelana 
ngesondo 
Female sterilization/tubal ligation/Udloliso 
lwabasetyhini ngotyando lobugqirha/ukubotshwa 
kwemibhobho 
Male sterilization/Udloliso lwendoda ngotyando 
lobugqirha 
Rhythm method/Indlela yesingqi 
Lactational amenorhhoea (Breastfeeding)/Ukuncancisa 





































 Condom with another method/Ikhondom kunye 
nayiphi enye indlela engentla (Interviewer: Please write 
out the another method……………… 














406 Since you tested positive for HIV, 
what family planning method(s) 




uvavanyo oluthi une-HIV, 
yeyiphi indlela/iindlela 
zokucwangcisa usapho wena 






Interviewer: Please read all the response 
options to the respondent then circle all 





Pills/birth control tablet/Iipilisi/ipilisi yokulawula 
inzala 
Male condom/Ikhondom yamadoda 
Female condom/Ikhondom yabasetyhini 
2 month (Nur-Isterate) or 3 month(Depo-provera) 
injectables/ Iinyanga ezi-2 (i-Nur-Isterate) okanye 




madlozi (igwebu lechiza/ijeli/amafutha 
okuthambisa) 
Emergency contraception/morning after pill/Uthintelo 
lwenzala lwengxakeko/ipilisi yasemva kokwabelana 
ngesondo 
Female sterilization/tubal ligation/Udloliso 
lwabasetyhini ngotyando lobugqirha/ukubotshwa 
kwemibhobho 
Male sterilization/Udloliso lwendoda ngotyando 
lobugqirha 
Rhythm method/Indlela yesingqi 
Lactational amenorhhoea (Breastfeeding)/Ukuncancisa 
Standard days method/Indlela yemihla esesikweni 
Withdrawal/Urhoxiso 
Condom with another method/Ikhondom kunye 
nayiphi enye indlela engentla (Interviewer: Please write 
out the method……………… 
















































































Why did you/your partner stop 




Advised by provider to use condoms instead/Ucetyiswe 
ngumnikeli wenkathalo ukusebenzisa iikhondom 
endaweni yoko 
No      Yes 







I am going to read a number of 
option please answer No or Yes to 
each 
Did you stop because….. 
 
Kutheni wena/umlingane 





Ndiza kufunda iindlela 
zokhetho eziliqela ngako 
phendula ngoHayi okanye 
ngo-Ewe kuhlobo ngalunye 




Interviewer: Please read all the response 
options to the respondent then circle all 
that are applicable  
  





Fear of HIV transmission to HIV-negative partner/ 
Uloyiko lokudlulisela i-HIV kumlingane ongenalo 
usulelo lwe-HIV 
 
Fear of getting infected with another HIV virus/Uloyiko 
lokufumana usulelo lwenye ivayirasi ye-HIV 
 
It can worsen HIV disease condition/Ingenza 
mandundu imeko yesifo se-HIV 
 
Positive partner HIV test result/Isiphumo sovavanyo 
somlingane one-HIV 
 
Lower success of HIV medications/Impumelelo 
ephantsi yamayeza e-HIV 
 
Provider advised to stop method/Umnikeli ucebise 
ukuyeka indlela 
 
Moved house/changed clinic/Ufudukile 
endlini/utshintshe ikliniki 
 
Broke up with partner/Wahlukene nomlingane 
 
Stopped having sex/Uyekile ukwabelana ngesondo 
 
Wanted a baby/Ufuna usana 
 
Partner wanted a baby/Umlingane ufuna usana 
 
Partner told me to stop/Umlingane undixelele ukuba 
ndiyeke 
 






0 1  
 
 
0              1 
             
               
0               1 
               
              
0               1 
    
             
0               1 
         
 
        




0             1 
 
 
0              1 
 
 
0              1 
 
 
0              1 
 
0              1 
 
0              1 
 
0              1 
    
0              1 
 































Hormonal contraceptive-related safety concerns: As you probably know, some women living with HIV would not take a 
hormonal method for birth control/pregnancy prevention (pills/birth control tablets, emergency contraceptive/morning 
after, 2 months/3 months injectables and implants) because it might make it more likely for them or their male sexual 
partners to develop a problem while using it. P lease tell me how much you agree or disagree with the statements I read to you.  
You can use the face that best describes your opinion.  
Amaxhala anxulumene nokhuseleko lokusebenzisa izithinteli ze-hormone: Njengoko mhlawumbi usazi, abanye 
abasetyhini abaphila ne-HIV abanakho ukusebenzisa indlela ye-hormone yokulawula inzala /ukuthintela 
ukukhulelwa (iipilisi/ipilisi yokulawula inzala, uthintelo lwenzala lwengxakeko /lwentsasa emva kwezesondo, 
iinyanga ezi-2 /iinyanga ezi-3 ezokutofa nezimiliselo) ngenxa yokuba kungabakho nangakumbi ukuba bona okanye 
abalingane babo abangamadoda banokuvelelwa yingxaki xeshikweni beyisebenzisa. Nceda undixelele ukuba 
uvumelana okanye awuvumelani kangakanani neengxelo endikufundela zona. Ingaba uyaVuma ngaMandla, 
uyaVuma, uneZimvo eziXubeneyo, AwuVumi okanye awuVumi ngaMandla? Ungasebenzisa ubuso obuchaza 
ngeyona ndlela ilungileyo uluvo lwakho.  
Umbuzi wodliwano-ndlebe: Nceda wazise abathathi-nxaxheba malunga neentlobo ngeentlobo zeendlela ze-hormone 
zokuthintela inzala.  
 
 














501 Let us assume that you wanted to 
use a hormonal method of birth 
control. Which of the following 
response options would apply to 
you regarding the statements I 
read to you. Interviewer: Please 
start each question (501a-d) with: 
Do you Strongly Agree, Agree, 
have Mixed feelings, Disagree or 
Strongly Disagree that 
 
Masithathe ngokuthi ubufuna 
ukusebenzisa indlela ye-































Zeziphi zeendlela ezilandelayo 
zokhetho zokuphendula 
ezingasebenza kuwe malunga 
neengxelo endikufundela zona. 
Umbuzi wodliwano-ndlebe: 
Nceda uqale umbuzo ngamnye 
(501a-d) ngokuthi: Ingaba 
uVuma ngaMandla, uyaVuma, 
uneZimvo eziXubeneyo, 
AwuVumi okanye awuVumi 
ngaMandla ukuba ………. 
 
Interviewer: Please explain the meaning 
of hormonal contraceptives to respondent. 
Note that hormonal contraceptives are 
birth control methods that act on the 
body system. Hormonal contraceptives 
include pills, injections and implants. 
 
 a)In your case, using hormonal 
contraceptive could make HIV 
disease progression to occur 
quickly (i.e. worsening HIV 
disease or cause AIDS)? 
 
Kwimeko yakho, ukusebenzisa 
isithinteli senzala se-hormone 
kungenza isifo se-HIV 
siqhubeke ukwenzeka 
ngokukhawuleza (oko kukuthi 
ukuba mandundu kwesifo se-
HIV okanye kudale i-AIDS)? 











b) In your case, hormonal 
contraceptive use could make 
passing the HIV virus to an 
uninfected male sexual partner to 
be more able? 
 
Kwimeko yakho, ukusebenzisa 
isithinteli senzala se-hormone 
kungenza ukugqithisa ivayirasi 
ye-HIV kumlingane 











c) In your case, the ability of HIV 
treatments/medicines to fight 
HIV virus/AIDS could be 
reduced with concurrent use of 
hormonal contraceptive.  
 
Kwimeko yakho, isakhono 
sonyango /samayeza e-HIV 
sokulwa nevayirasi ye-HIV 







d) In your case, birth control 
failure (i.e., a possibility of getting 
pregnant) could be more if 
hormonal contraceptive is used 
concurrently with HIV medicines 
because of the possible alterations 
in its ability to prevent pregnancy 
by HIV medicines.  
 
Kwimeko yakho, ukusilela 
kolawulo lwenzala (oko 
kukuthi, ithuba lokukhulelwa) 
lingenzeka kakhulu ukuba 
isithinteli senzala se-hormone 
sisetyenziswa 
ngokuhambelana namayeza e-
HIV ngenxa yeenguqu 
ezinokubakhona kwisakhono 
saso sokuthintela ukukhulelwa 
ngenxa yamayeza e-HIV. 
     
       
       
 
Please I would like to know about the relationship you have with your parent(s)/guardian(s) with regards to contraception/family 
planning/preventer/Ngesicelo ndingathanda ukwazi malunga nonxulumano onalo nomzali/nabazali bakho/ 
nomlondolozi/nabalondolozi bakho malunga nothintelo lwenzala/ucwangciso losapho/isithinteli? 
502 
 
Interviewer: Please ask participant to indicate her opinion on the response/diagram and then tick 





Do you strongly disagree, 
disagree, ……that  
Your mother talks to you about 
contraceptive/birth 





awuVumi, akukho Nanye 
yokuNgavumi okanye 
ukuVuma, uyaVuma, okanye 
uVuma ngaMandla ukuba:   
Umama wakho uthetha nawe 
malunga nokusebenzisa 
























Strongly    
Disagree/ 
Andivumi   








































Think about your closest 
female friend 
 
To what extent do you agree with 
the following: Your closest female 
friend  encourages you to use 
contraceptives/birth control 




Cinga ngomhlobo wakho 




nokulandelayo: Oyena mhlobo 




Andivumi   


















































wakho wasetyhini ukufuphi 
naye ukukhuthaza 
ukusebenzisa izithinteli 
zenzala /ulawulo lwenzala 














504 How often have you talked with 
your closest female friend about 
contraception/birth 
control/family planning method? 
 
Kukaninzi kangakanani 
uthethe nomhlobo wakho 






Interviewer: Please read all the response 
options to the respondent then circle 




  Never/Nakanye                      0               
  Once/Kanye                            1 
  Few times/amaxa ambalwa    2     
  Many times/amaxa amaninzi  3            





















Think about this community 
where you live/ 
 
Cinga malunga nolu luntu 
apho uhlala khona: 
 
 
How socially acceptable is it these 




ekuhlaleni kule mihla: Ukuba  
Amantombazana afumana 

























Is it Completely Unacceptable, Unacceptable, No idea, Acceptable or Completely 
Acceptable? Please you may use the face that best indicates your opinion.  
 
 
Ayamkeleki kwaPhelae, Ayamkeleki, Alukho uluvo, Iyamkeleka okanye 
Yamkeleka ngokuPheleleyo? Ngesicelo ungasebenzisa ubuso obubonisa 



































Sexual behaviour: Now I would like to ask some questions about sexual activity in order to gain a better understanding of some important life 
issues. Ukuziphatha kwezesondo: Ngoku ndingathanda ukubuza imibuzo ethile malunga nentshukumo yezesondo 
ukufumana ukuqonda okungcono ngemiba ethile ebalulekileyo yobomi.  
  
601 No/Hayi Yes/Ewe  
324 
 
Have you ever had/Ingaba wakhe 
wanamava  
  
Sexual intercourse through vagina 
(Vagina intercourse/Ukwabelana 




Sexual intercourse through Anus 
(Anal intercourse)/Ukwabelana 




Sexual intercourse through mouth 
(Oral intercourse)/Ukwabelana 





Interviewer: Please read all the response 
options to the respondent then circle all that 





































602 How old were you when you had 
sexual intercourse (vaginal 
intercourse) for the very first time?  
Ubumdala kangakanani xa 
unokwabelana ngesondo kwilungu 
langasese lowasetyhini (i-vaginal 




                      Years/iminyaka 
 
603 Since you tested positive for HIV, 
which contraceptive method(s) did 
you use the first time you had sexual 
intercourse (vaginal intercourse)? 
 
Ukususela ubenovavanyo oluthi 
une-HIV, yeyiphi indlela 
yothintelo lwenzala 
uyisebenzisileyo kwityeli lokuqala 
wabelana ngesondo kwilungu 




Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
Pills/birth control tablet/Iipilisi/ipilisi 
yokulawula inzala 
Male condom/Ikhondom yamadoda 
Female condom/Ikhondom yabasetyhini 
2 month (Nur-Isterate) or 3 month(Depo-
provera) injectables/ Iinyanga ezi-2 (i-Nur-








Emergency contraception/morning after 
pill/Uthintelo lwenzala 


























 Female sterilization/tubal ligation/Udloliso 
lwabasetyhini ngotyando 
lobugqirha/ukubotshwa kwemibhobho 
Male sterilization/Udloliso lwendoda 
ngotyando lobugqirha 
Rhythm method/Indlela yesingqi 
Lactational amenorhhoea 
(Breastfeeding)/Ukuncancisa 
Standard days method/Indlela yemihla 
esesikweni 
Withdrawal/Urhoxiso 
Condom with another method/Ikhondom 
kunye nayiphi enye indlela engentla 
(Interviewer: Please write out the 
method……………… 
























604 Think about all the times you have had 
sexual intercourse, how often would 
you say you or your partner used 
condom to prevent pregnancy? 
 
Cinga malunga namaxa onke ube 
nokwabelana ngesondo, ungathi 
kukaninzi kangakanani wena 
okanye umlingane wakho 
esebenzise ikhondom ukuthintela 
ukukhulelwa? 
 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
Every time/Ngamaxa onke 
Almost every time/Phantse ngamaxesha 
onke 
Sometimes/ Ngamanye amaxesha 
Never/Nakanye  
Don’t know/Andazi 












605 Think about all the times you have 
had sexual intercourse, how often 
would you say you or your partner 
used any method other than condom 
(i.e. birth control tablets/pills, 
injectables (Nur-Isterate or Depo-
provera), loop/coil/IUD, implant, 
Spermicide, or female/male 
sterilization) to prevent pregnancy? 
 
Cinga malunga namaxa onke ube 
nokwabelana ngesondo, ungathi 
kukaninzi kangakanani wena 
okanye umlingane wakho 
esebenzise nayiphi indlela 
ngaphandle kwekhondom (oko 
kukuthi ipilisi yokulawula 
Every time/Ngamaxa onke 
Almost every time/Phantse ngamaxesha 
onke 
Sometimes/ Ngamanye amaxesha 
Never/Nakanye  
Don’t know/Andazi 













Isterate okanye  i-Depo-provera), i-
loop/ikhoyili/i-IUD, isimiliselo, 
njlnjl) ukuthintela ukukhulela? 
 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
 
606 How frequently did you or your 
partner use condom all the times you 
had sexual intercourse during the last 
3 months? 
 
Kukaninzi kangakanani wena 
okanye umlingane wakho 
esebenzise ikhondom ngamaxa 
onke nisabelana ngesondo kwilixa 
leenyanga ezi-3 ezigqithileyo? 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
 
Every time/Ngamaxa onke 
Almost every time/Phantse ngamaxesha 
onke 
Sometimes/ Ngamanye amaxesha 
Never/Nakanye  
Don’t know/Andazi 










607 How frequently did you or your 
partner use any method other than 
condom (i.e. birth control 
tablets/pills, injectables (Nur-Isterate 
or Depo-provera), loop/coil/IUD, 
implant, Spermicide, or female/male 
sterilization) to prevent pregnancy all 
the times you had sexual intercourse 
during the last 3 months?  
 
Kukaninzi kangakanani wena 
okanye umlingane wakho 
esebenzise nayiphi indlela 
ngaphandle kwekhondom (oko 
kukuthi ipilisi yokulawula 
inzala/iipilisi, izitofu (i-Nur-
Isterate okanye  i-Depo-provera), i-
loop/ikhoyili/i-IUD, isimiliselo, 
njlnjl) ukuthintela ukukhulelwa 
ngamaxa onke nisabelana 
ngesondo kwithuba leenyanga ezi-
3 ezigqithileyo? 
 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
Every time/Ngamaxa onke 
Almost every time/Phantse ngamaxesha 
onke 
Sometimes/ Ngamanye amaxesha 
Never/Nakanye  
Don’t know/Andazi 









608 Which method other than condom did 
you or your partner use to prevent 








pregnancy all the times you had sexual 
intercourse during the last 3 months? 
 
Yeyiphi indlela ngaphandle 
kwekhondom wena okanye 
umlingane wakho ayisebenzisileyo 
ukuthintela ukukhulelwa ngamaxa 
onke nisabelana ngesondo 
kwithuba leenyanga ezi-3 
ezigqithileyo? 
 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
2 month (Nur-Isterate) or 3 month(Depo-
provera) injectables/ Iinyanga ezi-2 (i-Nur-








Emergency contraception/morning after 
pill/Uthintelo lwenzala 
lwengxakeko/ipilisi yasemva kokwabelana 
ngesondo 
Female sterilization/tubal ligation/Udloliso 
lwabasetyhini ngotyando 
lobugqirha/ukubotshwa kwemibhobho 





























































Since you tested positive for HIV, did 
you or your partner use condoms 
(male or female sub-type) the last time 
you had sexual intercourse (vaginal 
intercourse)? 
Ukususela kuvavanyo lokuthi une-
HIV, ingaba wena okanye 
umlingane wakho nisebenzise 
ikondom(eyamadoda okanye 
eyabafazi ilixa lokugqibela nibe 
nokwabelana ngesondo  kwilungu 
langasese lowasetyhini (i-vaginal 
intercourse)? 
 
Since you tested positive for HIV, did 
you or your partner use any method 
other than condom (i.e. birth control 
tablets/pills, injectables (Nur-Isterate 
or Depo-provera), loop/coil/IUD, 
implant, Spermicide, or female/male 
sterilization) the last time you had 
sexual intercourse (vaginal 
intercourse)? 
 
Ukususela kuvavanyo lokuthi une-
HIV, ingaba wena okanye 
umlingane wakho nisebenzise 
olunye uhlobo ngaphandle 
kwekondom(ukutsho; ipilisi 
zocwangciso,ukunqomfa((Nur-
Isterate okanye Depo-provera) 










































































Did you have sexual vaginal 
intercourse within the past 3 months? 
Uyewabelene ngokwesondo 
ngokwelungu langasese 


















610 How many sexual partners have you 
had in the past 12 months (one year)? 
 
Bangaphi abalingane bezesondo 
othe wanabo kwiinyanga ezili-12 
ezigqithileyo (unyaka omnye)? 
 
 
                      Number/Inani   
611 Which of this/these best describe/s 
why you did not use condom and any 
of these methods other than condoms 
listed below every time you had 
intercourse? 
 
Yeyiphi yoku/yezi echaza ngeyona 
ndlela ilungileyo ukuba kutheni 
ungasebenzisanga ikhondom 
kunye nayiphi yezi ndlela 
ngaphandle kwekhondom 
ezidweliswe ngezantsi ngamaxa 
onke nisabelana ngesondo? 
 
Interviewer: Please read all the response 
options to the respondent then circle all that 
are applicable. Please remind respondent 
that you are not judging her. 
 
Methods other than condom/ 
Ezinye iindlela ngaphandle 
kwekhondom 
Pills/birth control tablet/Iipilisi/ipilisi 
yokulawula inzala 
2 month (Nur-Isterate) or 3 month(Depo-
provera) injectables/Iinyanga ezi-2 (i-
Nur-Isterate) okanye iinyanga ezi-







Too expensive/Ibiza kakhulu 
Partner objected/Iqabane lalile  
Don’t like them/Andizithandi   
Used other contraceptive/Usebenzise 
ezinye izicwangciso  
Didn’t think it was necessary/Andizange 
ndicinge ukuba kuyimfuneko  
Didn’t think of it/Andizange ndicinge 
ngayo  
Partner is HIV positive/Iqabane 
linentsholongwane kaGawulayo  
Don’t enjoy sex with 
condom/Andilonwabeli isondo nge 
khondom  
Afraid to ask my partner to use it/Ndiyoyika 
ukucela iqabane lam liyisebenzise  
Drunk/used drugs/Nxilile/usebenzisa 
iziyobisi  
Embarrassed to used female condom/ 
Ndinentloni ukusebenzisa ikhondom 
yabasetyhini  






































































612 How old is your current main/regular 
sexual partner? 
 
Mdala kangakanani umlingane 
wakho wangoku ongundoqo 
/wesiqhelo wokwabelana 
ngesondo? 
                 Number (years)/Inani/Iminyaka 
 







To what extent do you agree or 
disagree with this statement: In your 
relationship, he (main/regular partner) 





Uvumelana okanye awuvumelani 
kangakanani nale ngxelo: 
Kunxibelelwano lwakho,  
(umlingane wakho 
ongundoqo/wesiqhelo) ukuxhasa 





     
                                                                            
Strongly 
Disagree/ 
Andivumi   
ngaMandla              
 




     
Disagree/ 


























614 Have you disclosed your HIV status to 
your current regular partner? 
 
Ingaba uyityhilile imo yakho ye-







615 Would you be willing to share 
information on the HIV status of your 
regular partner with me? 
 
Ingaba ungazimisela ukwabelana 
nam ngolwazi ngemo ye-HIV 





If No, Skip to 616  
616 What is your regular partner’s HIV 
status? 
 
Yeyiphi imo  ye-HIV yomlingane 
wakho wesiqhelo? 
Positive/Unalo usulelo  
Negative/Akanalo usulelo 







Contraceptive self-efficacy: “Please I would like you to rate each item (from 701a--d) according to how true the statement is of you”. Please 
indicate on the diagram below by ticking the appropriate box/response. Ukusebenza ngempumelelo ngokwaso isithinteli senzala: 
“Ngesicelo ndingathanda ukuba uxabise into nganye (ukusuka kuma-701a--d) ngokwendlela ingxelo inyanisekileyo 
kuwe”. Nceda ubonise kumfanekiso ongezantsi ngokuphawula ibhokisi/impendulo echanekileyo. 
 
Interviewer: Self-efficacy means one’s belief in one’s ability to succeed in a task. 
 
701 If you and your boyfriend were getting 
really heavy into sex (sexual vaginal 
intercourse) and moving towards 
intercourse and you were not 
protected … 
 
Ukuba wena nomlingane wakho 
osisihlobo esiyinkwenkwe ningene 
ngamandla kukwabelana 
ngesondo kwilungu langasese 
lowasetyhini ukwabelana 
ngesondo kwilungu langasese 
lowasetyhini) yaye malunga 
nokwabelana ngesondo 
ubungakhuselekanga (oko kukuthi 
uthintelo lokukhulelwa) 
Not at all/ 









Kancinci    
Somewhat/ 
Ngenye 







 701a You could easily ask him 
if he had protection 
(condom) (or tell him 
that you didn’t have a 
protection i.e you are not 
on birth control/family 
planning method).  
 
Ungambuza lula 
nokuba unalo ukhuselo 





 701b You could ask him to use 
male condom or excuse 
yourself to put in a female 
condom, diaphragm/cap, 
or foam(i.e., chemical 
jellies or creams) (if you 










okanye igwebu (oko 





        
 701c You could tell him you 
were on the pill/birth 
control tablet, 2 months 
(Nur-Isterate/3months 
(Depo-provera) 
injectables, inplants or 
had an IUD/loop/coil 














        
 701d You could stop things 
before intercourse, if you 
couldn't bring up the 
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Contraceptive service provision: “Please I would like to ask if you have received any of the following birth control services in 
government clinic(s) since you tested positive for HIV/ Ubonelelo lwenkonzo yothintelo lwenzala: “Ngesicelo 
ndingathanda ukubuza nokuba ufumene naziphi zeenkonzo zolawulo lwenzala ezilandelayo kwiikliniki 
zikarhulumente ukususela xa uvavanyo luthi une-HIV (Imibuzo yama-801-804). 
 Interviewers: Please note that the respondents might have received elsewhere but this research is only interested in their views of government clinics. 
 
801  
a) Have you received advice about 
contraception/birth control in 
government clinic(s) since testing 
positive? 
 
Ingaba ufumene icebiso malunga 
nesithinteli senzala/ulawulo lwenzala 
ukususela uvavanyo luthe unosulelo? 
 
b) If yes (to item 801a), was the advice 
offered in this clinic? 
 
Ukuba ngu-ewe (kwinqaku lama-










































 c)When was the most recent time you 
received this advice?  
 
Belinini elona xesha lakutshanje 
ufumene eli cebiso? 
Interviewer: Please read all the response options 













d) Who provided this most recent birth 
control advice received?  
Ngubani onikele ngeli cebiso lolawulo 
lwenzala elona lutsha lufunyenweyo? 
 
 
Last clinic visit day/Yimini 
yokuqhibela ndikunye 
nani namhlanje ekliniki 
(Date please if yes: 
 
Within past month/ 
Kwithuba lenyanga 
egqithileyo 
Within past 3 months/ 
Kwithuba leenyanga ezi-3 
ezigqithileyo 
 






























-mayeza(Interviewer: tick this 










Interviewer: Please read all the response options 



















e) How often did your HIV care provider 
in this clinic talk to you about birth 
control?  
 
Kukaninzi kangakanani umnikeli 
wakho wenkathalelo ye-HIV kule 
kliniki ethethe nawe malunga 
nolawulo lwenzala? 
 
Interviewer: Please read all the response options to 








f)What did your provider talk about when 
providing these services? 
 
Umnikeli wakho wenkonzo uthethe 
malunga nantoni xa ebonelela ngezi 
nkonzo? 
 
Interviewer: Please read all the response options 









consultation and patient received 

















Every time/Lonke ixesha 















































Clinic policies about 
contraception/Imigaqonk

























































802 a) Have you received condom provision in 
government clinic(s) since testing 
positive? 
 
Ingaba ufumene ubonelelo 
lweekhondom kwikliniki 
























b) If yes (to item 802a), was the condom 
provision offered in this clinic? 
 
Ukuba ngu-ewe (kwinqaku lama-
802a), ingaba ubonelelo lwekhondom 
















 c) When was the most recent time you 
received this service-condom provision?  
 
Leliphi elona xesha lakutshanje 
ofumene ngalo le nkonzo yobonelelo 
lwekhondom? 
 
Interviewer: Please read all the response options to 







Last clinic visit day/Yimini 
yokuqhibela ndikunye 
nani namhlanje ekliniki 
(Date please if yes: 
 




Within past 3 months/ 



























d) Which provider gave you this most 
recent service- condom provision?  
 
Ngowuphi umboneleli wenkathalelo 
ye-HIV okunike kutshanje inkonzo 
yobonelelo lweekhondom? 
 
Interviewer: Please read all the response options to 



































-mayeza(Interviewer: tick this 
if not provided by 
doctor/nurse/counsellor during 
consultation and patient received 
























803 a) Have you received birth 
control/family planning method 
provision other than condom in 
government clinic(s) since testing 
positive? (i.e. birth control tablets/pills, 
injectables (Nur-Isterate or Depo-
provera), loop/coil/IUD, implant, etc 
 
Ingaba ufumene ubonelelo lolawulo 
lwenzala /indlela yocwangciso 
losapho ngaphandle kwekhondom 
kwiikliniki zikarhulumente ukususela 
kuvavanyo lokuthi unosulelo? (oko 
kukuthi ipilisi yokulawula 
inzala/iipilisi, izitofu (i-Nur-Isterate 




b) If yes (to item 803b), was birth 
control/family planning method 





























































Ukuba ngu-ewe (kwinqaku lama-
803b), ingaba ulawulo lwenzala 
/unikelo locwangciso losapho 





c) When was the most recent time you 
receive this service- birth control/family 
planning method provision other than 
condom?  
 
Leliphi elona xesha lakutshanje 
ofumene ngalo le nkonzo – unikelo 
lolawulo lwenzala /indlela 
yesicwangciso sosapho ngaphandle 
kwekhondom? 
 
Interviewer: Please read all the response options to 










d) Which provider gave you this most 
recent service- birth control/family 
planning method provision other than 
condom?  
 
Ngowuphi umboneleli wenkathelelo 
ye-HIV okunike oku kutshanje, 
inkonzo – yolawulo lwenzala /indlela 
yokucwangcisa usapho ngaphandle 
kwekhondom? 
 
Interviewer:  Please read all the response options 













Last clinic visit day/Yimini 
yokuqhibela ndikunye 
nani namhlanje 
ekliniki(Date please if yes: 
 




Within past 3 months/ 
Kwithuba leenyanga ezi-3 
ezigqithileyo 
 
































-mayeza(Interviewer: tick this 
if not provided by 
doctor/nurse/counsellor during 
consultation and patient received 





















804 a) Have you received dual method 
provision (condom plus any other 
method such as pills/birth control 
tablets, 2 months (Nur-Isterate)/3 
months (depo-provera) injectables, 
IUD/loop/coil, or inplants) in 






















Ingaba ufumene ubonelelo lweendlela 
ezimbini (ikhondom kunye nayiphi 
enye indlela efana neepilisi/iipilisi 
zokulawula inzala, iinyanga ezi-2 (ze-
Nur-Isterate)/iinyanga ezi-3 (ze-
depo-provera) Izitofu, i-IUD/i-
loop/ikhoyili, okanye izimiliselo) 
kwiikliniki zikarhulumente ukususela 
kuvavanyo lokuthi unosulelo? 
 
b) If yes (to item 804a), was dual method 
provision offered in this clinic?  
 
Ukuba ngu-ewe (kwinqaku lama-
804a), ingaba ubonelelo lweendlela 
ezimbini lunikelwe kule kliniki?  
 




b) When was the most recent time you 
received this service- dual method 
provision?  
 
Leliphi elona xesha lakutshanje 
ofumene ngalo inkonzo yolu nikelo 
lweendlela ezimbini? 
 
Interviewer: please remind respondent what is dual 
method. Please read all the response options to the 












d) Which provider gave you this most 
recent service- dual method provision? 
 
Ngowuphi umnikeli wenkonzo ye-
HIV okubonelele ngale nkonzo 
yakutshanje yeendlela ezimbini? 
 
Interviewer: please remind respondent what is dual 
method. Please read all the response options to the 



























Last clinic visit day/Yimini 
yokuqhibela ndikunye 
nani namhlanje 
ikliniki(Date please if yes: 
 




Within past 3 months/ 
Kwithuba leenyanga ezi-3 
ezigqithileyo 
 


































-mayeza(Interviewer: tick this 
if not provided by 
doctor/nurse/counsellor during 
consultation and patient received 
































Contraceptive preferences, quality & satisfaction: “Please I would like to ask you about your impressions/feelings of the 
contraceptive/birth control services in this clinic. Once again, please note that none of the care providers in this clinic will be aware 
of the information you share in this interview and anything you say will not affect the care you receive”.  
Please tell me how much you disagree or agree with the following statements about your most recent contraceptive/birth control 
consultation visit or consultation for contraception services during attending HIV-related services in this clinic. Do you Strongly 
Disagree, Disagree, have Mixed Feelings, Agree or Strongly Agree? You can use the face the best indicates your opinion. 
 
Izithinteli zenzala ezikhethwayo, udidi nokwaneliseka: “Ngesicelo ndingathanda ukukubuza malunga 
nezimvo/iimbilini zeenkonzo zothintelo lwenzala /ulawulo lwenzala kule kliniki. Kwakhona, nceda uqaphela ukuba 
akukho namnye wabanikeli benkathalelo kule kliniki abaya kuqonda ngolwazi owabelana ngalo kolu dliwano-ndleba 
yaye nantoni oyithethayo ayinakuchaphazela inkathalelo oyifumanayo”.  
Nceda undixelele ukuba uvumelana okanye awuvumelani kangakanani neengxelo ezilandelayo malunga neenkonzo 
zakho ezona zakutshanje zesithinteli /utyelelo lokubonisana ngolawulo lwenzala okanye ukubonisana ngeenkonzo 
zothintelo ngexesha lokuya kwiinkonzo ezinxulumene ne-HIV kule kliniki. Ingaba awuVumi ngaMandla, AwuVumi, 







Interviewer: Please read out these sentences 
before each question (805-813):  
Do you Strongly Disagree, Disagree, 
have Mixed Feelings, Agree or Strongly 
Agree with the statement that ( please 
state each statement from items 805 
through 813) during your most recent 
contraceptive/birth control 
consultation visit or consultation for 




Andivumi   

























Ingaba awuVumi ngaMandla, 
AwuVumi, uneZimvo eziXubeneyo, 
uyaVuma okanye uyaVuma 
ngaMandla nengxelo yokuba (nceda 
xela ingxelo nganye evela kumanqaku 
ama-805 kwama-813) ngethuba 
lotyelelo lokubonisana elona 
lakutshanje lesithinteli senzala 
/lolawulo lwenzala okanye iikonzo 
zokubonisana zesithinteli ngethuba 
leenkonzo ezinxulumene ne-HIVkule 
kliniki? Ungasebenzisa ubuso obona 
bubonisa uluvo lwakho 
 
You can use the face the best indicates 
your opinion.Gebruik gerus die 




805 The staff were friendly 
Abasebenzi bebenobubele 
              
 
 





       
STRONGLY 
DISAGREE 











807 Young girls living with HIV 
requesting contraception are 
treated with respect 
 
Amantombazana aselula 
aphila ne-HIV acela isithinteli 
senzala aphathwa ngembeko 
                            
808 Information provided about birth 
control methods was 
understandable and sufficient (for 
examples, the degree/extent to 
which different methods is 
successful in achieving birth 
control, how to use a particular 
method)  
 
Ulwazi olunikelwa malunga 
neendlela zolawulo lwenzala 
bezivakala yaye zanelisa 
(ukwenza imizekelo 
umphakamo /ubungakanani 






               
809 The staff who work in this clinic 
do not make efforts to find out 
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your needs regarding birth 
control/contraception (including 
birth control advice and 
provision) without you asking. 
 
Abasebenzi abasebenza kule 
kliniki abazenzi iinzame 
zokufumanisa iintswelo zakho 
malunga nolawulo lwenzala/ 
isithinteli senzala (kuquka 




810 Your consultation was private 
(i.e. service providers and staff 
respect your privacy) 
 
Ukubonisana kwakho 





















811 Had  to wait for a long time to  be 
seen (i.e. time spent in the waiting 
room before a nurse or doctor is 
seen for consultation regarding 
contraception) after you arrived 
at the clinic   
 
Ndilinde ixesha elide ukuze 
ndibonwe (oko kukuthi ixesha 
olichithe kwigumbi lokulinda 
phambi kokuba umongikazi 
okanye ugqirha abonwe 
malunga nokubonisana 
ngokuphathelele kuthintelo 
lwenzala) emva kokufika 
ekliniki   
 
      
812 The clinic has the birth control 
method you needed 
 
Ikliniki inendlela yolawulo 
lwenzala oyifunayo 










813 You would recommend this clinic 
to a friend 
 
Ungayincoma le kliniki 
kumhlobo 
              
 
814 Services were organized 
 Iinkonzo ziququzelelwa 
 
              
815       
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The waiting room(s) was/were 
too crowded 
Amagumbi okulinda agcwele 
kakhulu 
 
816 One felt comfortable being 
around other patients who were 
there? 
Ingaba umntu uziva 
ekhululekile xa ephakathi 
kwezinye izigulana ezikhoyo? 
     
817 The family planning/birth 
control care/services you 
received was directed to your 
needs and preferences (e.g., able 
to see same provider in 
subsequent clinic visits, 
provider’s gender, provider’s age, 
methods of contraception) 
Ukhathalelo ngocwangciso 
olufumanayo kulekliniki 
luqonde ngqo kwimfuno 
zakho(umz,uyakwazi 
ukubonana nomboneleli 

















818 Before providing you a with birth 
control method, a staff in the 
clinic or doctor’s office talked to 
you about a variety of possible 
methods of birth control 
 
Phambi kokukunikela 
ngendlela yolawulo lwenzala, 
umsebenzi ekliniki okanye 
kwiofisi kagqirha uthethe  





     No/Hayi         0 
 





819 Have you Ever been pressured by 
a staff in the clinic or doctor’s 
office to use or continue to use a 
particular method of birth control 
when you would have rather used 
a particular method or no method 
at all.  
 
Ingaba wakhe wanyanzeliswa 
ngumsebenzi kwikliniki 
okanye kwiofisi yogqirha 
ukusebenzisa okanye 
ukuqhubeka ukusebenzisa 
uhlobo oluthile lolawulo 
lwenzala xa ubunokukhetha 
ukusebenzisa uhlobo oluthile 
okanye kungabikho naluphi 
uhlobo kwaphela. 
 
No/Hayi    0 
 
Yes/Ewe     1 
 
If Yes, Please ask 
which method she 













Please can you respond to the following questions about your a) experience during your last clinic visit (this same clinic) for 
contraception/family planning/birth control, and b) preferences for contraceptive services?   
Ngesicelo ingaba ungaphendula imibuzo elandelayo malunga) namava ngethuba lotyelelo lwakho lokugqibela ekliniki 
(le kliniki yesiqhelo) malunga nesithinteli senzala/ucwangciso losapho/ulawulo lwenzala, kunye b) Iinkonzo zokhetho 
zesithinteli senzala. 
 
901 Which birth control method did 
you plan to get during your last 
clinic visit for birth control that you 
did not get?  
 
Yeyiphi indlela yolawulo 
lwenzala obuceba ukuyifumana 
ngethuba lotyelelo lwakho 
lokugqibela ekliniki malunga 
nolawulo lwenzala 
ongalufumananga? 
Please specify/Nceda ucacise……….   
902 Able to see same provider for 
services related to birth 
control/family planning at 
subsequent clinic visits? 
 
Ingaba ndinakho ukubona 
















Please indicate from these photos 
the contraceptive/birth control 
methods that have been discussed 
or explained to you in this clinic? 
 
Nceda ubonise ukusuka kwezi 
foto iindlela zesithinteli senzala 
 
 
Condoms with another method  Yes         No 
Ikhondom kunye nayiphi enye indlela engentla  
 
Pills/birth control tablets    Yes          No 
Iipilisi/ipilisi yokulawula inzala 
 
 











/indlela zolawulo lwenzala 
ekuxoxwe ngazo okanye 
ezichaziweyo kule kliniki? 
 
Interviewer: Please read all the response 
options to the respondent then tick the 
appropriate boxes that apply. 
 
2 months (Nur-Isterate) or 3 months (depo-provera) injectable: 
Iinyanga ezi-2 (i-Nur-Isterate) okanye iinyanga ezi-3 (i-
Depo-provera) Ezokutofa                       Yes                    No 
                                                      
Male condom/Ikhondom yamadoda        Yes           No 
                                                                                    
Female condom/Ikhondom yabasetyhini  Yes            No 
                                                
Implants/Isimiliselo  Yes         No        
                             
Chemical foam/jell/cream/Isibulala-madlozi (igwebu 
lechiza/ijeli/amafutha okuthambisa) Yes         No   
  
IUD/loop/coil/I-IUD/i-loop/ikhoyili  Yes              No 
                                                 
Others (specify)/Omnye (Cacisa)...................... 
 
 
1              0 
 
 
1              0 
 
1              0 
 
1              0 
 
 




1               0 
904 Is it important to you to see the 
same service provider (doctors, 
nurses) at every visit for 
contraception/birth control, or do 
you not care? 
 
Kubalulekile ukubona  umnikeli 
wenkonzo ofanayo (oogqirha, 
abongikazi) kwelinye nelinye 
utyelelo lwesithinteli/ulawulo 
lwenzala, okanye awukhathali? 
 
 
Interviewer: Please read all the response 
options to the respondent then circle only 


















905 Would you prefer to have 
contraception/birth control service 
provided by : 
 
Ingaba ungakhetha ukuba 
nothintelo lwenzala/inkonzo 
yolawulo lwenzala enikelwa 
yinkqubo yenkonzo enikelwa : 
 
 
Interviewer: Please read all the response 
options to the respondent then circle only 






A male/Iqabane eliyindoda? 
 














906 Would you prefer to have 
contraception/birth control service 
provided by someone who is: 
 
Ingaba ungathanda ukuba 
isithinteli senzala/ ulawulo 
lwenkonzo  enikelwa ngomnye 
umntu: 
 
 Interviewer: Please read all the response 
options to the respondent then circle only 
one that is applicable 
 
18-19 years old/Iminyaka yobudala eli-18-19 
 
20-24 years old/Iminyaka yobudala engama-20-24 
 
More than 25 years old/Ngaphezulu  kuneminyaka engama-
25 
 
Don’t know/Andazi  
  














907 If you had your choice, would you 
prefer to get contraception/birth 
control services at:  
 







Interviewer: Please read all the response 
options to the respondent then circle only 
one that is applicable 
 
A place that provides care for only young persons (15-24 
years)/Indawo enikela ngenkathalo kubantu abancinci 
kuphela (iminyaka eli-15-24 yobudala)? 
 
A place that provides care for all ages but has a dedicated clinic 
day for young persons/Indawo ebonelela ngenkathalo 
ukwenzela yonke iminyaka kodwa enosuku lwekliniki 
olukhethekileyo labantu abaselula? 
 
HIV youth support group/Iqela lenkxaso labatsha abane-
HIV? 
 
General clinic (all ages clinic including adults)/Ikliniki kawonke 
wonke (yonke iminyaka iquka? 
 
School-based clinic/Ikliniki esekwe esikolweni? 
 























908 What is/are your preferred 







Interviewer: Please read all the response 
options to the respondent then circle all 
that are applicable 
 
 
Pills/birth control tablets/Iipilisi/ipilisi yokulawula inzala 
2 months (Nur-Isterate) or 3 months (Depo-provera) 
injectable/Iinyanga ezi-2 (i-Nur-Isterate) okanye iinyanga 
ezi-3 (i-Depo-provera) Ezokutofa                        
Emergency contraception/Uthintelo lwenzala 
lwengxakeko/ipilisi yasemva kokwabelana ngesondo 
Male condom/ Ikhondom yamadoda         
Female condom/ Ikhondom yabasetyhini   
Implants/Isimiliselo 
Chemical foam/jell/cream/Isibulala-madlozi (igwebu 
lechiza/ijeli/amafutha okuthambisa) 
IUD/loop/coil/I-IUD/i-loop/ikhoyili   
Condom with another method/Ikhondom kunye nayiphi enye 





























Others (specify)/Omnye (Cacisa)...................... 











909 Why do you prefer these methods? 
Kutheni ukhetha ezi ndlela? 
Specify please/Cacisa ngesicelo: 









Overall satisfaction: Please think back about all your visits to this clinic for contraception. “Please I would like to ask you about 
how satisfied you are with the contraceptive/birth control services in this clinic. Once again, please note that none of the care 
providers in this clinic will be aware of the information you share in this interview”.  
Ukwaneliseka kukonke: Nceda ucinge ngemva ngawo onke amatyelelo kule kliniki. “Ngesicelo ndingathanda 
ukukubuza malunga nokuthi waneliseke kangakanani ngeenkonzo zesithinteli, zolawulo lwenzala kule kliniki.. 
Kwakhona,  nceda uqaphele ukuba akukho namnye wabanikeli benkonzo kule kliniki abaya kuqonda malunga nolwazi 
owabelene ngalo kolu dliwano-ndlebe”.  
 
 
910 In general, how would you rate 
your satisfaction with the quality 
(i.e standard of care/degree of 
excellence) of 
contraception/birth control 
services you received in this clinic? 
Please indicate your opinion by ticking the appropriate box. You can use the face that 
best indicates your opinion. Nceda ubonise uluvo lwakho ngokuphawula ibhokisi 
elichanekileyo. Ungasebenzisa ubuso obubonisa ngeyona ndlela ingcono 







njani ukwaneliseka kwakho 
ziinkonzo zesithinteli senzala/ 




















Very dissatisfied          
/Andikholisek



















ka               







kakhulu                                               
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Clinic stigma“Please I would like to ask you about your impressions/feelings of the contraceptive/birth control services in this 
clinic. Once again, please note that none of the care providers in this clinic will be aware of the information you share in this 
interview”.  
Considering your most recent contraceptive/birth control consultation visit or consultation for contraception services during 
attending HIV-related services in this clinic, please tell me how much you agree or disagree with the following statements I read to 
you. You can use the face the best describes your opinion.  
 
Isiphako sekliniki “Ngesicelo ndithanda ukukubuza malunga nezimvo/iimbilini zakho zeenkonzo zesithintelo senzala/ 
ulawulo lwenzala kule kliniki. Kwakhona, nceda uqaphele ukuba akukho namnye wabanikeli benkonzo kule kliniki abaya 
kuqonda ulwazi owabelene ngalo kolu dliwano-ndlebe”.  
Xa ucinga ngolona tyelelo lokubonisana lakutshanje lwesithintelo senzala/uthintelo lwenzala/ ulawulo lwenzala okanye 
ukubonisana ngeenkonzo zokubonisana malunga neenkonzo zokubonisana malunga nesithinteli senzala kule kliniki 
ngethuba leenkonzo ezinxulumene ezijongene ne-HIVkule kliniki, nceda undixelele ukuba uvumelanaa kangakanani 
okanye ukungavumelani  neengxelo ezilandelayo endikufundela zona. Ungasebenzisa ubuso obuchaza ngokugqibeleleyo 

























Andivumi   




1001 Others can find out when you 
come to this clinic for 
contraception/birth control 
 
Abanye banokufumana xa uza 




     
1002 Others can find out your HIV 
status when you come to this 
clinic for contraception/birth 
control/family planning. 
 
Abanye bangafumana ulwazi 
ngemo yakho ye-HIV xa usiza 
kule kliniki malunga 




                       
1003 Staff members at this clinic might tell 
other people that you come for 
contraception/birth control/family 
planning method without your 
permission. 
 
Amalungu abasebenzi kule kliniki 
bangaxelela abanye abantu ukuba uza 
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malunga nesithinteli senzala/ulawulo 
lwenzala/ucwangciso losapho 
ngaphandle kwemvume yakho. 
 
 
Thank you for your participation. 
Interviewer signature/date…………………………………… 
 
Appendix 5: Exit Interview Questionnaire for Adolescent Girl Clients (14-19 years) in HIV Services. 
 
 
1Instruction to field staff: Tick the appropriate consent form completed for this respondent.  
Please note that participation is voluntary and consent is a must. A parent’s/legal guardian’s written consent is 
required for all participants aged 14-17 years. Informed consent can only be completed after a participant has 
been informed about the facts of the study using the attached information sheet (see appendix 2), and 
demonstrated understanding of the information.  
Please tick the appropriate boxes below: 
Consent form for girl 18 or 19 years:  Yes             No   
Parent/Guardian consent for girl 14 to 17 years: Yes           No   




2Instruction to field staff: Please tell every participant that her opinion and views to the questions are very 
important. Inform participants to answer every question carefully and honestly. In addition, tell participants that 
their answers will help in the development of better health services.  
 
2Instruksie aan veldwerker: Verduidelik asseblief aan elke deelnemer dat haar mening en sienings oor 
die vrae baie belangrik is. Vra deelnemers om elke vraag sorgvuldig en eerlik te beantwoord. Noem 
ook dat hulle antwoorde gesondheidsdienste sal help verbeter.  
 
Interviewer ID number:  
Participant Study number:  
 
Study clinic’s code (please circle appropriate code below):  
 
01: Gugulethu CHC         02: Nyanga CHC            03: Heidveld CHC      04: Brown Farms CHC 
 05: Mitchells Plain            06: Cross roads CHC      07: Khayelitsha (site B)  08: Michael M. CHC 
 09: Site B youth clinic      10: Site C Youth Clinic   11: Nolungile CHC ]       12: Vuyani Clinic 
 13: Mzamomhle Clinic     14: Weltevreden Valley Clinic   15: Kuyasa Clinic   16: Mathew Goniwe Clinic 
17: Town 2 Clinic 
 
 
Language of interview (please circle appropriate box below) 
English             isiXhosa                Afrikaans           
 
Date of interview:  




No Questions Responses Cod-ing 
 
Skip 
Section 1: Socio-demographic  
101 How old were you at your last 
birthday? 















102 What is your date of birth? 
Wat is jou geboortedatum? 
 
 












































Write 77 for day or 88 for month or 9999 for year if 
unknown 
103 What is the highest level of 
grade you have completed or 
what level of school are you 
presently? 
 
Wat is die hoogste 
skoolgraad wat jy voltooi het, 
of in watter graad is jy tans? 
 
 






































104 Currently, do you work for pay 
(i.e for money)? 
 
Werk jy tans teen betaling 















In the household/home where 
you currently live, do you have 
access to: 
 
Het jy in die 
huishouding/huis waar jy 
tans woon toegang tot: 
 
 
Interviewer: Please read all the 
response options to the respondent then 




A television/... ’n televisie?    Yes       No 
 
A landline/... ’n landlynfoon? Yes            No 
 
Own cellular phone/... ’n eie selfoon? Yes      No 
 
A computer/ ... ’n rekenaar? Yes          No 
 
A refrigerator/ ... ’n yskas?    Yes          No 
 
A car or truck/ ... ’n motor of bakkie?  
                                                   Yes       No 
                  
A motorcycle/scooter/... ’n motorfiets/bromponie? 
Yes          No          
A clothes washing machine/... ’n klerewasmasjien? Yes         
No 
                                                  
Piped water into house/... kraanwater in die huis? Yes       
No 
                                                                  
Flush toilet not shared with other households/... ’n 
spoeltoilet wat jy nie met ander huishoudings hoef te 
deel nie?                                           Yes        No 
                                                                          
 
Yes      No        
1             0 
 
1             0 
 
1             0 
 
1             0 
 
1             0 
 
 
1             0 
 
 
1             0 
 
1             0 
 
1             0 
 
 





























Interviewer: Please note below: 
Atheism/Ateïsme:  disbelief in the 
existence of God or gods/ Glo nie 
in die bestaan van God of 
gode nie. 
Agnosticism/Agnostisisme: 
doubting whether or not God 
exists/ Twyfel of God 
bestaan. 
 
Interviewer: Tick only one that applies 
Pentecostal/Pinkster 
Roman catholic/Rooms-Katoliek 
Protestant-Anglican, Methodist etc/Protestants – 
Anglikaan, Metodis, ens. 
Afrikaanse/Afrikaans 
Protestantse Kerk  
Traditional African belief/Tradisionele Afrikageloof 
Atheism/Ateïsme 
Agnosticism/Agnostisisme 














With whom do you live/Met 
wie woon u? 
 
Interviewer: Please read all the 
response options to the respondent then 
circle only one that is applicable. 
 
Live alone/Lewe alleen  
Live with parent(s)/Lewe met ouer (s) 
Live with other relatives/Lewe met ander familielede 
Live with male partner or married/Lewe met manlike 
lewensmaat of getroude 
Live with others (i.e friends/peers, dormitory)/Lewe met 





















What is the highest level of 
education of the person who 
assumes the most responsibility 
in caring for you? 
 
Hoe ver het die persoon 
geleer wat die grootste 
verantwoordelikheid vir jou 






Never went to school/Is nooit skool toe nie 
Primary (grade 7)/Laerskool (graad 7) 
























109 If you come straight from the 
home where you currently live, 
how long does it normally take 
you to get to this clinic? 
 
Hoe lank duur dit om reguit 
van jou blyplek tot by hierdie 







Have you ever had a glass of 
beer, wine, or a shot of liquor 
(not including while with your 
family at a banquet or 
celebration)? 
Het u al ooit 'n glas bier, wyn, 
of 'n dop van drank (nie 
insluitend terwyl u saam met 















111 Have you ever smoked 
cigarette?  









HIV service use 
 
201 What day, month and year did 
you enrol in this clinic for HIV 
care? 
 
Kan jy die dag, maand en jaar 
onthou toe jy vir MIV-sorg by 
hierdie kliniek geregistreer 
het? 
 
Interviewer: Write approximate 
month and year if exact time not 
known 
 
     
Day/Dag        Month/Maand             Year/Jaar 
 









Why did you decide to choose 
this clinic for HIV 
care/services? 
 





Interviewer: Please read all the 
response options to the respondent then 




Availability of ART?           Yes/Ja           No/Nee 
                                     
Close distance to residence? Yes/Ja        No/Nee 
                                     
Short waiting time?               Yes/Ja         No/Nee 
                             
Friendliness of providers?     Yes/Ja         No/Nee 
                                       
Attends to only youth?          Yes/Ja         No/Nee 
                                  
Confidentiality and privacy?   Yes/Ja          No/Nee 
                                        
Possibility to receive contraceptive services (counselling, 
contraception)?                           Yes/Ja          No/Nee 
                                                            
Referred/transferred from other clinic?  
                                          Yes/Ja                No/Nee   
                                                           
Recommended by friend/parent/family? 
                                              Yes/Ja          No/Nee           
                                                             
Others (specify)…………………….. 
 
Yes  No 
1        0 
 
1        0 
1        0 
 
1        0 
 
 
1        0 
 
1        0 
 
 
1         0 
 
 
1        0 
 
 










203 Please can you tell me, when 
you tested positive for HIV? 
 
Kan jy my asseblief sê 
wanneer jy positief getoets 
het vir MIV? 
 
 
Interviewer: Write approximate 
month and year if exact time not 
known.  
 
                     
   
At Birth (mother to child): Yes             No  
 
If not at birth, Please tell me the date: 
 
                                                                                   
     Day/Dag         Month/Maand            Year/Jaar 




204 Which of these best describes 
how you acquired HIV 
infection? 
 
Watter van hierdie antwoorde 
is die beste beskrywing van 
hoe jy MIV gekry het? 
 
Interviewer: Please read all the 
response options to the respondent 
then circle only one that is applicable 
 




Mother to child/Moeder-na-kind-oordrag 
 


























How many days have you 
missed taking all of your doses 
of HIV medications during the 
past four days? 
Hoe gereeld het jy die 






One day/Een dag 
Two days/Twee dae 
Three days/Drie dae 











207 What was your last CD4 count?  
 
Wat was jou CD4-telling 
laas?  
 
When was the date of this last 
CD4 count? 
 
                                      Number/Skryf telling neer. 
 




Day/Dag            Month/Maand                  Year/Jaar 
















 Bywoon u tans n MIV-Jeug 














301 How many living children do 
you have? 
 
Hoeveel kinders het jy wat 
leef? 
                 Number/Skryf telling neer.  
 
302 a) Since you tested positive for 
HIV, how many times have you 
been pregnant? 
 
Hoeveel keer was jy swanger 
sedert jy positief getoets het 
vir MIV? 
 
b)How many of these 
pregnancies (including current 
pregnancy) occurred:  
Hoeveel van hierdie 
swangerskappe (wat huidige 
swangerskap insluit) het 
gebeur: 
 
 When no children, or 
no more children, 
were desired? 
 ... al wou jy nie 
kinders, of nóg 
kinders, gehad het 
nie? 
 
 Earlier than desired? 
... vroeër as wat jy 
wou gehad het? 
 
 When you used a birth 
control method? 











                  Number/Skryf telling neer. 
                
                 
                          








 When you did not 
desire to become 
pregnant but did not 
use a birth control 
method?... 
 .... toe jy nie wou    
swanger raak nie, 








303 a)Would you like any more 
children in the future? 
Wil jy in die toekoms nóg 
kinders hê? 
 
Interviewer: this question is for 











If No, skip 
to 401 
b) In future would you like to 
have children? 
Wil jy in die toekoms kinders 
hê? 
 
Interviewer: this question is for 





Not sure/Nie seker nie 
N/A (for person who are physically unable to have 






If No, skip 
to 401 
304 How long would you like to wait 
before you become 
pregnant/next pregnancy? 
 
Hoe lank wil jy wag voordat 




                   Weeks/Weke 
   
                  Months/Maande 
   
                   Years/Jaar 
    
                   Not sure/Nie seker nie (please enter 88) 
  
Contraceptive behaviours: Now I would like to talk about family planning/contraception/preventer- the various 
ways or methods that a couple can use to delay or avoid a pregnancy. Voorbehoedingsgedrag: Nou wil ek met 
jou gesels oor gesinsbeplanning/voorbehoeding – die verskillende metodes of maniere waarop ’n man en 
vrou swangerskap kan uitstel of voorkom. 
 
401 Have you ever heard of the 
following (METHOD)/Het 
No/Nee Yes/Ja   
356 
 







b)2 months (Nur-Isterate) or 3 
months (Depo-provera) 
injectables/Inspuitings elke 
twee maande (Nur-Isterate) 
of drie maande (Depo-
provera)  
c)Implants/Inplantings 














oggend na die tyd)/Norlevo 





Interviewee: Please read all the 
response options to the respondent then 
























































































Interviewer: Please read all the 
response options to the respondent then 







Care provider (Doctors, nurses, etc)/Sorgverskaffer 
(dokter, verpleegkundige, ens.) 














403 Are you or your partner 
currently doing something or 
using any method to delay or 
avoid getting pregnant? 
Doen jy of jou seksmaat op 
die oomblik enigiets, of 
gebruik julle enige metode, 

















If Yes response to question 403, 
what methods are you currently 
using? 
Indien Ja op vraag 403, 
watter metodes gebruik u 
tans? 
 
Interviewer: Please read all the 
response options to the respondent then 
circle all that are applicable. Probe 
for use of condom with 
another method.  
 
  
Definition of terms: 
Rhythm Method: Sexual (vaginal) 
intercourse abstinence on days 12 
through 19 of the menstrual cycle i.e., 
days when pregnancy is not likely to 
occur. 
 
Ritme Metode: Seksuele 
(vaginale) omgang 
onthouding op dae 12 deur 
19 van die menstruele siklus 
d.w.s. dae toe swangerskap 
is nie geneig om te voorkom. 
 
Standard Days Method: Sexual 
(vaginal) intercourse abstinence on 
days 8 through 19 of the menstrual 
cycle i.e., (days when pregnancy is not 
likely to occur) by women with cycles 
consistently between 26 and 32 days. 
Standard Dae Metode: 
Seksuele (vaginale) omgang 
onthouding op dae 8 tot 19 
van die menstruele siklus 
d.w.s. (dae toe swangerskap 
is nie geneig om te voorkom) 
deur vroue met siklusse 
konsekwent tussen 26 en 32 
dae. 
 
Pills/birth control tablet/ Die Pil/geboortebeperkingspille 
Male condom/Manskondoom 
Female condom/Vrouekondoom 
2 month (Nur-Isterate) or 3 month(Depo-provera) 
injectables/Inspuitings elke twee maande (Nur-Isterate) of 
elke drie maande (Depo-provera) 
Implant/Inplantings 
IUD/loop/coil/“IUD”/veertjie 
Spermicide (chemical foam/jelly/cream)/Spermdoder (chemiese 
skuim/jel/room) 
Emergency contraception/morning after pill/ 
Noodvoorbehoeding/nabehoedpil 
Female sterilization/tubal ligation/Vroulike 
sterilisasie/buisafbinding 
Male sterilization/Manlike sterilisasie 
Rhythm method/Kalender-/ritmemetode 
Lactational amenorhhoea (Breastfeeding)/Laktasie-amenorree 
(afwesigheid van menstruasie weens borsvoeding) 
Standard days method/Standaarddagmetode 
Withdrawal/Onttrekking 
Condom with another method/Kondoom met 'n ander 
swangerskap voorkoming metode(Interviewer: Please write out 
the another method……………………. 
Other (specify)/Ander (spesifiseer)….... 















































If No to question 403, 
interviewer please ask this 
question:  
 
Since you tested positive for 
HIV, what family planning 
method(s) have you/your 
partner used to avoid getting 
pregnant? 
 
Het jy/jou seksmaat sedert jy 
positief getoets het vir MIV 
ooit enige 
gesinsbeplanningsmetodes 




Interviewer: Please read all the 
response options to the respondent then 










2 month (Nur-Isterate) or 3 month (Depo-provera) 
injectables/Inspuitings elke twee maande (Nur-
Isterate) of elke drie maande (Depo-provera) 
Implant/Inplantings 
IUD/loop/coil/“IUD”/veertjie 
Spermicide (chemical foam/jelly/cream)/ Spermdoder 
(chemiese skuim/jel/room) 
Emergency contraception/morning after pill/ 
Noodvoorbehoeding/nabehoedpil 
Female sterilization/tubal ligation/Vroulike 
sterilisasie/buisafbinding 
Male sterilization/Manlike sterilisasie 
Rhythm method/Kalender-/ritmemetode 
Lactational amenorhhoea (Breastfeeding)/ Laktasie-
amenorree (afwesigheid van menstruasie weens 
borsvoeding) 
Standard days method/Standaarddagmetode 
Withdrawal/Onttrekking 
Condom with another method/Kondoom met 'n ander 
swangerskap voorkoming metode (Interviewer: Please 
write out the another method……………………. 
Other (specify)/Ander (spesifiseer)….... 












































406 Since you tested positive for 
HIV, what family planning 
method(s) have you or your 
partner stopped using?  
 
Watter gesinsbeplannings-
metode(s) het jy of jou 
seksmaat ophou gebruik 
sedert jy positief getoets het 




Interviewer: Please read all the 
response options to the respondent then 








2 month (Nur-Isterate) or 3 month (Depo-provera) 
injectables/Inspuitings elke twee maande (Nur-
Isterate) of elke drie maande (Depo-provera) 
Implant/Inplantings 
IUD/loop/coil/“IUD”/veertjie 
Spermicide (chemical foam/jelly/cream)/ Spermdoder 
(chemiese skuim/jel/room) 
Emergency contraception/morning after pill/ 
Noodvoorbehoeding/nabehoedpil 
Female sterilization/tubal ligation/Vroulike 
sterilisasie/buisafbinding 








































 Lactational amenorhhoea (Breastfeeding)/ Laktasie-
amenorree (afwesigheid van menstruasie weens 
borsvoeding) 
Standard days method/Standaarddagmetode 
Withdrawal/Onttrekking 
Condom with another method/Kondoom met 'n ander 
swangerskap voorkoming metode (Interviewer: Please 
write out the another method……………………. 
Other (specify)/Ander (spesifiseer)….... 





























Why did you/your partner stop 
using the family planning 
method(s) above? 
I am going to read a number of 
option please answer No or Yes 
to each 
Did you stop because….. 
 




 Ek gaan 'n aantal opsie lees, 
asseblief beantwoord Geen 
of Ja om elk. Het u ophou 




Interviewer: Please read all the 
response options to the respondent then 
circle all that are applicable  
 
 
Advised by provider to use condoms instead/  
Sorgverskaffer het eerder kondome aanbeveel 
Problems with method/side-effects/Probleme met 
metode/newe-effekte 
Costs/Koste 
Fear of HIV transmission to HIV-negative partner/Bang 
vir MIV-oordrag aan MIV-negatiewe maat 
Fear of getting infected with another HIV virus/Bang vir 
infeksie met ’n ander MI-virus 
It can worsen HIV disease condition/Kan MIV-
siektetoestand vererger 
Positive partner HIV test result/Maat se positiewe 
MIV-toetsuitslag 
Lower success of HIV medications/Laer sukses van 
MIV-medisyne 
Provider advised to stop method/Sorgverskaffer het 
staking van metode aanbeveel 
Moved house/changed clinic/Het getrek/van kliniek 
verander 
Broke up with partner/Ek en maat is uitmekaar 
Stopped having sex/Het ophou seks hê 
Wanted a baby/Wou ’n baba hê 
Partner wanted a baby/Maat wou ’n baba hê 
Partner told me to stop/Maat het my gesê om te stop 
Others (specify)/Ander (spesifiseer):__ 
Don’t know/Weet nie  
 
Nee      Ja     




2 1  
             
 
0              1 
             
                  
0              1 
                          
0              1 
                
0              1 
            
0              1 
 
 
0             1 
 
 
0              1 
 
0              1 
0              1 
0              1 






























Hormonal contraceptive-related safety concerns: As you probably know, some women living with HIV would not take a 
hormonal method for birth control/pregnancy prevention (pills/birth control tablets, emergency contraceptive/morning 
after, 2 months/3 months injectables and implants) because it might make it more likely for them or their male sexual partners 
to develop a problem while using it. P lease tell me how much you agree or disagree with the statements I read to you.  You can 
use the face that best describes your opinion.  
 
Soos u waarskynlik weet, sommige vroue wat met MIV leef nie 'n hormonale metode vir     geboortebeperking / 
swangerskap voorkoming neem (pille / geboorte beheer pille, noodvoorbehoedmetodes /   morning after, 2 maande / 3 
maande inspuitings en inplantings), want dit kan dit meer waarskynlik maak dat hulle of hul manlike seksmaats om 
'n probleem te ontwikkel terwyl die gebruik daarvan. Se vir my asseblief  stem u saam met my of verskil u met die 







Interviewer: Please inform participants about the various hormonal methods for pregnancy prevention.  
 
  
501 Let us assume that you wanted 
to use a hormonal method of 
birth control. Which of the 
following response options 
would apply to you regarding 
the statements I read to you. 
Interviewer: Please start each 
question (501a-d) with: Do you 
Strongly Agree, Agree, have 
Mixed feelings, Disagree or 
Strongly Disagree that 
 
Kom ons neem aan dat u wou 
'n hormonale metode van 
geboortebeperking gebruik. 
Watter van die volgende 
reaksie opsies sal op u van 
toepassing ten opsigte van 
die stellings wat ek lees vir u. 
Onderhoudvoerder: Begin 
asseblief elke vraag (501a-d) 
met:  
Stem jy sterk saam, stem jy 
























gevoelens, verskil jy, of 
verskil jy sterk? Gebruik 
gerus die gesiggie wat die 




 a) In your case, using hormonal 
contraceptive could make HIV 
disease progression to occur 
quickly (i.e. worsening HIV 
disease or cause AIDS)? 
In u geval, hormonale 
voorbehoeding kan MIV-
siekte vinniger laat vorder 
(m.a.w. dit maak MIV-siekte 
erger of veroorsaak vigs). 
 











b) In your case, hormonal 
contraceptive use could make 
passing the HIV virus to an 
uninfected male sexual partner 
to be more able? 
In u geval, hormonale 
voorbehoedmiddel gebruik 
kan maak oordrag van die 
MI-virus 'n ongeïnfekteerde 
manlike seksmaat meer in 
staat wees? 
 
     
c) In your case, the ability of 
HIV treatments/medicines to 
fight HIV virus/AIDS could be 
reduced with concurrent use of 
hormonal contraceptive.  
 
 
In u geval, die vermoë van 
MIV-behandeling/-
medisyne om die MI-
virus/vigs te bestry, kan 






AGREE  MIXED 
FEELINGS  
DISAGREE  STRONGLY 
DISAGREE  
d) In your case, birth control 
failure (i.e., a possibility of 
getting pregnant) could be more 
if hormonal contraceptive is 
used concurrently with HIV 
medicines because of the 
possible alterations in its ability 
to prevent pregnancy by HIV 
medicines.  




In u geval, daar is ’n sterker 
moontlikheid dat 
geboortebeperking kan 
misluk (m.a.w. dat jy 
swanger kan raak) as jy 
hormonale voorbehoeding 
saam met MIV-medisyne 
gebruik, want die MIV-





Please I would like to know about the relationship you have with your parent(s)/guardian(s) with regards to contraception/family 




Interviewer: Please ask participant to indicate her opinion on the response/diagram and then tick the 
appropriate box.  
  
 
Do you strongly disagree, 
disagree, ……that  
Your mother talks to you about 
contraceptive/birth 
control/family planning use 
birth control use. 
 
Verskil jy sterk, verskil jy, het 
jy gemengde gevoelens, stem 
jy net saam, of Stem jy sterk 
saam............Jou ma gesels 









Strongly    
Disagree/Verskil 






















saam nie                                                                                 
 
Agree/Ste








Think about your closest 
female friend 
 
To what extent do you agree 
with the following: Your closest 
female friend  encourages you to 
use contraceptives/birth 






































control /family planning 
method 
 
Dink nou aan jou beste 
vriendin. 
 
In watter mate stem jy met die 
volgende saam: Jou beste 






























504 How often have you talked with 





Hoeveel het jy al met jou 





Interviewer: Please read all the 
response options to the respondent 




  Never/Nooit                  0               
  Once/Een Keer               1 
  Few times/Paar kere        2     
  Many times/Baie kere      3 
         













Think about this community 
where you live/Dink nou aan 





How socially acceptable is it 
these days: If Girls receiving 
HIV care use contraceptives? 
 
Hoe sosiaal aanvaarbaar is 























Is it Completely Unacceptable, Unacceptable, No idea, Acceptable or Completely 
Acceptable? Please you may use the face that best indicates your opinion.  
 
Is dit heeltemal onaanvaarbaar, net onaanvaarbaar, weet jy nie, is dit aanvaarbaar 










































Sexual behaviour: Now I would like to ask some questions about sexual activity in order to gain a better understanding of some important life issues. 
Seksuele gedrag: Nou wil ek jou graag ’n paar vrae oor seksuele aktiwiteit vra om sekere belangrike lewenskwessies 
beter te verstaan. 
 
601 Have you ever had/Het jy al ooit:  
 
 
Sexual intercourse through vagina 
(Vagina intercourse/... seksuele 
omgang deur die vagina (vaginale 
omgang) gehad? 
 
Sexual intercourse through Anus 
(Anal intercourse)/ ... seksuele 
omgang deur die anus (anale 
omgang) gehad? 
 
Sexual intercourse through mouth 
(Oral intercourse)/ ... seksuele 
































Interviewer: Please read all the response 
options to the respondent then circle all that 




602 How old were you when you had 
sexual intercourse (vaginal 
intercourse) for the very first time?  
Hoe oud was jy toe jy die eerste 
keer seksuele omgang (vaginale 




                      Years/Jaar 
 
603 Since you tested positive for HIV, 
which contraceptive method(s) did 
you use the first time you had sexual 
intercourse (vaginal intercourse)? 
 
 
INDIEN jy “ja” geantwoord het 
op vraag 601 hierbo: Watter 
voorbehoedingsmetode(s) het jy 
gebruik toe jy die eerste keer 
seksuele omgang (vaginale 
omgang) gehad het nadat jy 
positief getoets het vir MIV? 
 
 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
 





2 months (Nur-Isterate) or 3 months (Depo-
provera) injectables/Inspuitings elke twee 




Spermicide ( chemical foam/jelly/cream)/ 
Spermdoder (chemiese skuim/jel/room) 
Emergency contraception/morning after 
pills/Noodvoorbehoeding/nabehoedpil 











Condom with any other method 
above(specify) 
/Kondoom saam met enige ander 












































604 Think about all the times you have had 
sexual intercourse, how often would 
Every time/Elke keer 








you say you or your partner used 
condom to prevent pregnancy? 
 
Dink aan al die kere wat u 
seksuele omgang gehad het, hoe 
dikwels sou u sê het u of u maat 
kondome gebruik  om 
swangerskap te voorkom? 
 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
Never/Nooit 
Don’t know/Weet nie 







605 Think about all the times you have 
had sexual intercourse, how often 
would you say you or your partner 
used any method other than condom 
(i.e. birth control tablets/pills, 
injectables (Nur-Isterate or Depo-
provera), loop/coil/IUD, implant, 
Spermicide, or female/male 
sterilization) to prevent pregnancy? 
 
As u dink aan al die kere wat u al 
seksuele omgang gehad het, hoe 
gereeld sou u sê het u of jou maat 
enige ander metode as ’n 
kondoom gebruik om 
swangerskap te voorkom?[ 
(geboorte beheer pille / pille, 
inspuitings (Nur-Isterate of Depo-
Provera), lus / spoel / IUD, 
inplanting, spermdoder, of 
vroulike / manlike sterilisasie)? 
 
 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
 
Every time/Elke keer 
Almost every time/Byna elke keer 
Sometimes/Soms 
Never/Nooit 
Don’t know/Weet nie 









606 How frequently did you or your 
partner use condom all the times you 
had sexual intercourse during the last 
3 months? 
 
Hoe gereeld die afgelope drie 
maande het jy of jou maat ’n 
kondoom gebruik toe julle seksuele 
omgang gehad het? 
 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
Every time/Elke keer 
Almost every time/Byna elke keer 
Sometimes/Soms 
Never/Nooit 
Don’t know/Weet nie 












607 How frequently did you or your 
partner use any method other than 
condom to prevent pregnancy all the 
times you had sexual intercourse 
during the last 3 months?  
Hoe gereeld die afgelope drie 
maande het jy of jou maat enige 
ander metode as ’n kondoom 
gebruik om swangerskap te 
voorkom toe julle seksuele omgang 
gehad het? 
 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
Every time/Elke keer 
Almost every time/Byna elke keer 
Sometimes/Soms 
Never/Nooit 
Don’t know/Weet nie 









608 Which method other than condom did 
you or your partner use to prevent 
pregnancy all the times you had sexual 
intercourse during the last 3 months? 
 
Watter ander metode as ’n 
kondoom het jy of jou maat die 
afgelope drie maande gebruik om 
swangerskap te voorkom elke keer 
wat julle seksuele omgang gehad 
het? 
 
Interviewer: Please read all the response 
options to the respondent then circle only one 
that is applicable. Please remind respondent 
that you are not judging her. 
 
Pills/birth control tablets/Die 
Pil/geboortebeperkingspille 
2 months (Nur-Isterate) or 3 months 
(Depo-provera) injectables/Inspuitings 







Emergency contraception/morning after 
pills/Noodvoorbehoeding/nabehoedpil 











































Since you tested positive for HIV, did 
you or your partner use condoms 
(male or female sub-type) the last time 
you had sexual intercourse (vaginal 
intercourse)? 
Nadat u positief getoets het vir 
MIV, het u of jou maat (’n) 
gesinsbeplanningsmetode(s) 
gebruik toe julle laas seksuele 




Since you tested positive for HIV, did 
you or your partner use any method 

























































tablets/pills, injectables (Nur-Isterate 
or Depo-provera), loop/coil/IUD, 
implant, Spermicide, or female/male 
sterilization) the last time you had 
sexual intercourse (vaginal 
intercourse)?  
 
Nadat u positief getoets het vir 
MIV, het u of jou maat enige 
metode slegs kondome(dws 
geboorte beheer pille / pille, 
inspuitings (Nur-Isterate of Depo-
Provera), lus / spoel / IUD, 
inplanting, spermdoder, of 
vroulike / manlike sterilisasie) om 
swangerskap te voorkom? 
 gebruik toe julle laas seksuele 





Did you have sexual vaginal 
intercourse within the past 3 months? 
 
Het u 'n seksuele vaginale omgang 




















































610 How many sexual partners have you 
had in the past 12 months (one year)? 
 
Hoeveel seksmaats het jy die 




                      Number/Skryf getal neer.   
369 
 
611 Which of this/these best describe/s 
why you did not use condom and any 
of these methods other than condoms 
listed below every time you had 
intercourse? 
 
Watter van hierdie antwoorde 
beskryf die beste hoekom jy nie ’n 
kondoom of enige van die ander 
metodes hieronder gebruik het elke 
keer wat jy seks gehad het nie? 
 
Methods other than condom 
Pills/birth control tablets/Ander 
metodes as ’n kondoom 


















Interviewer: Please read all the response 
options to the respondent then circle all that 
are applicable. Please remind respondent 
that you are not judging her. 
 
Not available/Nie beskikbaar nie 
Too expensive/Te duur 
Partner objected/Maat het beswaar 
gemaak 
Don’t like them/Hou nie daarvan nie 
Used other contraceptive/Het ander 
voorbehoeding gebruik 
Didn’t think it was necessary/Nie gedink 
dit was nodig nie 
Didn’t think of it/Nie daaraan gedink nie 
Partner is HIV positive/Maat is MIV-
positief 
Don’t enjoy sex with condom/Geniet nie 
seks met kondoom nie 
Afraid to ask my partner to use it/Bang om 
my maat te vra om dit te gebruik 
 Drunk/used drugs/Was dronk/het 
dwelms gebruik 
Embarrassed to used female condom/Was 
skaam om vrouekondoom te gebruik  
Your Religion/Jou geloof 
Other/Ander ……………… 
Don’t know/Weet nie 




























612 How old is your current main/regular 
sexual partner? 
Hoe oud is jou huidige 
hoofseksmaat/gereelde seksmaat? 
                 Number (years)/Skryf 
ouderdom in jaar    neer. 
 























To what extent do you agree or 
disagree with this statement: In your 
relationship, he (main/regular partner) 
supports you to use birth control 
method? 
In watter mate verskil jy of stem jy 
saam met hierdie stelling? Hy (jou 
hoofmaat/ gereelde maat) 
ondersteun jou in julle verhouding 







     










     
Disagree/ 






saam nie                               
Agree/Ste
m saam     
Strongly 
Agree/Ste
m sterk                         









614 Have you disclosed your HIV status to 
your current regular partner? 
 
Het jy jou MIV-status aan jou 







615 Would you be willing to share 
information on the HIV status of your 
regular partner with me? 
 
Sou jy bereid wees om jou gereelde 







616 What is your regular partner’s HIV 
status? 
 










Contraceptive self-efficacy: “Please I would like you to rate each item (from 701a--d) according to how true the statement is of you”.Please indicate 
on the diagram below by ticking the appropriate box/response.  
Selfdoeltreffendheid met voorbehoeding: “Antwoord asseblief op elke item (van 701a tot d) op grond van hoe waar die 








701 If you and your boyfriend were getting 
really heavy into sex (sexual vaginal 
intercourse) and moving towards 
intercourse and you were not 
protected … 
As jy en jou ou by mekaar is en julle 
maak gereed om vaginale omgang 














waar   
Somewhat/








 701a You could easily ask him 
if he had protection (or 
tell him that you didn't).  
... kan jy hom maklik 
vra of hy beskerming 
het (of hom sê dat jy nié 
het nie). 
       
 701b You could ask him to use 
male condom or excuse 
yourself to put in a female 
condom, diaphragm/cap, 
or foam(i.e., chemical 
jellies or creams) (if you 
used them for birth 
control. 
... kan jy hom vra om ’n 
kondoom aan te sit, of 
jouself verskoon om ’n 
vrouekondoom, 
vaginale ring of skuim 
(d.w.s. chemiese jel of 
room) te gaan insit (as 
jy dit vir 
geboortebeperking 
gebruik). 
        
 701c You could tell him you 
were on the pill/birth 
control tablet, 2 months 
(Nur-Isterate/3months 
(Depo-provera) 
injectables, inplants or 
had an IUD/loop/coil 
(if you used them for 
birth control). 
... kan jy hom sê jy’s op 
die 
Pil/geboortebeperking




inplantings, of jy het ’n 
“IUD”/veertjie (as jy 






 701d You could stop things 
before intercourse, if you 
couldn't bring up the 
subject of protection. 
... kan jy dinge vóór 
omgang stop as jy dit 
nie regkry om oor 
beskerming te praat 
nie. 
    
Not at 
all/Glad nie 




waar   
Somewhat/








Contraceptive service provision: “Please I would like to ask if you have received any of the following birth control services in 
government clinic(s) since you tested positive for HIV/Ek wil,asseblief, graag vra of u enige van die volgende geboorte 
beheer dienste in die regering kliniek(s)  ontvang omdat u positief vir MIV getoets (Questions 801-804).  
Interviewers: Please note that the respondents might have received elsewhere but this research is only interested in their views of government clinics. 
 
801  
a) Have you received advice about 
contraception/birth control in 
government clinic(s) since testing 
positive? 
Het u  raad oor voorbehoeding / 
geboortebeperking in die regering 




b) If yes (to item 801a), was the advice 
offered in this clinic? 
 
Indien ja  na(item 801a), was die raad 






































 c)When was the most recent time you 
received this advice?  
Wanneer was die mees onlangse tyd 
wat u  hierdie raad advies/ontvang? 
Interviewer: Please read all the response options 









Last clinic visit day/laaste 
kliniek besoek(Date please 
if yes: 
Within past month/In die 
afgelope maand 
Within past 3 months/In 
die afgelope drie maande 
Within past 12 month/In 
die afgelope 12 maande 
More than past 12 
















d) Who provided this most recent birth 
control advice received?  
Wie het die mees onlangse geboorte 
beheer raad verskaf? 
 
Interviewer: Please read all the response options 














e) How often did your HIV care provider 
in this clinic talk to you about birth 
control?  
Hoe dikwels het u MIV-sorgverskaffer 
in hierdie kliniek met u gepraat oor 
geboortebeperking?  
 
Interviewer: Please read all the response options to 





f)What did your provider talk about when 
providing these services? 
Waaroor praat jou sorgverskaffer 
wanneer jy hierdie dienste ontvang?  
 
Interviewer: Please read all the response options 





















wer: tick this if not provided by 
doctor/nurse/counsellor during 
consultation and patient received 
























Every time/Elke keer 



















(geen seks nie) 
Need to use birth 
control/Belang van 
geboortebeperking 
Motivation to prevent 
pregnancy/Motivering om 
swangerskap te voorkom 
Choosing methods/Hoe 
om metodes te kies 
Proper use of 
method(s)/Behoorlike 




What to do about missed 
pills/Wat om te doen as jy 
pille oorslaan 
Clinic policies about 
contraception/Kliniekbelei









































802 a) Have you received condom provision in 
government clinic(s) since testing 
positive? 
Het u  kondoom voorsiening in die 




















b) If yes (to item 802a), was the condom 
provision offered in this clinic? 
 
Indien ja  na(item 802a), was die 
















 c) When was the most recent time you 
received this service-condom provision?  
 
Wanneer was die mees onlangse tyd 
wat u  hierdie gekry kondoom 
voorsiening? 
 
Interviewer: Please read all the response options to 






d) Which provider gave you this most 
recent service- condom provision?  
 
Watter verskaffer het u hierdie mees 
onlangse diens gegee- kondoom 
voorsiening? 
 
Interviewer: Please read all the response options to 
the respondent then circle only one that is 
applicable 
Last clinic visit day/laaste 
kliniek besoek(Date please 
if yes: 
Within past month/In die 
afgelope maand 
Within past 3 months/In 
die afgelope drie maande 
Within past 12 month/In 
die afgelope 12 maande 
More than past 12 



















































consultation and patient received 













803 a) Have you received birth control/family 
planning method provision other than 
condom in government clinic(s) since 
testing positive? (i.e. birth control 
tablets/pills, injectables (Nur-Isterate or 
Depo-provera), loop/coil/IUD, implant, 
etc 
 
Het u geboortebeperking / 
gesinsbeplanning metode voorsiening 
behalwe kondoom in die regering 
kliniek (s) gekry sedert u positief 
getoets het? (Die 
Pil/geboortebeperkingspille, 
Inspuitings elke twee maande (Nur-




b) If yes (to item 803b), was birth 
control/family planning method 
provision (other than condom) offered in 
this clinic? 
Indien ja na (item 803b), is 
geboortebeperking / gesinsbeplanning 
metode voorsiening (behalwe 








c) When was the most recent time you 
receive this service- birth control/family 
































































Last clinic visit day/laaste 










Wanneer was die mees onlangse tyd 
wat u  hierdie gekry 
geboortebeperking / gesinsbeplanning 
metode voorsiening (behalwe 
kondoom)? 
 Interviewer: Please read all the response options 






d) Which provider gave you this most 
recent service- birth control/family 
planning method provision other than 
condom?  
 
Watter verskaffer het u hierdie mees 
onlangse diens gegee- 
geboortebeperking / gesinsbeplanning 
metode voorsiening behalwe 
kondoom? 
 
Interviewer:  Please read all the response options 
to the respondent then circle only one that is 
applicable 
 
Within past month/In die 
afgelope maand 
Within past 3 months/In 
die afgelope drie maande 
Within past 12 month/In 
die afgelope 12 maande 
More than past 12 


















wer: tick this if not provided by 
doctor/nurse/counsellor during 
consultation and patient received 























804 a) Have you received dual method 
provision (condom plus any other 
method such as pills/birth control 
tablets, 2 months (Nur-Isterate)/3 
months (depo-provera) injectables, 
IUD/loop/coil, or inplants) in 
government clinic(s) since testing 
positive? 
Het u 'n dubbele metode voorsiening 
(kondoom plus enige ander metode 
soos pille / geboorte beheer pille, 2 
maande (Nur-Isterate) / 3 maande 
(Depo-Provera) inspuitings, IUD / lus 
/ spoel, of inplants) in die regering 
kliniek (s) ontvang sedert u positief 
getoets is vir MIV? 
 
 
b) If yes (to item 804a), was dual method 
provision offered in this clinic?  
Indien ja na (item 804a), was 'n 
dubbele metode voorsiening in 





































b) When was the most recent time you 
received this service- dual method 
provision?  
Wanneer was die mees onlangse tyd 
wat u  hierdie gekry dubbele metode 
voorsiening 
Interviewer: please remind respondent what is dual 
method. Please read all the response options to the 





d) Which provider gave you this most 
recent service- dual method provision? 
 
Watter verskaffer het u hierdie mees 
onlangse diens gegee-'n dubbele 
metode voorsiening? 
 
Interviewer: please remind respondent what is dual 
method. Please read all the response options to the 









Last clinic visit day/laaste 
kliniek besoek(Date please 
if yes: 
Within past month/In die 
afgelope maand 
Within past 3 months/In 
die afgelope drie maande 
Within past 12 month/In 
die afgelope 12 maande 
More than past 12 
























wer: tick this if not provided by 
doctor/nurse/counsellor during 
consultation and patient received 























Contraceptive preferences, quality & satisfaction: “Please I would like to ask you about your impressions/feelings of the 
contraceptive/birth control services in this clinic. Once again, please note that none of the care providers in this clinic will be aware 
of the information you share in this interview and anything you say will not affect the care you receive”.  
Please tell me how much you agree or disagree with the following statements about your most recent contraceptive/birth control 
consultation visit or consultation for contraception services during attending HIV-related services in this clinic. Do you Strongly 
disagree, disagree, have Mixed Feelings, Agree or Strongly Agree? You can use the face the best indicates your opinion. 
 
Voorbehoedingsvoorkeure, -gehalte en -tevredenheid: “Nou wil ek graag met jou gesels oor jou indrukke van/gevoelens 
oor die voorbehoeding-/geboortebeperkingsdienste by hierdie kliniek. Onthou, nie een van die sorgverskaffers by hierdie 
kliniek sal weet wat jy my in hierdie onderhoud vertel nie.”  
Sê my asseblief in watter mate jy saamstem of verskil met die volgende stellings oor jou vorige voorbehoeding-/ 
geboortebeperkingskonsultasie, of konsultasie vir voorbehoedingsdienste terwyl jy MIV-verwante dienste by hierdie 
kliniek ontvang het. Verskil jy sterk, verskil jy, het jy gemengde gevoelens, stem jy net saam, of Stem jy sterk saam? 










Interviewer: Please read out these 
sentences before each question (805-
813):  
Do you Strongly Disagree, 
Disagree, have Mixed Feelings, 
Agree or Strongly Agree with 
the statement that ( please state 
each statement from items 805 
through 813) during your most 
recent contraceptive/birth 
control consultation visit or 
consultation for contraception 
services in this clinic? Verskil 
jy sterk, verskil jy, het jy 
gemengde gevoelens, stem 
jy net saam, of Stem jy sterk 
saam nie saam met die 
stelling wat ek aan u lees oor 
u mees onlangse 
kontraseptiewe / geboorte 
beheer konsultasie besoek of 
konsultasie vir 
voorbehoeding dienste in 
hierdie kliniek? 
 
You can use the face the best indicates 
your opinion.Gebruik gerus die 




























805 The staff were friendly 
Die personeel was vriendelik. 
              
 
 
806 The nurses and doctors listened 
to you 
Die verpleegkundiges en 
dokters luister na jou. 
          










807 Young girls living with HIV 
requesting contraception are 
treated with respect 
Jong meisies met MIV wat vir 
voorbehoeding vra, word met 
respek behandel. 
                            
379 
 
808 Information provided about birth 
control methods was 
understandable and sufficient (for 
examples, the degree/extent to 
which different methods is 
successful in achieving birth 
control, how to use a particular 
method)  
Die inligting wat hulle jou oor 
geboortebeperkingsmetodes 
gee, is verstaanbaar en 
voldoende (soos oor hoe 
suksesvol die verskillende 
metodes is om te keer dat jy 
swanger raak, en hoe om ’n 
sekere metode te gebruik). 
               
809 The staff who work in this clinic 
do not make efforts to find out 
your needs regarding birth 
control/contraception (including 
birth control advice and 
provision) without you asking. 
Die personeel wat in hierdie 
kliniek werk maak geen 
pogings nie om uit te vind van 
u behoeftes met betrekking tot 
geboortebeperking / 
kontrasepsie (insluitend 
geboorte beheer raad en 
voorsiening) sonder dat u 












810 Your consultation was private 
(i.e. service providers and staff 
respect your privacy) 
Die konsultasie was privaat 
(d.w.s. diensverskaffers en 













811 Had  to wait for a long time to  be 
seen (i.e. time spent in the waiting 
room before a nurse or doctor is 
seen for consultation regarding 
contraception) after you arrived 
at the clinic   
Moes lank wag vir die 
konsultasie nadat jy by die 
kliniek aangekom het (d.w.s. 
in die wagkamer voordat jy 
met ’n verpleegkundige of 
dokter oor voorbehoeding kon 











812 The clinic has the birth control 
method you needed 
Die kliniek het die 
geboortebeperkingsmetode 
gehad wat jy wou hê. 












813 You would recommend this clinic 
to a friend 
Jy sal hierdie kliniek by ’n 
vriendin aanbeveel. 
              
 
814 Services were organized 
Dienste was georganiseer 
              
815 The waiting room(s) was/were 
too crowded 
Die wagkamer (s) was  oorvol 
 
     
816 One felt comfortable being 
around other patients who were 
there? 
Voel  n mens gemaklik om 















817 The family planning/birth 
control care/services you 
received was directed to your 
needs and preferences (e.g., able 
to see same provider in 
subsequent clinic visits, 
provider’s gender, provider’s age, 
methods of contraception) 
die gesinsbeplanning / 
geboorte beheer sorg wat u in 
hierdie kliniek ontvang word 
na u behoeftes en voorkeure 
(bv, in staat om dieselfde 
verskaffer in die 
daaropvolgende 
kliniekbesoeke sien, geslag 
van verskaffer, ouderdom van 
verskaffer, metodes van 
geboortebeperking) 
 
     
818 Before providing you a with birth 
control method, a staff in the 
clinic or doctor’s office talked to 
you about a variety of possible 
methods of birth control 
     No/Nee       0 
 





Het ’n personeellid by die 
kliniek of in die dokter se 
spreekkamer met jou oor al die 
verskillende moontlike 
geboortebeperkingsmetodes 
gesels voordat jy ’n 
geboortebeperkingsmetode 
ontvang het? 
819 Have you Ever been pressured by 
a staff in the clinic or doctor’s 
office to use or continue to use a 
particular method of birth control 
when you would have rather used 
a particular method or no method 
at all.  
Het ’n personeellid by die 
kliniek of in die dokter se 
spreekkamer jou ooit onder 
druk geplaas om ’n sekere 
geboortebeperkingsmetode te 
gebruik of aan te hou gebruik, 
al wou jy eintlik ’n ander 
metode gebruik of selfs niks 
gebruik nie? 
No/Nee    0 
 
Yes/Ja       1 
 
If Yes, Please ask 
which method she 














Please can you respond to the following questions about your a) experience during your last clinic visit (this same clinic) for 
contraception/family planning/birth control, and b) preferences for contraceptive services?  Kan u asseblief reageer op die 
volgende vrae oor u a) ervaring met jou vorige kliniekbesoek vir voorbehoeding/gesinsbeplanning/geboortebeperking 




901 Which birth control method did 
you plan to get during your last 
clinic visit for birth control that you 
did not get?  
Watter geboorte beheer metode 
was u  op plan te kry tydens die 
vorige kliniek besoek vir 
geboortebeperking dat u nie 
gekry nie? 
Please specify/Spesifiseer asseblief ……….……….   
902 Able to see same provider for 
services related to birth 
control/family planning at 
subsequent clinic visits? 
 
Kon jy met daaropvolgende 






Not sure/Nie seker nie 
1 
2 




Please indicate from these photos 
the contraceptive/birth control 
methods that have been discussed 




Condoms with another method  
Kondoom saam met enige ander metode hierbo Yes       No 
 








Dui asseblief op hierdie foto’s 
aan watter voorbehoeding-
/geboortebeperkingsmetodes 
by hierdie kliniek met jou 
bespreek of aan jou verduidelik 
is? 
 
Interviewer: Please read all the response 
options to the respondent then tick the 
appropriate boxes that apply. 
 
 
Pills/birth control tablets    Yes          No 
Die Pil/geboortebeperkingspille 
 
2 months (Nur-Isterate) or 3 months (depo-provera) injectable: 
Inspuitings elke twee maande (Nur-Isterate) of drie maande (Depo-
provera)   Yes                    No 
                                                      
Male condom/Manskondoom   Yes           No 
                                                                                    
Female condom/Vrouekondoom  Yes        No 
                                                
Implants/Inplantings   Yes         No        
                             
Chemical foam/jell/cream/Chemiese skuim/jel/room  Yes         No   
 
IUD/loop/coil/“IUD”/veertjie    Yes         No        
                                         
Others (specify)/Ander (spesifiseer) ……………… 













1              
0 
 
1              
0 
 
1              
0 
 
1              
0 
 
1              
0 
904 Is it important to you to see the 
same service provider (doctors, 
nurses) at every visit for 
contraception/birth control, or do 
you not care? 
 
Is dit vir jou belangrik om met 
elke besoek vir 
voorbehoeding/geboortebeperk
ing met dieselfde sorgverskaffer 
(dokter, verpleegkundige) te 
praat, of maak dit nie saak nie? 
 
Interviewer: Please read all the response 
options to the respondent then circle only 













905 Would you prefer to have 
contraception/birth control service 
provided by : 
Sou jy verkies dat die 
voorbehoeding-/ 
geboortebeperkingsdiens 
voorsien word deur: 
 
A female/... ’n vrou? 
A male/... ’n man? 











Interviewer: Please read all the response 
options to the respondent then circle only 




906 Would you prefer to have 
contraception/birth control service 
provided by someone who is: 
 
Sou jy verkies dat die 
voorbehoeding-/ 
geboortebeperkingsdiens 
voorsien word deur iemand wat: 
 
 Interviewer: Please read all the response 
options to the respondent then circle only 
one that is applicable 
 
18-19 years old/... 18-19 jaar oud is? 
20-24 years old/... 20-24 jaar oud is? 
More than 25 years old/... ouer as 25 is? 
Don’t know/ Weet nie? 









907 If you had your choice, would you 
prefer to get contraception/birth 
control services at:  
 
As jy kon kies, sou jy verkies om 
voorbehoeding-/ 
geboortebeperkingsdienste te 
ontvang by:  
 
Interviewer: Please read all the response 
options to the respondent then circle only 
one that is applicable 
 
A place that provides care for only young persons (15-24 years)/... ’n plek wat 
sorg aan slegs jongmense (15-24 jaar) verskaf? 
 
A place that provides care for all ages but has a dedicated clinic day for young 
persons/... ’n plek wat sorg aan alle ouderdomme verskaf, maar wat ’n 
toegewyde kliniekdag vir jongmense het? 
 
HIV youth support group/... ’n MIV-jeugsteungroep? 
 
General clinic (all ages clinic including adults)/... ’n algemene kliniek (kliniek 
vir alle ouderdomme, onder meer volwassenes)? 
? 
School-based clinic/... ’n skoolgebaseerde kliniek? 
 
No preference/Geen voorkeur nie? 
 





















908 What is/are your preferred 






Interviewer: Please read all the response 
options to the respondent then circle all 
that are applicable 
 
 
Pills/birth control tablets/Die Pil/geboortebeperkingspille  
2 months (Nur-Isterate) or 3 months (Depo-provera) injectable/ Inspuitings 
elke twee maande (Nur-Isterate) of drie maande (Depo-provera) 





Chemical foam/jell/cream/Chemiese skuim/jel/room   
IUD/loop/coil/“IUD”/veertjie     
Condom with another method/Kondoom met 'n ander swangerskap 
voorkoming metode(Interviewer:Please write out the another 
method……………………. 
Others (specify)/Ander (spesifiseer) 


























909 Why do you prefer these methods? 
Hoekom verkies jy hierdie 
metodes? 
Specify please/Spesifiseer asseblief 










Overall satisfaction: Please think back about all your visits to this clinic for contraception. “Please I would like to ask you about 
how satisfied you are with the contraceptive/birth control services in this clinic. Once again, please note that none of the care 
providers in this clinic will be aware of the information you share in this interview”.  
Algehele tevredenheid: Dink asseblief terug aan ál jou besoeke vir voorbehoeding by hierdie kliniek. “Nou wil ek jou 
graag vra oor hoe tevrede jy is met die voorbehoeding-/geboortebeperkingsdienste by hierdie kliniek. Onthou asseblief, 









910 In general, how would you rate 
your satisfaction with the quality ( 
i.e standard of care/degree of 
excellence) of 
contraception/birth control 
services you received in this clinic? 
Hoe tevrede is u oor die 
algemeen met die gehalte van 
die voorbehoeding-
/geboortebeperkingsdienste 











Please indicate your opinion by ticking the appropriate box. You can use the face that 
best indicates your opinion. Dui asseblief jou mening aan deur die toepaslike 




dissatisfied                                     
/Baie 























































Clinic stigma“Please I would like to ask you about your impressions/feelings of the contraceptive/birth control services in this 
clinic. Once again, please note that none of the care providers in this clinic will be aware of the information you share in this 
interview”.  
Considering your most recent contraceptive/birth control consultation visit or consultation for contraception services during 
attending HIV-related services in this clinic, please tell me how much you agree or disagree with the following statements I read to 
you. You can use the face the best describes your opinion.  
 
Kliniekstigma: “Nou wil ek jou graag vra oor jou indrukke van/gevoelens oor die voorbehoeding-
/geboortebeperkingsdienste by hierdie kliniek. Onthou asseblief, nie een van die sorgverskaffers by hierdie kliniek sal 
weet wat jy my in hierdie onderhoud vertel nie.”  
As jy dink aan jou vorige voorbehoeding-/geboortebeperkingskonsultasie, of konsultasie vir voorbehoedingsdienste 
terwyl jy MIV-verwante dienste by hierdie kliniek ontvang het, in watter mate stem jy saam of verskil jy met die stellings 





























1001 Others can find out when you 
come to this clinic for 
contraception/birth control 
Ander kan uitvind as jy vir 
voorbehoeding/geboortebepe
rking na hierdie kliniek toe 
kom. 
 
     
1002 Others can find out your HIV 
status when you come to this 
clinic for contraception/birth 
control/family planning. 
Ander kan jou MIV-status 
uitvind as jy vir 
voorbehoeding/geboortebepe
rking/gesinsbeplanning na 
hierdie kliniek toe kom. 
                       
1003 Staff members at this clinic 
might tell other people that you 
come for contraception/birth 
control/family planning method 
without your permission. 
Personeellede by hierdie 
kliniek kan ander mense 
sonder jou toestemming vertel 






         


















Appendix 6: Excerpts from cognitive interviews 
 
Respondent 1 (19-year-old HIV-positive female, education – Matric, Language of interview- English) 
Participant was encouraged to think aloud – to say out loud – by talking through the process by which she 
arrived at her answers to the questions on the questionnaire. 
Follow-up probes: 
1. a. What do you think I meant by “Which of these best describes how you acquired HIV infection?”  
Respondent: Asking me how did I get HIV. 
        b. How did you arrive at your answers?  
       Respondent: I already knew this answer. 
        c. Can you tell me more about that?  
       Respondent: I got it from my former male partner. 
 
2. Can you repeat this question in your own words: Q501c: In your case, the ability of HIV 
treatments/medicines to fight HIV virus/AIDS could be reduced with concurrent use of hormonal 
contraceptive (information on hormonal methods are provided on the questionnaire). 
        Respondent: I think it means the medicine I am taking for HIV – If I could use hormonal   
contraception and HIV medicine at the same time –whether HIV medicine could be weakened. 
 
3. Can you tell me in your own word what you consider the important qualities (i.e the degree of 
excellence of contraceptive services) of service that young girls in HIV care should have? (This question 
was asked prior to the administration of the questionnaire) 
Respondent: They should listen to us, not give their own opinions and understand us when we come 
to the clinic for family planning. 
 
4. How confident are you of your answers to the questions on the questionnaire? 
Respondent: Highly confident and honest. 
 
5. a. Do you really understand the following response options: Strongly Disagree, Disagree……..Agree, 
Strongly Agree 
 
Respondent: I understand them. Strong means am very sure of my answers.  
b. Between the smiley faces and your feelings- which would you like to choose in deciding your 
response/answer? 
Respondent: I used my feelings during the interview. 
c. Why?  
Respondent: Because that is how I feel. I was expressing how I felt. 
d. Why did you choose strongly agree for question 805? The staff were friendly? 
Respondent: Because they treated me very nice as a patient here.  
e. How did you translate your feelings to match the Disagree/Agree Scale? 
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Respondent: I thought about Yes or No. It is like saying strongly Yes for Strongly Agree. 
 
Respondent 2 (16-year-old HIV-positive female, education – Grade 10, Language of interview: isiXhosa) 
Participant was encouraged to think aloud – to say out loud – by talking through the process by which she 
arrived at her answers to the questions on the questionnaire. 
Follow-up probes: 
 
1. a. How did you arrive at your answer to this question? “Which of these best describes how you 
acquired HIV infection?”  
Respondent: Because I got it from my mother (Respondent chose mother-child transmission) 
 
2. What do you think I meant by: Q613: To what extent do you agree or disagree with this statement: 
In your relationship, he (main/regular partner) supports you to use birth control method? 
Respondent: Trying to find out if my partner wants me to use family planning. 
 
3. Can you tell me in your own word what I meant by this question: The staff who work in this clinic do 
not make efforts to find out your needs regarding birth control/contraception (including birth control 
advice and provision) without you asking. 
Respondent: You are trying to say- I don’t have to ask for services before they provide it.  
 
4. How confident are you are you of your answers to the questions on the questionnaire? 
Respondent: Very confident about my answers. 
 
5. a. Do you really understand the following response options: Strongly Disagree, Disagree……..Agree, 
Strongly Agree 
Respondent: Yes 
b. Between the smiley faces and your feelings- which would you like to choose in deciding your 
response/answer? 
Respondent: I used my feelings because those questions touched feelings – they are more personal. 
c. Why did you choose strongly agree for question 810? Your consultation was private (i.e. service 
providers and staff respect your privacy) 
Respondent: Strong means I am very sure of my response. I chose strongly agree because other 
patients don’t people don’t know my HIV status here. In this clinic- they respect our privacy very well 
because others will be judgemental if they know.  
 
 
Appendix 7 (isixhosa): Information sheet: HIV, adolescent and contraception study 
uxwebhu lolwazi: hiv, abaselula kunye  nophando ngocwangciso 
 
PARTICIPANT ID NUMBER: ……………….DATE…………………………. 




Invitation to participate 
 Hello. I am [INTERVIEWER NAME]. I am a researcher working with a student who is doing this survey 
for his PhD degree at the University of Cape Town. We are conducting research with young girls 
young girls 14-19 years in HIV care in selected clinics in Khayelitsha, Klipfontein and Mitchells Plain. 
I would like to invite you to participate in the research. The aim of this research is to improve our 
understanding of the needs related to birth control/preventer in adolescent girls in HIV care. We 
would like to achieve this by inviting young girls 14-19 years attending HIV care in this clinic to take 
part in this research. To assist you decide if you would like to take part, I would like to share the 
information about the research with you. If you have any questions while I am explaining information 
about the research to you, please feel free to ask me.  
 
Isimemo sokuthatha inxaxheba 
• Molo. Ndingu[IGAMA LOMBHEXESHI WO DLIWANO NDLEBE].  Ndingumphandi osebenza nomfundi 
ofundela isidanga se PhD kwi Yunivesithi yase Kapa. Siqhuba uphando namantombazana aselula 14-
19 yeminyaka abakukhathalelo lukagawulayo kwi kliniki ezikhethiweyo e Khayelitsha,Klipfontein 
nase Mitchell’s Plain. Ndingathanda ukumema ukuba uthathe inxaxheba koluphando. Injongo 
yoluphando kukuphucula ukuqonda kwethu iimfuneko ezinxulumelene nocwangciso 
kumantombazana aselula akhathalelwe nge HIV. Oku singathanda ukukwenza ngokumema 
amantombazana aselula 14-19 yeminyaka ahambela ukhathalelo lwe HIV kule kliniki ukuba bathathe 
inxaxheba koluphando. Ukuncedisana nawe ekwenzeni isigqibo sokubayingxenye, ndingathanda 
ukwabelana nawe  ngolwazi loluphando. Ukuba unayo imibuzo xa ndicacisayo ulwazi ngoluphando, 
zive ukhululekile ukubuza imibuzo. 
 Why are we doing this research study? 
We are doing this research to better understand issues related to birth control/contraception use 
among young girls in HIV care. We are also looking at how different clinics provide family 
planning/birth control services for young girls in HIV care. This will help us to come up with a way to 
tailor family planning (birth control) services to what young girls in HIV care need and prefer.  
• Kutheni sisenza oluphando nje? 
Senza oluphando kuba sifuna ukuqonda ngcono malunga nemiba enxulumelene 
nocwangciso/ukusetyenziswa kocwangciso ngamantombazana aselula abakukhathalelo 
lukagawulayo .Kwaye sifuna ukujonga ukuba ikliniki ezahlukeneyo zinikezela njani iinkonzo 
zocwangciso kumantombazana aselula abakukhathalelo lukagawulayo. Oku kuyasinceda 
ekufumaneni indlela yokulungisa iinkonzo zocwangciso ezifunwa nezikhetwa ngamantombazana 
aselula nabakukhathalelo lukagawulayo 
 Why have you been invited to take part? 
You are being invited to participate in this research because we feel that your experiences as a young 
girl aged 14 -19 years will help us to understand how to improve family planning/birth control 
services for young girls in HIV care. We are inviting young girls aged 14 to 19 years to participate in 
this research study. 
• Kutheni umenywa ukuthabatha inxaxheba? 
Uyamenywa ukuba uthathe inxaxheba koluphando  sibona ukuba amava akho njengentombazana 
eselula ekwiminyaka ye 14-19 ubudala angasinceda ekuqondeni indlela yokuphucula iikonzo 
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zocwangciso kumantombazana aselula akukhathalelo lukagawulayo. Simema amantombazana 
aminyaka 14-19 yeminyaka ukuba athathe inxaxheba koluphando. 
 What will happen if you decide to participate?   
For young girls aged 14 to 17 years, we will seek your parent’s/legal guardian’s approval to allow you 
to participate in this research. This means the lead researcher/PhD candidate and/or the 
interviewer/research assistant will ask you to give the consent form to him/her and return the signed 
consent form on your next scheduled clinic/interview visit. In case we contact your parent/legal 
guardian physically, we will deliver the consent form ourselves and collect the signed version (Please 
note we will not tell your parent or guardian your HIV status). 
 We will request you to sign an assent form (for persons aged 14-17 years) or consent form (for 
persons aged 18 years and above). 
We will ask you to answer questions about yourself including your medical and treatment history, 
and experiences with birth control/family planning/preventer. 
We will ask you to spend 40-45 mins with an interviewer answering questions.  
The interview will take place in a comfortable location in the clinic where your privacy can be assured. 
You will be provided with a light refreshment, and you will be reimbursed only if you have incurred 
travel costs.  
• Kuyakuqhubeka ntoni xa ugqibe ukuthatha inxaxheba? 
Kumantombazana aminyaka 14-17 iminyaka, sizakufuna imvume yomzali/umgcini  ehambisana 
nokuthatha kwakho inxaxheba. Oko kukuthi umkhokeli wophando/umfundi we PhD/umbhexeshi 
wo dliwano ndlebe/umphandi oncedisayo bazakudibana nomzali/mgcini ngomnxeba okanye baye 
kuye ngqo) ukumazisa malunga nophando,kunye noxwebhu lwemvume emva koko kuzakufuneka 
imvume ebhaliweyo yomzali.Ukuba umzali utsalelwe umnxeba kwaye ekuvumela ukuthatha kwakhi 
inxaxheba, sizakucela ukuba umnike uxwebhu lwemvume ubuyise uxwebhu olutyikityiweyo xa 
uphinde wanikwa usuku lokubuyela e kliniki. 
Ukuba kuthe  sadibana nomzali/mgcini ngqo, sizakulisa ngokwethu ixwebhu lwemvume siqokelele 
uxwebhu elityikityiweyo. 
Sizakucela ukuba utyikitye uxwebhu lokwamkela oku(kubantu aba kwi 14-17 yeminyaka) okanye 
elokuvuma(kubantu aba kwi 18 nangaphezulu) 
Sizakubuza uphendule imibuzo malunga nawe kuquka  indlela onyangwa ngayo, kwaye namava 
ngocwangciso/isikhuselo 
Sizakucela ukuba ucithe  40-45 yemizuzu nombhexeshi wo dliwano-ndlebe uphendula imibuzo. 
Udliwano-ndlebe luzakuqhutywa kwindawo efihlakeleyo noziva ukhululekile kuyo. 
Uzakunikwa amaqebengwana alula, uzakubhatalwa xa uthe wasebenzisa imali yokukhwela. 
 Do you have to take part?  
The decision to take part is yours and is voluntary, and you can ask for time to think about it. You 
don’t have to take part if you don’t wish to. If you decide to take part, that’s nice. Whether you 
participate or not you will still get the same care as usual at the clinic.  
• Unyanzelekile ukuthatha inxaxheba? 
Isigqibo sokuthatha inxaxheba sesakho kwaye uyazikhethela, ungacela ixesha elongeziweyo 
ukucingisisa isigqibo sakho. Awunyanzelekanga ukuthatha inxaxheba ukuba awufuni. Ukuba ugqibe 
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ekuthatheni inxaxheba, intle lo nto. . Nokuba uthe warhoxa okanye waqhubekeka, uzakufumana 
impatho obuqhele ukuyifumana kwi kliniki yakho. 
 Will you be able to withdraw from the research study?  
Yes. You can stop taking part at any time during the interview without giving any reason. If you decide 
to stop participating at any time during the interview, please let the interviewer know before you 
withdraw. Whether you withdraw or continue your participation in the interview you will still get the 
same care as usual at the clinic. 
 Ungakwazi ukurhoxa koluphando? 
Ewe. Ungarhoxa nangaliphi ixesha ukudliwano-ndlebe ngaphandle kokunika isizathu. Ukuba ufuna 
ukurhoxa, nceda xelela umbhexeshi kwangethuba ukuba ufuna ukuyeka. Nokuba uthe warhoxa 
okanye waqhubekeka, uzakufumana impatho obuqhele ukuyifumana kwi kliniki yakho. 
 Are there risks and discomforts of taking part? 
We understand that some participants may feel uncomfortable talking about personal issues, 
including sexual and contraceptive behaviours. Every effort will be made to make you comfortable 
during the interview. The research team is committed to ensuring your comfort during the interview. 
During the interview, if there are some questions you feel uncomfortable to answer, just tell the 
researcher [interviewer] to move on to the next question. We will offer counselling for those that 
feel the interview made them uncomfortable.  
 Zikhona izichenge nokungaziva ukhululekile  xa  uthabatha inxaxheba? 
Siyaqonda ukuba abanye babathathi nxaxheba ngahlebazive bengakhululekanga  ngokuthetha 
ngempilo yaboo kuquka ngezesondo nocwangciso. Kuza kwenziwa konke  ukuqinisekisa ukuba uziva 
ukhululekile.Iqela lophando lizimisele ukba uzive ukhululekile kudliwano-ndlebe.Ukuba kukho 
imibuzo ekwenza ungaziva kakuhle ngexesha lo dlliwano-ndlebe, xelela umbhexheshi adlulele 
komnye umbuzo. 
Siyakubanika iingcebiso abathathi-nxaxheba abathe baziva bengakhulekanga ngenxa yodliwani-
ndlebe. 
 What are the possible benefits of taking part? 
You will get no direct benefit from taking part in the research study, but your participation may help 
the researchers better understand the best way to provide birth control/family planning services for 
young girls in HIV care. 
You will get no direct benefit from taking part in the research study, but your participation may help 
the researchers better understand the best way to provide birth control/family planning services for 
young girls in HIV care. 
 Inzuzo ngokuthatha inxaxheba 
Akukho nzuzo egqole ngqo kuwe, kodwa ukuthatha kwakho inxaxheba kungasinceda ekwazini nzulu  
ngeenkozo zocwangciso ukuhlangabezana neemfuno zabafazi abaselula 
 If you take part, will anyone have knowledge of what you say?  
All the information you share with the interviewer during the interview will be kept confidential 
(private). Only the research team will know your answers to the questions in this study. Your 
healthcare providers (nurses, doctors, counsellors etc ), family members, teachers, friends etc will 
not have an idea of what you say. The only time that what you say may be divulged to appropriate 
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person/authority is when we are concerned about your safety or that of others. If this occurs, you 
would be asked if it is okay for us to talk to your clinical care providers or any person of your choice 
so that we can assist.  
 Ukuba uthatha inxaxheba,ukhona omnye onganolwazi ngoko okuthethileyo? 
Lonke ulwazi owabelana ngalo kudliwano ndlebe kuyimfihlelo(bucala). Liqela lwezophando 
abazakwazi impendulo zakho kwimibuzo. Abanikezela ngonyango( oogqhira, amaNesi, abacebisi 
ngokunjalo, amalungu osapho, ootishala, izihlobo abazokwazi okuthethileyo. Ixesha apho konukuthi 
sikuxele oko okuthethileyo kwabo bafaneleyo kuxa sixhalabe ngokukhuseleka kwempilo 
yakho,okanye yabanye. Ukuba kuyenzeka oku, uzakucelwa ukuba kulungile na sikuxele oko kwabo 




 Your daughter/ward will receive a light refreshment on completion of the interview.  
 Intombi yakho/iwadi iyakunikwa amaqebengwana alula akugqiba udliwano-ndlebe 
 What will happen to the information you give?  
Your answers will be recorded on a paper-based questionnaire developed for this research study and 
in addition, the information from the questionnaire will be stored on a password protected computer 
at the University of Cape Town.  
All interview materials will be stored in a locked filing cabinet. Only the research team will have 
access to the study documents. At the end of study (i.e after writing study results), all study 
documents will be destroyed. 
 Kuzakwenzeka ntoni kulwazi olukhuphileyo? 
Iimpendulo zakho zizakushicelelwa kuxwebhu lwephepha lophando kwaye ukongeza, lwazi 
olukuxwebhu lazakugcinwa lukhuselekile kwi Yunivesithi yase Kapa. 
Konke okunxulumelene no dliwano ndlebe buyakugcinwa kukhuselekile. Liqela lwezophando lodwa 
abanokufikelela kumaxwebhu ophando. Ekupheleni kophando,(ukutsho,emveni kokubhala 
iziphumo) onke amaxwebhu ayakutshatyalaliswa. 
 
For participants <18 years of age: 
 Every person, including project staff, in South Africa has the duty to report known or suspected child 
abuse or neglect.  
Project staff (i.e., fieldstaff/interviewers and lead researcher) will report any form of physical abuse 
causing injury, deliberate neglect and sexual abuse (e.g rape, sexual assault , sexual grooming, sexual 
exploitation, and use of children in pornography including photographs) against you ( if your age is 
less than 18 years), as indicated in terms of the Children’s and Sexual Offences Acts, to a child 
protection agency/child welfare society, the provincial social development department, or to a police 
official if you report these directly to them, or if they reasonably suspect neglect or abuse. 




Your confidentiality will be protected and we will provide counselling and manage expectations 
honestly.  
These actions are necessary to protect you. 
 Kuba thathi- nxaxheba <kweminyaka eli-18 ubudala: 
Wonke umntu, kubandakanywa abasebenzi iprojekthi, eMzantsi Afrika unoxanduva lokuxela 
okwaziwayo okanye ekurhanelwa ukuhlukumezwa okanye ukungakhathelelwa komntwana. 
Basebenzi  be projekthi (oko kukuthi, basebenzi / babhexeshi bo dliwano- ndlebe kunye no mkhokeli 
wophando) bayakuxela   naluphi uhlobo lokuxhatshazwa ngokwasemzimbeni eyenza umonzakalo, 
ukungahoywa ngabom kunye nokuxhatshazwa ngokwesondo (umzekelo, ukudlwengula, 
ukuhlaselwa ngokwesini, ukuqeqeshwa ngokwesondo, ukuxhatshazwa ngokwesondo, kunye 
nokusetyenziswa abantwana amanyala kuquka iifoto) ngokuchasene wena (ukuba ubudala bakho 
bunga ngaphantsi kwe-18 iminyaka), njengoko kuchazwe ku Mthetho waBantwana kunye ne Zenzo 
zokuxhapaza ngokwe Sondo, kwabo aba khusela abantwana, i Sebe lo Phuhliso lo Luntu le Phondo, 
okanye ipolisa ukuba ingxelo uyizisa ngqo kubo, okanye ukuba bathandabuza ukungahoywa okanye 
impatho embi. 
Inkqubo efanelekileyo  ikhona ukuqinisedkisa  ukuba wena nomzali  nithunyelwa kwi arhente 
yokhuseleko.Imfihlelo yakho iyakukhuselwa kwaye sikunike neengcebiso ngokunyanisekileyo. 
La manyathelo ayimfuneko ukukhusela wena. 
 Who will know whether you are taking part in the research study?  
Only the research team will know you are taking part in this research study. Your name will not be 
entered in any study records. The information you provide will only be identified by a code.   
 Ngubani uzakwazi ukuba uthatha inxaxheba? 
Liqela lwezophando lodwa abaza kuba nolwazi ngokuthatha kwakho inxaxheba. Ulwazi olunikayo 
luyakunikwa uphawu. 
 What will happen to the results of this research study?  
The results will be published in scientific journals so that researchers, policy makers, and healthcare 
practitioners can read. The information from the study would be very useful in service delivery. 
Summary of the results will also be sent to the Western Cape Department of Health and City of Cape 
Town’s Health Directorate.  
 Kuzakwenzeka ntoni  kwiziphumo zoluphando? 
Iziphumo zizakupapashwa kumaxwebhu enzululwazi khon ukuze abaphandi,abasemagunyeni 
kwakunye nabanyangayo bakwazi ukuzifunda.Ulwazi ngophando luyakunceda kakhulu ngokuzisa 
iinkonzo ebantwini. 
 Who has reviewed/approved the study?  
The research study has been reviewed and approved by the Human Research Ethics Committee at 
the University of Cape Town and the Western Cape Provincial department of Health and City of Cape 
Town Directorate of Health as well.  
 Ngubani oqwalasele/wavuma oluphando? 
Oluphando luqwalaselwe kwaye lwavunywa yi Komiti yo Phando ngo Luntu kwi Yunivesiti yase Kapa 
ne Sebe le Mpilo lase Ntshona Koloni nesi Xeko sase Kapa kwicandelo lezeMpilo. 
 What should you do to participate in this research study?  
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If you have decided to participate in this research, we would like to work you through the information 
sheet and assent/consent form. Once we are sure that you understand the information sheet and 
the assent/consent form, you will be asked to sign the assent/consent form. Please note that 
participants aged 14-17 years will be asked to provide a written parent’s or legal guardian’s consent 
before they can participate.  
 Yintoni ekufuneka uyenzile ukuthatha inxaxheba? 
Ukuba ugqibe ekuthatheni inxaxheba koluphando, singathanda ukusebenzisana nawe ngoxwebhu 
lwemvume nelo lwazi. Xa sithe sabona ukuba uyaluqonda uxwebhu lo lwazi nolwe mvume, 
uzakucelwa ukuba utyikitye uxwebhu lwemvume. Nceda uqonde ukuba abathathi-nxaxheba 
abaphakathi kwe 14-17 yeminyaka bayakucelwa beze nemvume ebhaliweyo yomzali/mgcini phambi 
kokuthatha inxaxheba. 
 Who do you contact if there is a problem? 
If you have any concerns or queries regarding your participation in this research, you may wish to 
contact: 
 Udibana nabani xa kukho ingxaki? 
Ukuba unazo naziphina iinxalabo malunga nokuthatha kwakho inxaxheba koluphando, ungathanda 
ukudibana no: 
 
Biodun Olagbuji (Principal Researcher) 
Doctoral Candidate, School of Public Health 




Appendix 8 (Afrikaans): Information sheet: HIV, adolescent and contraception study (inligtingsblad: miv, 
adolescent en voorbehoedmiddels studie) 
PARTICIPANT ID NUMBER: ……………….DATE…………………………. 
DEELNEMER ID NOMMER:…………………DATUM……………………. 
 
Invitation to participate 
 Hello. I am [INTERVIEWER NAME]. I am a researcher working with a student who is doing this survey 
for his PhD degree at the University of Cape Town. We are conducting research with young girls 14-
19 years attending HIV-related services in selected clinics in Khayelitsha, Klipfontein and Mitchells 
Plain. I would like to invite you to participate in the research. The aim of this research is to improve 
our understanding of the needs related to birth control/preventer in adolescent girls in HIV care. We 
would like to achieve this by inviting young girls 14-19 years attending HIV care in this clinic to take 
part in this research. To assist you decide if you would like to take part, I would like to share the 
information about the research with you. If you have any questions while I am explaining information 
about the research to you, please feel free to ask me.  
Hello. I am [INTERVIEWER NAME]. I am a researcher working with a student who is doing this survey 
for his PhD degree at the University of Cape Town. We are conducting research with young girls 
young girls 14-19 years in HIV care in selected clinics in Khayelitsha, Klipfontein and Mitchells Plain. 
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I would like to invite you to participate in the research. The aim of this research is to improve our 
understanding of the needs related to birth control/preventer in adolescent girls in HIV care. We 
would like to achieve this by inviting young girls 14-19 years attending HIV care in this clinic to take 
part in this research. To assist you decide if you would like to take part, I would like to share the 
information about the research with you. If you have any questions while I am explaining information 
about the research to you, please feel free to ask me.  
Uitnodiging om deel te neem 
 Hello. Ek is [ONDERHOUDVOERDER NAAM]. Ek is 'n navorser wat werk met 'n student wat besig is 
met hierdie opname vir sy PhD-graad aan die Universiteit van Kaapstad. Ons is besig met n navorsing 
met jong meisies 14-19 jare oud wat in MIV-sorg dienste in geselekteerde klinieke in Khayelitsha, 
Klipfontein en Mitchells Plain. Ek wil u uitnooi om deel te neem in die navorsing. Die doel van hierdie 
navorsing is om ons begrip van die behoeftes wat verband hou met geboortebeperking / verhoed in 
tienermeisies in MIV-sorg te verbeter. Ons wil graag om dit te bereik deur te nooi jong meisies 14-
19 jaar oud wat bywoon MIV-sorg in hierdie kliniek om deel te neem in hierdie navorsing. Om u te 
help besluit of u wil deelneem, wil ek graag die inligting oor die navorsing met u te deel. As u enige 
vrae het, terwyl ek inligting oor die navorsing verduidelik aan u, voel asseblief vry om my te vra. 
 Why are we doing this research study? 
We are doing this research to better understand issues related to birth control/contraception use 
among young girls living with HIV. We are also looking at how different HIV clinics provide family 
planning/birth control services for young girls living with HIV. This will help us to come up with a way 
to tailor family planning (birth control) services to what young girls living with HIV need and prefer. 
We are doing this research to better understand issues related to birth control/contraception use 
among young girls in HIV care. We are also looking at how different clinics provide family 
planning/birth control services for young girls in HIV care. This will help us to come up with a way to 
tailor family planning (birth control) services to what young girls in HIV care need and prefer.  
 
 Hoekom doen ons die navorsingstudie? 
Ons doen hierdie navorsing om kwessies wat verband hou met geboortebeperking / kontrasepsie 
gebruik onder jong meisies wat in MIV-sorg is beter te verstaan. Ons is ook op soek na hoe 
verskillende MIV klinieke verskaf gesinsbeplanning / geboorte beheer dienste vir jong meisies wat in 
MIV-sorg is. Dit sal ons help om vorendag te kom met 'n manier om gesinsbeplanning (geboorte 
beheer) dienste op maat aan wat jong meisies wat in MIV-sorg is nodig het en verkies. 
 
 Why have you been invited to take part? 
You are being invited to participate in this research because we feel that your experiences will help 
us to understand how to improve family planning/birth control services for young girls in HIV care. 
We are inviting young girls aged 14 to 19 years to participate in this research study. 
You are being invited to participate in this research because we feel that your experiences as a young 
girl aged 14 -19 years will help us to understand how to improve family planning/birth control 
services. for young girls in HIV care. We are inviting young girls aged 14 to 19 years to participate in 




 Hoekom  is u genooi om deel te neem? 
U word uitgenooi om deel te neem in hierdie navorsing omdat ons voel dat u ervarings   as  n meisie 
van 14-19 jare oud sal ons help om te verstaan hoe om gesinsbeplanning / geboorte beheer dienste 
te verbeter vir jong meisies in MIV-sorg. Ons nooi jong meisies tussen die ouderdomme van 14 tot 
19 jaar om deel te neem in hierdie navorsingstudie 
 
 What will happen if you decide to participate?   
For young girls aged 14 to 17 years, we will seek your parent’s/legal guardian’s approval to allow you 
to participate in this research. This means the lead researcher/PhD candidate and/or the 
interviewer/research assistant will approach your parent or legal guardian (either via telephone or 
physical contact) to inform him/her about the research and the parent/legal guardian consent form 
and thereafter a written parent’s/legal guardian’s consent will be sought. If your parent/legal 
guardian is telephoned and willing to give consent for your participation in the research study, we 
will ask you to give the consent form to him/her and return the signed consent form on your next 
scheduled clinic visit. In case we contact your parent/legal guardian physically, we will deliver the 
consent form ourselves and collect the signed version. 
For young girls aged 14 to 17 years, we will seek your parent’s/legal guardian’s approval to allow you 
to participate in this research. This means the lead researcher/PhD candidate and/or the 
interviewer/research assistant will ask you to give the consent form to him/her and return the signed 
consent form on your next scheduled clinic/interview visit. In case we contact your parent/legal 
guardian physically, we will deliver the consent form ourselves and collect the signed version (Please 
note we will not tell your parent or guardian your HIV status). 
 
 Wat sal gebeur as u besluit om deel te neem? 
Vir jong meisies tussen die ouderdomme van 14-17 jaar, sal ons goedkeuring van u ouer / wettige 
voog nodig om u toelaat om deel te neem in hierdie navorsing. Dit beteken dat die hoofnavorser / 
PhD kandidaat en / of die onderhoudvoerder / navorsingsassistent sal nader u ouer of wettige voog 
(hetsy telefonies of fisiese kontak) aan hom / haar oor die navorsing en die ouer / wettige voog 
toestemming vorm en daarna 'n skriftelike  toestemming van ouer / wettige voog  sal gesoek word. 
As u ouer / wettige voog gebel is en is bereid  om toestemming te gee vir u deelname aan die 
navorsingstudie, sal ons u vra om die toestemmingsvorm gee aan hom / haar en  die getekende 
toestemmingsvorm terug bring op u volgende geskeduleerde kliniek besoek. In geval ons u ouer / 
wettige voog fisies kontak , sal ons die toestemming vorm onsself lewer en  die getekende weergawe 
versame.(Let wel: ons sal nooit vir u ouer/wettige voog se van u MIV-status) 
 We will request you to sign an assent form (for persons aged 14-17 years) or consent form (for 
persons aged 18 years and above). 
 Ons sal u versoek om 'n instemming onderteken (vir persone 14-17 jaar) of toestemming vorm (vir 
persone tussen die ouderdomme van 18 jaar en ouer). 
 
 We will ask you to answer questions about yourself including your medical and treatment history, 
and experiences with birth control/family planning/preventer. 
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 Ons sal u vra om vrae oor u self  insluitend u mediese en behandeling geskiedenis en ervarings met 
geboortebeperking / gesinsbeplanning / verhoed beantwoord. 
 
 We will ask you to spend 40-45 mins with an interviewer answering questions.  
 Ons sal u vra om 40-45 minute te spandeer met 'n onderhoudvoerder en die vrae antwoord. 
 
 The interview will take place in a comfortable location in the clinic where your privacy can be assured. 
 Die onderhoud sal in 'n gemaklike plek in die kliniek plaasvind, waar u privaatheid kan verseker wees. 
 
 You will be provided with a light refreshment, and you will be reimbursed only if you have incurred 
travel costs.  
 U sal voorsien word met 'n ligte verversings, en u sal vergoed word slegs as u reiskoste aangegaan. 
 
 Do you have to take part?  
The decision to take part is yours and is voluntary, and you can ask for time to think about it. You 
don’t have to take part if you don’t wish to. If you decide to take part, that’s nice. Whether you 
participate or not you will still get the same care as usual at the clinic.  
 Moet u deel te neem? 
Die besluit om deel te neem is joune en is vrywillig, en u kan vir meer tyd vra om oor dit te dink.U 
hoef nie om deel te neem as u nie wil nie. As u besluit om deel te neem, dit is lekker. Of u deelneem 
of nie,u sal nog steeds dieselfde sorg kry soos gewoonlik by die kliniek. 
 
 Will you be able to withdraw from the research study?  
Yes. You can stop taking part at any time during the interview without giving any reason. If you decide 
to stop participating at any time during the interview, please let the interviewer know before you 
withdraw. Whether you withdraw or continue your participation in the interview you will still get the 
same care as usual at the clinic. 
 Sal u in staat wees om te onttrek van die navorsingstudie? 
Ja. U kan ophou om deel te neem enige tyd gedurende die onderhoud en sonder  enige rede. As u 
besluit om op te hou te enige tyd gedurende die onderhoud, kan u die onderhoudvoerder laat weet 
voordat u trek. Of u onttrek of voortgaan met u deelname aan die onderhoud,u sal nog steeds 
dieselfde sorg soos gewoonlik by die kliniek kry. 
 
 Are there risks and discomforts of taking part? 
We understand that some participants may feel uncomfortable talking about personal issues, 
including sexual and contraceptive behaviours. Every effort will be made to make you comfortable 
during the interview. The research team is committed to ensuring your comfort during the interview. 
During the interview, if there are some questions you feel uncomfortable to answer, just tell the 
researcher [interviewer] to move on to the next question. We will offer counselling for those that 
feel the interview made them uncomfortable.  
 Is daar risiko's en ongemak as u deel te neem? 
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Ons verstaan dat sommige deelnemers ongemaklik voel as hulle  oor hul persoonlike kwessies praat, 
insluitend seksuele en kontraseptiewe gedrag. Alles moontlik sal gedoen word om u gemaklik tydens 
die onderhoud te maak. Die navorsingspan is daartoe verbind om u gemak voel tydens die onderhoud. 
Tydens die onderhoud, indien daar 'n paar vrae is wat u voel ongemaklik om te antwoord, sê net vir 
die navorser [onderhoudvoerder] aan te beweeg na die volgende vraag. Ons bied berading vir die ene 
wat voel die onderhoud het hulle ongemaklik voel. 
 What are the possible benefits of taking part? 
You will get no direct benefit from taking part in the research study, but your participation may help 
the researchers better understand the best way to provide birth control/family planning services for 
young girls in HIV care. 
You will get no direct benefit from taking part in the research study, but your participation may help 
the researchers better understand the best way to provide birth control/family planning services for 
young girls in HIV care. 
 Wat is die moontlike voordele van deelname? 
U sal geen direkte voordeel te kry om deel te neem in die navorsingstudie, maar u deelname kan help 
om die navorsers beter te verstaan die beste manier om geboortebeperking / gesinsbeplanning 
dienste vir jong meisies wat in MIV-sorg is. 
 
 If you take part, will anyone have knowledge of what you say?  
All the information you share with the interviewer during the interview will be kept confidential 
(private). Only the research team will know your answers to the questions in this study. Your 
healthcare providers (nurses, doctors, counsellors etc ), family members, teachers, friends etc will not 
have an idea of what you say. The only time that what you say may be divulged to appropriate 
person/authority is when we are concerned about your safety or that of others. If this occurs, you 
would be asked if it is okay for us to talk to your clinical care providers or any person of your choice 
so that we can assist.  
 As u deelneem, sal 'n mens weet wat u gesê het? 
Al die inligting wat u deel met die onderhoudvoerder tydens die onderhoud sal vertroulik (privaat) 
gehou word. Slegs die navorsingspan sal u antwoorde op die vrae in hierdie studie te leer ken. U 
voorsieners van gesondheidsorg (verpleegsters, dokters, beraders, ens), familielede, onderwysers,  
vriende ens sal nie 'n idee het van wat u gesê. Die enigste keer dat dit wat u sê kan bekend gemaak 
word aan geskikte persoon / gesag is wanneer ons is bekommerd oor u veiligheid of dié van ander. As 
dit gebeur, sal u gevra word of dit in orde is vir ons om u kliniese sorg of iemand van u keuse praat 
sodat ons kan help. 
 
 
 What will happen to the information you give?  
Your answers will be recorded on a paper-based questionnaire developed for this research study and 
in addition, the information from the questionnaire will be stored on a password protected computer 
at the University of Cape Town.  
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All interview materials will be stored in a locked filing cabinet. Only the research team will have access 
to the study documents. At the end of study (i.e after writing study results), all study documents will 
be destroyed. 
 Wat sal gebeur met die inligting wat u gee? 
U antwoorde sal aangeteken word op 'n papier-gebaseerde vraelys wat is ontwikkel vir hierdie 
navorsingstudie en benewens, die inligting van die vraelys word gestoor op 'n wagwoord beskerm 
rekenaar by die Universiteit van Kaapstad. Alle onderhoud materiaal sal gestoor word in 'n geslote 
liasseerkabinet. Slegs die navorsingspan sal toegang tot die studie dokumente. Aan die einde van 
studie (d.w.s na aflegging van studie resultate), al die studie vernietig sal word. 
 
For participants <18 years of age: 
 Every person, including project staff, in South Africa has the duty to report known or suspected child 
abuse or neglect.  
Project staff (i.e., fieldstaff/interviewers and lead researcher) will report any form of physical abuse 
causing injury, deliberate neglect and sexual abuse (e.g rape, sexual assault , sexual grooming, sexual 
exploitation, and use of children in pornography including photographs) against you ( if your age is 
less than 18 years), as indicated in terms of the Children’s and Sexual Offences Acts, to a child 
protection agency/child welfare society, the provincial social development department, or to a police 
official if you report these directly to them, or if they reasonably suspect neglect or abuse. 
An appropriate referral system is in place to ensure you or your parent is referred to a welfare or 
protection agency. 
Your confidentiality will be protected and we will provide counselling and manage expectations 
honestly.  
These actions are necessary to protect you. 
 
Vir deelnemers <18 jaar oud: 
 Elke persoon, insluitende projek personeel, in Suid-Afrika het die plig om bekend of vermoedelike 
kindermishandeling of verwaarlosing aanmeld. Projek personeel (dit wil sê, gebied personeel / 
onderhoudvoerders en hoofnavorser) sal enige vorm van fisiese mishandeling rapporteer letsel, 
doelbewuste verwaarlosing en seksuele mishandeling (bv verkragting, seksuele aanranding, seksuele 
versorging, seksuele uitbuiting, en die gebruik van kinders in pornografie insluitend foto's) teen u (of 
u ouderdom is minder as 18 jaar oud), soos aangedui in terme van die Kinderwet en Seksuele 
Misdrywe Hand, 'n kinderbeskermingseenheid agentskap / Kindersorgvereniging, die provinsiale 
departement maatskaplike ontwikkeling, of aan 'n polisiebeampte as u rapporteer dit direk vir hulle 
of hulle redelik verdagte verwaarlosing of mishandeling. 'N Gepaste verwysingstelsel in plek om u te 
verseker of u ouers verwys na 'n welsyn of Protection Agency. U vertroulikheid sal beskerm  word en 
ons sal berading verskaf en te bestuur verwagtinge eerlik. Hierdie optrede is nodig om u te beskerm. 
 
 Who will know whether you are taking part in the research study?  
Only the research team will know you are taking part in this research study. Your name will not be 




 Wie sal weet of u  deel te neem in die navorsingstudie? 
Slegs die navorsingspan sal weet u is deel te neem aan hierdie navorsingstudie. U naam sal nie in enige 
studie rekords aangeteken word. Die inligting wat u verskaf, sal slegs geïdentifiseer word deur 'n kode. 
   
 
 What will happen to the results of this research study?  
The results will be published in scientific journals so that researchers, policy makers, and healthcare 
practitioners can read. The information from the study would be very useful in service delivery. 
Summary of the results will also be sent to the Western Cape Department of Health and City of Cape 
Town’s Health Directorate.  
 Wat sal gebeur met die resultate van hierdie navorsingstudie? 
Die resultate sal gepubliseer in wetenskaplike tydskrifte sodat navorsers, beleidmakers, en praktisyns 
gesondheidsorg kan lees. Die inligting van die studie sou baie nuttig in dienslewering wees. 
Opsomming van die resultate sal ook aan die Wes-Kaapse Departement van Gesondheid en die Stad 
Kaapstad se Gesondheid Direktoraat gestuur. 
 
 Who has reviewed/approved the study?  
The research study has been reviewed and approved by the Human Research Ethics Committee at the 
University of Cape Town and the Western Cape Provincial department of Health and City of Cape 
Town Directorate of Health as well. (Note to reader/reviewer: I have added this section for 
completeness. This section is only valid after HREC approval. 
 
 Wie het die studie nagegaan / goedgekeur ? 
Die navorsingstudie is hersien en deur die Menslike Navorsingsetiekkomitee aan die Universiteit van 
Kaapstad en die Wes-Kaapse Provinsiale Departement van Gesondheid en die Stad Kaapstad 
Direktoraat van Gesondheid goedgekeur sowel. (Nota aan die leser / resensent: Ek het hierdie artikel 
vir volledigheid bygevoeg. Hierdie afdeling is slegs geldig nadat HREC goedkeuring.. 
 
 What should you do to participate in this research study?  
If you have decided to participate in this research, we would like to work you through the information 
sheet and assent/consent form. Once we are sure that you understand the information sheet and the 
assent/consent form, you will be asked to sign the assent/consent form. Please note that participants 
aged 14-17 years will be asked to provide a written parent’s or legal guardian’s consent before they 
can participate.  
 
 Wat moet u doen om deel te neem in hierdie navorsingstudie? 
As u besluit het om deel te neem in hierdie navorsing, wil ons graag met u werk deur die inligtingstuk 
en instemming / toestemming vorm. Sodra ons is seker dat u die inligtingsblad en die instemming / 
toestemming dokument verstaan, sal u gevra word om die instemming / toestemming te onderteken. 
Let asseblief daarop dat deelnemers 14-17 jaar oud sal gevra word om 'n skriftelike ouer of wettige 




 Who do you contact if there is a problem? 
If you have any concerns or queries regarding your participation in this research, you may wish to 
contact: 
 Wie sal u kontak indien daar 'n probleem is? 
As u enige probleme ondervind of navrae oor u deelname aan hierdie navorsing, kan u vir ons kontak: 
 
Biodun Olagbuji (Principal Researcher) 
Doctoral Candidate, School of Public Health 




Appendix 9: Comprehension assessment sheet: HIV, adolescent and contraception study exit 
survey (uxwebhu lokuvavanya ukuqonda: HIV, abaselula kunye nophando ngocwangciso) 
PARTICIPANT ID NUMBER: ……………….DATE…………………………. 
ISAZISI SOMTHATHI-NXAXHEBA:……………………………………….UMHLA……………………………………… 
 
Please provide response to each question below to show that you have adequate 
knowledge of what the study is about. 
Nceda unikeze impendulo kumbuzo ngamye kule ingaphantsi ukubonakalisa ukuba unalo 
ngokwaneleyo ulwazi malunga noluphando. 
 
1 I confirm that the study information 
sheet and consent form have been 
adequately explained to me and I 
understand the information on the 
study. 
Ndiyangqina ukuba ixwebhu lolwazi 
ngophando kunye noxwebhu 
lemvume zicaciswe ngokwaneleyo 




2 I have had the opportunity to ask 
questions about the content of the 
Yes  Ewe 
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information sheet and consent form, 
and satisfied with the explanations 
provided by the interviewer. 
Bendinalo ithuba lokubuza imibuzo 
malunga ngokuqulathwe kwixwebhu 
lolwazi nexwebhu lemvume kwaye 




3 I understand why I am being asked to 
participate in the study, and the 
purpose of the study. 
Ndiyaqonda kutheni ndicelwa ukuba 
ndithathe  inxaxheba koluphando, 
kunye nenjongo yoluphando. 
 
Yes  Ewe 
No  Hayi 
4 I understand that my participation is 
voluntary. 
Ndiyaqonda ukuthatha inxaxeba 
kungokuthanda kwam. 
 
Yes  Ewe 
No  Hayi 
5 I understand that I can withdraw from 
the interview at any time without 
providing any reason 
Ndiyaqonda ukuba ndingarhoxa 
kudliwano-ndlebe nangaliphinina 
ixesha nangaphandle kwesizathu. 
 
Yes  Ewe 
No  Hayi 
6 I understand that whether I withdraw 
or continue my participation in the 
Yes  Ewe 
No  Hayi 
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interview I will still get the same care 
as usual at the clinic. 
Ndiyaqonda ukuba nokuba 
ndiyarhoxa okanye ndiyaqhubekeka 
nodliwano-ndlebe ndizakufumana 
inkathelelo endiyiqhelileyo apha 
ekliniki. 
 
7 I understand the possible discomforts 
that may occur during interviews. 
Ndiyaqonda ukuba ngahle ungaziva 
ukhululekile kudliwano-ndlebe. 
 
Yes  Ewe 
No  Hayi 
8 I understand that there is no direct 
benefit of the study to me. 
Ndiyaqonda ukuba akukho nzuzo 
yophando egqole kum ngqo 
 
Yes  Ewe 
No  Hayi 
9 I understand that my privacy/identity 
will be protected. 
Ndiyaqonda ukuba isazisi sam 
siyakuhlala sikhuselekile bucala. 
 
Yes  Ewe 
No  Hayi 
10 I understand that all the information I 
provide will be kept secret, and only 
the research team will know the 
information. 
Ndiyaqonda ukuba lonke ulwazi 
endilukhuphileyo luyakuhlala 
Yes  Ewe 
No  Hayi 
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luyimfihlelo, kwaye liqela lophando 
lodwa eliyakwazi ngulolwazi. 
 
11 I have information on whom to 
contact if I have any problem or 
concern about my participation in the 
research. 
Ndinalo ulwazi lokuba ngubani 
endinokunxumelelana naye 
ngokuthatha inxaxheba koluphando 
 
Yes  Ewe 
No  Hayi 
12 I agree to participate in the research 
study. 
Ndiyavuma ukuthatha inxaxheba 
koluphando 
 
Yes  Ewe 
No  Hayi 
13 I have not previously participated in 
this particular research in this same 
clinic or any other clinic.  
Andizange ndithabathe inxaxheba 
koluphando ngaphambili kule kliniki 
okanye nayiphina I kliniki. 
Yes  Ewe 
No  Hayi 
14 The information about the study has 
been provided to me in a language I 
understand.  
Ulwazi malunga noluphando 
ndilufumene ngolwimi endiliqondayo. 
 
Yes  Ewe 
No Hayi 
 
Participant ID Number…………….                    Signature/thumbprint…………….Date…………………. 
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ISAZISI SOMTHATHI-NXAXHEBA………………..    Umtyikityo/bhontsi…………..Umhla……………………. 
 
Interviewer 
 I, [Name of interviewer] have explained the research purpose, procedures, and the risks 
and benefits relating to the research in a language of choice of the interviewee.  
Mbhexeshi wo dliwano-ndlebe 
 Mna,(igama lombhexeshi wo dliwano-ndlebe) ndiyicacisile injongo, imigaqo, kwakunye 
nezichenge, nenzuzo ezinxulumelene noluphando ngolwimi olukhethwe ngumthathi-
nxaxheba. 
                Name …………….                       Signature…………….               Date…………………. 
                Igama…………………                    Umtyikityo…………………        Umhla…………………… 
 
Appendix 10 (Afrikaans): Participant assent/consent form: HIV, adolescent and contraception 
study exit survey (ixwebhu lokwamkela/lwemvume: hiv, abaselula naku phando 
ngocwangciso) 
PARTICIPANT ID NUMBER: ……………….DATE…………………………. 
ISAZISI SOMTHATHI-NXAXHEBA:……………….UMHLA…………………. 
 
Adolescent informed assent/consent 
Imvume/ukwamkela okucacisiweyo koselula 
 Hello. Thank you for accepting to discuss with us today. I am [INTERVIEWER NAME]. Before 
you sign the assent/consent form, I would like to share further the information about the 
research with you. The purpose of this information is to help you decide whether you will 
participate in the study or not.  
• Molo. Enkosi ukwamkela ukuxoxa kunye nathi namhlanje.Ndingu [ IGAMA LOMBHEXESHI 
WO DLIWANO NDLEBE]. Phambi kokuba utyikitye uxwebhu lokwamkela / imvume, 
Ndingathanda ukwabelana kunye nawe ngakumbi ulwazi malunga nophando. Injongo yale 
ngcaciso imfutshane kukunceda wena wenze isigqibo sokuba uzathatha inxaxheba 
kuphando okanye hayi. 
Introduction/study purpose 




You are being asked to participate in a research study on birth control/preventer. This 
study does not involve drawing blood from you or giving you medications.  
We are inviting young girls aged 14 to 19 years in HIV care to participate in this research 
study. 
The information on this form will be explained to you. 
Please feel free to ask any questions that you may have. 
Intshayelelo / injongo yophando                                                
 Abaphandi abasuka kwiYunivesithi  yaseKapa bacela ukuba uthathe inxaxheba 
kwisifundo sophando. 
Wena uyacelwe ukuba uthathe inxaxheba kwisifundo sophando ngolawulo lenzalo / 
isikhuseli. Olu Uphando  alubandakanyi ukutsalwa kwegazi  kuwe okanyeukunika 
amayeza. 
Simema amantombazana aselula abaneminyaka engama-14 ukuya kwi-19 
abakhathalelwe nge HIV ukuba bathathe inxaxheba kwesi sifundo sophando. 
Ulwazi kweli xwebhu luza kucaciswa kuwe. 
Nceda uzive ukhululekile ukubuza nayiphi na imibuzo onokuba unayo 
Purpose of Study   
 The purpose of this research is to better understand issues related to birth 
control/contraception use among young girls living with HIV. Ultimately, the findings of 
this research would help to increase our understanding of the ways to improve access to 
contraceptive services. 
Injongo yoluphando 
 Injongo yoluphando kukufuna ukuqonda ngcono malunga nemiba enxulumelene 
nocwangciso/ukusetyenziswa kocwangciso ngamantombazana aselula aphila 
nentsholongwane ka gawulayo(HIV).  Ekugqibeleni, iziphumo zoluphando 
zizakunceda ekunyuseni izinga lokuqonda iindlela zokuphucula ukufumaneka 
kweenkonzo zocwangciso. 
Description of the Study Procedures 
 If you agree to participate in the research study, you will be asked to provide answers to 
some questions about birth control/preventer and the related services in the clinic.  
The interview will take place in a comfortable location in the clinic where your privacy 
can be assured.   
We aim for an interview that will last approximately 40–45 minutes.  
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The information shared during the interview will be kept private, and only key members 
of the research team will have access to it.  
Ingcaciso yemigaqo yoluphando 
 Ukuba uyavuma  ukuthabatha inxaxheba koluphando, uzakucelwa ukuba usinike 
iimpendulo kweminye iimibuzo malunga neenkonzo zocwangciso/isikhuseli  nezinye 
iinkonzo ezingqameneyo  apha ekliniki. 
Udliwano-ndlebe luyakuqhutywa kwindawo ekhululekileyo apha ekliniki nalapho 
siyakuqinisekisa ukuba isecaleni. 
Sijonge ekubeni  udliwano-ndlebe luthabathe into epha kwi  40-45 yemizuzu 
Ulwazi owabelene ngalo kudliwano-ndlebe luyakugcinwa luyimfihlelo, kwaye 
ngamalungu ophando aphambili odwa  azakufikelela kulo. Ulwazi alusayi kwabelwana  
nalo nomzali 
Risks/Discomforts of Being in this Study 
 There are no major risks.  
You may feel uncomfortable talking about your personal life. You do not have to answer 
any question that may make you feel uncomfortable.  
We will offer counselling for participants that feel the interview made them 
uncomfortable.  
Izichenge/Ukungaziva ukhululekilei  xa ukuphando 
 Azikho izichenge ezikhulu. 
Ngahle uziveungakhululekanga  ngokuthetha ngempilo yakho. Awunyazelekanga 
ukuphendula nawuphina umbuzo onokuthi ukwenze uzive ungakhululekanga. 
Siyakubanika iingcebiso abathathi-nxaxheba abathe baziva bengakhulekanga ngenxa 
yodliwani-ndlebe. 
Benefits of Being in the Study 
 There is no direct benefit to you, but your participation is likely to assist us to know more 
about how to tailor birth control/preventer services to meet the needs of young women 
in HIV care.  
Inzuzo ngokuthatha inxaxheba 
 Akukho nzuzo egqole ngqo kuwe, kodwa ukuthatha kwakho inxaxheba kungasinceda 




 The confidentiality of documents and records of this study will be maintained and the 
only thing that will be disclosed is any form of maltreatment (including physical ill-
treatment, emotional maltreatment, sexual abuse or neglect) of a participant who is 14 
years of age or older but under the age of 18 years, but this will be reported to the social 
development department, a child welfare agency, or a police official in terms of 
legislation.  
If you are 14 years of age or older but under the age of 18 years and you disclose 
experiencing some form of violence or maltreatment (including physical ill-treatment, 
emotional maltreatment, sexual abuse or neglect) or if a research staff reasonably 
suspects violence or maltreatment, and that this has not been reported to a relevant 
agency, we are required by law to report this to the social development department, a 
child welfare agency, or a police official in terms of legislation. Someone will then 
investigate and see what needs to be done to keep you safe. Your confidentiality will be 
protected and we will provide counselling and manage expectations honestly. These 
actions are necessary to protect you.  
All the research data will not be available to anyone outside the research team.  
Research documents and records will be kept in a locked file, and all electronic 
information will be coded and secured using a password protected file.  
Once we have completed the study and written the results, all study documents will be 
destroyed.  
Imfihlelo 
 Amaxwebhu oluphando ayakuhlala eyimfihlelo kwaye eyonanto iyakuthi ivezwe kuxa 
kukho ukuhlukunyezwa(kuquka ukuhlukunyezwa ngokwasemzimbeni, emoyeni, 
ngokwesini okanye ukungakhathalelwa),  komthathi nxaxheba  ominyaka eyi 14 okanye 
ukunyuka kodwa abengaphantsi kwe 18 iminyaka, kodwa kuyakuxelwa kwisebe 
lezoluntu, i-arhente ejongene nemfuno zabantwana, okanye ipolisa njengoko umthetho 
usitsho. 
Ukubangaba uneminyaka eyi 14 okanye ukunyuka kodwa ungapahantsi kwe 18 iminyaka 
kwaye usixelele ukuba ebeke wadibana nobundlobongela okanye ukungaphathwa 
kakuhle(kuquka ukungaphathwa kakuhle emzimbeni,emoyeni,ngesini okanye 
ukungakhathalelwa) okanye ukuba umqeshwa wophando uhlanela ubundlobongela 
okanye impatho embi, kwaye akuzange kuxelwe kwi arhente ezingqamane noku, 
siyagunyaziswa ngumthetho ukuba sikuxele oku sebe lezoluntu, kwi arhente ezijongene 
nokukhuselwa kwabantwana, okanye kwi polisa njengoko umthetho usitsho. Ukhona 
umntu ozakuphanda abone ukuba yintoni na enokwenziwa ukugcina ukhuselekile. 
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Imfihlelo yakho iyakukhuselwa kwaye uyakucetyiswa  ngendlela enyanisekileyo. 
Lamanyathelo ayafuneka ukukhusela wena. 
Onke amaxwebhu noko kushicelelweyo akusayi kufumaneka nakubani na ongaphandle  
kwiqela loluphando. 
Amaxwebhu ophando noko  kushicelelweyo ayakugcinwa eluvalelweni, kwaye lonke 
ulwazi locwephesho luyakukhuselwa ngenombolo yokuvula. 
Xa uphando lugqityiwe kwaye neziphumo zibhaliwe, onke amaxwebhu ophando 
ayakutshatyalaliswa. 
Reimbursement 
You will receive a light refreshment on completion of the interview.  
Imbuyekezo 
Uyakunikwa amaqebengwana alula akugqiba udliwano-ndlebe. 
Right to Refuse or Withdraw 
 The decision to participate in this research study is entirely up to you. It is entirely 
voluntary. 
If you are uncomfortable about any of the interview questions you can choose not to 
answer or participate in that part of the question.  
You have the right to withdraw from the interview at any time during the interview 
process. 
There will be no penalty if you decide to quit at any time during the interview 
Whether you participate or not you will still get the same care as usual at the clinic.  
Igunya lokungavumi okanye urhoxe 
 Isigqibo sokuthatha inxaxheba koluphando sixhomekeke kuwe. Uyazikhethela. 
Ukuba uziva ungakhululekanga malunga nayiphina imibuzo yodliwano-ndlebe unakho 
ukukhetha ukungaphenduli okanye ungathathi inxaxheba kulombuzo. 
Unalo igunya lokurhoxa kudliwano-ndlebe nakweliphina ixesha ukudliwano-ndlebe. 
Akusayi kubakho isohlwayo ukuba  ugqibe ekubekeni phantsi  nangaliphi ixesha 
ukudliwano-ndlebe 
Right to Ask Questions and Report Concerns 
 You have the right to ask any questions in relation to this research study and to have 
information about this research study less confused or more understandable.  
If you have any questions about this research study, you can contact me at 0717243901. 
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If you have any problems or concerns that occur as a result of your participation in the 
research study, you can contact the lead researcher at 0717243901. 
If you have any concerns about your right as a research participant that have not been 
adequately address by the interviewer, you contact the lead researcher at 0717243901  
If you think your concerns are not well addressed, you can report to Human Research 
Ethics Committee at the Faculty of Health Sciences University of Cape Town at 
+27214066346 
Igunya lokubuza imibuzo nokuxela iinxalabo 
 Unalo igunya lokubuza nayiphina imibuzo enxulumene noluphando, kwaye ubenolwazi 
olungaphixanisiyo okanye uqonde ngcono. 
Ukuba unemibuzo malunga noluphando, unganxibelelana nam apha:0717243901 
Ukuba unazo naziphina iinxalabo malunga namalungelo akho njengomthathi-nxaxheba 
koluphando ezithe azaphendululeka ngendlela ngumbhexeshi wophando, unakho 
ukunxibelelana nomkhokeli wophando  apha:0717243901 
Ukuba  ucinga ukuba iinxalabo zakho aziphendulekanga  ngendlela, ungaxelela I- Komiti 
Yophando Yoluntu kwi Candelo lwe Zempilo kwi Dyunivesiti yase Kapa 
apha+27214066346 
Consent/assent 
 Your signature/thumbprint below confirms that you have agreed to participate in the 
research study, and that you have sufficient understanding of the information sheet and 
consent form. You will be given a signed/thumb printed copy of this form to keep. The 
lead researcher will keep a copy.  
 Umtyikityo wakho/ubhontsi ungqina ukuba uvumile ukuthabatha inxaxheba koluphando, 
kwaye unako ukuqonda okwaneleyo  ngexwebhu lolwazi nelemvume. Uzakunikwa i-kopi 
etyikityiweyo/enobhontsi yelixwebhu. Umphandi oyintloko uzakugcina i-kopi. 
Biodun Olagbuji (Principal Researcher) 
Doctoral Candidate, School of Public Health 
University of Cape Town 
Mobile: 0717243901 
E-mail: biodun_olagbuji@yahoo.com 
Signature/thumbprint of participant…………………………   Date…………………….. 





Appendix 11. (Afrikaans): Participant assent/consent form: HIV, adolescent and contraception 
study exits urvey (deelnemer instemming/toestemmings vorm: miv, adolescent en 
voorbehoedmiddels studie opname) 
 
PARTICIPANT ID NUMBER: ……………….DATE…………………………. 
DEELNEMER ID NOMMER:…………………DATUM………………………. 
Adolescent informed assent/consent 
 Hello. Thank you for accepting to discuss with us today. I am [INTERVIEWER NAME]. Before 
you sign the assent/consent form, I would like to share further the information about the 
research with you. The purpose of this information is to help you decide whether you will 
participate in the study or not.  
Adolessente ingeligte instemming / toestemming 
• Hello. Dankie vir die aanvaarding van vandag om te gesels met ons. Ek is 
[ONDERHOUDVOERDER NAAM]. Voordat u die instemming / toestemming vorm te 
onderteken, wil ek graag die inligting oor die navorsing met u verdere deel. Die doel van 
hierdie inligting is om u te help besluit of u sal deelneem aan die studie of nie. 
 
Introduction/study purpose 
 Researchers from the University of Cape Town are requesting you to take part in a research 
study. 
You are being asked to participate in a research study on birth control/preventer. This study 
does not involve drawing blood from you or giving you medications.  
We are inviting young girls aged 14 to 19 years in HIV care to participate in this research study. 
The information on this form will be explained to you. 
Please feel free to ask any questions that you may have. 
Inleiding / studie doeleindes 
 Navorsers van die Universiteit van Kaapstad  versoek u om deel te neem aan 'n 
navorsingstudie. 
U word gevra om deel te neem aan 'n navorsingstudie oor geboortebeperking / verhoed. 
Hierdie studie behels nie om bloed te trek uit u of gee u medikasie. 
Ons nooi jong meisies 14 tot 19 jaar oud in MIV-sorg om deel te neem in hierdie 
navorsingstudie. 
Die inligting op hierdie vorm sal aan u verduidelik word. 
Voel asseblief vry om enige vrae wat u mag hê te vra. 
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Purpose of Study   
 The purpose of this research is to better understand issues related to birth 
control/contraception use among young girls living with HIV. Ultimately, the findings of this 
research would help to increase our understanding of the ways to  improve access to 
contraceptive services. 
Doel van studie 
 Die doel van hierdie navorsing is om kwessies wat verband hou met geboortebeperking / 
kontrasepsie gebruik onder jong meisies wat met MIV leef beter te verstaan. Uiteindelik sal die 
bevindinge van die navorsing te help om ons begrip van die maniere om toegang tot 
voorbehoedmiddels dienste te verbeter verhoog. 
Description of the Study Procedures 
 If you agree to participate in the research study, you will be asked to provide answers to some 
questions about birth control/preventer and the related services in the clinic.  
The interview will take place in a comfortable location in the clinic where your privacy can be 
assured.   
We aim for an interview that will last approximately 40–45 minutes.  
The information shared during the interview will be kept private, and only key members of 
the research team will have access to it.  
Beskrywing van die studie prosedures 
 As u saam stem om deel te neem in die navorsingstudie, sal u gevra word om antwoorde op 
'n paar vrae oor geboortebeperking / verhoed en die verwante dienste in die kliniek verskaf. 
Die onderhoud sal plaasvind in 'n gemaklike plek in die kliniek waar u privaatheid kan verseker 
wees. 
Ons streef na 'n onderhoud wat ongeveer 40-45 minute sal duur. 
Die inligting gedeel tydens die onderhoud sal privaat gehou, en net die belangrikste lede van 
die navorsingspan sal toegang daartoe het. 
Risks/Discomforts of Being in this Study 
 There are no major risks.  
You may feel uncomfortable talking about your personal life. You do not have to answer any 
question that may make you feel uncomfortable.  
We will offer counselling for participants that feel the interview made them uncomfortable.  
Risiko's / ongemak daarvan om in hierdie studie 
 Daar is nie 'n groot risiko's. 
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U kan ongemaklik voel as u praat oor u persoonlike lewe. U hoef nie om enige vraag wat mag 
u ongemaklik  laat voel beantwoord. 
Ons bied berading vir deelnemers wat die onderhoud voel het hulle ongemaklik. 
Benefits of Being in the Study 
 There is no direct benefit to you, but your participation is likely to assist us to know more 
about how to tailor birth control/preventer services to meet the needs of young women in 
HIV care.  
 
Voordele om in die studie te wees 
 Daar is geen direkte voordeel vir u, maar u deelname is geneig om ons te help om meer oor 
hoe om op maat van geboorte beheer / verhoed dienste aan die behoeftes van jong vroue in 
MIV-sorg ontmoet weet. 
Confidentiality  
 The confidentiality of documents and records of this study will be maintained and the only 
thing that will be disclosed is any form of maltreatment (including physical ill-treatment, 
emotional maltreatment, sexual abuse or neglect) of a participant who is 14 years of age or 
older but under the age of 18 years, but this will be reported to the social development 
department, a child welfare agency, or a police official in terms of legislation.  
If you are 14 years of age or older but under the age of 18 years and you disclose experiencing 
some form of violence or maltreatment (including physical ill-treatment, emotional 
maltreatment, sexual abuse or neglect) or if a research staff reasonably suspects violence or 
maltreatment, and that this has not been reported to a relevant agency, we are required by 
law to report this to the social development department, a child welfare agency, or a police 
official in terms of legislation. Someone will then investigate and see what needs to be done 
to keep you safe. Your confidentiality will be protected and we will provide counselling and 
manage expectations honestly. These actions are necessary to protect you.  
All the research data will not be available to anyone outside the research team.  
Research documents and records will be kept in a locked file, and all electronic information 
will be coded and secured using a password protected file.  
Once we have completed the study and written the results, all study documents will be 
destroyed.  
Vertroulikheid 
 Die vertroulikheid van dokumente en rekords van hierdie studie sal gehandhaaf word en die 
enigste ding wat sal bekend gemaak word is enige vorm van mishandeling (insluitende fisiese 
mishandeling, emosionele mishandeling, seksuele misbruik of verwaarlosing) van 'n 
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deelnemer wat 14 jaar oud of ouer, maar jonger as 18 jaar, maar dit sal gerapporteer word 
aan die ontwikkeling afdeling maatskaplike, 'n kindersorg-agentskap, of 'n polisiebeampte in 
terme van wetgewing. 
As u 14 jaar of ouer is, maar onder die ouderdom van 18 jaar en u openbaar ervaar een of 
ander vorm van geweld of mishandeling (insluitende fisiese mishandeling, emosionele 
mishandeling, seksuele misbruik of verwaarlosing) of as 'n navorsing personeel vermoed 
geweld of mishandeling, en dat dit nog nie gerapporteer word aan 'n toepaslike agentskap, 
ons is deur die wet vereis om dit te rapporteer aan die ontwikkeling afdeling maatskaplike, 'n 
Kinderwelsyn agentskap, of 'n polisiebeampte in terme van wetgewing. Iemand sal dan 
ondersoek en kyk wat  kan gedoen  word om u veilig te hou. U vertroulikheid sal beskerm  
word en ons sal berading verskaf en eerlik verwagtinge te bestuur . Hierdie optrede is nodig 
om u te beskerm. 
Al die navorsing data is nie beskikbaar aan enigiemand buite die navorsingspan wees. 
Navorsing dokumente en rekords sal in 'n geslote lêer gehou word, en alle elektroniese 
inligting sal gekodeer word en verseker met behulp van 'n wagwoord beskermde lêer.Sodra 




 You will receive a light refreshment on completion of the interview.  
Vergoeding 
 U sal 'n ligte verversings ontvang na afloop van die onderhoud. 
Right to Refuse or Withdraw 
 The decision to participate in this research study is entirely up to you. It is entirely voluntary. 
If you are uncomfortable about any of the interview questions you can choose not to answer 
or participate in that part of the question.  
You have the right to withdraw from the interview at any time during the interview process. 
There will be no penalty if you decide to quit at any time during the interview 
Whether you participate or not you will still get the same care as usual at the clinic.  
Reg om te weier of te onttrek 
 Die besluit om deel te neem in hierdie navorsingstudie is heeltemal aan u. Dit is heeltemal 
vrywillig. 
As u ongemaklik oor enige van die onderhoud vrae is, u kan kies om nie te antwoord of deel 
te neem in daardie deel van die vraag. 
U het die reg om te onttrek van die onderhoud te enige tyd gedurende die onderhoud proses. 
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Daar sal geen straf wees as  besluit om op te hou te enige tyd gedurende die onderhoud. 
Of u deelneem of nie, u sal nog steeds dieselfde sorg soos gewoonlik by die kliniek kry. 
Right to Ask Questions and Report Concerns 
 You have the right to ask any questions in relation to this research study and to have 
information about this research study less confused or more understandable.  
If you have any questions about this research study, you can contact me at 0717243901. 
If you have any problems or concerns that occur as a result of your participation in the 
research study, you can contact the lead researcher at 0717243901. 
If you have any concerns about your right as a research participant that have not been 
adequately address by the interviewer, you contact the lead researcher  at 0717243901  
If you think your concerns are not well addressed, you can report to Human Research Ethics 
Committee at the Faculty of Health Sciences University of Cape Town at +27214066346 
Reg om Vrae te Vra en Rapporteer Kommernisse 
 U het die reg om enige vrae met betrekking om hierdie navorsingstudie vra  en om 
inligting oor hierdie navorsingstudie minder verward of meer verstaanbaar te hê. 
Indien u enige vrae oor hierdie navorsingstudie, kan u my kontak by 0717243901. 
Indien u enige probleme of bekommernisse wat plaasvind as gevolg van u deelname 
aan die navorsingstudie het, kan u die hoofnavorser kontak by 0717243901. 
Indien u enige kommer oor u regte as 'n navorsingsdeelnemer wat nie voldoende aan te 
spreek deur die onderhoudvoerder, kontak u die hoofnavorser by 0717243901 
As u dink u besorgdheid is nie goed aangespreek is, kan u by die Fakulteit 
Gesondheidswetenskappe om Menslike Navorsingsetiekkomitee Universiteit van 
Kaapstad by +27214066346   rapporteer. 
Consent/assent 
 Your signature/thumbprint below confirms that you have agreed to participate in the 
research study, and that you have sufficient understanding of the information sheet 
and consent form. You will be given a signed/thumb printed copy of this form to keep. 
The lead researcher will keep a copy. 
Toestemming / instemming 
 U handtekening / duimafdruk hieronder bevestig dat u ingestem het om deel te neem 
in die navorsingstudie, en dat u genoeg begrip van die inligtingstuk en 
toestemmingsvorm. U sal 'n getekende / duim gedrukte afskrif van hierdie vorm gegee 
word aan te hou. Die hoofnavorser sal 'n afskrif hou. 
Biodun Olagbuji (Principal Researcher) 
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Doctoral Candidate, School of Public Health 
University of Cape Town 
Mobile: 0717243901  
E-mail: biodun_olagbuji@yahoo.com 
Signature/thumbprint of participant…………………………   Date…………………….. 
Handtekening / duimafdruk van 
deelnemer.................................Datum.................................... 
Signature of research staff…………………………   Date…………………….. 
  Handtekening van navorsingspersoneel...............................Datum.................................. 
 
Appendix 12: Protocol for reporting child maltreatment (abuse or neglect).  
Below are steps to follow if a study participant (who is 14 years of age or older but under the 
age of 18 years) discloses any form of abuse (sexual, physical or emetional) or neglect to a field 
worker, or if a suspicion is made by a field worker:  
The definition of child maltreatment (abuse and neglect) is as follows: Child maltreatment refers 
to all forms of physical ill-treatment, emotional maltreatment, sexual abuse or neglect resulting 
in actual or potential harm to the child well-being (Note to interviewers/field workers: The 
indicators of all forms of maltreatment are provided in Form 22 - Reporting of Abuse or 
Deliberate Neglect of Child).  
1. Interviewer should immediately contact the lead researcher (PhD candidate). 
2. Respondent/participant should be asked -by the interviewer and/or lead researcher- whether 
the incident was already reported to a relevant agency e.g., a child protection agency, the 
provincial social development department, or to a police official. 
2. If the incident has not been reported or when in doubt about whether the incident was already 
reported, the lead researcher will immediately contact a social worker (or a referral person) at 
the study site upon knowing or having reason to believe that a study participant who is in  14-17 
age group  has experienced some form of sexual /physical abuse or neglect.  
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3. Completion of Form 22 (Reporting of Abuse or Deliberate Neglect of Child) and Form 23 
(Reporting of Abuse or Deliberate Neglect of Child to Director General) by a social worker and an 
interviewer (research assistant) at study site and the lead researcher (PhD candidate) as well (see 
attached forms 22 and 23). 
4. Written documentation of reports and submission of aforementioned forms 22 and 23 to 
Western Cape Department of Social Development by a social worker at study site. 
5. Keeping/updating (by the lead researcher/PhD candidate) a log of reports.  
Appendix 13: Template for reporting child maltreatment (abuse or neglect) or any other 
traumatic events to a social worker/clinic counsellor at the study site. 
(Note: Both verbal and written reports will be made) 
Name of study facility:……………………………………………………………………………….. 
Name and age of the child:…………………………………………………………………………... 
Name and age of child who disclosed (suspected to have) traumatic event (sexual abuse, 
maltreatment or neglect):…………………………………………………………………………… 
Name and address of the child’s parent/legal guardian………………………………………………. 
Summary of abuse disclosed by the child or reasons why interviewer/field worker and lead 




Approximate date and time the abuse occurred:……………………………………………………... 







Actions taken by field worker/lead researcher (please tick all that apply): 
 Psychological support  
 Verbal report to a social worker  
 Contact to treatment unit  
 Others (please specify)…………………………………………………………………….. 
Signature of Fieldworker/trained researcher………………………Date…………………………..    
Signature of lead researcher/PhD candidate…………………………………. Date………………. 
 
Appendix 14: Psychosocial or victim referral protocol. 
1. If a report of abuse or neglect is made or if the respondent discloses any traumatic event to an 
interviewer/a field worker or need for further counselling or assistance (and care and 
interventions), a fieldworker should encourage the victim to talk about the abuse or neglect 
without embarrassment or anxiety and report to (contact) the lead researcher/PhD candidate at 
the same time.  
2. Immediate psychological support is to be given to a victim by a fieldworker (all field workers 
and the lead researcher will be trained by an adolescent psychologist to do this)  and the lead 
researcher/PhD candidate. 
3. Any suspicions or disclosures about abuse (and maltreatment) or discomfort should be 
reported by the field worker (The lead researtcher/PhD candidate would assist in this task) on a 
reporting template (see Appendix 9). 
3. Where a disclosure of psychological/emotional discomfort arising during interviews on 
personal sensitive issues is made and, where further counselling or assistance is needed, the lead 
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researcher/PhD candidate would make referral to a clinic counsellor or social worker at the study 
site, and further referral to a child psychologist, if needed, can be made by the clinic counsellor 
or social worker. 
4. All instances of child abuse or maltreatment should be referred in the first instance to a social 
worker at a study site for further counselling and referral for other  sexual  abuse services needed, 
in accordance with Western Cape provincial guidelines, at study healthcare facility (where a study 
site does not offer child abuse treatment, referral will be made to the nearest facility offering 
child abuse treatment).  
Appendix 15: Key informants’ in-depth interview: Demographic information and question 
guide 
Thank you for agreeing to take part in this research study. As I have stated earlier, the purpose 
of this research study is to learn more about health care providers’ understandings of 
contraception for HIV-positive adolescent girls. I would like to ask you some questions to know 
your views and experiences regarding contraceptive services for HIV-positive adolescent girls in 
your current working environment.  I would like to remind you that there are no right or wrong 
answers to the questions. Before we start, do you have any questions for me?   
Participant Study ID Number:                                              Interview date: ………………… 
Clinic (Tick) 
 Gugulethu CHC     Mitchells Plain CHC     Khayelitsha (Site B) CHC  Nyanga CHC             
 Michael M. CHC    Heideveld CHC     Browns Farm CHC   Nolungile CHC  Site B Youth Clinic                                              
Site C Youth Clinic   Mzamomhle Clinic    Weltevreden Valley Clinic,      Kuyasa Clinic                                                                                                                                                                              
Provincial sub-district managers                            City Health sub-district managers 
Klipfontein                                                                        Klipfontein          
Khayelitsha                                                                        Khayelitsha         
Mitchells Plain                                                                   Mitchells Plain   
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Time interview started:  
Time interview ended:    
Informed consent obtained:  
 
 Demographic sheet: Background information 
1 How old are you?   
2 Please tick your gender Male                                                  
 





3 What is your current job/status in this 
health care facility?  
(Please tick all that apply) 
Doctor                                               













4 How long have you been in current 
job? 
  
5 How many years of experience do you 
have in HIV programme? 
  
6 How many years of experience do you 
have in contraception programme? 
  
7 What is your highest professional 
qualification? 
Diploma in Nursing                       
Bachelor/Nursing degree              
Doctor-Medical degree                                             







Other- Specify                                    5 
 
 
Question guide: Indepth interviews with key informants 
(Note: Participants were provided with the summaries of their responses at various intervals 
during the interviews and at the end to elicit clarifications 
 Socio-Demographics: [ See Demographic sheet] 
First, I would like to know your thoughts about contraceptive methods choice for HIV-
positive adolescent young girls. 
 What do you know about contraception services for the a) general adolescent girl 
populations, and b) HIV-positive adolescent girls? How did you get this knowledge about 
contraception services for the general adolescent girl populations and HIV-positive 
adolescent girls? 
 Can you talk about what contraceptive methods are available in this facility? In your 
experience, which contraceptive methods are commonly used by HIV-positive adolescent 
girls and why? (Please speak about different groups of girls:  minors/older adolescents, 
BHIV/PHIV adolescent girls, married/unmarried, in-school/out-of-school, working/not 
working). Probe about methods they used before and after they came to the interviewee. If 
they already used any methods before coming to you for contraceptive services, who 
recommended the methods? Probe: friends, partner, family/parents, social media, 
healthcare providers, teachers etc. What methods are commonly recommended by 
providers, and why? 
  Do you have any ideas about how the contraceptive methods used by HIV-positive 
adolescent girls differ from that of HIV-negative girls, HIV-positive young adult women (20-
24 years) and older HIV-positive women and why?  
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 What do you understand by the term dual method contraception? Do you (or any other 
provider) usually recommend a condom (male or female subtype) plus any other 
contraceptive to HIV-positive adolescent girls? Why or why not? If yes, probe about other 
methods recommended and reasons (e.g. unintended pregnancy, HIV transmission via 
mother-to-child etc.). How do HIV-positive adolescent girls feel about dual method use? Why 
do some not use dual method consistently? 
I would now like to ask you about the delivery of contraception for HIV-positive adolescent 
girls. 
 In your experience, can you please tell me what you (and/or those of other providers) think 
about the delivery of contraception services to HIV-positive adolescent girls? Do you think it 
has been successful/effective? Why or why not? Are choices offered? Why or why not? If 
choices are not available, what do you tell an adolescent client? Probe: to come back again, 
go to another clinic, and advise to use available methods.  
 Can you talk about how service providers are doing in delivering contraception services to 
HIV-positive adolescent girls? How interested do you think providers in this community are 
in the provision of these services to HIV-positive adolescent clients? What do they think 
about HIV-positive adolescent girls accessing these services? Probe about positive or 
negative reactions and reasons? What have your experiences been with other providers’ 
attitudes towards offering contraception services to HIV-positive adolescent girls? Probe 
about judgemental attitudes, verbal abuse, confidentiality and privacy, respect for 
adolescents, and denial of contraceptive care for HIV-positive adolescent girls. 
 Can you talk about how effective/organized you think the hospital, local and/or provincial 
authority is/are doing in supporting the provision of these services? Please explain reasons.  
 Can you tell me what you know about the current South Africa’s contraception policy and 
service delivery guidelines (launched in 2014) as it regards HIV-positive populations, 
specifically women? How did you know about them? Probe about sources of introduction- 
hospital, providers, seminars, training etc. Do you have any idea about how these policy and 
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service delivery guidelines address the specific needs of HIV-positive adolescent girls? If yes, 
please explain.  
 How are they interpreted and implemented for HIV positive adolescent girls in your working 
environment? How do they impact the delivery of contraception services for these girls? 
Probe: age of the client at which providers initiate service delivery, contraceptive method 
choices.  
 Thinking about your involvement/experiences in contraceptive service provision to HIV-
positive adolescent girls, what are the specific/particular contraceptive needs do they have? 
Probe: provider’s age (peer provider); gender, racial/ethnic and native language 
concordance; and continuity of care (with same provider); method choice; access sites (youth 
only or all ages clinics). Are contraceptive services tailored to their needs and preferences? 
If yes, how? 
 Why do they have these needs (ask about each)? Do you think their contraceptive needs 
differ by a) sub-group (PHIV- versus BHIV adolescent girls); b) from those of HIV-negative 
girls, HIV-positive young adult women (20-24 years), and older HIV-positive women? If yes, 
how (ask about each aforementioned population)?  
 Thinking back to your involvement in HIV care service delivery (including contraception 
services), what would you recommend be done differently in your working environment in 
terms of tailoring contraception services to meet the needs of HIV-positive girls? Probe: 
youth only clinics, separate clinic days, peer providers, provider’s gender/age, school health 
services, continuity of care (same provider).  
 Can you describe to me the relationship providers have with HIV-positive adolescent girls 
during consultation for contraception services (i.e., interaction between providers and 
adolescent service users)? Probe: respect, courtesy, friendliness, empathy, and client’s 




 How well-equipped (i.e with skills and knowledge) are providers for delivering contraception 
services to HIV-positive girls? What methods do they have more and less experience with 
and why? How comfortable are providers in the provision of contraception services to these 
girls? 
 If you (and other providers) were trained on adolescent friendly contraceptive services – can 
you tell me what it entails? Probe: Elements of adolescent-friendly contraceptive services: 
non-judgemental services, confidentiality & privacy, offering wide range of methods, 
services regardless of age, sex etc 
 If you (and other providers) were trained on contraceptive service provision to HIV-positive 
adolescent girls- can you tell about the training? What did it cover? Probe: counselling, 
method choice, hormonal contraceptive use, insertion and removal of implanon and IUD. 
What more would you (and other providers) like to know? If you were not trained, why were 
you not trained and what training would you like to have? 
 Can you talk a little about why and when HIV-positive girls are introduced (offered) to 
contraceptive services in your working environment? Probe: circumstances, usual age, 
guidelines/policies. What else informs your recommendations? How do you and/or other 
providers introduce a contraceptive method to them? What do you tell them (ask about 
during introduction and subsequent visits)? Probe: method choice, benefits and side-effects, 
efficacy, how a method works, method switching and clinic policies.  How do they respond? 
In your experience, how are choices chosen and by who? Probe: providers, adolescent 
clients, both providers and adolescent clients.  
Now I am interested in knowing about the influences on contraception for HIV-positive 
adolescent clients  
 Based on your experience, what and who influence them in the final process of decisions 
about using a contraceptive method and why? Probe: friends, partners, family, teachers, 
healthcare providers, social media, societal/cultural norms (ask for particular methods).  
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 What do HIV-positive adolescent girls say give cause for concern about hormonal 
contraception (pills, injectables, and implanon) since they have been using it? Probe: any 
problems; physical side effects- menstrual irregularities, weight gain, pregnancy risk, fear of 
subfertility, partner dissatisfaction, and excessive nausea; and safety considerations  specific 
to HIV-populations- HIV-reinfection, disease progression and transmission to uninfected 
male partner and efficacy of hormonal contraception or HIV medications (ask about which 
hormonal contraceptive method is associated with concerns mentioned). Probe specifically 
about their beliefs regarding hormonal contraceptive induced amenorrhea and viral 
load/loss. Probe for how any side-effects impacted on their well-being. What do you and 
other providers say about any of these concerns they may have, and how do they respond?  
 What do providers say give cause for concern about hormonal contraception use in HIV-
positive adolescent girls? (use same probes as above-Question 19). How did any of these 
concerns impact on their delivery of hormonal contraception for adolescent clients in HIV 
care? 
 Based on your experience, what are the factors that promote HIV-positive adolescent girls 
(in this community) coming for contraception, and what factors act as barriers? Please speak 
about different groups of girls:  minors/older adolescents, BHIV/PHIV adolescent girls, 
married/unmarried, in-school/out-of-school, working/not working, those who are naïve to 
contraception and who have stopped using). Probe: partners, peers, family, poverty/socio-
economic status (higher or low), gender role, dwelling place (e.g informal/formal 
settlements, shacks), working or not working, schooling/not schooling and cultural norms.  
How do you think any of these factors impacted on their use/non-use of contraception? 
 Can you tell me what thoughts you have about how and why HIV-positive adolescent girls 
discontinue contraceptive use? What about switching to another method? Probe: any 
reasons, physical side effects, hormonal contraceptive-related safety considerations.  
Is there anything else you would like to tell me? 
Thank you for your participation. 
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Appendix 16: Key informants’ informed consent 
Participant ID #.......................Date of Interview…………………………. 
 
 Hello. Thank you for agreeing to this interview today. I am [INTERVIEWER: Biodun Olagbuji]. 
Before you sign the consent form, I would like to share the information about the research 
with you. The purpose of this information is to help you decide whether you would like to 
participate in the study or not.  
What you should know about the study 
 A student from the University of Cape Town is requesting you to take part in a research study 
for his PhD degree. 
 Your participation is entirely voluntary. It is your choice whether to participate or not, and if 
you decide to take part, you may discontinue your participation at any time without penalty 
to you.  
 Whether you participate or not will not affect your job security. 
Purpose of the research 
 The purpose of this research is to better understand issues related to birth 
control/contraception use among young girls living with HIV.  
   Ultimately, the findings of this research would help to increase our understanding of the ways 
to improve access to contraceptive services. 
Why you are being asked to participate 
 You are being invited to participate in this research study because we feel that your 
experience will help us to understand how policies and programs can better address HIV 
positive adolescent girls’ contraceptive needs. 
Procedures 
 If you agree to participate in the research study, you will be asked to provide your thoughts 
and opinions about issues regarding contraception for HIV positive adolescent girls.  
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 The interview will take place in a comfortable place at the clinic/office or anywhere you think 
is suitable.   
 Before we start the interview, you will fill out a brief form asking you questions around some 
demographic variables. The interview will be guided by me [INTERVIEWER: Biodun 
Olagbuji].  
 The interview guide will explore issues related to your understandings around knowledge, 
attitudes and beliefs; access to and use of contraception; existing regulations and policies; 
service quality; and barriers to contraceptive care among HIV positive adolescent girls.  
 The information from this interview will be collected using field notes and audio-tape 
recorder.  
 The interview will last approximately 45-60 minutes.  
Risks/discomfort 
 There is a risk that you may share some very personal views and confidential information by 
chance, and you may feel uncomfortable talking about some topics.  
 You do not have to answer any question that you feel talking about them makes you 
uncomfortable.  
 Taking part in this research will not compromise your job security in any way.  
Benefits 
 There will be no direct benefit to you, but your involvement is likely to assist us know more 
about how to improve access to and use of contraception by adolescent girls living with HIV.  
Reimbursements 







Protecting Data Confidentiality 
 We will want you to be very comfortable and provide your honest views. Your thoughts and 
opinions will help to tailor contraceptive programs to the needs of adolescent girls living 
with HIV.  
 We will not share information about you to anyone outside of the research team. 
 The information that we collect from this research project will be kept private. 
 Any information about you will have a number on it instead of your  name 
 All study documents including field notes, tapes and transcripts will be kept confidential.  
 Only the researchers will have access to the study documents. 
 Research documents and records will be kept in a locked file, and all electronic information 
will be coded and secured using a password protected file.  
 At the end of data analysis, all study documents including recordings will be destroyed.   
 Once we have completed the study and written the results, all study documents will be 
destroyed.  
Do you agree to be interviewed? Yes/No 
Do I have your permission to tape record this group interview: Yes/No 
Do I have your permission for note taking during this interview? Yes/No 
Who to contact if you have questions or problems 
If you have any questions or discomforts, you can ask them now. If you have questions or 
discomforts later, you may contact:  
 
Biodun Olagbuji (Principal Researcher) 
Doctoral Candidate, School of Public Health 






Appendix 17: Key informants’ informed consent 
Participant ID #.......................Date of Interview…………………………. 
 Hello. Thank you for agreeing to this interview today. I am [INTERVIEWER: Biodun Olagbuji]. 
Before you sign the consent form, I would like to share the information about the research 
with you. The purpose of this information is to help you decide whether you would like to 
participate in the study or not.  
 
What you should know about the study 
 A student from the University of Cape Town is requesting you to take part in a research study 
for his PhD degree. 
 Your participation is entirely voluntary. It is your choice whether to participate or not, and if 
you decide to take part, you may discontinue your participation at any time without penalty 
to you.  
 Whether you participate or not will not affect your job security. 
 
Purpose of the research 
 The purpose of this research is to better understand issues related to birth 
control/contraception use among young girls living with HIV.  
 Ultimately, the findings of this research would help to increase our understanding of the ways 
to improve access to contraceptive services. 
Why you are being asked to participate 
 You are being invited to participate in this research study because we feel that your 
experience will help us to understand how policies and programs can better address HIV 




 If you agree to participate in the research study, you will be asked to provide your thoughts 
and opinions about issues regarding contraception for HIV positive adolescent girls.  
 The interview will take place in a comfortable place at the clinic/office or anywhere you think 
is suitable.   
 Before we start the interview, you will fill out a brief form asking you questions around some 
demographic variables. The interview will be guided by me [INTERVIEWER: Biodun 
Olagbuji].  
 The interview guide will explore issues related to your understandings around knowledge, 
attitudes and beliefs; access to and use of contraception; existing regulations and policies; 
service quality; and barriers to contraceptive care among HIV positive adolescent girls.  
 The information from this interview will be collected using field notes and audio-tape 
recorder.  
 The interview will last approximately 45 minutes.  
Risks/discomfort 
 There is a risk that you may share some very personal views and confidential information by 
chance, and you may feel uncomfortable talking about some topics.  
 You do not have to answer any question that you feel talking about them makes you 
uncomfortable.  
 Taking part in this research will not compromise your job security in any way.  
Benefits 
 There will be no direct benefit to you, but your involvement is likely to assist us know more 
about how to improve access to and use of contraception by adolescent girls living with HIV.  
Reimbursements 
 You will not be reimbursed for your participation in the research study.  
Protecting Data Confidentiality 
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 We will want you to be very comfortable and provide your honest views. Your thoughts and 
opinions will help to tailor contraceptive programs to the needs of adolescent girls living 
with HIV.  
We will not share information about you to anyone outside of the research team. 
 The information that we collect from this research project will be kept private. 
 Any information about you will have a number on it instead of your  name 
 All study documents including field notes, tapes and transcripts will be kept confidential.  
 Only the researchers will have access to the study documents. 
 Research documents and records will be kept in a locked file, and all electronic information 
will be coded and secured using a password protected file.  
 At the end of data analysis, all study documents including recordings will be destroyed.   
 Once we have completed the study and written the results, all study documents will be 
destroyed.  
 Do you agree to be interviewed? Yes/No 
 Do I have your permission to tape record this group interview: Yes/No 
 Do I have your permission for note taking during this interview? Yes/No 
Who to contact if you have questions or problems 
 If you have any questions or discomforts, you can ask them now. If you have questions or 
discomforts later, you may contact:  
 
Biodun Olagbuji (Principal Researcher) 
Doctoral Candidate, School of Public Health 






Signature of participant….............................................. Date……………………… 
Signature of research staff…………………………   Date…………………….. 
 
